CRISPR-TRANSPOSON SYSTEMS FOR DNA MODIFICATION

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Nos. 63/351,753, filed Jun. 13, 2022, 63/380,330, filed Oct. 20, 2022, and 63/479,481, filed Jan. 11, 2023, the contents of which are herein incorporated by reference in their entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under grant number HG011650 and AI168976 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD

The present invention relates to methods and systems for DNA modification, gene targeting, and gene tagging comprising an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon (CAST) system having a donor DNA comprising at least one engineered transposon end sequence and/or at least one integration co-factor protein.

SEQUENCE LISTING STATEMENT

The contents of the electronic sequence listing titled COLUM_40991_601.xml (Size: 6,329,222 bytes; and Date of Creation: Jun. 13, 2023) is herein incorporated by reference in its entirety.

BACKGROUND

CRISPR-Cas systems can be used for programmable DNA integration, in which the nuclease-deficient CRISPR-Cas machinery (either Cascade from Type I systems, or Cas12 from Type V systems) coordinates with Tn7 transposon-associated proteins to mediate RNA-guided DNA targeting and DNA integration, respectively. This activity may be leveraged in bacterial or eukaryotic cells for the targeted integration of user-defined genetic payloads at user-defined genomic loci, via a mechanism that obviates requirements for DNA double-strand breaks (DSBs) necessary for homology-directed repair.

SUMMARY

Provided herein are systems for RNA-guided nucleic acid modification. The systems comprise a) an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon (CAST) system or one or more nucleic acids encoding the engineered CAST system, wherein the CAST system comprises at least one or all of: i) at least one Cas protein; ii) at least one transposon-associated protein; and iii) at least one guide RNA (gRNA) complementary to at least a portion of a target nucleic acid sequence; and b) a donor nucleic acid comprising a cargo nucleic acid sequence flanked by at least one or both of: an engineered transposon right end sequence or an engineered transposon left end sequence; and/or c) at least one integration co-factor protein, or a nucleic acid encoding thereof.

In some embodiments, the engineered transposon right end sequence and/or the engineered left end sequence encodes an amino acid linker sequence. In some embodiments, the engineered transposon right end sequence and/or the engineered left end sequence is fully or partially AT rich. In some embodiments, the engineered transposon right end sequence and/or the engineered left end sequence comprises a 5 to 8 bp terminal end sequence.

In some embodiments, the engineered transposon right end sequence and/or the engineered left end sequence comprises at least two TnsB binding sites (TBSs). In some embodiments, each TBS comprises a sequence individually selected from: SEQ ID NO: 11, or SEQ ID NO: 12, wherein each M is individually A or C; each W is independently A or T; each R is independently A or G; each D is independently A, G or T; each Y is independently T or C; each K is G or T; B is G, T, or C; and each H is independently A, C or T.

In some embodiments, the engineered transposon right end sequence is at least about 75 basepairs (bp). In some embodiments, the engineered transposon right end sequence comprises a sequence of: SEQ ID NO: 1, or a variant sequence having one or more additions, substitutions or deletions thereof; any of SEQ ID NOs: 2-8; any of SEQ ID NOs: 18-844; SEQ ID NOs: 9, or a variant sequence having one or more additions, substitutions or deletions thereof; any of SEQ ID NOs: 845-2690; any of SEQ ID NOs: 2691-2702; or any of SEQ ID NOs: 2703-3119.

In some embodiments, the engineered transposon left end sequence is at least about 115 basepairs (bp). In some embodiments, the engineered transposon left end sequence further comprises an Integration Host Factor (IHF) binding site (IBS), wherein the IBS comprises a sequence of WATCARNNNNTTR, wherein W is A or T, R is A or G, and N is any nucleotide. In some embodiments, the engineered transposon left end sequence comprises a sequence of: SEQ ID NO: 10, or a variant sequence having one or more substitutions thereof; any of SEQ ID NOs: 3120-4665; any of SEQ ID NOs: 4666-4673; or any of SEQ ID NOs: 4674-5135.

In some embodiments, the cargo nucleic acid sequence encodes a peptide tag or a polypeptide.

In some embodiments, the at least one integration co-factor protein comprises Integration Host Factor (IHF), Factor for Inversion Stimulation (Fis), or a combination thereof.

In some embodiments, the engineered transposon right end sequence and/or the engineered transposon left end sequence is derived from Vibrio cholerae Tn6677 or Pseudoalteromonas Tn7016.

Provided herein are systems for RNA-guided nucleic acid modification. The systems comprise a) an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon (CAST) system or one or more nucleic acids encoding the engineered CAST system, wherein the CAST system comprises at least one or all of: i) at least one Cas protein; ii) at least one transposon-associated protein; iii) at least one guide RNA (gRNA) complementary to at least a portion of a target nucleic acid sequence; and b) a donor nucleic acid comprising a cargo nucleic acid sequence flanked by at least one engineered transposon end sequence; and/or c) at least one integration co-factor protein, or a nucleic acid encoding thereof. In some embodiments, the at least one engineered transposon end sequence encodes an amino acid linker sequence.

In some embodiments, the systems comprise a) an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon (CAST) system or one or more nucleic acids encoding the engineered CAST system, wherein the CAST system comprises at least one or all of: i) at least one Cas protein; ii) at least one transposon-associated protein; iii) at least one guide RNA (gRNA) complementary to at least a portion of a target nucleic acid sequence; and b) a donor nucleic acid comprising a cargo nucleic acid sequence flanked by at least one engineered transposon end sequence. In some embodiments, the at least one engineered transposon end sequence encodes an amino acid linker sequence.

In some embodiments, the systems comprise a) an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon (CAST) system or one or more nucleic acids encoding the engineered CAST system, wherein the CAST system comprises at least one or all of: i) at least one Cas protein; ii) at least one transposon-associated protein; iii) at least one guide RNA (gRNA) complementary to at least a portion of a target nucleic acid sequence; and b) at least one integration co-factor protein, or a nucleic acid encoding thereof.

In some embodiments, the systems comprise a) an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon (CAST) system or one or more nucleic acids encoding the engineered CAST system, wherein the CAST system comprises at least one or all of: i) at least one Cas protein; ii) at least one transposon-associated protein; iii) at least one guide RNA (gRNA) complementary to at least a portion of a target nucleic acid sequence; b) a donor nucleic acid comprising a cargo nucleic acid sequence flanked by at least one engineered transposon end sequence; and c) at least one integration co-factor protein, or a nucleic acid encoding thereof. In some embodiments, the at least one engineered transposon end sequence encodes an amino acid linker sequence.

In some embodiments, the donor nucleic acid comprises a cargo nucleic acid sequence flanked by one native transposon end sequence and one engineered transposon end sequence.

In some embodiments, the at least one engineered transposon end sequence is fully or partially AT-rich.

In some embodiments, the at least one engineered transposon end sequence comprises at least two TnsB binding sites (TBSs). In some embodiments, each TBS comprises a sequence individually selected from: CAMCCATAWRDTGATAWYKH (SEQ ID NO: 11), or CMMCBRWAWNNTGAHWWYWN (SEQ ID NO: 12), wherein each M is individually A or C; each W is independently A or T; each R is independently A or G; each D is independently A, G or T; each Y is independently T or C; each K is G or T; B is G, T, or C; and each H is independently A, C or T.

In some embodiments, the at least one engineered transposon end sequence comprises a 5 to 8 bp terminal end sequence. In some embodiments, the terminal end sequence comprises a terminal TG dinucleotide. In some embodiments, the terminal end sequence is immediately adjacent to the distal end of the transposase binding site farthest from the cargo nucleic acid sequence. In some embodiments, the terminal end sequence is separated from the distal end of the transposase binding site farthest from the cargo nucleic acid sequence by 1 to 3 basepairs (bp).

In some embodiments, the at least one engineered transposon end sequence is a transposon right end sequence 3′ to the cargo nucleic acid sequence, relative to transcription direction. In some embodiments, the at least one engineered transposon end sequence is a transposon left end sequence 5′ to the cargo nucleic acid sequence, relative to transcription direction. In some embodiments, the donor nucleic acid comprises a cargo nucleic acid sequence flanked by two engineered transposon sequences: an engineered transposon right end sequence and an engineered transposon left end sequence.

In some embodiments, the engineered transposon right end sequence and/or the engineered transposon left end sequence is derived from a Vibrio cholerae Tn6677 native transposon end sequence. In some embodiments, the engineered transposon right end sequence and/or the engineered transposon left end sequence is derived from a Pseudoalteromonas Tn7016 native transposon end sequence.

In some embodiments, the engineered transposon right end sequence is at least about 50 basepairs (bp). In some embodiments, the engineered transposon right end sequence is at least about 75 basepairs (bp).

In some embodiments, the engineered transposon right end sequence comprises two TBSs.

In some embodiments, the engineered transposon right end sequence comprises a sequence of: TGTTGATACAACCATAAAATGATAATTACACCCATAAATTGATAATTATCACACCCA (SEQ ID NO: 1), or a variant sequence having one or more additions, deletions, or substitutions thereof.

In some embodiments, the engineered transposon right end sequence comprises a sequence of:

	(SEQ ID NO: 2)
	TGTgGATACAACCATAAAATGATAATTACACCCATAAATgGATcA
	TTATCACcCCCA;
	(SEQ ID NO: 3)
	TGTgGATACAACCATAAAAcGATAATTACACCCATAAATgGATcA
	TTATCACACCCA;
	(SEQ ID NO: 4)
	TGTgGATcCAACCATAAAATGATAATTACACCCATAAATgGATcA
	TTATCACACCCA;
	(SEQ ID NO: 5)
	TGTTGATACAACCATAAAAgGATtATTACACCCATtAATTGATAA
	TTATCACACCCA;
	(SEQ ID NO: 6)
	TGTTGATACAACCATcAAATGgTAATTACACCCATAAATTGATAA
	TTATCACACCCA;
	(SEQ ID NO: 7)
	TGTTGATACAACCATtAAATGATAATTcCACCCATAAtTTGATAA
	TTATCACACCCA;
	or
	(SEQ ID NO: 8)
	TGTTGATACAACCATtAAATGgTAATTcCACCCAaAtATTGATAA
	TTATCACACCCA.

In some embodiments, the engineered transposon right end sequence comprises a sequence of SEQ ID NOs: 18-844.

In some embodiments, the engineered transposon right end sequence comprises a sequence of: TGTTGATACAACCATAAAATGATAATTACACCCATAAATTGATAATTATCACACCCATAAA TTGATATTGCCTCT (SEQ ID NO: 9), or a variant sequence having one or more additions, deletions, or substitutions thereof.

In some embodiments, the engineered transposon right end sequence comprises a sequence of SEQ ID NOs: 845-2690.

In some embodiments, the engineered transposon right end sequence is hyperactive. In some embodiments, the engineered transposon right end sequence comprises a sequence of SEQ ID NOs: 2691-2702. In some embodiments, the engineered transposon right end sequence comprises a sequence of SEQ ID NOs: 2703-3119.

In some embodiments, the engineered transposon left end sequence is at least about 105 basepairs (bp). In some embodiments, the engineered transposon left end sequence is at least about 115 bp.

In some embodiments, the engineered transposon left end sequence comprises three transposase TBSs.

In some embodiments, the engineered transposon left end sequence comprises an Integration Host Factor (IHF) binding site (IBS). In some embodiments, the IBS comprises a sequence of WATCARNNNNTTR, wherein W is A or T, R is A or G, and N is any nucleotide. In some embodiments, the engineered transposon left end sequence does not include an Integration Host Factor (IHF) binding site (IBS).

In some embodiments, the engineered transposon left end sequence comprises a sequence of: TGTTGATGCAACCATAAAGTGATATTTAATAATITATTTATAATCAGCA ACTTAACCACAAA ACAACCATATATTGATATCTCACAAAACAACCATAAGTTGATATITITGTGAAT (SEQ ID NO: 10), or a variant sequence having one or more additions, deletions, or substitutions thereof.

In some embodiments, the engineered transposon left end sequence comprises a sequence of SEQ ID NOs: 3120-4665.

In some embodiments, the engineered transposon left end sequence is hyperactive. In some embodiments, the engineered transposon left end sequence comprises a sequence of SEQ ID NOs: 4666-4673. In some embodiments, the engineered transposon left end sequence comprises a sequence of SEQ ID NOs: 4674-5135.

In some embodiments, the cargo nucleic acid sequence encodes a peptide tag. In some embodiments, the cargo nucleic acid sequence encodes a polypeptide. In some embodiments, the polypeptide comprises a fluorescent protein.

In some embodiments, the at least one integration co-factor protein comprises Integration Host Factor (IHF), Factor for Inversion Stimulation (Fis), or a combination thereof. In some embodiments, the at least one integration co-factor protein is provided as a fusion protein with TnsA and TnsB, or a nucleic acid encoding thereof. In some embodiments, the at least one integration co-factor protein fused to a localization agent. In some embodiments, the at least one integration co-factor protein comprises an amino acid sequence of any of SEQ ID NOs: 5136-5152.

In some embodiments, the at least one Cas protein is derived from a Type-I CRISPR-Cas system. In some embodiments, the engineered CAST system is a Type I-F system.

In some embodiments, the at least one Cas protein comprises Cas5, Cas6, Cas7, and Cas8. In some embodiments, the at least one Cas protein comprises a Cas8-Cas5 fusion protein.

In some embodiments, the at least one transposon protein is derived from a Tn7 or Tn7-like transposon system. In some embodiments, the at least one transposon-associated protein comprises TnsA, TnsB, TnsC, or a combination thereof. In some embodiments, the at least one transposon protein comprises a TnsA-TnsB fusion protein. In some embodiments, the at least one transposon-associated protein comprises TnsD and/or TniQ.

In some embodiments, the engineered transposon system is derived from Vibrio cholerae Tn6677. In some embodiments, the engineered transposon system is derived from Pseudoalteromonas Tn7006.

In some embodiments, the at least one gRNA is a non-naturally occurring gRNA. In some embodiments, the at least one gRNA is encoded in a CRISPR RNA (crRNA) array.

In some embodiments, the systems further comprise a target nucleic acid. In some embodiments, the target nucleic acid sequence comprises a TSD region having a 5′-CWG-3′ sequence motif.

In some embodiments, the one or more nucleic acids encoding the engineered CAST system comprises one or more messenger RNAs, one or more vectors, or a combination thereof. In some embodiments, the at least one Cas protein, the at least one transposon-associated protein, and the at least one gRNA are encoded by different nucleic acids. In some embodiments, the one or more of the at least one Cas protein, the at least one transposon-associated protein, and the at least one gRNA are encoded by a single nucleic acid.

In some embodiments, the nucleic acid encoding the at least one integration co-factor protein comprises at least one messenger RNA, at least one vector, or a combination thereof. In some embodiments, the at least one integration co-factor protein is encoded on a nucleic acid encoding one or more of: the at least one Cas protein, the at least one transposon-associated protein, and the at least one gRNA.

Also provided are compositions and cells comprising the disclosed system. In some embodiments, the cell is a prokaryotic cell. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a human cell.

Further provided are methods for nucleic acid integration comprising contacting a target nucleic acid sequence with a disclosed system or composition. In some embodiments, the target nucleic acid sequence comprises a TSD region having a 5′-CWG-3′ sequence motif.

In some embodiments, the target nucleic acid encodes a polypeptide gene product or is adjacent to a sequence encoding a polypeptide gene product.

In some embodiments, the target nucleic acid sequence is in a cell. In some embodiments, the contacting a target nucleic acid sequence comprises introducing the system into the cell. In some embodiments, the cell is a prokaryotic cell. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a human cell.

In some embodiments, the introducing the system into the cell comprises administering the system to a subject. In some embodiments, introducing the system into the cell comprises administering the system to a subject. In some embodiments, the administering comprises in vivo administration. In some embodiments, the administering comprises transplantation of ex vivo treated cells comprising the system.

Other aspects and embodiments of the disclosure will be apparent in light of the following detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1E show the pooled library approach to investigate transposon end mutability. FIG. 1A is a schematic of RNA-guided transposition with VchCAST. FIG. 1B is a graph of integration efficiency of the WT mini-transposon in both orientations when directed to a genomic lacZ target site, as measured by qPCR. FIG. 1C is a table of the number of transposon right and left end library variants tested in each category. FIG. 1D is a schematic of an exemplary pooled library transposition approach. Library members were synthesized as single-stranded oligos and cloned into a plasmid donor library (pDonor), with 8-bp barcodes (gray) located between the transposon end and cargo used to uniquely identify each variant. The donor library was used for transposition into the E. coli genome, and junction amplicons were generated to determine the representation of each library member within integrated products by NGS. FIG. 1E is a schematic of the native VchCAST system from Vibrio cholerae (top), and relative T-RL integration activity for library members in which the left and right ends were sequentially mutagenized beginning internally (bottom). Each point represents the average activity from two transposition experiments using the same pooled donor library. Left end sequence is SEQ ID NO: 5229; right end sequence is SEQ ID NO: 5230.

FIGS. 2A-2E show transposase binding site (TBS) characterization for VchCAST. FIG. 2A is a schematic representation of the VchCAST transposon end sequences. Bioinformatically predicted transposase binding site (TBS) sequences are indicated with blue boxes and labeled L1-L3 and R1-R3. The 8-bp terminal end sequences that dictate the transposon boundaries are marked with yellow boxes. Left end sequence is SEQ ID NO: 5231; right end sequence is SEQ ID NO: 5230. FIG. 2B is a WebLogo depicting the sequence conservation of the six bioinformatically predicted TBSs. FIG. 2C is a graph of the relative integration efficiencies (log 2-transformed) for mutagenized TBS sequences averaged over all six binding sites, shown as the mean for two biological replicates. FIG. 2D, top is Tn7002 transposon end sequences colored based VchCAST transposon end library data, where red indicates a relatively inefficient residue (L1-SEQ ID NO: 5232; L2-SEQ ID NO: 5233; L3-SEQ ID NO: 5234; R1-SEQ ID NO: 5235; R2-SEQ ID NO: 5236; R3-SEQ ID NO: 5237). FIG. 2D, bottom is relative integration efficiencies of VchCAST/Tn7002 chimeric ends verify critical compatibility sequence requirements of TBSs. Data are shown for two biological replicates. FIG. 2E is a graph of relative integration efficiencies for transposon variants containing altered distances between the indicated TBSs. Orange arrows highlight the 10-bp periodic pattern of activity. Data are shown for two biological replicates.

FIGS. 3A-3D shows transposase sequence preferences influence on integration site patterns. FIG. 3A shows VchCAST exhibits target-specific heterogeneity in the distance (d) between the target site and integration site, which could result from sequence preferences within the downstream region (top). Deep sequencing revealed biases in integration site preference, with integration patterns shown for four target sites (4-7) located in the lac operon of the E. coli BL21(DE3) genome (top row) or encoded on a separate target plasmid (second row). Chimeric target plasmids that either maintain the 32-bp target site (third row) or 60-bp downstream region (bottom row) of target 4 were also tested. These data reveal that sequence identity of the downstream region (including the integration site), but not the target site, governs the observed in integration distance distribution. FIG. 3B is a schematic of integration site library experiment, in which integration was directed into an 8-bp degenerate sequence encoded on a target plasmid (pTarget). FIG. 3C is a sequence logo of preferred integration site, generated by selecting nucleotides from the top 5000 enriched sequences across all integration positions in each library, with a minimum threshold of four-fold enrichment in the integrated products compared to the input. FIG. 3D shows the preferred 5′-CWG-3′ motif in the center of the TSD is predictive of integration site distribution, as the displacement of this motif within the degenerate sequence shifts the preferred integration site distance, indicated by the red number.

FIGS. 4A-4E show that engineered transposon right ends enable functional in-frame protein tagging. FIG. 4A is an illustration of a minimal transposon right end sequence (“WT-min.” SEQ ID NO:1) and the amino acids it encodes in three different reading frames. The 8-bp terminal end (yellow box) and TBSs (blue boxes) are shown. ORF-1 (SEQ ID NOs: 5238 and 5239); ORF-2 (SEQ ID NOs: 5240 and 5241) and ORF-3 (SEQ ID NOs: 5242 and 5243). FIG. 4B is a graph of integration efficiencies for individual pDonor variants in which stop codons and codons encoding bulky/charged amino acids were replaced, as determined by qPCR. “Vector only” refers to the negative control condition where pEffector was co-transformed with a vector that did not encode a transposon. FIG. 4C shows select right end linker variants cloned in between the 10^th and 11th β-strands of GFP, in order to identify stable polypeptide linkers that still allow for proper formation and fluorescence activity of GFP. Normalized fluorescence intensity (NFI) was calculated using the optical density of each culture and is plotted for each linker variant alongside wildtype GFP. A schematic of a proof-of-concept experiment in which the endogenous E. coli gene msrB is tagged by targeted, site-specific RNA-guided transposition (FIG. 4D, top). Fluorescence microscopy images reveal functional tagging of MsrB with the linker variant right end, but not the WT, stop codon-containing right end (FIG. 4D, bottom). Scale bar represents 10 μm. FIG. 4E is western blots with anti-GFP antibody (top) and anti-GAPDH antibody (bottom) as loading control. The four samples are unmodified BL21(DE3) cells (‘-’), cells that underwent transposition with a GFP-encoding donor plasmid using either the WT transposon end (‘WT’) or the modified ORF2a transposon end (‘Variant’), and cells expressing a plasmid encoding GFP driven by a T7 promoter (‘pGFP’). The expected size of GFP alone is 26.8 kDa, while the expected size of the MsrB-GFP fusion product is ˜42 kDa.

FIGS. 5A-5G show IHF involvement in RNA-guided transposition by VchCAST. FIG. 5A shows library mutagenesis data for the transposon left end (SEQ ID NO: 5244). Each point represents the effect of 4-bp mutations, averaged across 4 variants per base. FIG. 5B shows integration activity of VchCAST in WT, ΔihfA, and ΔihfB cells. Integration activity was rescued by a plasmid encoding both ihfA and ihfB (pRescue). Each point represents integration efficiency measured by qPCR for one independent biological replicate. FIG. 5C shows integration activity when the IHF binding site (IBS) is mutated (Mut), in which all consensus bases within the IBS were modified (from 5′-AATCAGCAAACTTA-3′ (SEQ ID NO: 13) to 5′-CCGACTCAACGGC-3′(SEQ ID NO: 14)). FIG. 5D shows conservation of the IBS in the transposon left end of twenty Type I-F CAST systems, described in Klompe et al., 2022 (Mol Cell, 82, 616-628.e5). IBS sequences are SEQ ID NOs: 5245-5264, top to bottom. FIG. 5E shows a sequence logo generated by aligning the left end sequence of all homologs around the conserved IHF binding site. FIG. 5F shows integration activity in WT and ΔIHF cells for five highly active Type I-F CAST systems. Asterisks indicate the degree of statistical significance:* p≤0.05, ** p≤0.01, ***p≤0.001. FIG. 5G shows an exemplary model: IHF binds the left end to resolve the spacing between the first two TBSs, bringing together TnsB protomers to form an active transpososome.

FIGS. 6A-6E show sequencing and characterization of pDonor right end and left end pooled libraries. FIG. 6A is a histogram showing read counts for each of the input libraries, as defined by barcode sequences. All library members are represented in both the transposon left end and right end libraries. FIG. 6B is a histogram showing the percentage of each library member's high-quality reads in which the correct barcode is coupled to the correct transposon end sequence. Library members are identified by their barcodes. FIG. 6C is a histogram showing the highest percentage of each library member's uncoupled reads mapping to a single incorrect sequence. In other words, for a given library member, the incorrect (uncoupled) sequence with the highest read count was selected and expressed as the percent of total reads for that library member. These analyses demonstrate that only a small minority of all barcode reads for a given library member are associated with an incorrect (uncoupled) transposon end sequence. FIG. 6D shows all enrichment scores for library members in either integration orientation, for both the left end and right end libraries. Enrichment scores were calculated by dividing the abundance of each member in the output library by its abundance in the input library, and then taking the log 2 transformation of that value. Library member dropouts were arbitrarily assigned a score of −15, which fell below the minimum enrichment score across all samples, in order to be plotted on the same graphs. FIG. 6E shows the correlation between two independent biological replicates for the transposon left and right end library transposition experiments. For each graph, the upper R² value (black) includes enrichment scores for all transposon end variants, where dropouts were arbitrarily set to −15. The lower R² value (colored) includes only the enrichment scores for transposon end variants that were detected in both output libraries.

FIGS. 7A-7D show the sequence and spatial characterization of VchCAST TBSs. FIG. 7A shows sequence conservation among the six bioinformatically predicted TBS sequences, with nucleotides conserved among all six sites highlighted in gray. L1 is SEQ ID NO: 5265; L2 is SEQ ID NO: 5266; L3 is SEQ ID NO: 5267; R1 is SEQ ID NO: 5268; R2 is SEQ ID NO: 5269; R #is SEQ ID NO: 5270. FIG. 7B is integration activity for mutagenized TBS sequences at individual binding sites, shown as the mean of two biological replicates. Integration activity is represented as the library variant enrichment score normalized to WT. A schematic representation of the transposon end architecture is shown in FIG. 7C, top. Enrichment of individual transposon end variants for which the TBS were shuffled are shown as a heatmap (FIG. 7C, bottom left). The overall effect of each TBS is represented in a boxplot for the individual sites within both the left and right transposon ends, including their numerical mean (FIG. 7C, bottom right). A schematic representation of the spacing in between the TBS sequences of the transposon left and right ends is shown in FIG. 7D, top left. Integration efficiencies, calculated from enrichments within the larger transposon end library dataset, are shown for alternative spacing between the TBS sequences of the left and right end sequences.

FIGS. 8A-8E show transposase sequence preferences at the site of DNA integration. FIG. 8A is a schematic of target A integration products, with corresponding sequence logos of enriched sequences at each integration position. Sequence logos were generated by selecting all sequences with 4-fold enrichment in the integrated products compared to the input libraries. The y-axis of each sequence logo was set to a maximum of 1 bit. FIG. 8B shows integration site distance distribution for degenerate sequences containing multiple preferred CWG motifs, with preferred distances indicated in red. FIG. 8C shows integration site distance distributions of previously tested genomic target sites, as determined through deep sequencing. The TSD sequence+/−3-bp is shown for distances of 48, 49, and 50 bp. Integration occurs primarily 49-bp downstream of the target site but can be biased to occur 48- and/or 50-bp downstream due to sequence preferences at the site of integration. The TSD is bold, and favored (green) or disfavored (orange and red) nucleotides according to the preference sequence logo are indicated. SEQ ID NOs: 5282-5284 in the upper left panel; SEQ ID NOs: 5285-5287 in the upper middle panel: SEQ ID NOs: 5288-5290 in the upper right panel: SEQ ID NOs: 5291-5293 in the lower left panel; SEQ ID NOs: 5294-5296 in the lower middle panel; SEQ ID NOs: 5297-5299 in the lower right panel. FIG. 8D shows integration site distance distribution for two targets, A and B, with preferred distances indicated in red. FIG. 8E shows nucleotide preferences surrounding the degenerate sequence may be responsible for differences in the overall integration site distance distribution.

FIGS. 9A-9F show the effect of target-transposon boundary sequences and internal sequences on DNA integration. A schematic representation of DNA cleavage by TnsA and TnsB, leading to full excision of the transposon from the donor site is shown in FIG. 9A, top. Different transposon-flanking sequences were tested on both the left and right transposon boundaries, and integration efficiencies were determined by calculating the enrichment of each library member from within the larger transposon end pool (FIG. 9A, bottom). An illustration of the imperfect 8-bp terminal end sequences for VchCAST is shown in FIG. 9B, top. Calculated integration efficiencies are plotted for transposon end variants in which either the left or right terminal end sequence was mutated (FIG. 9B, bottom). An illustration of the transposon end sequences including the target site duplication (TSD), 8-bp terminal end, and first transposase binding site (TBS1) is shown in FIG. 9C, top. The specific sequence shown (SEQ ID NO: 5302) is derived from the VchCAST left end. Integration efficiencies relative to WT are shown for transposon end variants in which the distance between the 8-bp terminal end and TBS1 was altered for either the transposon left or right end (FIG. 9C, middle). Analysis of deep sequencing data revealed TnsB cleavage sites for the right end and left end variants that were functional for transposition; cleavage sites are indicated with red arrows (FIG. 9C, bottom). TBS1 sequence is SEQ ID NO: 5304. Right end sequences are SEQ ID NOs: 5303, 5305 and 5306 for WT, +1 and +3, respectively. Left end sequences are SEQ ID NOs: 5307-5311 for −3, −2, WT, +1 and +3, respectively. FIG. 9D is an illustration of WT and modified transposon right end sequences. The 8-bp terminal end (yellow boxes), transposase binding sites (blue boxes), and palindromic sequences (blue and pink lines), are indicated. The native sequence (SEQ ID NO: 5312) encompasses 130 bp from V. cholerae Tn6677, whereas only 75 bp were used in the “WT” sequence (SEQ ID NO: 5313) used in library experiments. FIG. 9E is a graph of the integration activity of right end library variants, in which the palindromic sequence was altered. Integration activity is represented as the library variant enrichment score normalized to WT. Each variant included a distinct combination of palindromic sequences P_B and P_A, with the ordering as shown. Blue text (“native”) indicates the native palindromic sequence. Orange text (“G-T”) refers to variants in which palindrome nucleotides were mutated from G to T and A to C. Green text (“G-C”) refers to variants in which palindrome nucleotides were mutated from G to C and A to T. FIG. 9F is a graph of the integration efficiencies of right end variants in which different internal promoter sequences point inwards of the transposon (In) or outwards across the transposon end (Out). Promoter strengths are indicated pJ23114 (+), pJ23111 (++), pJ23119 (+++).

FIGS. 10A-10D show engineering of the VchCAST right end. FIG. 10A is integration data for transposon right end variants that were modified to encode functional protein linker sequences in each of three open reading frames (ORF1-3). Integration efficiencies were calculated based on enrichment values within the library dataset. A schematic representation of the linker functionality assay in which GFP includes a linker sequence encoded by a mutated right end is shown in FIG. 10B, top. The fluorescence of E. coli cells expressing each of the indicated GFP constructs was visualized upon excitation with blue light (FIG. 10B, bottom). FIG. 10C shows fluorescence microscopy images of negative control samples for the C-terminal GFP-tagging experiment, showing a brightfield image (left), fluorescence image (center), and composite merge (right). Controls included experiments testing a non-targeting pEffector alone (top) or in combination with either a transposon encoding a functional linker variant (middle) or a wildtype transposon (bottom). Scale bar represents 10 μm. FIG. 10D is a schematic of transposon right end linker variants. Shading indicates amino acids that differ from the WT ORF. WT-min is SEQ ID NO: 1. WT ORF-1 is SEQ ID NOs: 5238 and 5239; WT is ORF-2 SEQ ID NOs: 5240 and 5241 and WT ORF-3 is SEQ ID NOs: 5242 and 5243. Variant ORF1a DNA sequence is SEQ ID NO: 2 and amino acid sequence is SEQ ID NO: 5354. Variant ORF1b DNA sequence is SEQ ID NO: 3 and amino acid sequence is SEQ ID NO: 5355. Variant ORF1v DNA sequence is SEQ ID NO: 4 and amino acid sequence is SEQ ID NO: 5356. Variant ORF2a DNA sequence is SEQ ID NO: 5 and amino acid sequence is SEQ ID NO: 5357. Variant ORF3a DNA sequence is SEQ ID NO: 6 and amino acid sequence is SEQ ID NO: 5358. Variant ORF3b DNA sequence is SEQ ID NO: 7 and amino acid sequence is SEQ ID NO: 5359. Variant ORF3c DNA sequence is SEQ ID NO: 8 and amino acid sequence is SEQ ID NO: 5360.

FIGS. 11A-11F show transposition efficiency of VchCAST and other Type I-F CAST systems in WT and NAP-knockout cells. FIG. 11A is the integration efficiency under different expression systems and induction conditions for VchCAST in WT and ΔihfA cells. pSPIN is a single plasmid that encodes both the donor molecule and transposition machinery, as described in Vo, et al (2021) Nat Biotechnol, 39, 480-489. pEffector+pDonor refers to separate plasmids that encode the transposition machinery and donor DNA, respectively. The indicated promoters were also tested, with J23119 and J23101 being constitutively active whereas the T7 promoter is induced by growing cells on IPTG. FIG. 1B is an alignment of the sequence between the first two TnsB binding sites (L1 and L2) in the left end, generated by Clustal Omega and colored in Jalview to highlight conserved residues. The consensus IHF binding site (IBS) is shown below the alignment. Sequences listed are from top to bottom SEQ ID NOs: 5314-5332, respectively, except for SEQ ID NO: 5321 for both Tn6677 and Tn7000. FIG. 11C shows integration orientation preference in WT and ΔihfA cells for VchCAST and Tn7000. For Tn7000, T-RL integration products were not detected (N.D.) after 35 cycles of qPCR, indicating an integration efficiency less than 0.01%. Integration orientation (FIG. 11D) and efficiency (FIG. 11E) of transposons with symmetric end sequences in WT and ΔihfA cells. R-L refers to a WT-like sequence in which the transposon end identity has not been changed, whereas R-R or L-L refer to transposons in which the left or right end sequence have been mutated to the opposite end sequence, resulting in a transposon with symmetric ends. FIG. 11F shows the effect of nucleoid associated protein knockouts for VchCAST. Transposition was measured by qPCR after expressing pSPIN in each of the indicated E. coli knockout strains.

FIGS. 12A-12C show the effect of NAP knockouts on Tn7 transposition efficiency and fidelity. FIG. 12A is a schematic of an NGS-based Tn7 transposition assay. The transposon cargo encodes genomic primer binding sites (“P1”) adjacent to the right and left ends, such that the NGS amplicon length (“C”) is the same for unintegrated products and for integrated products in both orientations. Using this strategy, a single NGS library reports both the integrated and unintegrated products, while avoiding PCR bias that might arise from amplifying products of different lengths or primer binding sites. FIG. 12B shows the Tn7 integration efficiencies in the indicated NAP knockout strains are shown, quantified using both qPCR and NGS. The dotted line shows the WT integration value as measured by NGS. ΔihfA or ΔihfB have no effect on integration activity, whereas Δfis increases integration activity ˜4-fold. FIG. 12C shows the integration distance and orientation distribution downstream of the glmS locus for Tn7 in WT and Δfis cells. The x-axis refers to the distance in bp between the stop codon of glmS and the integration site. For WT and knockout cells, the dominant distance is the canonical 25 bp downstream of glmS. The y-axes are shown as linear scale (top) and as log 10 scale (bottom), in order to highlight low frequency integration events at non-canonical distances and orientations.

FIG. 13, similar to FIG. 4A, shows the sequence of the native transposon right end derived from Vibrio cholerae Tn6677 (SEQ ID NO: 5333) and the amino acids it encodes Frame 1 (SEQ ID NOs: 5238 and 5239); Frame 2 (SEQ ID NOs: 5240 and 5241); Frame 3 (SEQ ID NOs: 5242 and 5243); Frame 4 (SEQ ID NO: 5334); Frame 5 (SEQ ID NO: 5335); and Frame 6 (SEQ ID NO: 5336-5337). Shown in the middle is the DNA sequence of the transposon right end, orientated such that the end of the transposon, including the 8-bp terminal repeat colored in yellow, is at the far left, whereby the genomic flanking sequence would be to the left of the right end, and the internal cargo encoded within the mini-transposon would be to the right of the right end sequence shown. TnsB binding sites are colored in light blue. Were this sequence to be transcribed and translated into protein, it would yield the six potential coding sequences shown about and below the DNA sequence, according to the direction of translation and the specific open reading frame (ORF) selected during the integration event.

FIGS. 14A and 14B are schematics of the advantages of CAST-based protein tagging. Multi-spacer CRISPR arrays allow multiplexing, meaning CASTs can be harnessed for tagging multiple target genes in parallel through a single plasmid construct (FIG. 14A). The ability of CASTs to efficiently integrate large cargos (e.g., ˜10 kb) suggests lengthier tags and, for example, low tandem FP arrays are well-suited for CAST-based insertion, enabling signaling amplification (FIG. 14B).

FIG. 15 shows the result of the mutational panel revealing high sequence plasticity for certain positions within the TnsB binding sites and critical sequence constraints in others. These data support a consensus sequence of: CMMCBRWAWNNTGAHWWYWN (SEQ ID NO: 12).

FIG. 16 shows the preferential transposase binding site spacing. Manipulating the spacing between the first and the distal two TnsB binding sites on the right or left transposon end revealed a ˜10-bp periodic preference for integration. The distance of this preference corresponds to a single turn of the DNA double helix, which suggests that TnsB protomers are able to form an active paired-end complex if they are positioned on a consistent side of donor DNA.

FIG. 17 is a graph showing that mutating the putative IBS decreases integration efficiency in WT but not ihfA knockout cells. The first mutant, “AT< >CG” (SEQ ID NO: 5339), has all adenines and thymines substituted with cytosines and guanines, respectively, which disrupts all non-N bases in the E. coli IBS consensus (5′-WATCARNNNNTTR). The second mutant (SEQ ID NO: 5340) has the IBS inverted to the reverse complement, which would cause IHF to bind on the reverse strand in the opposite direction. WT sequence is SEQ ID NO: 5338.

FIG. 18 shows a proposed model of IHF binding to the transposon end and bending the left transposon end between two TnsB binding sites, facilitating formation of the strand transfer complex.

FIG. 19A is a schematic of exemplary TnsA-IHF-B fusion constructs. The single chain IHF sequence was encoded internally between TnsA-NLS and TnsB. Different linkers were screened between scIHF and the surrounding subunits to ensure proper flexibility and spatial requirements were met to maintain functional TnsA and TnsB subunits. FIG. 19B is a graph of E. coli transposition assays to measure the efficiency of various TnsA-IHF-TnsB variants. All variants showed robust transposition activity. ΔIHF represents a construct in which no IHF or linker sequences were present between TnsA-NLS and TnsB. GSGSGG is SEQ ID NO: 5341 and (GGS)₆ is SEQ ID NO: 5342.

FIG. 20 is a schematic of exemplary transposon end sequences (SEQ ID NOs: 3120-4665 for left end transposon sequences and SEQ ID NOs: 845-2690 for right end transposon sequences). Transposon end library sequences were designed to include the minimally necessary transposon end sequence—115-bp for the Tn6677 transposon left end (SEQ ID NO: 5345), and 75-bp for the Tn6677 transposon right end (SEQ ID NO: 5346)—together with a ‘stuffer’ sequence that was designed in order to facilitate oligoarray synthesis of the library members with a constant oligonucleotide length across all library members and added protein binding sites or modified AT content. Additionally, ‘stuffer’ sequences enabled consistency when designing transposon end variants in which the spacing between TnsB binding sites was increased by N nucleotides, which necessitated eliminating a corresponding number of N nucleotides from the ‘stuffer’ sequence to maintain a constant total length of transposon end variant. The starting point ‘stuffer’ sequence used for transposon left end variants was 32-bp in length, and contained the sequence 5′-CGAGTATTTCAGCAAAACTACTGCAGTAAGAA-3′ (SEQ ID NO: 5343). The starting point ‘stuffer’ sequence used for transposon right end variants was 47-bp in length, and contained the sequence 5′-GATCATAGTCAGACCAACATTGCTACGACCCGTATTCGCACCGACAC-3′ (SEQ ID NO: 5344).

FIGS. 21A-21C show identification of hyperactive transposon end variants. A hypoactive background was established in order to facilitate identification of modified transposon end sequences that increase activity relative to the WT, native transposon end sequence. To reduce overall integration activity, cells were plated on solid LB-agar media lacking any inducer (IPTG). When compared to plating cells on ˜0.1 mM IPTG (+ column), the integration efficiency without IPTG (− column) decreased approximately 3-fold, from ˜80% to ˜25% (FIG. 21A). Transposon library experiments were performed within this hypoactive background to identify hyperactive transposon end variants that were improved relative to WT (FIG. 21B). The four barcoded WT transposon end library members are indicated by dashed horizontal lines, and the left and right graphs show transposon right end and left end variants, respectively, as described at the top of the graph. Each transposon end variant is identified with a description of the sequence, or with an identifier; in both cases, the sequences of the modified transposon ends can be found in Table 5 (SEQ ID NOs: 291-2702) or Table 6 (SEQ ID NOs:4666-4673). “rc” denotes the reverse complement of a binding site sequence. Integration data are reported as a fold-change, normalized to WT, based on the number of sequencing reads in the integration product library divided by the starting abundance in the input library, relative to the four barcoded WT library members. FIG. 21C shows the validation of hyperactive variants by cloning select right end variants into a pDonor substrate and measuring integration efficiency via qPCR. Sequences of the variant transposon ends are illustrated, along with their corresponding integration efficiencies. A WT pDonor substrate with native transposon left and right ends is shown for comparison. WT is SEQ ID NO: 5347; IHF is SEQ ID NO: 5348; IHF(rc) is SEQ ID NO: 5349; H-NC is SEQ ID NO: 5350; and H-NS(rc) is SEQ ID NO: 5351.

DETAILED DESCRIPTION

The disclosed systems, kits, and methods provide systems and methods for nucleic acid integration utilizing engineered CRISPR-associated transposon systems. The disclosed systems, kits, and methods provide systems and methods for RNA-guided DNA integration utilizing engineered CRISPR-associated transposon systems.

What distinguishes mobile DNA from other non-mobile DNA are the transposon end sequences. These transposon ends contain repetitive sequence elements to which the transposase binds, thereby identifying the mobilized genetic payload. Although CRISPR-associated transposons hold great potential for many different types of genome engineering purposes, the integration events are not scarless, as the desired payload must be flanked by the transposon end sequences recognized by the transposases, thus leaving scars behind at these regions within the integrated site in the genome. Because the transposon ends are essential for DNA mobilization, the scars cannot be outright eliminated, however their sequences can be modified through both rational engineering or directed evolution.

Herein, pooled library screening and high-throughput sequencing reveal sequence preferences during transposition by the Type I-F Vibrio cholerae CAST system. On the donor DNA, large mutagenic libraries identified core binding sites recognized by the TnsB transposase, as well as an additional conserved region that encoded a consensus binding site for integration host factor (IHF). Remarkably, VchCAST utilized IHF for efficient transposition, thus revealing a cellular factor involved in CRISPR-associated transpososome assembly. In fact, two host factors can aid in RNA-guided DNA integration. The first factor is IHF, which in Escherichia coli is encoded by two genes, ihfA and ihfB. The second factor is factor for inversion stimulation (Fis), encoded by one gene, fis. Loss of either component decreased integration activity. On the target DNA, preferred sequence motifs were uncovered at the integration site that explained previously observed heterogeneity with single-base pair resolution. Finally, the library data was utilized to design modified transposon variants to enable in-frame protein tagging.

Section headings as used in this section and the entire disclosure herein are merely for organizational purposes and are not intended to be limiting.

Definitions

The terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. As used herein, comprising a certain sequence or a certain SEQ ID NO usually implies that at least one copy of said sequence is present in recited peptide or polynucleotide. However, two or more copies are also contemplated. The singular forms “a,” “and” and “the” include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments “comprising,” “consisting of,” and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.

For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.

Unless otherwise defined herein, scientific, and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. For example, any nomenclature used in connection with, and techniques of cell and tissue culture, molecular biology, genetics and protein and nucleic acid chemistry and hybridization described herein are those that are well known and commonly used in the art. The meaning and scope of the terms should be clear; in the event, however of any latent ambiguity, definitions provided herein take precedent over any dictionary or extrinsic definition. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

As used herein, “nucleic acid” or “nucleic acid sequence” refers to a polymer or oligomer of pyrimidine and/or purine bases, preferably cytosine, thymine, and uracil, and adenine and guanine, respectively (See Albert L. Lehninger, Principles of Biochemistry, at 793-800 (Worth Pub. 1982)). The present technology contemplates any deoxyribonucleotide, ribonucleotide, or peptide nucleic acid component, and any chemical variants thereof, such as methylated, hydroxymethylated, or glycosylated forms of these bases, and the like. The polymers or oligomers may be heterogenous or homogenous in composition and may be isolated from naturally occurring sources or may be artificially or synthetically produced. In addition, the nucleic acids may be DNA or RNA, or a mixture thereof, and may exist permanently or transitionally in single-stranded or double-stranded form, including homoduplex, heteroduplex, and hybrid states. In some embodiments, a nucleic acid or nucleic acid sequence comprises other kinds of nucleic acid structures such as, for instance, a DNA/RNA helix, peptide nucleic acid (PNA), morpholino nucleic acid (see. e.g., Braasch and Corey, Biochemistry. 41(14): 4503-4510 (2002)) and U.S. Pat. No. 5,034,506), locked nucleic acid (LNA; see Wahlestedt et al., Proc. Natl. Acad. Sci. U.S.A., 97: 5633-5638 (2000)), cyclohexenyl nucleic acids (see Wang, J. Am. Chem. Soc., 122: 8595-8602 (2000)), and/or a ribozyme. Hence, the term “nucleic acid” or “nucleic acid sequence” may also encompass a chain comprising non-natural nucleotides, modified nucleotides, and/or non-nucleotide building blocks that can exhibit the same function as natural nucleotides (e.g., “nucleotide analogs”); further, the term “nucleic acid sequence” as used herein refers to an oligonucleotide, nucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin, which may be single or double-stranded, and represent the sense or antisense strand. The terms “nucleic acid,” “polynucleotide,” “nucleotide sequence,” and “oligonucleotide” are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof.

Nucleic acid or amino acid sequence “identity,” as described herein, can be determined by comparing a nucleic acid or amino acid sequence of interest to a reference nucleic acid or amino acid sequence. The percent identity is the number of nucleotides or amino acid residues that are the same (e.g., that are identical) as between the sequence of interest and the reference sequence divided by the length of the longest sequence (e.g., the length of either the sequence of interest or the reference sequence, whichever is longer). A number of mathematical algorithms for obtaining the optimal alignment and calculating identity between two or more sequences are known and incorporated into a number of available software programs. Examples of such programs include CLUSTAL-W, T-Coffee, and ALIGN (for alignment of nucleic acid and amino acid sequences), BLAST programs (e.g., BLAST 2.1, BL2SEQ, and later versions thereof) and FASTA programs (e.g., FASTA3x, FAST™, and SSEARCH) (for sequence alignment and sequence similarity searches). Sequence alignment algorithms also are disclosed in, for example, Altschul et al., J. Molecular Biol., 215(3): 403-410 (1990), Beigert et al., Proc. Natl. Acad. Sci. USA, 106(10): 3770-3775 (2009), Durbin et al., eds., Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids, Cambridge University Press, Cambridge, UK (2009), Soding, Bioinformatics, 21(7): 951-960 (2005), Altschul et al., Nucleic Acids Res., 25(17): 3389-3402 (1997), and Gusfield, Algorithms on Strings, Trees and Sequences, Cambridge University Press, Cambridge UK (1997)).

The term “homology” and “homologous” refers to a degree of identity. There may be partial homology or complete homology. A partially homologous sequence is one that is less than 100% identical to another sequence.

As used herein, the term “hybridization” is used in reference to the pairing of complementary nucleic acids. Hybridization and the strength of hybridization (e.g., the strength of the association between the nucleic acids) is influenced by such factors as the degree of complementary between the nucleic acids, stringency of the conditions involved, and the Tm of the formed hybrid. Hybridization methods involve the annealing of one nucleic acid to another, complementary nucleic acid, e.g., a nucleic acid having a complementary nucleotide sequence. The ability of two polymers of nucleic acid containing complementary sequences to find each other and “anneal” or “hybridize” through base pairing interaction is a well-recognized phenomenon. The initial observations of the “hybridization” process by Marmur and Lane, Proc. Nal. Acad. Sci. USA, 46: 453 (1960) and Doty et al., Proc. Nal. Acad. Sci. USA, 46: 461 (1960), have been followed by the refinement of this process into an essential tool of modem biology. For example, hybridization and washing conditions are now well known and exemplified in Sambrook et al., supra. The conditions of temperature and ionic strength determine the “stringency” of the hybridization.

As used herein, a “double-stranded nucleic acid” may be a portion of a nucleic acid, a region of a longer nucleic acid, or an entire nucleic acid. A “double-stranded nucleic acid” may be, e.g., without limitation, a double-stranded DNA, a double-stranded RNA, a double-stranded DNA/RNA hybrid, etc. A single-stranded nucleic acid having secondary structure (e.g., base-paired secondary structure) and/or higher order structure (e.g., a stem-loop structure) may also be considered a “double-stranded nucleic acid.” For example, triplex structures are considered to be “double-stranded.” In some embodiments, any base-paired nucleic acid is a “double-stranded nucleic acid.”

The term “gene” refers to a DNA sequence that comprises control and coding sequences necessary for the production of an RNA having a non-coding function (e.g., a ribosomal or transfer RNA), a polypeptide, or a precursor of any of the foregoing. The RNA or polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired activity or function is retained. Thus, a “gene” refers to a DNA or RNA, or portion thereof, that encodes a polypeptide or an RNA chain that has functional role to play in an organism. For the purpose of this disclosure, it may be considered that genes include regions that regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences. Accordingly, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites, and locus control regions.

The terms “non-naturally occurring,” “engineered,” and “synthetic” are used interchangeably and indicate the involvement of the hand of man. The terms, when referring to nucleic acid molecules or polypeptides mean that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and as found in nature.

A “vector” or “expression vector” is a replicon, such as plasmid, phage, virus, or cosmid, to which another DNA segment, e.g., an “insert,” may be attached or incorporated so as to bring about the replication of the attached segment in a cell.

A cell has been “genetically modified,” “transformed,” or “transfected” by exogenous DNA, e.g., a recombinant expression vector, when such DNA has been introduced inside the cell. The presence of the exogenous DNA results in permanent or transient genetic change. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. For example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones that comprise a population of daughter cells containing the transforming DNA. A “clone” is a population of cells derived from a single cell or common ancestor by mitosis. A “cell line” is a clone of a primary cell that is capable of stable growth in vitro for many generations.

A “subject” or “patient” may be human or non-human and may include, for example, animal strains or species used as “model systems” for research purposes, such a mouse model as described herein. Likewise, patient may include either adults or juveniles (e.g., children). Moreover, patient may mean any living organism, preferably a mammal (e.g., human or non-human) that may benefit from the administration of compositions contemplated herein. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish, and the like. In one embodiment of the methods and compositions provided herein, the mammal is a human.

The term “contacting” as used herein refers to bring or put in contact, to be in or come into contact. The term “contact” as used herein refers to a state or condition of touching or of immediate or local proximity. Contacting a composition to a target destination, such as, but not limited to, an organ, tissue, cell, or tumor, may occur by any means of administration known to the skilled artisan.

As used herein, the terms “providing,” “administering,” and “introducing,” are used interchangeably herein and refer to the placement of the systems of the disclosure into a cell, organism, or subject by a method or route which results in at least partial localization of the system to a desired site. The systems can be administered by any appropriate route which results in delivery to a desired location in the cell, organism, or subject.

Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the present disclosure. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.

Systems

In bacteria and archaea, CRISPR/Cas systems provide immunity by incorporating fragments of invading phage, virus, and plasmid DNA into CRISPR loci and using corresponding CRISPR RNAs (“crRNAs”) to guide the degradation of homologous sequences. Transcription of a CRISPR locus produces a “pre-crRNA,” which is processed to yield crRNAs containing spacer-repeat fragments that guide effector nuclease complexes to cleave dsDNA sequences complementary to the spacer. Several different types of CRISPR systems are known, (e.g., type I, type II, or type III), and classified based on the Cas protein type and the use of a proto-spacer-adjacent motif (PAM) for selection of proto-spacers in invading DNA.

Although RNA-guided targeting typically leads to endonucleolytic cleavage of the bound substrate, recent studies have uncovered a range of noncanonical pathways in which CRISPR protein-RNA effector complexes have been naturally repurposed for alternative functions. For example, some Type I (Cascade) and Type II (Cas9) systems leverage truncated guide RNAs to achieve potent transcriptional repression without cleavage and other Type I (Cascade) and Type V (Cas12) systems lie inside unusual bacterial Tn7-like transposons and lack nuclease components altogether.

Disclosed herein are systems or kits for nucleic acid modification comprising: a) an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon (CAST) system or one or more nucleic acids encoding the engineered CAST system, wherein the CAST system comprises at least one or all of: i) at least one Cas protein; ii) at least one transposon-associated protein; iii) at least one guide RNA (gRNA) complementary to at least a portion of a target nucleic acid sequence; and b) a donor nucleic acid comprising a cargo nucleic acid sequence flanked by at least one engineered transposon end sequence; and/or c) at least one integration co-factor protein, or a nucleic acid encoding thereof.

In some embodiments, the systems comprise a) an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon (CAST) system or one or more nucleic acids encoding the engineered CAST system, wherein the CAST system comprises at least one or all of: i) at least one Cas protein; ii) at least one transposon-associated protein; iii) at least one guide RNA (gRNA) complementary to at least a portion of a target nucleic acid sequence; and b) a donor nucleic acid comprising a cargo nucleic acid sequence flanked by at least one engineered transposon end sequence.

In some embodiments, the systems comprise a) an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon (CAST) system or one or more nucleic acids encoding the engineered CAST system, wherein the CAST system comprises at least one or all of: i) at least one Cas protein; ii) at least one transposon-associated protein; iii) at least one guide RNA (gRNA) complementary to at least a portion of a target nucleic acid sequence; and b) at least one integration co-factor protein, or a nucleic acid encoding thereof.

In some embodiments, the systems comprise a) an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon (CAST) system or one or more nucleic acids encoding the engineered CAST system, wherein the CAST system comprises at least one or all of: i) at least one Cas protein; ii) at least one transposon-associated protein; iii) at least one guide RNA (gRNA) complementary to at least a portion of a target nucleic acid sequence; b) a donor nucleic acid comprising a cargo nucleic acid sequence flanked by at least one engineered transposon end sequence; and c) at least one integration co-factor protein, or a nucleic acid encoding thereof.

In some embodiments, one or more of the at least one Cas protein are part of a ribonucleoprotein complex with the gRNA.

In some embodiments, the engineered CRISPR-Tn system is derived from Vibrio parahaemolyticus, Aliibrio sp., Pseudoalteromonas sp., Endozoicomonas ascidiicola, Vibrio cholerae, Photobacterium iliopiscarium, Vibrio parahaemolyticus, Pseudoalteromonas sp., Pseudoalteromonas ruthenica, Photobacterium ganghwense, Shewanella sp., Vibrio diazotrophicus, Vibrio sp. 16, Vibrio sp. F12, Vibrio splendidus, Aliivibrio wodanis, and Aliivibrio sp. Pseudoalteromonas sp. includes, but is not limited to, Pseudoalteromonas sp. SG43-3, Pseudoalteromonas sp. P1-13-1a, Pseudoalteromonas arabiensis, Pseudoalteromonas sp. Strain P1-25, Pseudoalteromonas sp. strain S983.

In some embodiments, the engineered transposon system is from a bacteria selected from the group consisting of: Vibrio cholerae strain 4874, Photobacterium iliopiscarium strain NCIMB, Pseudoalteromonas sp. P1-25, Pseudoalteromonas ruthenica strain S3245, Photobacterium ganghwense strain JCM, Shewanella sp. UCD-KL21, Vibrio cholerae strain OYP7G04, Vibrio cholerae strain M1517, Vibrio diazotrophicus strain 60.6F, Vibrio sp. 16, Vibrio sp. F12, Vibrio splendidus strain UCD-SED10, Aliivibrio wodanis 06/09/160, and Parashewanella spongiae strain HJ039. In an exemplary embodiment, the engineered transposon system is derived from Vibrio cholerae Tn6677. In an exemplary embodiment, the engineered transposon system is derived from Pseudoalteromonas Tn7016.

In some embodiments, the system comprises two or more engineered CAST systems. Pairing of orthogonal systems with their orthogonal donor substrates enables tandem insertion of multiple distinct payloads directly adjacent to each other without any risk of repressive effects from target immunity. For example, one, two, three, four, five, or more orthogonal CAST systems may be used to integrate large tandem arrays of payload DNA.

The system may be a cell free system. Also disclosed is a cell comprising the system described herein. In some embodiments, the cell is a prokaryotic cell. In some embodiments, the cell is a eukaryotic cell. In some embodiments, the cell is a mammalian cell (e.g., a cell of a non-human primate or a human cell). Thus, in some embodiments, disclosed herein are systems or kits for nucleic acid integration into a target nucleic acid sequence in a eukaryotic cell (e.g., a mammalian cell, a human cell).

a. Donor Nucleic Acid and Engineered Transposon Sequences

The system may further include a donor nucleic acid to be integrated. The donor nucleic acid may be a part of a bacterial plasmid, bacteriophage, a virus, autonomously replicating extra chromosomal DNA element, linear plasmid, linear DNA, linear covalently closed DNA, mitochondrial or other organellar DNA, chromosomal DNA, and the like.

In some embodiments, the donor nucleic acid comprises a cargo nucleic acid sequence. In some embodiments, the donor nucleic acid comprises a cargo nucleic acid sequence flanked by at least one engineered transposon end sequence. In some embodiments, the donor nucleic acid is flanked on the 5′ and the 3′ end with a transposon end sequence. In some embodiments, the donor nucleic acid comprises a cargo nucleic acid sequence flanked by one native transposon end sequence and one engineered transposon end sequence. In some embodiments, the donor nucleic acid comprises a cargo nucleic acid sequence flanked by two engineered transposon end sequences, a left end sequence 5′ to the cargo nucleic acid sequence, relative to transcription direction, and a right end sequence 3′ to the cargo nucleic acid sequence, relative to transcription direction.

The term “transposon end sequence” refers to any nucleic acid comprising a sequence capable of forming a complex with the transposase enzymes thus designating the nucleic acid between the two ends for rearrangement. Usually, native CRISPR-transposon end sequences contain inverted repeats and may be about 10-150 base pairs long. The engineered transposon end sequences, comprise sequences which have one or more basepair or nucleotide additions, deletions, or substitutions as compared to a native transposon end sequence. The engineered transposon ends sequences may or may not include additional sequences that promote or augment transposition, enhance binding to other protein factors, or allow the sequence to adopt an energetically favorable conformation state for binding.

In some embodiments, the engineered transposon end sequence comprises a sequence having one or more substitutions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) as compared to a native transposon end sequence. In some embodiments, the engineered transposon end sequence comprises a sequence having one or more additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) as compared to a native transposon end sequence. In some embodiments, the engineered transposon end sequence comprises a sequence having one or more deletions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) as compared to a native transposon end sequence. The engineered transposon end sequence may comprise a truncation of the native transposon end sequences. For example, in some embodiments, the transposon end sequence may have an approximate 10, 20, 30, 40, 50, 60, or more base pair (bp) deletion relative to the native CRISPR-transposon end sequence. The deletion may be in the form of a truncation at the distal (in relation to the cargo) end of the transposon end sequences. The deletion may be in the form of a truncation at the proximal (in relation to the cargo) end of the transposon end sequences.

In some embodiments, the at least one engineered transposon end sequence encodes an amino acid linker sequence. The engineered transposon end sequence may comprise a sequence related to the native transposon end sequence but lacking any stop codons. For example, the engineered transposon end sequence may comprise one or more point mutations which alter the encoded amino acids.

In some embodiments, the engineered transposon right end sequence and/or the engineered transposon left end sequence is derived from a Vibrio cholerae Tn6677 native transposon end sequence. In some embodiments, the engineered transposon right end sequence and/or the engineered transposon left end sequence is derived from a Pseudoalteromonas Tn7016 native transposon end sequence.

In some embodiments, the at least one engineered transposon end sequence is fully or partially AT rich. In some embodiments, the entirety of the transposon end sequence is AT rich. In some embodiments, a region of the transposon end sequence distal to the cargo nucleic acid is AT rich. For example, the distal 10 bp, 20 bp, 30 bp, 40 bp, 50 bp, or 60 bp may be AT rich. In some embodiments, a region of the transposon end sequence proximal to the cargo nucleic acid is AT rich. For example, the proximal 10 bp, 20 bp, 30 bp, 40 bp, 50 bp, or 60 bp may be AT rich. In some embodiments, regions outside of specific protein binding sites (e.g., TnsB binding sites) are AT rich.

Nucleic acid sequences containing a high level of A or T bases compared to the level of G or C bases are referred as AT rich or having high AT content. Accordingly, AT rich sequences can have relatively high levels of A bases, T bases or both A and T bases. Nucleic acid sequences having greater than about 52% AT content are AT rich sequences. In some embodiments, a portion of, as described above, or the entire transposon end sequence is greater than 55%, greater than 60%, greater than 65%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 95% or greater than 99% AT content.

In a CAST system, TnsB confers sequence specificity for the transposon ends through recognition of repetitive sequence elements known as TnsB binding sites (TBSs). The at least one engineered transposon end sequence(s) may comprise at least one (e.g., 1, 2, 3, 4, 5, or more) TBSs. In some embodiments, the at least one engineered transposon end sequence comprises two TBSs. In some embodiments, the at least one engineered transposon end sequence comprises three TBSs.

The engineered transposon sequence may comprise native transposase binding sites and/or engineered transposase binding sites which facilitate TnsB binding as the native site. The TBS may comprise any native or engineered sequence that facilitates recognitions by TnsB. In some embodiments, each TBS comprises a sequence individually selected from: CAMCCATAWRDTGATAWYKH (SEQ ID NO: 11), or CMMCBRWAWNNTGAHWWYWN (SEQ ID NO: 12), wherein each M is individually A or C: each W is independently A or T; each R is independently A or G; each D is independently A, G or T; each Y is independently T or C; each K is G or T; B is G, T, or C; and each H is independently A, C or T. In some embodiments, the TBS sequences are selected from those shown in FIGS. 2 & 7.

Each individual TBS may be separated from another TBS by one or more basepairs (bp). For example, any one TBS may be separated from the adjacent TBS by 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more bp. In some embodiments, the transposon end sequence comprises two immediately adjacent TBSs. In some embodiments, the transposon end sequence comprises two TBS separated by one to ten bp. In some embodiments, the transposon end sequence comprises two TBS separated by 30-40 bp.

In some embodiments, the at least one engineered transposon end sequence further comprises a 5 to 8 bp terminal end sequence. A terminal end sequence is any sequence that dictates the transposon boundary. In some embodiments, the terminal end sequence comprises a terminal TG dinucleotide. In some embodiments, the terminal end sequence is immediately adjacent to the distal end of TBS farthest from the cargo nucleic acid sequence. In some embodiments, the terminal end sequence is separated from the distal end of the transposase binding site farthest from the cargo nucleic acid sequence by 1, 2 or 3 basepairs (bp).

In some embodiments, the at least one engineered transposon end sequence is a transposon right end sequence 3 to the cargo nucleic acid sequence, relative to transcription direction. The engineered transposon right end sequence is at least about 50 basepairs (bp). In some embodiments, the engineered transposon right end sequence is at least about 55 bp, 60 bp, 70 bp, 75 bp, or more. In some embodiments, engineered transposon right end sequence is about 50 bp, about 55 bp, about 60 bp, about 65 bp, about 70 bp, about 75 bp, about 80 bp, about 85 bp, about 90 bp, about 95 bp, about 100 bp, about 105 bp, about 110 bp, about 115 bp, about 120 bp, about 125 bp, or more.

In some embodiments, the engineered transposon right end sequence comprises two TBSs. In some embodiments, the engineered transposon right end sequence comprises three TBSs. In some embodiments, the TBSs in the engineered transposon right end sequence are each less than 10 bp from the adjacent TBS. In select embodiments, the TBSs in the engineered transposon right end sequence are immediately adjacent or separated by 1 to 5 bp.

In some embodiments, the engineered transposon right end sequence comprises a sequence of: TGTTGATACAACCATAAAATGATAATTACACCCATAAATTGATAATTATCACACCCA (SEQ ID NO: 1), or a variant sequence having one or more substitutions thereof. In some embodiments, the engineered transposon right end sequence comprises a sequence of:

	(SEQ ID NO: 2)
	TGTgGATACAACCATAAAATGATAATTACACCCATAAATgGATcA
	TTATCACcCCCA;
	(SEQ ID NO: 3)
	TGTgGATACAACCATAAAAcGATAATTACACCCATAAATgGATcA
	TTATCACACCCA;
	(SEQ ID NO: 4)
	TGTgGATcCAACCATAAAATGATAATTACACCCATAAATgGATcA
	TTATCACACCCA;
	(SEQ ID NO: 5)
	TGTTGATACAACCATAAAAgGATtATTACACCCATtAATTGATAA
	TTATCACACCCA;
	(SEQ ID NO: 6)
	TGTTGATACAACCATcAAATGgTAATTACACCCATAAATTGATAA
	TTATCACACCCA;
	(SEQ ID NO: 7)
	TGTTGATACAACCATtAAATGATAATTcCACCCATAAtTTGATAA
	TTATCACACCCA;
	or
	(SEQ ID NO: 8)
	TGTTGATACAACCATtAAATGgTAATTcCACCCAaAtATTGATAA
	TTATCACACCCA.

In some embodiments, the engineered transposon right end sequence comprises a sequence of SEQ ID NOs: 18-844.

In some embodiments, the engineered transposon right end sequence comprises a sequence of: TGTTGATACAACCATAAAATGATAATTACACCCATAAATTGATAATATCACACCCATAAA TTGATATTGCCTCT (SEQ ID NO: 9), or a variant sequence having one or more substitutions thereof. In some embodiments, the engineered transposon right end sequence comprises a sequence of SEQ ID NOs: 845-2690.

In some embodiments, the engineered transposon right end sequence is hyperactive. Hyperactive transposon end sequences are those sequences which result in improved integration activity compared to wildtype, For example, hyperactive transposon end sequences may increase integration activity about 1.1 fold, about 1.2 fold, about 1.3 fold, about 1.4 fold, about 1.5 fold, about 1.6 fold, about 1.7 fold, about 1.8 fold, about 1.9 fold, about 2.0 fold, about 2.1 fold, about 2.2 fold, about 2.3 fold, about 2.5 fold, about 2.6 fold, about 2.7 fold, about 2.8 fold, about 2.9 fold, about 3.0 fold, or more. In some embodiments, the engineered transposon right end sequence comprises a sequence of SEQ ID NOs: 2691-2702. In some embodiments, the engineered transposon right end sequence comprises a sequence of SEQ ID NOs: 2703-3119.

In some embodiments, the at least one engineered transposon end sequence is a transposon left end sequence 5′ to the cargo nucleic acid sequence, relative to transcription direction. In some embodiments, the engineered transposon left end sequence is at least about 105 basepairs (bp). In some embodiments, the engineered transposon left end sequence is at least about 115 basepairs (bp). The engineered transposon left end sequence may be about 105 bp, about 110 bp, about 115 bp, about 120 bp, about 125 bp, about 130 bp, about 135 bp, about 140 bp, about 145 bp, about 150 bp, about 155 bp, about 160 bp, about 165 bp, about 170 bp, about 175 bp, about 180 bp, about 185 bp, about 190 bp, about 195 bp, about 200 bp, or more.

In some embodiments, the engineered transposon left end sequence comprises three transposase TBSs. The distal TBS, in reference to the cargo sequence may be separated from the next closest TBS by at least 10 bp. In some embodiments, the distal TBS is separated from the next closest TBS by about 20 bp to about 40 bp. In select embodiments, the distal TBS is separated from the next closest TBS by about 23-26 bp or about 30-35 bp. In some embodiments, the two proximal TBSs are separated from each other by less than 10 bp. In some embodiments the two proximal TBSs are separated from each other by 5-7 bp.

In some embodiments, the engineered transposon left end sequence further comprises an Integration Host Factor (IHF) binding site (IBS), as described above. In some embodiments, the engineered transposon left end sequence does not include an Integration Host Factor (IHF) binding site (IBS).

In some embodiments, the engineered transposon left end sequence comprises a sequence of: TGTTGATGCAACCATAAAGTGATATTTAATAATTATTTATAATCAGCAACTTAACCACAAA ACAACCATATATTGATATCTCACAAAACAACCATAAGTTGATATTITGTGAAT (SEQ ID NO: 10), or a variant sequence having one or more substitutions thereof. In some embodiments, the engineered transposon left end sequence comprises a sequence of SEQ ID NOs: 3120-4665.

In some embodiments, the engineered transposon left end sequence is hyperactive. In some embodiments, the engineered transposon left end sequence comprises a sequence of SEQ ID NOs: 4666-4673. In some embodiments, the engineered transposon left end sequence comprises a sequence of SEQ ID NOs: 4674-5135.

In some embodiments, the donor nucleic acid comprises a cargo nucleic acid sequence flanked by two engineered transposon end sequences; an engineered transposon right end sequence, as described above, and an engineered transposon left end sequence, as described above.

The cargo nucleic acid comprises a sequence encoding the desired nucleic acid to be inserted into the target nucleic acid.

The cargo nucleic acid may encode any peptide or polypeptide which is desired to be inserted into the target nucleic acid and is not limited by the type or identity of the peptide or polypeptide. For example, if the target site encodes an endogenous protein, the peptide or polypeptide may be so configured to form a fusion protein with the endogenous protein and the amino acid linker encoded by the transposon end sequence.

In some embodiments, the cargo nucleic acid sequence includes a peptide tag. The invention is not limited by the choice of peptide tag. Usually, a peptide tag is an amino acid sequence which facilitates the identification, detection, measurement, purification and/or isolation of the protein to which it is linked or fused. Peptide tags are usually relatively short compared to the protein fused to the peptide tag. As an example, peptide tags, in some embodiments, have amino acids of 4 or more lengths, such as 5, 6, 7, 8, 9, 10, 15, 20, or 25. Peptide tabs include, but are not limited to: HA (blood cell agglutinin), c-myc, simple herpesvirus glycoprotein D (gD), T7, GST, MBP, Strep tags, His tags, Myc tags, TAP tags, and FLAG tags. For example, if the target site encodes an endogenous protein, the cargo and peptide tag may be so configured to tag or label an endogenous protein and the amino acid linker encoded by the transposon end sequence.

In some embodiments, the cargo nucleic acid encodes a polypeptide. The invention is not limited by the choice of polypeptide. In select embodiments, the polypeptide comprises a fluorescent protein. “Fluorescent protein” refers to any protein capable of fluorescence when excited with appropriate electromagnetic radiation. This includes fluorescent proteins whose amino acid sequences are either natural or engineered.

The donor nucleic acid, and by extension the cargo nucleic acid, may of any suitable length, including, for example, about 50-100 bp (base pairs), about 100-1000 bp, at least or about 10 bp, at least or about 20 bp, at least or about 25 bp, at least or about 30 bp, at least or about 35 bp, at least or about 40 bp, at least or about 45 bp, at least or about 50 bp, at least or about 55 bp, at least or about 60 bp, at least or about 65 bp, at least or about 70 bp, at least or about 75 bp, at least or about 80 bp, at least or about 85 bp, at least or about 90 bp, at least or about 95 bp, at least or about 100 bp, at least or about 200 bp, at least or about 300 bp, at least or about 400 bp, at least or about 500 bp, at least or about 600 bp, at least or about 700 bp, at least or about 800 bp, at least or about 900 bp, at least or about 1 kb (kilobase pair), at least or about 2 kb, at least or about 3 kb, at least or about 4 kb, at least or about 5 kb, at least or about 6 kb, at least or about 7 kb, at least or about 8 kb, at least or about 9 kb, at least or about 10 kb, or greater.

b. Integration Co-Factor Protein

The present systems may further include at least one integration co-factor protein. The at least one integration co-factor protein may comprise Integration Host Factor (IHF), Factor for Inversion Stimulation (Fis), variants or derivatives thereof, or a combination thereof.

In some embodiments, the at least one integration co-factor protein comprises Integration Host Factor (IHF). In one embodiment, IHFα (also referred to as IHFα) and IHFβ (also referred to as IHFb) are provided as separate polypeptides. Alternatively, the IHFα and IHFβ subunits can be fused together to be expressed as a single polypeptide (See, Corona et al., Nucleic Acids Research 31, 5140-5148 (2003)). In certain embodiments, the single chain IHF (scIHF) is appended with various short sequences, such as NLS tags, on either the N-terminus or the C-terminus, or both termini, or encoded internally.

The at least one integration co-factor protein is not limited from which organism it is derived. In some embodiments, the IHF sequence is derived from the E. coli genome. In other embodiments, the IHF sequence is derived from the cognate strain from which the CRISPR-associated sequence is derived. For example, the IHFα and IHFβ sequences from Vibrio cholerae HE-45 can be used alongside RNA-guided DNA integration machinery derived from Tn6677, while IHFα and IHFβ sequences from Psuedoalteromonas sp. 5983 can be used alongside RNA-guided DNA integration machinery derived from Tn7016. In some embodiments, the at least one integration co-factor protein comprises an amino acid sequence of any of SEQ ID NOs: 5136-5152, See Table 3.

In some embodiments, the at least one integration factor protein sequences are fused to a localization agent (e.g., proteins or domains thereof to promote localization to the transposon ends). In one such embodiment, the at least one integration co-factor protein sequence is fused to a nuclease deficient Cas9 (dCas9). Then, using a sgRNA for Cas9 that targets nearby the at least one integration co-factor protein binding sequence within the transposon end, the local concentration of the at least one integration co-factor protein is increased to promote correct binding and bending of the transposon end. In other embodiments, other DNA-binding proteins are used to promote the localization of the at least one integration co-factor protein to the transposon, such as, but not limited to, TALE proteins and zinc-finger domain proteins.

The integration co-factor protein may be fused to protein components of Type I-F CRISPR-associated transposon systems to tether its location proximally to integration co-factor protein binding sites in the transposon ends. In some embodiments, the at least one integration co-factor protein is fused internally to a fusion construct of transposase proteins TnsA and TnsB, as described elsewhere herein. In some embodiments, the at least one integration co-factor protein is fused within the linker of the TnsA-TnsB fusion protein.

In some embodiments, the at least one integration co-factor protein is purified and pre-complexed with the donor DNA to ensure proper protein-DNA interactions. In such embodiments, the pre-formed complexes may be electroporated into cells or delivered via other means.

c. CAST System

CRISPR-Cas systems are currently grouped into two classes (1-2), six types (I-VI) and dozens of subtypes, depending on the signature and accessory genes that accompany the CRISPR array. The engineered CAST system herein may be derived from a Class 1 CRISPR-Cas system or a Class 2 CRISPR-Cas system.

Type I CRISPR-Cas systems encode a multi-subunit protein-RNA complex called Cascade, which utilizes a crRNA (or guide RNA) to target double-stranded DNA during an immune response. Cascade itself has no nuclease activity, and degradation of targeted DNA is instead mediated by a trans-acting nuclease known as Cas3.

The CAST system may be derived from a Type I CRISPR-Cas system (such as subtypes I-B and I-F, including I-F variants). In some embodiments, the engineered CAST is a Type I-F system. In some embodiments, the engineered CAST system is a Type I-F3 system.

In some embodiments, the engineered CAST system comprises Cas5, Cas6, Cas7, Cas8, or any combination thereof. In some embodiments, the engineered CAST system comprises Cas8-Cas5 fusion protein.

A CAST system of the present invention may comprise one or more transposon-associated proteins (e.g., transposases or other components of a transposon). The transposon-associated proteins may facilitate recognition or cleavage of the target nucleic acid and subsequent insertion of the donor nucleic acid into the target nucleic acid.

In some embodiments, the transposon-associated proteins are derived from a Tn7 or Tn7-like transposon. Tn7 and Tn7-like transposons may be categorized based on the presence of the hallmark DDE-like transposase gene, tnsB (also referred to as tniA), the presence of a gene encoding a protein within the AAA+ATPase family, tnsC (also referred to as tniB), one or more targeting factors that define integration sites (which may include a protein within the tniQ family, also referred to as tnsD, but sometimes includes other distinct targeting factors), and inverted repeat transposon ends that typically comprise multiple binding sites thought to be specifically recognized by the TnsB transposase protein. In Tn7, the targeting factors, or “target selectors,” comprise the genes tnsD and insE. Based on biochemical and genetics studies, it is known that TnsD binds a conserved attachment site in the 3′ end of the glmS gene, directing downstream integration, whereas TnsE binds the lagging strand replication fork and directs sequence-non-specific integration primarily into replicating/mobile plasmids.

The most well-studied member of this family of transposons is Tn7, hence why the broader family of transposons may be referred to as Tn7-like. “Tn7-like” term does not imply any particular evolutionary relationship between Tn7 and related transposons; in some cases, a Tn7-like transposon will be even more basal in the phylogenetic tree and thus Tn7 can be considered as having evolved from, or derived from, this related Tn7-like transposon.

Whereas Tn7 comprises tnsD and tnsE target selectors, related transposons comprise other genes for targeting. For example, Tn5090/Tn5053 encode a member of the tniQ family (a homolog of E. coli tnsD) as well as a resolvase gene tniR; Tn6230 encodes the protein TnsF; and Tn6022 encodes two uncharacterized open reading frames orf2 and orf3; Tn6677 and related transposons encode variant Type I-F and Type I-B CRISPR-Cas systems that work together with TniQ for RNA-guided mobilization; and other transposons encode Type V-U5 CRISPR-Cas systems that work together with TniQ for random and RNA-guided mobilization. Any of the above transposon systems are compatible with the systems and methods described herein.

In some embodiments, the one or more transposon-associated proteins comprise TnsA, TnsB, TnsC, or a combination thereof. In some embodiments, the one or more transposon-associated proteins comprise TnsB and TnsC. In some embodiments, the one or more transposon-associated proteins comprise TnsA, TnsB, and TnsC.

In some embodiments, the at least one transposon protein comprises a TnsA-TnsB fusion protein. TnsA and TnsB can be fused in any orientation: N-terminus to C-terminus: C-terminus to N-terminus; N-terminus to N-terminus; or C-terminus to C-terminus, respectively. Preferably the C-terminus of TnsA is fused to the N-terminus of TnsB.

In some embodiments, the TnsA-TnsB fusion may be fused using an amino acid linker peptide of various lengths to provide greater physical separation and allow more spatial mobility between the fused portions. The linker may comprise any amino acids and may be of any length. In some embodiments, the linker may be less than about 50 (e.g., 40, 30, 20, 10, or 5) amino acid residues.

In some embodiments, the linker is a flexible linker, such that TnsA and TnsB can have orientation freedom in relationship to each other. For example, a flexible linker may include amino acids having relatively small side chains, and which may be hydrophilic. Without limitation, the flexible linker may contain a stretch of glycine and/or serine residues. In some embodiments, the linker comprises at least one glycine-rich region. For example, the glycine-rich region may comprise a sequence comprising [GS]n, wherein n is an integer between 1 and 10.

In some embodiments, the linker further comprises a nuclear localization sequence (NLS). The NLS may be embedded within a linker sequence, such that it is flanked by additional amino acids. In some embodiments, the NLS is flanked on each end by at least a portion of a flexible linker. In some embodiments, the NLS is flanked on each end by a glycine rich region of the linker. Suitable nuclear localization sequences for use with the disclosed system are described further below and are applicable to use with the TnsA-TnsB fusion protein.

In some embodiments, the CAST system comprises TnsA, TnsB, TnsC, TnsD and TniQ. In some embodiments, the CAST system comprises Cas5, Cas6, Cas7, Cas8, TnsA, TnsB, TnsC, and at least one or both of TnsD or TniQ. In certain embodiments, the CAST system comprises TnsD. In certain embodiments, the CAST system comprises TniQ. In certain embodiments, the CAST system comprises TnsD and TniQ.

In some embodiments, any combination of the at least one Cas protein and the at least one transposon associated protein may be expressed as a single fusion protein.

Sequences of exemplary Cas proteins and transposon-associated proteins can also be found in International Patent Applications WO2020181264 and PCT/US22/32541, incorporated herein by reference. However, the invention is not limited to the disclosed or referenced exemplary sequences. Indeed, genetic sequences can vary between different strains, and this natural scope of allelic variation is included within the scope of the invention.

In other embodiments, any of the proteins described or referenced herein may comprise a sequence corresponding to, or substantially corresponding to, the wild-type version of the protein. For example, the sequence may substantially correspond to the wild-type protein sequence except for changes made for facile cloning or removal of known restriction sites. Thus, protein products from potential alternative start codons compared to the predicted nucleic acid sequences in this document are therefore not excluded.

Any of the proteins described or referenced herein may comprise one or more amino acid substitutions as compared to the recited sequences. An amino acid “replacement” or “substitution” refers to the replacement of one amino acid at a given position or residue by another amino acid at the same position or residue within a polypeptide sequence. Amino acids are broadly grouped as “aromatic” or “aliphatic.” An aromatic amino acid includes an aromatic ring. Examples of “aromatic” amino acids include histidine (H or His), phenylalanine (F or Phe), tyrosine (Y or Tyr), and tryptophan (W or Trp). Non-aromatic amino acids are broadly grouped as “aliphatic.” Examples of “aliphatic” amino acids include glycine (G or Gly), alanine (A or Ala), valine (V or Val), leucine (L or Leu), isoleucine (I or He), methionine (M or Met), serine (S or Ser), threonine (T or Thr), cysteine (C or Cys), proline (P or Pro), glutamic acid (E or Glu), aspartic acid (A or Asp), asparagine (N or Asn), glutamine (Q or Gin), lysine (K or Lys), and arginine (R or Arg).

The amino acid replacement or substitution can be conservative, semi-conservative, or non-conservative. The phrase “conservative amino acid substitution” or “conservative mutation” refers to the replacement of one amino acid by another amino acid with a common property. A functional way to define common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz and Schirmer, Principles of Protein Structure, Springer-Verlag, New York (1979)). According to such analyses, groups of amino acids may be defined where amino acids within a group exchange preferentially with each other, and therefore resemble each other most in their impact on the overall protein structure (Schulz and Schirmer, supra). Examples of conservative amino acid substitutions include substitutions of amino acids within the sub-groups described above, for example, lysine for arginine and vice versa such that a positive charge may be maintained, glutamic acid for aspartic acid and vice versa such that a negative charge may be maintained, serine for threonine such that a free —OH can be maintained, and glutamine for asparagine such that a free —NH₂ can be maintained. “Semi-conservative mutations” include amino acid substitutions of amino acids within the same groups listed above, but not within the same sub-group. For example, the substitution of aspartic acid for asparagine, or asparagine for lysine, involves amino acids within the same group, but different sub-groups. “Non-conservative mutations” involve amino acid substitutions between different groups, for example, lysine for tryptophan, or phenylalanine for serine, etc.

In some embodiments, the engineered CAST systems further comprise a gRNA complementary to at least a portion of the target nucleic acid sequence, or a nucleic acid encoding the at least one gRNA.

The gRNA may be a crRNA, crRNA/tracrRNA (or single guide RNA, sgRNA). The terms “gRNA,” “guide RNA,” “crRNA,” and “CRISPR guide sequence” may be used interchangeably throughout and refer to a nucleic acid comprising a sequence that determines the binding specificity of the CAST system. A gRNA hybridizes to (complementary to, partially or completely) a target nucleic acid sequence (e.g., the genome in a host cell). In some embodiments, the at least one gRNA is encoded in a CRISPR RNA (crRNA) array.

The system may further comprise a target nucleic acid. In some embodiments, target nucleic acid sequence comprises a human sequence.

gRNAs or sgRNA(s) used in the present disclosure can be between about 5 and 100 nucleotides long, or longer (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59 60, 61, 62, 63, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 92, 93, 94, 95, 96, 97, 98, 99, or 100 nucleotides in length, or longer). In some embodiments, the gRNA sequence that hybridizes to the target nucleic acid is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.

To facilitate gRNA design, many computational tools have been developed (See Prykhozhij et al. (PLoS ONE, 10(3): (2015)); Zhu et al. (PLoS ONE, 9(9) (2014)); Xiao et al. (Bioinformatics. January 21 (2014)); Heigwer et al. (Nat Methods, 11(2): 122-123 (2014)). Methods and tools for guide RNA design are discussed by Zhu (Frontiers in Biology, 10 (4) pp 289-296 (2015)), which is incorporated by reference herein. Additionally, there are many publicly available software tools that can be used to facilitate the design of sgRNA(s); including but not limited to, Genscript Interactive CRISPR gRNA Design Tool, W U-CRISPR, and Broad Institute GPP sgRNA Designer. There are also publicly available pre-designed gRNA sequences to target many genes and locations within the genomes of many species (human, mouse, rat, zebrafish, C. elegans), including but not limited to, IDT DNA Predesigned Alt-R CRISPR-Cas9 guide RNAs, Addgene Validated gRNA Target Sequences, and GenScript Genome-wide gRNA databases.

In addition to a sequence that binds to a target nucleic acid, in some embodiments, the gRNA may also comprise a scaffold sequence (e.g., tracrRNA). In some embodiments, such a chimeric gRNA may be referred to as a single guide RNA (sgRNA). Exemplary scaffold sequences will be evident to one of skill in the art and can be found, for example, in Jinek, et al. Science (2012) 337(6096):816-821, and Ran, et al. Nature Protocols (2013) 8:2281-2308, incorporated herein by reference in their entireties.

In some embodiments, the gRNA sequence does not comprise a scaffold sequence and a scaffold sequence is expressed as a separate transcript. In such embodiments, the gRNA sequence further comprises an additional sequence that is complementary to a portion of the scaffold sequence and functions to bind (hybridize) the scaffold sequence.

As described elsewhere herein the protein and gRNA components of the system may be expressed and transcribed from the nucleic acids using any promoter or regulatory sequences known in the art. In some embodiments, the gRNA is transcribed under control of an RNA Polymerase II promoter. In some embodiments, the gRNA is transcribed under control of an RNA Polymerase III promoter.

In some embodiments, the gRNA sequence is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or at least 100% complementary to a target nucleic acid. In some embodiments, the gRNA sequence is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or at least 100% complementary to the 3′ end of the target nucleic acid (e.g., the last 5, 6, 7, 8, 9, or 10 nucleotides of the 3′ end of the target nucleic acid).

The gRNA may be a non-naturally occurring gRNA.

The system may further comprise a target nucleic acid having a target nucleic acid sequence. The target nucleic acid sequence may be any sequence of interest which facilitates modification. In some embodiments, the target nucleic acid sequence may comprise regions and sequence motifs which promote, influence, or facilitate TnsB strand transfer for integration of the donor nucleic acid.

The target nucleic acid sequence comprises both the site of gRNA binding and recognition but also the site of integration. Accordingly, the target nucleic acid sequence comprises the target-site duplication (TSD) region which upon insertion generates identical sequences on both sides of the insert. The TSD regions can be of variable length, usually between about 3 bp and about 8 bp, but sometimes longer. In some embodiments, the TSD region is 5 bp. In some embodiments, the TSD region comprises a YWR motif within the central three nucleotides of the target-site duplication (TSD). In some embodiments, the TSD region comprises a 5′-CWG-3′ motif.

The site of integration may be influenced by TSD motif as well as sequences upstream and/or downstream of the TSD region. In some embodiments, the nucleotide 3-bp upstream of the TSD is A, G, or T. In some embodiments, the nucleotide 3 bp downstream of the TSD is T, A, or C. Overall, C and G are less preferred for nucleotides 3 bp upstream and 3 bp downstream from the TSD.

In some embodiments, gRNAs may be selected for integration at defined and desired distances, ranging from ˜47-52 bp, or integration properties (e.g., homogenous vs. heterogeneous integration site) based on the target nucleic acid sequence, specifically the TSD region and the nucleotides 3 bp upstream and 3 bp downstream from the TSD. For example, the 3 end of the gRNA may be ˜47-52-bp upstream from the desired site of integration.

The target nucleic acid may be flanked by a protospacer adjacent motif (PAM). A PAM site is a nucleotide sequence in proximity to a target sequence. For example, PAM may be a DNA sequence immediately following the DNA sequence targeted by the CRISPR-Tn system.

The target sequence may or may not be flanked by a protospacer adjacent motif (PAM) sequence. In certain embodiments, a nucleic acid-guided nuclease can only cleave a target sequence if an appropriate PAM is present, see, for example Doudna et al., Science, 2014, 346(6213): 1258096, incorporated herein by reference. A PAM can be 5′ or 3′ of a target sequence. A PAM can be upstream or downstream of a target sequence. In one embodiment, the target sequence is immediately flanked on the 3′ end by a PAM sequence. A PAM can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotides in length. In certain embodiments, a PAM is between 2-6 nucleotides in length. The target sequence may or may not be located adjacent to a PAM sequence (e.g., PAM sequence located immediately 3′ of the target sequence) (e.g., for Type I CRISPR/Cas systems). In some embodiments, e.g., Type I systems, the PAM is on the alternate side of the protospacer (the 5′ end). Makarova et al. describes the nomenclature for all the classes, types, and subtypes of CRISPR systems (Nature Reviews Microbiology 13:722-736 (2015)). Guide structures and PAMs are described in by R. Barrangou (Genome Biol. 16:247 (2015)).

Non-limiting examples of the PAM sequences include: CC, CA, AG, GT, TA, AC, CA, GC, CG, GG, CT, TG, GA, AGG, TGG, T-rich PAMs (such as TTT, TTG, TITC, etc.), NGG, NGA, NAG, NGGNG and NNAGAAW, NNNNGATT, NAAR (R=A or G), NNGRR (R=A or G), NNAGAA, and NAAAAC, where N is any nucleotide. In some embodiments, the PAM may comprise a sequence of CN, in which N is any nucleotide. In select embodiments, the PAM may comprise a sequence of CC.

“Complementarity” refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types. A percent complementarity indicates the percentage of residues in a nucleic acid molecule, which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence. Full complementarity is not necessarily required, provided there is sufficient complementarity to cause hybridization. There may be mismatches distal from the PAM.

In some embodiments, when the system comprises TnsA, TnsB, TnsC, TnsD and TniQ binding to the target nucleic acid may be mediated through a TnsD binding site within the target nucleic acid sequence. Thus, the recognition of the target nucleic acid utilizing the systems described herein may proceed in a gRNA-dependent and/or -independent manner.

d. Nuclear Localization Sequence

In the systems disclosed herein, one or more of the at least one Cas protein, the at least one transposon-associated protein, or the integration co-factor protein may comprise a nuclear localization signal (NLS). The nuclear localization sequence may be appended to the one or more of the at least one Cas protein, the at least one transposon-associated protein and the integration co-factor protein at a N-terminus, a C-terminus, embedded in the protein (e.g., inserted internally within the open reading frame (ORF)), or a combination thereof.

In some embodiments, one or more of the at least one Cas protein, the at least one transposon-associated protein, and integration co-factor protein comprises two or more NLSs. The two or more NLSs may be in tandem, separated by a linker, at either end terminus of the protein, or embedded in the protein (e.g., inserted internally within the ORF instead).

The nuclear localization sequence may comprise any amino acid sequence known in the art to functionally tag or direct a protein for import into a cell's nucleus (e.g., for nuclear transport). Usually, a nuclear localization sequence comprises one or more positively charged amino acids, such as lysine and arginine.

In some embodiments, the NLS is a monopartite sequence. A monopartite NLS comprises a single cluster of positively charged or basic amino acids. In some embodiments, the monopartite NLS comprises a sequence of K-K/R-X-K/R, wherein X can be any amino acid. Exemplary monopartite NLS sequences include those from the SV40 large T-antigen, c-Myc, and TUS-proteins.

In some embodiments, the NLS is a bipartite sequence. Bipartite NLSs comprise two clusters of basic amino acids, separated by a spacer of about 9-12 amino acids. Exemplary bipartite NLSs include the NLS of nucleoplasmin, KR[PAATKKAGQA]KKKK (SEQ ID NO: 15), and the NLS of EGL-13, MSRRRKANPTKLSENAKKLAKEVEN (SEQ ID NO: 16). In some embodiments, the NLS comprises a bipartite SV40 NLS. In certain embodiments, the NLS comprises an amino acid sequence having at least 70% similarity to KRTADGSEFESPKKKRKV (SEQ ID NO: 17). In select embodiments, the NLS consists of an amino acid sequence of KRTADGSEFESPKKKRKV (SEQ ID NO: 17).

The protein components of the disclosed system (e.g., the Cas proteins, the transposon-associated proteins, or the integration co-factor protein) may further comprise an epitope tag (e.g., 3×FLAG tag, an HA tag, a Myc tag, and the like). In some embodiments, the epitope tag may be adjacent, either upstream or downstream, to a nuclear localization sequence. The epitope tags may be at the N-terminus, a C-terminus, or a combination thereof of the corresponding protein.

e. Nucleic Acids

The one or more nucleic acids encoding the engineered CAST system or the nucleic acid encoding the integration co-factor protein may be any nucleic acid including DNA, RNA, or combinations thereof. In some embodiments, nucleic acids comprise one or more messenger RNAs, one or more vectors, or any combination thereof.

The at least one Cas protein, the at least one transposon-associated protein, the at least one integration co-factor protein, the at least one gRNA, and the donor nucleic acid may be on the same or different nucleic acids (e.g., vector(s)). In some embodiments, the at least one Cas protein, the at least one transposon associated protein, and the at least one integration co-factor protein are encoded by different nucleic acids. In some embodiments, the at least one Cas protein and the at least one transposon associated protein encoded by a single nucleic acid. In some embodiments, the at least one Cas protein, the at least one transposon associated protein, and the at least one integration co-factor protein are encoded by a single nucleic acid. In some embodiments, the at least one gRNA is encoded by a nucleic acid different from the nucleic acid(s) encoding the at least one Cas protein, the at least one transposon associated protein, and the at least one integration co-factor protein. In some embodiments, the at least one gRNA is encoded by a nucleic acid also encoding the at least one Cas protein, the at least one transposon associated protein, the at least one integration co-factor protein, or a combination thereof. In some embodiments, the nucleic acid encoding the at least one Cas protein, at least one transposon associated protein, the at least one integration co-factor protein, the at least one gRNA, or any combination thereof further comprises the donor nucleic acid.

In select embodiments, a single nucleic acid encodes the gRNA and at least one Cas protein. The gRNA may be encoded anywhere in the nucleic acid encoding the at least one Cas protein. In some embodiments, the gRNA is encoded in the 3′ UTR of the Cas protein-coding gene.

The one or more nucleic acids encoding the protein components may further comprise, in the case of RNA, or encode, as in the case of DNA, a sequence capable of forming a triple helix adjacent to the sequence encoding the protein component. In some embodiments, the sequence capable of forming a triple helix is downstream of the protein coding sequence. In some embodiments, the sequence capable of forming a triple helix is in a 3′ untranslated region of the protein coding sequence.

A triple helix is formed after the binding of a third strand to the major groove of a duplex nucleic acid through Hoogsteen base pairing (e.g., hydrogen bonds) while maintaining the duplex structure of two strands making the major groove. Pyrimidine-rich and purine-rich sequences (e.g., two pyrimidine tracts and one purine tract or vice versa) can form stable triplex structures as a consequence of the formation of triplets (e.g., A-U-A and C-G-C).

In some embodiments, the triple helix forming sequence comprises two uracil-rich tracts and an adenosine-rich tract, each separated by linker or loop regions. As used herein, the term “A-rich tract” refers to a strand of consecutive nucleosides in which at least 80% of the consecutive nucleosides are adenosine. Similarly, the term “U-rich motif” refers to a strand of consecutive nucleosides in which at least 80% of the consecutive nucleosides are uridine.

In some embodiments, the triple helix sequence is derived from the 3′ terminal triple helix sequences of triple helix terminators from a long non-coding RNAs (lncRNAs), e.g., metastasis-associated lung adenocarcinoma transcript 1 (MALAT1).

One or more of the protein components of the system (e.g., the at least one Cas protein, the at least one transposon associated protein, the at least one integration co-factor protein) may comprise a sequence of an internal ribosome entry site (IRES) or a ribosome skipping peptide. This is particularly advantageous when a single nucleic acid or vector is used to express multiple components of the system.

The ribosome skipping peptide may comprise a 2A family peptide. 2A peptides are short (˜18-25 aa) peptides derived from viruses. There are four commonly used 2A peptides, P2A, T2A, E2A and F2A, that are derived from four different viruses. Any known 2A peptide sequence is suitable for use in the disclosed system.

In certain embodiments, engineering the system for use in eukaryotic cells may involve codon-optimization. It will be appreciated that changing native codons to those most frequently used in mammals allows for maximum expression of the system proteins in mammalian cells (e.g., human cells). Such modified nucleic acid sequences are commonly described in the art as “codon-optimized,” or as utilizing “mammalian-preferred” or “human-preferred” codons. In some embodiments, the nucleic acid sequence is considered codon-optimized if at least about 60% (e.g., 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 98%) of the codons encoded therein are mammalian preferred codons. Furthermore, in some embodiments, engineering the CRISPR-Cas system involves incorporating elements of the native CRISPR array into the disclosed system.

The present disclosure also provides for DNA segments encoding the proteins and nucleic acids disclosed herein, vectors containing these segments and cells containing the vectors. The vectors may be used to propagate the segment in an appropriate cell and/or to allow expression from the segment (e.g., an expression vector). The person of ordinary skill in the art would be aware of the various vectors available for propagation and expression of a nucleic acid sequence.

The present disclosure further provides engineered, non-naturally occurring vectors and vector systems, which can encode one or more or all of the components of the present system. The vector(s) can be introduced into a cell that is capable of expressing the polypeptide encoded thereby, including any suitable prokaryotic or eukaryotic cell.

The vectors of the present disclosure may be delivered to a eukaryotic cell in a subject. Modification of the eukaryotic cells via the present system can take place in a cell culture, where the method comprises isolating the eukaryotic cell from a subject prior to the modification. In some embodiments, the method further comprises returning said eukaryotic cell and/or cells derived therefrom to the subject.

Viral and non-viral based gene transfer methods can be used to introduce nucleic acids encoding components of the present system into cells, tissues, or a subject. Such methods can be used to administer nucleic acids encoding components of the present system to cells in culture, or in a host organism. Non-viral vector delivery systems include DNA plasmids, cosmids, RNA (e.g., a transcript of a vector described herein), a nucleic acid, and a nucleic acid complexed with a delivery vehicle. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. Viral vectors include, for example, retroviral, lentiviral, adenoviral, adeno-associated and herpes simplex viral vectors.

In certain embodiments, plasmids that are non-replicative, or plasmids that can be cured by high temperature may be used, such that any or all of the necessary components of the system may be removed from the cells under certain conditions. For example, this may allow for DNA integration by transforming bacteria of interest, but then being left with engineered strains that have no memory of the plasmids or vectors used for the integration.

Drug selection strategies may be adopted for positively selecting for cells that underwent DNA integration. A donor nucleic acid may contain one or more drug-selectable markers within the cargo. Then presuming that the original donor plasmid is removed, drug selection may be used to enrich for integrated clones. Colony screenings may be used to isolate clonal events.

A variety of viral constructs may be used to deliver the present system (such as one or more Cas proteins, Tns proteins, integration co-factor protein(s), gRNA(s), donor DNA, etc.) to the targeted cells and/or a subject. Nonlimiting examples of such recombinant viruses include recombinant adeno-associated virus (AAV), recombinant adenoviruses, recombinant lentiviruses, recombinant retroviruses, recombinant herpes simplex viruses, recombinant poxviruses, phages, etc. The present disclosure provides vectors capable of integration in the host genome, such as retrovirus or lentivirus. See, e.g., Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989; Kay, M. A., et al., 2001 Nat. Medic. 7(1):33-40; and Walther W. and Stein U., 2000 Drugs, 60(2): 249-71, incorporated herein by reference.

In one embodiment, a DNA segment encoding the present protein(s) is contained in a plasmid vector that allows expression of the protein(s) and subsequent isolation and purification of the protein produced by the recombinant vector. Accordingly, the proteins disclosed herein can be purified following expression, obtained by chemical synthesis, or obtained by recombinant methods.

To construct cells that express the present system, expression vectors for stable or transient expression of the present system may be constructed via conventional methods as described herein and introduced into host cells. For example, nucleic acids encoding the components of the present system may be cloned into a suitable expression vector, such as a plasmid or a viral vector in operable linkage to a suitable promoter. The selection of expression vectors/plasmids/viral vectors should be suitable for integration and replication in eukaryotic cells.

In certain embodiments, vectors of the present disclosure can drive the expression of one or more sequences in prokaryotic cells. Promoters that may be used include T7 RNA polymerase promoters, constitutive E. coli promoters, and promoters that could be broadly recognized by transcriptional machinery in a wide range of bacterial organisms. The system may be used with various bacterial hosts.

In certain embodiments, vectors of the present disclosure can drive the expression of one or more sequences in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed. Nature (1987) 329:840, incorporated herein by reference) and pMT2PC (Kaufman, et al., EMBO J. (1987) 6:187, incorporated herein by reference). When used in mammalian cells, the expression vector's control functions are typically provided by one or more regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd eds., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989, incorporated herein by reference.

Vectors of the present disclosure can comprise any of a number of promoters known to the art, wherein the promoter is constitutive, regulatable or inducible, cell type specific, tissue-specific, or species specific. In addition to the sequence sufficient to direct transcription, a promoter sequence of the invention can also include sequences of other regulatory elements that are involved in modulating transcription (e.g., enhancers, Kozak sequences and introns). Many promoter/regulatory sequences useful for driving constitutive expression of a gene are available in the art and include, but are not limited to, for example, CMV (cytomegalovirus promoter), EF1a (human elongation factor 1 alpha promoter), SV40 (simian vacuolating virus 40 promoter), PGK (mammalian phosphoglycerate kinase promoter), Ubc (human ubiquitin C promoter), human beta-actin promoter, rodent beta-actin promoter, CBh (chicken beta-actin promoter), CAG (hybrid promoter contains CMV enhancer, chicken beta actin promoter, and rabbit beta-globin splice acceptor), TRE (Tetracycline response element promoter), H1 (human polymerase III RNA promoter), U6 (human U6 small nuclear promoter), and the like. Additional promoters that can be used for expression of the components of the present system, include, without limitation, cytomegalovirus (CMV) intermediate early promoter, a viral LTR such as the Rous sarcoma virus LTR, HIV-LTR, HTLV-1 LTR, Maloney murine leukemia virus (MMLV) LTR, myeoloproliferative sarcoma virus (MPSV) LTR, spleen focus-forming virus (SFFV) LTR, the simian virus 40 (SV40) early promoter, herpes simplex tk virus promoter, elongation factor 1-alpha (EF1-α) promoter with or without the EF1-α intron. Additional promoters include any constitutively active promoter. Alternatively, any regulatable promoter may be used, such that its expression can be modulated within a cell.

Moreover, inducible and tissue specific expression can be accomplished by placing the nucleic acid encoding such a molecule under the control of an inducible or tissue specific promoter/regulatory sequence. Examples of tissue specific or inducible promoter/regulatory sequences which are useful for this purpose include, but are not limited to, the rhodopsin promoter, the MMTV LTR inducible promoter, the SV40 late enhancer/promoter, synapsin 1 promoter, ET hepatocyte promoter, GS glutamine synthase promoter and many others. Various commercially available ubiquitous as well as tissue-specific promoters and tumor-specific are available, for example from InvivoGen. In addition, promoters which are well known in the art can be induced in response to inducing agents such as metals, glucocorticoids, tetracycline, hormones, and the like, are also contemplated for use with the invention. Thus, it will be appreciated that the present disclosure includes the use of any promoter/regulatory sequence known in the art that is capable of driving expression of the desired protein operably linked thereto.

The vectors of the present disclosure may direct expression of the nucleic acid in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Such regulatory elements include promoters that may be tissue specific or cell specific. The term “tissue specific” as it applies to a promoter refers to a promoter that is capable of directing selective expression of a nucleotide sequence of interest to a specific type of tissue (e.g., seeds) in the relative absence of expression of the same nucleotide sequence of interest in a different type of tissue. The term “cell type specific” as applied to a promoter refers to a promoter that is capable of directing selective expression of a nucleotide sequence of interest in a specific type of cell in the relative absence of expression of the same nucleotide sequence of interest in a different type of cell within the same tissue. The term “cell type specific” when applied to a promoter also means a promoter capable of promoting selective expression of a nucleotide sequence of interest in a region within a single tissue. Cell type specificity of a promoter may be assessed using methods well known in the art, e.g., immunohistochemical staining.

Additionally, the vector may contain, for example, some or all of the following: a selectable marker gene, such as the neomycin gene for selection of stable or transient transfectants in host cells; enhancer/promoter sequences from the immediate early gene of human CMV for high levels of transcription; transcription termination and RNA processing signals from SV40 for mRNA stability; 5′- and 3′-untranslated regions for mRNA stability and translation efficiency from highly-expressed genes like α-globin or β-globin; SV40 polyoma origins of replication and ColE1 for proper episomal replication; internal ribosome binding sites (IRESes), versatile multiple cloning sites; T7 and SP6 RNA promoters for in vitro transcription of sense and antisense RNA; a “suicide switch” or “suicide gene” which when triggered causes cells carrying the vector to die (e.g., HSV thymidine kinase, an inducible caspase such as iCasp9), and reporter gene for assessing expression of the chimeric receptor. Suitable vectors and methods for producing vectors containing transgenes are well known and available in the art. Selectable markers also include chloramphenicol resistance, tetracycline resistance, spectinomycin resistance, streptomycin resistance, erythromycin resistance, rifampicin resistance, bleomycin resistance, thermally adapted kanamycin resistance, gentamycin resistance, hygromycin resistance, trimethoprim resistance, dihydrofolate reductase (DHFR), GPT; the URA3, HIS4, LEU2, and TRP1 genes of S. cerevisiae.

When introduced into the cell, the vectors may be maintained as an autonomously replicating sequence or extrachromosomal element or may be integrated into host DNA.

In one embodiment, the donor DNA may be delivered using the same gene transfer system as used to deliver the Cas protein, and/or transposon associated proteins (included on the same vector) or may be delivered using a different delivery system. In another embodiment, the donor DNA may be delivered using the same transfer system as used to deliver gRNA(s).

In one embodiment, the present disclosure comprises integration of exogenous DNA into the endogenous gene. Alternatively, an exogenous DNA is not integrated into the endogenous gene. The DNA may be packaged into an extrachromosomal or episomal vector (such as AAV vector), which persists in the nucleus in an extrachromosomal state, and offers donor-template delivery and expression without integration into the host genome. Use of extrachromosomal gene vector technologies has been discussed in detail by Wade-Martins R (Methods Mol Biol. 2011; 738:1-17, incorporated herein by reference).

The present system (e.g., proteins, polynucleotides encoding these proteins, donor polynucleotides and compositions comprising the proteins and/or polynucleotides described herein) may be delivered by any suitable means. In certain embodiments, the system is delivered in vivo. In other embodiments, the system is delivered to isolated/cultured cells (e.g., autologous iPS cells) in vitro to provide modified cells useful for in vivo delivery to patients afflicted with a disease or condition.

Vectors according to the present disclosure can be transformed, transfected, or otherwise introduced into a wide variety of cells. Transfection refers to the taking up of a vector by a cell whether or not any coding sequences are in fact expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for example, lipofectamine, calcium phosphate co-precipitation, electroporation, DEAE-dextran treatment, microinjection, viral infection, and other methods known in the art. Transduction refers to entry of a virus into the cell and expression (e.g., transcription and/or translation) of sequences delivered by the viral vector genome. In the case of a recombinant vector, “transduction” generally refers to entry of the recombinant viral vector into the cell and expression of a nucleic acid of interest delivered by the vector genome.

Any of the vectors comprising a nucleic acid sequence that encodes the components of the present system is also within the scope of the present disclosure. Such a vector may be delivered into host cells by a suitable method. Methods of delivering vectors to cells are well known in the art and may include DNA or RNA electroporation, transfection reagents such as liposomes or nanoparticles to delivery DNA or RNA; delivery of DNA, RNA, or protein by mechanical deformation (see, e.g., Sharei et al. Proc. Natl. Acad. Sci. USA (2013) 110(6): 2082-2087, incorporated herein by reference); or viral transduction. In some embodiments, the vectors are delivered to host cells by viral transduction. Nucleic acids can be delivered as part of a larger construct, such as a plasmid or viral vector, or directly, e.g., by electroporation, lipid vesicles, viral transporters, microinjection, and biolistics (high-speed particle bombardment). Similarly, the construct containing the one or more transgenes can be delivered by any method appropriate for introducing nucleic acids into a cell. In some embodiments, the construct or the nucleic acid encoding the components of the present system is a DNA molecule. In some embodiments, the nucleic acid encoding the components of the present system is a DNA vector and may be electroporated to cells. In some embodiments, the nucleic acid encoding the components of the present system is an RNA molecule, which may be electroporated to cells.

Additionally, delivery vehicles such as nanoparticle- and lipid-based mRNA or protein delivery systems can be used. Further examples of delivery vehicles include lentiviral vectors, ribonucleoprotein (RNP) complexes, lipid-based delivery system, gene gun, hydrodynamic, electroporation or nucleofection microinjection, and biolistics. Various gene delivery methods are discussed in detail by Nayerossadat et al. (Adv Biomed Res. 2012; 1: 27) and Ibraheem et al. (Int J Pharm. 2014 Jan. 1; 459(1-2):70-83), incorporated herein by reference.

Methods

Also disclosed herein are methods for nucleic acid modification (e.g., insertion or deletion) utilizing the disclosed systems or kits. The methods may comprise contacting a target nucleic acid sequence with a system disclosed herein or a composition comprising the system. The descriptions and embodiments provided above for the engineered CAST system, the at least one integration co-factor protein, the gRN A, and the donor nucleic acid are applicable to the methods described herein.

The target nucleic acid sequence may be in a cell. In some embodiments, contacting a target nucleic acid sequence comprises introducing the system into the cell. As described above the system may be introduced into eukaryotic or prokaryotic cells by methods known in the art. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a human cell.

In some embodiments, the target nucleic acid is a nucleic acid endogenous to a target cell. In some embodiments, the target nucleic acid is a genomic DNA sequence. The term “genomic,” as used herein, refers to a nucleic acid sequence (e.g., a gene or locus) that is located on a chromosome in a cell.

In some embodiments, the target nucleic acid encodes a gene or gene product. The term “gene product,” as used herein, refers to any biochemical product resulting from expression of a gene. Gene products may be RNA or protein. RNA gene products include non-coding RNA, such as tRNA, rRNA, micro RNA (miRNA), and small interfering RNA (siRNA), and coding RNA, such as messenger RNA (mRNA). In some embodiments, the target nucleic acid sequence encodes a protein or polypeptide.

The methods may be used for a variety of purposes. For example, the methods may include, but are not limited to, inactivation of a microbial gene, RNA-guided DNA integration in a plant or animal cell, methods of treating a subject suffering from a disease or disorder (e.g., cancer, Duchenne muscular dystrophy (DMD), sickle cell disease (SCD), fp-thalassemia, and hereditary tyrosinemia type I (HTI)), and methods of treating a diseased cell (e.g., a cell deficient in a gene which causes cancer).

The disclosed methods may be used to fuse or link an endogenous protein with the protein cargo encoded in the donor nucleic acid. In some embodiments, when the target nucleic acid sequence encodes a protein or polypeptide or is adjacent to a sequence encoding a protein or polypeptide, the donor nucleic acid having the engineered transposon end sequence encoding an amino acid linker and a peptide or polypeptide cargo fuses or links the endogenous protein with the peptide or polypeptide cargo upon successful insertion. Thus, the disclosure also provides methods of tagging a protein, e.g., an endogenous protein in a cell.

Polynucleotides containing the target nucleic acid sequence may include, but is not limited to, purified chromosomal DNA, total cDNA, cDNA fractionated according to tissue or expression state (e.g., after heat shock or after cytokine treatment other treatment) or expression time (after any such treatment) or developmental stage, plasmid, cosmid, BAC, YAC, phage library, etc. Polynucleotides containing the target site may include DNA from organisms such as Homo sapiens, Mus domesticus, Mus spretus, Canis domesticus, Bos, Caenorhabditis elegans, Plasmodium falciparum, Plasmodiwn vivax, Onchocerca volvulus, Brugia malayi, Dirofilaria immitis, Leishmania, Zea maize. Arabidopsis thaliana, Glycine max, Drosophila melanogaster, Saccharomnyces cerevisiae, Schizosaccharomyces pombe, Neurospora, Escherichia coli, Salmonella typhimuriwn, Bacillus subtilis, Neisseria gonorrhoeae, Staphylococcus aureus, Streptococcus pneumonia, Mycobacterium tuberculosis, Aquifex, Thermus aquaticus, Pyrococcus furiosus, Thermus littoralis, Methanobacterium thermoautotrophicum, Sulfolobus caldoaceticus, and others.

The methods may comprise administering to the subject, in vivo, or by transplantation of ex vivo treated cells, an effective amount of the described system. In some embodiments, the vector(s) is delivered to the tissue of interest by, for example, an intramuscular, intravenous, transdermal, intranasal, oral, mucosal, or other delivery methods.

The components of the present system or ex vivo treated cells may be administered with a pharmaceutically acceptable carrier or excipient as a pharmaceutical composition. In some embodiments, the components of the present system may be mixed, individually or in any combination, with a pharmaceutically acceptable carrier to form pharmaceutical compositions, which are also within the scope of the present disclosure.

In some embodiments, an effective amount of the components of the present system or compositions as described herein can be administered. As used herein the term “effective amount” may be used interchangeably with the term “therapeutically effective amount” and refers to that quantity that is sufficient to result in a desired activity upon administration to a subject in need thereof. Within the context of the present disclosure, the term “effective amount” refers to that quantity of the components of the system such that successful DNA integration is achieved.

When utilized as a method of treatment, the effective amount may depend on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size, gender and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. In some embodiments, the effective amount alleviates, relieves, ameliorates, improves, reduces the symptoms, or delays the progression of any disease or disorder in the subject. In some embodiments, the subject is a human.

In the context of the present disclosure insofar as it relates to any of the disease conditions recited herein, the terms “treat,” “treatment,” and the like mean to relieve or alleviate at least one symptom associated with such condition, or to slow or reverse the progression of such condition. Within the meaning of the present disclosure, the term “treat” also denotes to arrest, delay the onset (e.g., the period prior to clinical manifestation of a disease) and/or reduce the risk of developing or worsening a disease. For example, in connection with cancer the term “treat” may mean eliminate or reduce a patient's tumor burden, or prevent, delay, or inhibit metastasis, etc.

The phrase “pharmaceutically acceptable,” as used in connection with compositions and/or cells of the present disclosure, refers to molecular entities and other ingredients of such compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a subject (e.g., a mammal, a human). Preferably, as used herein, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and more particularly in humans. “Acceptable” means that the carrier is compatible with the active ingredient of the composition (e.g., the nucleic acids, vectors, cells, or therapeutic antibodies) and does not negatively affect the subject to which the composition(s) are administered. Any of the pharmaceutical compositions and/or cells to be used in the present methods can comprise pharmaceutically acceptable carriers, excipients, or stabilizers in the form of lyophilized formations or aqueous solutions.

Pharmaceutically acceptable carriers, including buffers, are well known in the art, and may comprise phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; amino acids; hydrophobic polymers: monosaccharides; disaccharides; and other carbohydrates; metal complexes; and/or non-ionic surfactants. See, e.g., Remington: The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Williams and Wilkins, Ed. K. E. Hoover.

Kits

Also within the scope of the present disclosure are kits that include the components of the present system.

The kit may include instructions for use in any of the methods described herein. The instructions can comprise a description of administration of the present system or composition to a subject to achieve the intended effect. The instructions generally include information as to dosage, dosing schedule, and route of administration for the intended treatment. The kit may further comprise a description of selecting a subject suitable for treatment based on identifying whether the subject is in need of the treatment.

The kits provided herein are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging, and the like.

The packaging may be unit doses, bulk packages (e.g., multi-dose packages) or sub-unit doses. Instructions supplied in the kits of the disclosure are typically written instructions on a label or package insert. The label or package insert indicates that the pharmaceutical compositions are used for treating, delaying the onset, and/or alleviating a disease or disorder in a subject.

Kits optionally may provide additional components such as buffers and interpretive information. Normally, the kit comprises a container and a label or package insert(s) on or associated with the container. In some embodiment, the disclosure provides articles of manufacture comprising contents of the kits described above.

The kit may further comprise a device for holding or administering the present system or composition. The device may include an infusion device, an intravenous solution bag, a hypodermic needle, a vial, and/or a syringe.

The present disclosure also provides for kits for performing DNA integration in vitro. The kit may include the components of the present system. Optional components of the kit include one or more of the following: buffer constituents, control plasmid, sequencing primers, cells, and the like.

EXAMPLES

The following are examples of the present invention and are not to be construed as limiting.

Materials and Methods

Cloning, testing, and analysis of pooled pDonor libraries. Donor plasmid (pDonor) libraries were generated by cloning transposon left or end variants into a donor plasmid, which was co-transformed with an effector plasmid (pEffector) that directed transposition into the E. coli genome (schematized in FIG. 1D). Each transposon end variant was associated with a unique 10-bp barcode that was used to uniquely identify variants in the sequencing approach, which relied on sequencing the starting plasmid libraries (input) and integrated products from genomic DNA (output) by NGS to determine the representation of each library member before and after transposition. To sequence the output, integration events in the T-RL and T-LR orientations were independently amplified using a cargo-specific primer flanking the transposon end and a genomic primer either upstream or downstream of the integration site. Custom python scripts compared each library member's representation in the output to its representation in the input, allowing calculation of the relative transposition efficiency of the custom transposon end variants.

To clone the transposon donor libraries, library variants were first generated as 200-nt single stranded pooled oligos (Twist Bioscience). 1 ng of oligoarray library DNA was PCR amplified for 12 cycles in 40 μL reactions using Q5 High-Fidelity DNA Polymerase (NEB) and primers specific to the right or left end library, in order to add restriction enzyme digestion sites. Amplicons were cleaned up and eluted in 45 μL mQ H₂O (QIAquick PCR Purification Kit). As the backbone vector, a plasmid encoding a 775-bp mini-transposon, delineated by 147-bp of the native transposon left end and 75-bp of the native transposon right end, on a pUC57 backbone was used. The backbone vector and library insert amplicons were digested (AscI and SapI for the right end library, and NcoI and NotI for the left end library) at 37° C. for 1 h, gel purified, and ligated in 20 μL reactions with T4 DNA Ligase (NEB) at 25° C. for 30 min. Ligation reactions were cleaned up and eluted in 10 μL mQ H₂O (MinElute PCR Purification Kit), and then used to transform electrocompetent NEB 10-beta cells in five individual electroporation reactions according to the manufacturer's protocol. After recovery (37° C. for 1 h), transformed cells were plated on large 245 mm×245 mm bioassay plates containing LB-agar with 100 μg/mL carbenicillin. Plates were scraped to collect cells, and plasmid DNA was isolated using the QIAGEN Plasmid Midi Kit.

Transposition experiments were performed in E. coli BL2I(DE3) cells, pEffector encoded a CRISPR array (repeat-spacer-repeat), a native tniQ-cas8-cas7-cas6 operon, and a native tnsA-tnsB-tnsC operon, all under the control of a single T7 promoter on a pCDFDuet-1 backbone. 2 μL of DNA solution containing 200 ng of pDonor and pEffector in equal molar amount was used to co-transform electrocompetent cells according to the manufacturer's protocol (Sigma-Aldrich). Four transformations were performed for each sample, and following recovery at 37° C. for 1 h, each transformation was plated on a large bioassay plate containing LB-agar with 100 μg/mL spectinomycin, 100 μg/mL carbenicillin, and 0.1 mM IPTG. Cells were grown at 37° C. for 18 h. Thousands of colonies were scraped from each plate, and genomic DNA was extracted using the Wizard Genomic DNA Purification Kit (Promega).

Next-generation sequencing (NGS) amplicons were prepared by PCR amplification using Q5 High-Fidelity DNA Polymerase (NEB). 250 ng of template DNA was amplified in 15 cycles during the PCR1 step. PCR1 samples were diluted 20-fold and amplified in 10 cycles during the PCR2 step. PCR1 primer pairs contained one pDonor backbone-specific primer and one transposon-specific primer (input library), or one genomic target-specific primer and one transposon-specific primer (output library). PCR amplicons were resolved by 2% agarose gel electrophoresis and gel-purified (QIAGEN Gel Extraction Kit). Libraries were quantified by qPCR using the NEBNext Library Quant Kit (NEB). Sequencing for both input and output libraries were performed using a NextSeq Mid or High Output Kit with 150-cycles (Illumina). Additionally, the input libraries were also sequenced using a MiSeq with 300-cycles (Illumina).

NGS data analysis was performed using custom Python scripts. Demultiplexed reads were filtered to remove reads that did not contain a perfect match to the 19-bp primer binding sequence at the 3′-terminus of the transposon end. Then, the 10-bp sequence directly downstream of the primer binding sequence was extracted, which encodes a barcode that uniquely identifies each transposon end variant. The number of reads containing each library member barcode was counted. If a read did not contain a barcode that matched a library member barcode, it was discarded. The barcode counts were summed across two NGS runs using the same PCR2 samples for the input libraries. Two biologically independent replicates were performed for the output libraries. The relative abundance of each library member was then determined by dividing the barcode count of each library member by the total number of barcode counts. The fold-change between the output and input libraries was calculated by dividing the relative abundance of each library member in the output library by its relative abundance in the input library. This fold-change was then normalized by dividing the fold-change of each library member by the average fold-change of four wildtype library members that contained identical transposon ends but unique barcodes.

One source of experimental noise in the approach came from PCR recombination, in which barcodes became uncoupled from their associated transposon end variants during PCR amplification. The frequency of uncoupling was quantified by performing long-read Illumina sequencing (MiSeq, 250 cycles) to sequence both the barcode and full-length transposon end, and found that not all barcodes were coupled to their correct transposon end sequence (FIG. 6B). However, uncoupled reads mapped to a diverse pool of sequences, with the most abundant incorrect sequence for each library member representing only a low percentage of total reads (FIG. 6C). These data therefore indicate that uncoupling events did not largely affect the ability to calculate relative integration efficiencies for each library member.

Sequence logos were generated with WebLogo 3.7.4, and the VchCAST sequence logo in FIG. 2B was generated from the six predicted TnsB binding sites. Consensus sequences were generated from the logo where bases with a bitscore >1 are represented as capital letters and bases with a bit score >1 are represented as small letters.

One limitation of the experimental setup is the inability to directly compare relative integration orientation within the same NGS libraries since integration events were amplified independently in the T-RL and T-LR orientations. Instead, approximate integration efficiencies were inferred by comparing the enrichment scores of transposon end variants to those of wildtype variants within the same library. All transposition assays with pDonor libraries were performed heterologously in E. coli under overexpression conditions, and thus subtleties of transposon end recognition and binding that depend on regulated TnsB expression levels may be obscured.

Cloning, testing, and analysis of pooled pTarget libraries. pTarget libraries were designed to include an 8-bp degenerate sequence positioned 42 bp downstream of one of two potential target sites, as schematized in FIG. 3B. Integration was directed to one of the two target sites flanking the degenerate sequence by a single plasmid (pSPIN) encoding both the donor molecule and transposition machinery under the control of a T7 promoter, on a pCDF backbone. To generate insert DNA for cloning the pTarget libraries, two partially overlapping oligos were annealed by heating to 95° C. for 2 min and then cooling to room temperature. Annealed DNA was treated with DNA Polymerase I, Large (Klenow) Fragment (NEB) in 40 μL reactions and incubated at 37° C. for 30 min, then gel-purified (QIAGEN Gel Extraction Kit). Double-stranded insert DNA and vector backbone was digested with BamHI and AvrII (37° C., I h); the digested insert was cleaned-up (MinElute PCR Purification Kit) and the digested backbone was gel-purified. Backbone and insert were ligated with T4 DNA Ligase (NEB), and ligation reactions were used to transform electrocompetent NEB 10-beta cells in four individual electroporation reactions according to the manufacturer's protocol. After recovery (37° C. for 1 h), cells were plated on large bioassay plates containing LB-agar with 50 μg/mL kanamycin. Thousands of colonies were scraped from each plate, and plasmid DNA was isolated using the QIAGEN Plasmid Midi Kit. Plasmid DNA was further purified by mixing with Mag-Bind TotalPure NGS Beads (Omega) at a vol:vol ratio of 0.60× and extracting the supernatant to remove contaminating fragments smaller than ˜450 bp.

2 μL of DNA solution containing 200 ng of pTarget and pSPIN at equal mass amounts were used to co-transform electrocompetent E. coli BL21(DE3) cells according to the manufacturer's protocol (Sigma-Aldrich). Three transformations were performed and plated on large bioassay plates containing LB-agar with 100 μg/mL spectinomycin and 50 μg/mL kanamycin. Thousands of colonies were scraped from each plate, and plasmid DNA was isolated using the QIAGEN Plasmid Midi Kit.

Integration into pTarget yielded a larger plasmid than the starting input plasmid. To isolate the larger plasmid, a digestion step was performed that facilitated resolution of the integrated and unintegrated bands on an agarose gel, for extraction of the larger integrated plasmid. This digestion step was performed on both input and output libraries, digesting with NcoI-HF (37° C. for 1 h) and running them on a 0.7% agarose gel. The products were gel-purified (QIAGEN Gel Extraction Kit) and eluted in 15 μL EB in a MinElute Column (QIAGEN). 6.5 μL of cleaned-up DNA was used in each PCR1 amplification with Q5 High-Fidelity DNA Polymerase (NEB) for 15 cycles. PCR1 samples were diluted 20-fold and amplified in 10 cycles for PCR2. PCR1 primer pairs contained pTarget backbone-specific primers flanking a 45-bp region encompassing the degenerate sequence. Sequencing was performed with a paired-end run using a NextSeq High Output Kit with 150-cycles (Illumina).

NGS data analysis was performed using a custom Python script. Demultiplexed reads were filtered to remove reads that did not contain a perfect match to the 34- to 35-bp sequence upstream of the degenerate sequence for any i5-reads, or to the 45- to 46-bp sequence for any i7-reads. 35-bp and 46-bp was used for reads that were amplified from primers containing an additional nucleotide, which were used in PCR I to generate cluster diversity during sequencing. For all reads that passed filtering, the 8-bp degenerate sequence was extracted and counted. The integration distance was determined in the output libraries by examining the i5 read sequence at an integration distance of 43-bp to 56-bp downstream of each target for the presence of the transposon right or left end sequence (20-nt of each end). The degenerate sequence was then extracted from either or both of the i5 and i7 reads, depending on the integration position. The degenerate sequence counts were summed across the two primer pairs. The relative abundance was determined by dividing the degenerate sequence count by the total number of degenerate sequence counts. Finally, the fold-change between the output and input libraries was calculated by dividing the relative abundance of each degenerate sequence at each integration position in the output library by its relative abundance in the input library, and then log 2-transformed.

Sequence logos were generated with WebLogo 3.7.4. The preferred integration site logos in FIG. 8A were generated from all degenerate sequences that were enriched four-fold in the integrated products compared to the input. The overall preferred integration site logos in FIGS. 3C and 8D were generated by first applying the minimum threshold of four-fold enrichment in the integrated products compared to the input, and then selecting nucleotides from the top 5,000 enriched sequences across all integration positions. Nucleotides were selected from the top 5,000 sequences from each library, yielding a total of 10,000 nucleotides at each position.

Endogenous gene tagging experiments. All VchCAST constructs were subcloned from pEffector and pDonor as described previously, using a combination of inverse (around-the-horn) PCR, Gibson assembly, restriction digestion-ligation, and ligation of hybridized oligonucleotides. pEffector encodes a CRISPR array (repeat-spacer-repeat), a native tniQ-cas8-cas7-cas6 operon, and a native tnsA-tnsB-tnsC operon, all under the control of a single T7 promoter on a pCDFDuet-1 backbone. Donor plasmids (pDonor) were designed to encode a mini-transposon (mini-Tn) with a wild-type 147-bp transposon left end and 57-bp linker-coding right end variant, on a pUC19 backbone. For endogenous gene tagging experiments, superfolder GFP (sfGFP) lacking a ribosome binding site (rbs) and start codon was cloned into the mini-Tn cargo region, and the mini-Tn was further cloned into a temperature-sensitive pSIM6 backbone.

Linker functionality constructs were designed to encode sfGFP with an extended 32-amino acid (aa) loop region between the 10th and 11th β-strands, under the control of a single T7 promoter, as described by Feng and colleagues. Linker variants encoding 18-19 aa were subcloned into the 32-aa loop region as follows. An entry vector was generated on a pCOLADuet-I (pCOLA) vector harboring sfGFP, such that the 11th β-strand (GFP11) was replaced by the aforementioned extended 32-aa loop. Fragments encoding transposon right end linker variants and GFP11 were then amplified by conventional PCR and inserted into the extended loop region of the entry vector downstream of β-strands 1-10 (GFP1-10), such that total length of the loop remained constant at 32 aa.

To perform linker functionality assays, chemically competent E. coli BL21(DE3) cells were co-transformed with T7-controlled sfGFP linker functionality constructs (pCOLA) and an equal mass amount of empty pUC19 vector. Negative control transformants harbored either unfused sfGFP1-10 and sfGFP11 fragments on separate pCOLA and pUC19 backbones, respectively, or isolated sfGFP fragments. Transformed cells were plated on LB-agar plates with antibiotic selection (100 μg/mL carbenicillin, 50 μg/mL kanamycin), and single colonies were used to inoculate 200 μL of LB medium (100 μg/mL carbenicillin, 50 μg/mL kanamycin, 0.1 mM IPTG) in a 96-well optical-bottom plate. The optical density at 600 nm (OD600) was measured every 10 min, in parallel with the fluorescence signal for sfGFP, using a Synergy Neo2 microplate reader (Biotek) while shaking at 37° C. for 15 h. To derive normalized fluorescence intensities (NFI), all measured fluorescence intensities were divided by their corresponding OD600 values across all time points. A single representative NFI value was calculated per well by averaging all NFI values per well corresponding to OD600 values between 0.20 and 0.30, inclusive.

Transposition experiments were performed by transforming chemically competent E. coli BL21(DE3) cells harboring pEffector plasmids with pDonor plasmids by heat shock at 42° C. for 30 sec, followed by recovery in fresh LB medium. Recovery was performed at 30° C. for 1.5 h for temperature-sensitive pDonor plasmids, and 37° C. for 1 h for all other pDonor plasmids. Transformants were isolated on LB-agar plates containing the proper antibiotics and inducer (100 μg/mL carbenicillin, 50 μg/mL spectinomycin, 0.1 mM IPTG). After 43 h growth at 30° C. for temperature-sensitive pDonor plasmids, and 18 h growth at 37° C. for all other pDonor plasmids, samples were prepared for downstream qPCR analysis of integration efficiency or colony PCR identification of integration events.

For qPCR quantification, colonies were scraped from plates and resuspended in LB medium, and cell lysates were prepared for qPCR as described in Klompe, et al., (2019) Nature, 571, 219-225. Pairs of transposon- and target DNA-specific primers were designed to amplify fragments from integrated transposition products at the expected loci in either of two possible orientations. In parallel, a separate pair of genome-specific primers was designed to amplify an E. coli reference gene (rssA) for normalization purposes. qPCR reactions (10 μL) contained 5 μL of SsoAdvanced Universal SYBR Green Supermix (BioRad), 1 μL H2O, 2 μL of 2.5 μM primers, and 2 μL of hundredfold-diluted cell lysate and were prepared following transposition experiments as described above. Reactions were prepared in 384-well clear/white PCR plates (BioRad), and measurements were obtained in a CFX384 Real-Time PCR Detection System (BioRad). The following thermal cycling parameters were used: polymerase activation and DNA denaturation (98° C. for 3 min), and 35 cycles of amplification (98° C. for 10 s, 60° C. for 30 s). Each biological sample was analyzed in three parallel reactions: one reaction contained a primer pair for the E. coli reference gene, a second reaction contained a primer pair for one integration orientation, and a third reaction contained a primer pair for the other integration orientation. Transposition efficiency was calculated for each orientation as 2ΔCq, in which ΔCq is the Cq difference between the experimental and control reactions. Total transposition efficiency for a given experiment was calculated by summing transposition efficiencies across both orientations. All measurements presented were determined from three independent biological replicates.

For colony PCR identification of integration events, colonies were scraped from plates after transposition assays, resuspended in fresh LB medium, and re-streaked on LB-agar plates with the appropriate antibiotics and without IPTG inducer. To generate lysates, individual colonies were each transferred to 10 μL of H2O, followed by incubation at 95° C. for 2 min and centrifugation at 4,000 g for 5 min to pellet cell debris. Pairs of transposon- and target DNA-specific primers were designed to amplify fragments from integrated transposition products in the expected locus and orientation. In parallel, a separate pair of genome-specific primers was designed to amplify an E. coli reference gene (rssA) and determine whether the crude lysates were sufficiently dilute to allow successful amplification of the integrated transposition product. Transposition-less negative control samples were always analyzed in parallel with experimental samples to identify mispriming products that could result from the pDonor-containing crude lysates. PCR reactions (15 μL) contained 7.5 μL of 2× OneTaq 2× Master Mix with Standard Buffer (NEB), 5.9 μL H₂O, 0.6 μL of 10 μM primers, and 1 μL of undiluted cell lysate as described above. PCR amplicons were resolved by 1% agarose gel electrophoresis and visualized by staining with SYBR Safe (Thermo Scientific). To verify in-frame integration events, amplicons of the expected length were excised after gel electrophoresis, isolated by the Gel Extraction Kit (Qiagen), and sent for Sanger sequencing (GENEWIZ).

Fluorescence microscopy experiments were performed as follows. A pEffector plasmid was designed to C-terminally tag the native E. coli msrB gene by integrating a mini-Tn encoding a linker variant (ORF2a) and sfGFP cargo in-frame with the coding sequence, thereby interrupting the endogenous stop codon. Transposition experiments were performed as described above by transforming chemically competent E. coli BL21(DE3) cells harboring pEffector plasmids with temperature-sensitive pDonor plasmids. Colonies were then scraped and resuspended in fresh LB medium. Resuspensions were diluted and re-streaked on double antibiotic LB-agar plates lacking IPTG (100 μg/mL carbenicillin, 50 μg/mL spectinomycin). After overnight growth on solid medium at 37° C., individual colonies were used to inoculate liquid cultures (50 μg/mL spectinomycin) for overnight heat-curing at 37° C., followed by replica plating on single and double antibiotic plates to isolate heat-cured samples. In tandem, colony PCR and Sanger sequencing (GENEWIZ) were performed to identify colonies with in-frame transposition products as described above. In preparation for fluorescence microscopy, Sanger-verified samples were inoculated in overnight 37° C. liquid cultures. On the day of imaging, 500 μL of saturated overnight cultures were transferred to 5 ml of fresh LB medium with the appropriate antibiotics. Aliquots of the newly inoculated cultures were removed around the stationary or mid-log phases and immobilized in glass slides coated with partially dehydrated aqueous I % agarose-TAE pads. Immediately after immobilization, fluorescent microscopy was performed with a Nikon ECLIPSE 80i microscope using an oil immersion ×100 objective lens, which was equipped with a Spot CCD camera and SpotAdvance software. All images were processed in ImageJ by normalizing background fluorescence.

Generating and testing E. coli knockout mutants. E. coli genomic knockouts of ihfA, ihfB, ycbG, hupA, hupB, hns, and fis were generated using Lambda Red recombineering, as previously described (Sharan, S. K., et al., (2009) Nat Protoc, 4, 206-223). Knockouts were designed to replace of each gene with a kanamycin resistance cassette, which was PCR amplified with Q5 High-Fidelity DNA Polymerase (NEB) using primers that contained 50-nt homology arms to knockout gene locus. PCR amplicons were resolved on a 1% agarose gel and gel-purified, eluting with 40 μL MQ (QIAGEN Gel Extraction Kit). Electrocompetent E. coli BL21(DE3) cells were prepared containing a temperature-sensitive plasmid that encodes the Lambda Red machinery under the control of a temperature-sensitive promoter (pSIM6). Protein expression from the temperature-sensitive promoter was induced by incubating cells at 42° C. for 25 min immediately prior to electrocompetent cell preparation. 300-600 ng of each insert was used to transform cells via electroporation (2 kV, 200 Ω, 25 μF), and cells were recovered overnight at 30° C. by shaking in 3 mL of SOC media. After recovery, 250 μL of culture was spread on 100 mm standard plates (LB-agar with 50 μg/mL kanamycin) and grown overnight at 30° C. Kanamycin-resistant colonies were picked, and the genomic knock-in was confirmed by PCR amplification and Sanger sequencing using primer pairs flanking the knock-in locus.

VchCAST transposition experiments in E. coli knockout strains were performed by first preparing chemically competent WT and mutant cells and then transforming these strains with a single plasmid (pSPIN), which encodes the donor molecule and the native transposition machinery under the control of a T7 promoter and a crRNA targeting the lacZ genomic locus, on a pCDF backbone. After transformation by heat shock, cells were plated onto LB-agar with 100 μg/mL spectinomycin and 0.1 mM IPTG to induce protein expression, and incubated at 37° C. for 18 h. Hundreds of colonies were scraped from each plate, and integration efficiencies were quantified by the same qPCR assay described for the endogenous gene tagging experiments. Transposition experiments for other Type I-F homologs were performed as in the VchCAST experiments, except that the concentration of IPTG was reduced to 0.01 mM to mitigate toxicity.

Experiments that tested protein expression conditions in WT and ΔIHF cells were performed as described in the VchCAST transposition experiments. Promoters were varied from constitutive promoters (J23119, J23101) to inducible promoters (T7), for which different concentrations of IPTG were also tested.

For the complementation experiments, cells were co-transformed with pSPIN and a rescue plasmid (pRescue) that encoded both E. coli ihfA and ihfB under the control of separate T7 promoters on a pACYC backbone, and plated onto LB-agar with 100 μg/mL spectinomycin, 25 μg/mL chloramphenicol, and 0.1 mM IPTG to induce protein expression. Cells were incubated at 37° C. for 18 h, before colonies were scraped from each plate and integration efficiencies in both orientations were measured by qPCR.

To test DNA donor molecules with symmetric transposon ends, mutant pDonor encoding two right or two left transposon ends was cloned, and integration efficiency was measured by co-transforming pDonor with pEffector under the control of a T7 promoter on a pCDF backbone. Cells were plated onto LB-agar with 100 μg/mL spectinomycin, 100 μg/mL carbenicillin, and 0.1 mM IPTG and incubated at 37° C. for 18 h, before colonies were scraped from each plate and integration efficiencies in both orientations were measured by qPCR.

EcoTn7 transposition experiments and NGS analysis. To measure the integration efficiencies and distance distributions of EcoTn7 in WT and E. coli mutant cells, genomic primer binding sites were cloned into the mini-Tn cargo of a single plasmid for Tn7 transposition, which encoded a native tnsA-tnsB-tnsC-tnsD operon under the control of a constitutive pJ23119 promoter, on a pCDF backbone. The genomic primer binding sites were cloned adjacent to the transposon left and right ends such that the NGS amplicon length would be the same for unintegrated products and integrated products in either orientation (schematized in FIG. 12A). To quantify integration efficiencies using qPCR, primer pairs designed to amplify integrated products in both orientations, with one primer adjacent to the right transposon end a second primer either upstream or downstream of the integration site were used.

To quantify integration efficiencies by NGS, genomic DNA was amplified using a single primer pair with one primer complementary to the genomic primer binding site and the second primer complementary to the 3′-end of the glmS locus. Genomic DNA was extracted using the Wizard Genomic DNA Purification Kit (Promega). 250 ng of genomic was used in each PCR1 amplification with Q5 High-Fidelity DNA Polymerase (NEB) for 15 cycles. PCR1 samples were diluted 20-fold and amplified in 10 cycles for PCR2. Sequencing was performed with a paired-end run using a NextSeq High Output Kit with 150-cycles (Illumina).

NGS data analysis was performed using a custom Python script. Demultiplexed reads were filtered to remove reads that did not contain a perfect match to the first 65-bp of expected sequence resulting from either non-integrated genomic products or from integration events spanning 0-bp to 30-bp downstream of the glmS locus, and then counted the number of reads matching each of these possible products.

A table of plasmids used is provided in Table 9.

Example 1

Pooled Library to Characterize Transposon End Sequences

To systematically mutagenize the transposon left and right end sequences of V. cholerae Tn6677 large pooled oligoarray libraries, built off the previous study of the VchCAST system (Klompe, et al. (2019) Nature, 571, 219-225), were used. Starting with a minimal pDonor design that directed efficient genomic integration in both of two possible orientations (FIG. 1B), thousands of variants of the left (L) and right (R) end sequences, including truncations, base-pair substitutions, and transposase binding site modifications (FIGS. 1C, SEQ ID NOs: 845-2690 (right end) and SEQ ID NOs: 3120-4665 (left end)) were designed. Each variant was assigned a unique 8-bp barcode located between the mutagenized transposon end and the cargo, obviating the requirement to sequence across the entire transposon end to identify each variant. Each library also included four wildtype (WT) variants associated with unique barcodes, which were used to approximate the relative integration efficiency of each mutagenized library member. Libraries were then synthesized as single-stranded oligos, cloned into a mini-transposon donor (pDonor), and carefully characterized using next-generation sequencing (NGS), which demonstrated that all members were represented in the input sample for both transposon left and right end libraries (FIGS. 6A-D).

Transposition experiments were performed by transforming E. coli BL21(DE3) cells expressing the transposition machinery with pDonor encoding either the left end or right end library, amplifying successful genomic integration products in both orientations via junction PCR (FIG. 1D), and subjecting PCR products to NGS analysis. An enrichment score was then calculated for each variant, revealing a wide range of integration efficiencies, with most library members exhibiting diminished integration relative to the four WT samples (FIG. 6D). Finally, enrichment scores of the WT library members were used for normalization, yielding a score for each variant that represented its relative activity. To validate the approach, two biological replicates for each library transposition experiment were performed and strong concordance between both datasets was found, especially in the dominant T-RL integration orientation (FIG. 6E). Importantly, given the high degree of sequence similarity between library members, the background level of library member-barcode uncoupling was also rigorously determined, which established contributors of experimental noise in our datasets (FIGS. 6B-C and Methods).

The strength of the pooled-library approach was apparent by examining the effect of one category of variations, in which the transposon end sequences were sequentially mutated starting 120-nt into the transposon end, effectively creating end truncations, albeit without a change in overall mini-transposon size (FIG. 1E). These results revealed the minimal transposon end sequence length: in the left end, ˜105 bp were required for efficient integration, corresponding to all three predicted transposase (TnsB) binding sites, whereas in the right end, only ˜50 bp were required, corresponding to the first two transposase binding sites. These findings add single-bp resolution to the minimal transposon end sequences needed for efficient integration.

Example 2

Transposase Activity and Transposon End Sequences

TnsB is integral to the mobilization of Tn7-like transposons, in that it catalyzes the excision and integration chemistry while also conferring sequence specificity for the transposon ends through recognition of repetitive sequence elements known as TnsB binding sites (TBSs). Sequence analysis of the native VchCAST ends revealed three conserved TBSs in both the left and right ends (FIGS. 2A, 2B and 7A), and these sequences were verified by examining a mutational panel at single-bp resolution (FIGS. 2C and 7B). This dataset revealed that individual TBS point mutations can affect efficiency, particularly for positions 1, 6-9, and 12-14, but are not critical for integration. This more lenient sequence requirement is in line with recently published cryo-EM structures of DNA-bound TnsB from Tn7 and Type V-K CAST systems, which revealed that many protein-DNA interactions occur with the phosphodiester backbone rather than specific nucleobases.

Experiments with E. coli Tn7 showed that the internal TBSs are occupied before the more terminal sites. To test this if the few bases which account for the difference in the six TBSs of VchCAST, all possible combinations of TBSs for the left and right ends were tested, which are defined herein as L1-L3 and R1-R3 (FIG. 7C). For both VchCAST ends, site 1 displayed the greatest TBS preference and preferred the L1/L3/R1 sequence, whereas site 2 preferred L1/R1/R2 and site 3 exhibited the least TBS preference but favored L3. A preference for R1 was observed in the first position on the left end, and a preference for L I was observed in the first position on the right end, suggesting that transposition might be favored when the terminal end sequences are identical (whether based on equal affinity or otherwise).

Apart from regulating transposition frequency, TBS sequence identity could also explain the propensity of a given CAST system to cross-react with related transposon substrates. Previously VchCAST was shown to efficiently mobilize mini-transposon substrates from three homologous CAST systems, but not Tn7002. To determine which Tn7002 sequences were incompatible with mobilization by VchCAST machinery, chimeric transposon ends that contain parts of both the VchCAST and Tn7002 transposon ends were designed (FIG. 2D). The data revealed that chimeric left ends allowed for near WT integration efficiencies whereas chimeric right ends drastically decreased integration efficiency, likely due to the deleterious presence of a cytidine at position 9 of R1-R3 (FIG. 2D). Thus, TBS sequence identity imparts at least some constraints on the substrate recognition of a transposase for its cognate transposon DNA.

After testing a mutagenic panel in which the length between TBSs was systematically varied (FIGS. 2E and 7D), it was found that even single-bp perturbations caused drastic changes in integration efficiency. Additionally, an intriguing pattern of increasing and decreasing integration efficiencies were detected at roughly 10-bp intervals, suggesting that the three-dimensional positioning of transposase proteins on helical DNA is important for transposition.

Example 3

Transposase Sequence Preferences Influence Integration Site Patterns

VchCAST integration patterns differed in subtle but reproducible ways between distinct genomic target sites. Integration site patterns were compared for four endogenous E. coli target sequences, designated 4-7, either at their native genomic location or on an ectopic target plasmid by deep sequencing (FIG. 3A). Integration site patterns were notably distinct between the four targets but were highly consistent between genomic and plasmid contexts, suggesting that these patterns are dependent on local sequence alone and independent of other factors such as DNA replication or local transcription. Next, to disentangle contributions of the 32-bp target sequence (complementary to crRNA guide) from the downstream region including the integration site, target plasmids that contained chimeras of the four target regions were tested (FIG. 3A). Remarkably, integration patterns for these chimeric substrates closely mirrored the patterns observed for the non-chimeric substrates when the ‘downstream region’ was kept constant, indicating that the 32-bp target sequence does not modulate selection of the integration site.

To test if TnsB might exhibit local sequence preferences immediately at the site of DNA insertion, and explain the observed heterogeneity in integration site patterns, a target plasmid (pTarget) library encoding two target sequences flanking an 8-bp degenerate sequence was generated, such that integration events directed by a crRNA matching either target would lead to insertion directly into the degenerate 8-mer sequence (FIG. 3B). The target plasmids were sequenced before and after transposition and the representation of integration site sequences were compared to determine which sequences were enriched after transposition. These analyses revealed striking nucleotide preferences at conserved positions relative to the integration site (FIGS. 3C and 8A). Specifically, there were clear biases for a YWR motif within the central three nucleotides of the target-site duplication (TSD), as well as a preference for D (A, T, or G) and H (A, T, or C) at the −3 and +3 positions relative to the TSD, respectively.

To further explore the deterministic role of the preferred motif within the TSD, the distribution of reads containing a central 5′-CWG-3′ motif at different positions within the degenerate sequence was plotted. This motif was a focus because it favored a more unimodal distribution for the integration site by avoiding a centrally-preferred A or T nucleotide flanking the W. This motif was predictive of the preferred integration site distance that was sampled by VchCAST (FIG. 3D). By plotting the distribution of reads containing multiple 5′-CWG-3′ motifs within the integration site, it was found that two copies of this preferred motif within the integration site conferred a bimodal distribution, wherein there were not one but two preferred integration sites within the degenerate sequence (FIG. 8B). Finally, the library data was leveraged to predict the integration site distribution of previously targeted locations and could explain their differences at single-bp resolution (FIG. 8E).

Both of the two distinct crRNAs and corresponding target sites on pTarget yielded consistent sequence preferences for both the TSD and +/−3-bp positions (FIG. 8A), but it was surprising to find that the preferred integration distance was shifted by 1-bp when comparing the two (FIG. 8C). This difference could have been due to sequence preferences at the +/−3-bp position that fell outside the degenerate sequence, and indeed, when the sequences flanking the 8-mer library were examined, it was found that the downstream target (target B) contained a disfavored nucleotide in the −3-bp position for insertions that would occur with the 49-bp distance (FIG. 8D).

Example 4

Role of Boundary Sequences and Right End Internal Features on DNA Integration

VchCAST and many other Tn7-like transposons encode an 8-bp terminal end immediately adjacent to the first transposase binding site, with the terminal TG dinucleotide highly conserved among a broad spectrum of transposons including IS3, Tn7, Mu and even retrotransposons. Integration data with library variants that featured mutations within these terminal residues revealed that positions 1-3, but not 4-8, were critical for efficient transposition (FIG. 9B). This result is consistent with the DNA-bound cryo-EM structure of TnsB from a Type V-K CAST system. However, library variants with mutations in the 5-bp sequence flanking the mini-transposon were integrated with equivalent efficiencies (FIG. 9A), indicating that transposition machinery does not exhibit sequence specificity within this region.

To investigate whether the spacing between the terminal TG dinucleotide and the first TBS mattered, variants that modulated the distance between the 8-bp terminal end and TBS1 were tested (FIG. 9C). Adding a single base pair in either the left or right end still allowed for efficient transposition, whereas transposition was completely ablated with the removal of 1 bp or addition of 2 bp, indicating tight control over this spacing. Interestingly, larger bp additions or deletions between the TG dinucleotide and first TBS were in some cases also permitted, but always with a concomitant shift in the transposon boundary that was actually mobilized and integrated at the target site (FIG. 9C); in all cases, transposition still required a terminal TG. These data therefore suggest that a controlling feature within the terminal end sequence is the TG dinucleotide, and that the ˜8-bp spacing between this dinucleotide and the first TBS is a constraint for efficient transposition.

Previous work suggested that the palindromic sequence found 97-107 bp from the transposon right end boundary might affect integration orientation, possibly by promoting transcription of the tnsABC operon, which would be consistent with empirical expression data and the AT-richness of the transposon end. To test this possibility, the palindromic sequence was mutated and variants with this sequence shifted the orientation preference towards T-LR, with just one arm of the palindrome (Pa) being sufficient to shift the orientation bias (FIGS. 9D-E). Constitutive promoters were included in place of the palindromic sequence and it was found that promoters directing transcription inwards (towards the cargo) did not impact integration orientation, whereas promoters directed outwards (across the right end) shifted the orientation preference towards T-LR, perhaps by antagonizing stable assembly of TnsB selectively at the right end (FIG. 9F).

Example 5

Endogenous Protein Tagging with Rationally Engineered Right Ends

The left and right end sequences facilitate transposon DNA recognition and excision/integration, and transposition products therefore include these sequences as ‘scars’ at the site of insertion. To convert these scars into functional sequences that encode amino acid linkers for downstream protein tagging applications, the shorter right end, starting with a minimal 57-bp sequence, was found to have stop codons in all three possible open reading frames (ORF) for the WT sequence (FIG. 4A). When a library of rationally designed right end variants (SEQ ID NOs: 18-844, Tables 1 &2) that replaced stop codons and codons encoding bulky and/or charged amino acids was tested (FIG. 10D), numerous candidates for each possible ORF that maintained near-wild-type integration efficiency were identified (FIG. 10A; SEQ ID NOs: 1-8; Tables 2 and 4). After validating library data by testing individual linker variants for genomic integration in E. coli (FIG. 4B), a fluorescence-based assay was designed to test for functionality of the encoded amino acid linkers.

GFP naturally consists of eleven β-strands that are connected by small loop regions, and a prior study demonstrated that the loop region between the 10^th and 11^th β-strand can be extended with novel linker sequences while still allowing for proper folding and fluorescence of the variant GFP protein. Selected transposon right end variants were cloned into the loop region between J3-strand 10 and 11 and GFP fluorescence intensity was measured after expression of each construct, revealing a subset of variants that were fully functional (FIGS. 4C and 10B). Next, the endogenous E. coli gene nsrB was selected for C-terminal tagging in a proof-of-concept experiment (FIG. 4D). After generating a pDonor construct that encodes a right end linker variant with an adjacent, in-frame GFP gene lacking a promoter or start codon, transposition experiments followed by Sanger sequencing were used to verify that integration interrupted the endogenous stop codon while placing the linker and GFP sequence directly in-frame. Finally, proper expression of MsrB-GFP fusion proteins was analyzed by analyzing cells via fluorescence microscopy that received either the WT transposon right end or the linker variant, demonstrating that only the modified right end variant elicited the expected cellular fluorescence (FIGS. 4D and IOC). To confirm that GFP was translationally fused to MsrB, we performed an anti-GFP western blot and found that GFP was not detected in the WT transposon end fusion but was detected at the expected size in the modified linker variant (FIG. 4E). Together, these data provide the basis for new genome engineering tools that allow for facile, endogenous gene tagging with single-bp control.

Example 6

Integration Host Factor (IHF) Binds the Left Transposon End to Stimulate Transposition

Closer inspection of the transposon left end mutational data revealed a sequence between the two terminal TnsB binding sites (TBSs) that, when mutated, led to reproducible transposition defects (FIG. 5A). The corresponding DNA sequence perfectly matched a consensus binding sequence for Integration Host Factor (IHF), a heterodimeric nucleoid-associated protein (NAP) that binds to the consensus sequence 5′-WATCARNNNNTTR-3′ and induces a DNA bend of more than 160°. First identified as a host factor for bacteriophage λ integration, IHF is also involved in diverse cellular activities including chromosome replication initiation, transcriptional regulation, and various site-specific recombination pathways.

Visual examination of the transposon left ends of twenty homologous systems revealed a highly conserved IBS across all homologs (FIGS. 5D and 5E), and aligning the sequence between the first two TBSs using Clustal Omega also revealed the IBS consensus as a conserved feature (FIG. 11B). To test whether IHF stimulated transposition for these systems, experiments were performed in WT and ΔIHF cells for five other systems and only two (Tn7000 and Tn7014) showed a strong IHF dependence (FIG. 5F).

Given the involvement of IHF and, more generally, the importance of donor/target DNA supercoiling and topology for other mobile elements, we decided to broadly investigate whether other E. coli NAPs might play a role in transposition. After generating individual knockouts of 5 additional nucleoid-associated proteins (NAP) genes (ycbG, hupA, hupB, hns, and fis) and measuring integration efficiency within these mutant backgrounds, only the loss of fis decreased integration efficiency, by 2-fold (FIG. 11F). When the same cohort of NAP knockouts were tested for transposition with the prototypic Tn7 system, IHF had no effect whereas Fis (factor for inversion stimulation) again influenced integration efficiency, though with a ˜4-fold increase in the knockout strain (FIG. 12B).

Interestingly, the amplicon-sequencing detection approach for E. coli Tn7 transposition also yielded new information about the nature of DNA integration products for the well-studied TnsABCD pathway. Whereas prior studies concluded that TnsD binding defines a single integration site downstream of the essential glmS gene, surprisingly heterogeneous insertion patterns were observed that sampled a wider sequence space, including rare but reproducible transposition products in the less-common T-LR orientation (FIG. 12C). These findings highlight the value of deep sequencing to thoroughly and unbiasedly query the range of potential integration products for a given transposable element.

After testing bidirectional transposition for two CAST systems in both a WT and ΔIHF strain of E. coli, it was found that although the loss of IHF did not affect orientation preference for VchCAST, its loss reversed the dominant orientation for Tn7000 from T-RL to T-LR (FIG. 12C). This result raised the intriguing possibility that IHF may be involved in establishing a transpososome architecture that controls the directionality of DNA insertions, at least for some systems. Previous work with the prototypic Tn7 system found that transposon substrates with two right ends were competent for integration whereas two left ends were not. The loss of IHF had no impact on transposition with a substrate containing two transposon right ends, which was integrated without orientation bias, while a substrate containing two left ends exhibited severely reduced integration efficiency that retained a dependence on IHF (FIGS. 12D-E). Overall, the data support a model (FIG. 5G) in which IHF binds the region between TBSs L1 and L2 to bend the transposon left end and drive DNA integration, akin to the proposed role of HU in Mu transposition. Exemplary sequences of IHF constructs are shown in Table 3.

Example 7

Hyperactive Tn6677 Transposon End Variants

A pooled library-based cellular transposition assay was developed in order to test a large panel of modified transposon end variants. In initial transposon end library experiments, the efficiency of the wild-type (unmodified) transposon substrate, with native end sequences, was high (˜80% efficiency), which limited the ability to confidently identify variants with improved integration activity compared to wildtype. In order to identify hyperactive variants, a modified experimental approach was established in which the overall system on WT transposon end substrates was less active. Cells were plated on media lacking inducer (IPTG), which reduced integration efficiency in the dominant T-RL orientation by approximately 3-fold (FIG. 21A). Then, the transposon end library experiment were repeated using this hypoactive condition, allowing detection of transposon end variants that exhibited hyperactive activity relative to WT. These variants increased transposition efficiency by between 1.5-2.5-fold (FIG. 21B, Tables 5 and 6).

In the transposon right end, hyperactive variants contained mutations in the sequence adjacent to the TnsB binding sites (the right end “stuffer” sequence, illustrated in FIG. 21C). The strongest hyperactive variant contained a binding site for the factor H-NS in this region, while other hyperactive variants contained mutations in this region, either through the addition of binding sites for other DNA-binding proteins, or through mutations that randomly varied the GC-richness of this region. In the left transposon end, hyperactive variants contained mutations in the transposon ends that converted the sequence to be more similar to the transposon end sequence of a related Type I-F CAST homolog, known as Tn7002.

To confirm that mutating the right end “stuffer” sequence was able to increase transposition efficiency, several transposon end variants with mutations in this sequence were cloned and the integration efficiency of these variants was directly measured individually, in a non-library format. Mutations that introduced binding sites for two DNA-binding and bending proteins, IHF or H-NS, both increased transposition efficiency relative to WT (FIG. 21C). Although these variants increased integration in a E. coli bacterial cell context in which these factors are naturally expressed, the improved integration efficiencies may be generalizable across any cell type of interest for these engineered transposon end sequences, whether or not the DNA binding/bending protein factors are present.

Example 8

Hyperactive Tn7016 Transposon End Variants

Using the above, a panel of putative hyperactive transposon end sequences were designed for a related CAST system, Tn7016, which shows significantly higher RNA-guided DNA integration activity in mammalian cells. The design of these variants, listed as SEQ ID NOs: 2703-3119 for right end variants and SEQ ID NOs: 4674-5135 for left end variants, was directly informed by mutations that increased the activity of RNA-guided DNA integration for Tn6677. The tested variants include rationally engineered modifications with added binding sites for DNA-binding and bending proteins; modifications that convert the transposon ends to be more similar to the transposon end sequences from homologous CAST systems; modifications that mutate the transposon right end such that the modified sequence encodes functional protein linkers without any in-frame stop codons; and modifications that systematically vary the GC-richness of the sequence adjacent to the TnsB binding sites within either transposon end. Mutations to either the left or right transposon end sequence, or to both transposon end sequences concurrently, in order to incorporate these aforementioned sequence features, result in increased DNA integration activity of the Tn7016 CAST system. These mutations also modify the orientation preference between T-RL and T-LR of a CAST system of interest. These variants are currently designed with modifications to either the transposon right end or the transposon left end, however hyperactive transposon left and right end variants are combined to further increase DNA integration activity.

This transposon end library is cloned into a pDonor substrate which is used in various cell types that may include bacterial cells, plant cells, animal cells, or human cells. For example, the pDonor library is used to transfect mammalian cells together with the necessary CAST protein and RNA machinery, and targeted sequencing of the integration product is performed, in order to uncover transposon end modifications with hyperactivity. Library members with enriched sequence abundances after integration are further investigated as highly active transposon end variants in human cells.

Library members may include variants in which the transposon end does not contain stop codons in any reading frame. These modifications enable mini-transposon genetic payloads to be integrated directly into or downstream of a gene body, such that read-through translation across the transposon end enables seamless fusions, at the protein level, with custom polypeptides encoded within the genetic payload of the transposon. These transposon end variants are used to enable protein tagging, in which targeted integration occurs immediately downstream of the start codon, or immediately upstream of the stop codon, of a gene of interest. Therefore, translation will read through the transposon, appending a sequence of interest to a target protein encoded within the genome.

TABLE 1
Library of transposon right end variant sequences tested for transposition

SEQ
ID	DNA sequence 5′ → 3′ (57 bp:
NO	TIR-R1-R2-Space-[R3)	Amino Acid sequence

Frame 1

18	TGTTGATACAACCATAAAATGATAATTACACCCAT	YNHKMIITPIN (SEQ ID NO: 5352) * *LSHP (SEQ ID
	AAATTGATAATTATCACACCCA	NO: 5353)
22	TGTCGATACAACCATAAAATGATAATTACACCCAT	CRYNHKMIITPIN (SEQ ID NO: 5361)* *LSHP (SEQ
	AAATTGATAATTATCACACCCA	DD NO: 5353)
23	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPIN(SEQ ID NO: 5362)* *LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
24	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMIITPIN(SEQ ID NO: 5363)* *LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
25	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPING(SEQ ID NO: 5364)* LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
26	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPINS(SEQ ID NO: 5365)* LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
27	TGTCGATACAACCATAAAATGATAATTACACCCAT	CRYNHKMIITPING(SEQ ID NO: 5366)* LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
28	TGTCGATACAACCATAAAATGATAATTACACCCAT	CRYNHKMIITPINS(SEQ ID NO: 5367)* LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
29	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPING(SEQ ID NO: 5368) * LSHP
	AAATGGATAATTATCACACCCA	(SEQ ID NO: 5353)
30	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPINS(SEQ ID NO: 5369) * LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
31	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMIITPING(SEQ ID NO: 5370) * LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
32	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMIITPINS(SEQ ID NO: 5371) * LSHP (SEQ
	AAATTCATAATTATCACACCCA	DD NO: 5353)
33	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPIN (SEQ ID NO: 5352) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
34	TGTCGATACAACCATAAAATGATAATTACACCCAT	CRYNHKMIITPIN(SEQ ID NO: 5361) * SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
35	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPIN(SEQ ID NO: 5362) * SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
36	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMIITPIN(SEQ ID NO: 5363) * SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
37	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPINGSLSHP (SEQ ID NO: 5373)
	AAATGGATCATTATCACACCCA
38	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMITPINSSLSHP (SEQ ID NO: 5374)
	AAATTCATCATTATCACACCCA
39	TGTCGATACAACCATAAAATGATAATTACACCCAT	CRYNHKMITPINGSLSHP (SEQ ID NO: 5375)
	AAATGGATCATTATCACACCCA
40	TGTCGATACAACCATAAAATGATAATTACACCCAT	CRYNHKMIITPINSSLSHP (SEQ ID NO: 5376)
	AAATTCATCATTATCACACCCA
41	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPINGSLSHP (SEQ ID NO: 5377)
	AAATGGATCATTATCACACCCA
42	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPINSSLSHP (SEQ ID NO: 5378)
	AAATTCATCATTATCACACCCA
43	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMITPINGSLSHP (SEQ ID NO: 5379)
	AAATGGATCATTATCACACCCA
44	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMIITPINSSLSHP (SEQ ID NO: 5380)
	AAATTCATCATTATCACACCCA
45	GGTTGATACAACCATAAAATGATAATTACACCCAT	G*YNHKMIITPIN (SEQ ID NO: 5352)**LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
46	GGTCGATACAACCATAAAATGATAATTACACCCAT	GRYNHKMIITPIN (SEQ ID NO: 5381) * *LSHP
	AAATTGATAATTATCACACCCA	(SEQ ID NO: 5353)
47	GGTGGATACAACCATAAAATGATAATTACACCCAT	GGYNHKMIITPIN (SEQ ID NO: 5382) * *LSHP
	AAATTGATAATTATCACACCCA	(SEQ ID NO: 5353)
48	GGTTCATACAACCATAAAATGATAATTACACCCAT	GSYNHKMIITPIN (SEQ ID NO: 5383) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
49	GGTTGATACAACCATAAAATGATAATTACACCCAT	G*YNHKMIITPING(SEQ ID NO: 5364) * LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
50	GGTTGATACAACCATAAAATGATAATTACACCCAT	G*YNHKMIITPINS(SEQ ID NO: 5365) * LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
51	GGTCGATACAACCATAAAATGATAATTACACCCAT	GRYNHKMIITPING (SEQ ID NO: 5385) *LSHP
	AAATGGATAATTATCACACCCA	(SEQ ID NO: 5353)
52	GGTCGATACAACCATAAAATGATAATTACACCCAT	GRYNHKMIITPINS (SEQ ID NO: 5384) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
53	GGTGGATACAACCATAAAATGATAATTACACCCAT	GGYNHKMIITPING (SEQ ID NO: 5387) *LSHP
	AAATGGATAATTATCACACCCA	(SEQ ID NO: 5353)
54	GGTGGATACAACCATAAAATGATAATTACACCCAT	GGYNHKMIITPINS(SEQ ID NO: 5388) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
55	GGTTCATACAACCATAAAATGATAATTACACCCAT	GSYNHKMIITPING (SEQ ID NO: 5389) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
56	GGTTCATACAACCATAAAATGATAATTACACCCAT	GSYNHKMIITPINS(SEQ ID NO: 5390) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
57	GGTTGATACAACCATAAAATGATAATTACACCCAT	G*YNHKMIITPIN (SEQ ID NO: 5352)*SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
58	GGTCGATACAACCATAAAATGATAATTACACCCAT	GRYNHKMIITPIN (SEQ ID NO: 5381) * SLSHP
	AAATTGATCATTATCACACCCA	(SEQ ID NO: 5372)
59	GGTGGATACAACCATAAAATGATAATTACACCCAT	GGYNHKMIITPIN (SEQ ID NO: 5382) * SLSHP
	AAATTGATCATTATCACACCCA	(SEQ ID NO: 5372)
60	GGTTCATACAACCATAAAATGATAATTACACCCAT	GSYNHKMIITPIN (SEQ ID NO: 5383) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
61	GGTTGATACAACCATAAAATGATAATTACACCCAT	G*YNHKMIITPINGSLSHP (SEQ ID NO: 5373)
	AAATGGATCATTATCACACCCA
62	GGTTGATACAACCATAAAATGATAATTACACCCAT	G*YNHKMIITPINSSLSHP (SBQ ID NO: 5374)
	AAATTCATCATTATCACACCCA
63	GGTCGATACAACCATAAAATGATAATTACACCCAT	GRYNHKMIITPINGSLSHP (SEQ ID NO: 5391)
	AAATGGATCATTATCACACCCA
64	GGTCGATACAACCATAAAATGATAATTACACCCAT	GRYNHKMIITPINSSLSHP (SEQ ID NO: 5392)
	AAATTCATCATTATCACACCCA
65	GGTGGATACAACCATAAAATGATAATTACACCCAT	GGYNHKMIITPINGSLSHP (SEQ ID NO: 5393)
	AAATGGATCATTATCACACCCA
66	GGTGGATACAACCATAAAATGATAATTACACCCAT	GGYNHKMIITPINSSLSHP (SEQ ID NO: 5394)
	AAATTCATCATTATCACACCCA
67	GGTTCATACAACCATAAAATGATAATTACACCCAT	GSYNHKMIITPINGSLSHP (SEQ ID NO: 5395)
	AAATGGATCATTATCACACCCA
68	GGTTCATACAACCATAAAATGATAATTACACCCAT	GSYNHKMIITPINSSLSHP (SEQ ID NO: 5396)
	AAATTCATCATTATCACACCCA
69	TCTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPIN (SEQ ID NO: 5352)**LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
70	TCTCGATACAACCATAAAATGATAATTACACCCAT	SRYNHKMIITPIN (SEQ ID NO: 5397) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
71	TCTGGATACAACCATAAAATGATAATTACACCCAT	SGYNHKMIITPIN (SEQ ID NO: 5398) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
72	TCTTCATACAACCATAAAATGATAATTACACCCAT	SSYNHKMIITPIN (SEQ ID NO: 5399) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
73	TCTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPING(SEQ ID NO: 5364) * LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
74	TCTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPINS(SEQ ID NO: 5365) ** LSHP
	AAATTCATAATTATCACACCCA	(SEQ ID NO: 5353)
75	TCTCGATACAACCATAAAATGATAATTACACCCAT	SRYNHKMITPING (SEQ ID NO: 5400) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
76	TCTCGATACAACCATAAAATGATAATTACACCCAT	SRYNHKMIITPINS (SEQ ID NO: 5401) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
77	TCTGGATACAACCATAAAATGATAATTACACCCAT	SGYNHKMITPING (SEQ ID NO: 5402) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
78	TCTGGATACAACCATAAAATGATAATTACACCCAT	SGYNHKMIITPINS (SEQ ID NO: 5403) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
79	TCTTCATACAACCATAAAATGATAATTACACCCAT	SSYNHKMIITPING (SEQ ID NO: 5404) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
80	TCTTCATACAACCATAAAATGATAATTACACCCAT	SSYNHKMIITPINS (SEQ ID NO: 5405) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
81	TCTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPIN (SEQ ID NO: 5352)*SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
82	TCTCGATACAACCATAAAATGATAATTACACCCAT	SRYNHKMIITPIN (SEQ ID NO: 5397) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
83	TCTGGATACAACCATAAAATGATAATTACACCCAT	SGYNHKMIITPIN (SEQ ID NO: 5398) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
84	TCTTCATACAACCATAAAATGATAATTACACCCAT	SSYNHKMIITPIN (SEQ ID NO: 5399) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
85	TCTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPINGSLSHP (SEQ ID NO: 5373)
	AAATGGATCATTATCACACCCA
86	TCTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPINSSLSHP (SEQ ID NO: 5374)
	AAATTCATCATTATCACACCCA
87	TCTCGATACAACCATAAAATGATAATTACACCCAT	SRYNHKMIITPINGSLSHP (SEQ ID NO: 5406)
	AAATGGATCATTATCACACCCA
88	TCTCGATACAACCATAAAATGATAATTACACCCAT	SRYNHKMITPINSSLSHP (SEQ ID NO: 5407)
	AAATTCATCATTATCACACCCA
89	TCTGGATACAACCATAAAATGATAATTACACCCAT	SGYNHKMIITPINGSLSHP (SEQ ID NO: 5408)
	AAATGGATCATTATCACACCCA
90	TCTGGATACAACCATAAAATGATAATTACACCCAT	SGYNHKMIITPINSSLSHP (SEQ ID NO: 5409)
	AAATTCATCATTATCACACCCA
91	TCTTCATACAACCATAAAATGATAATTACACCCAT	SSYNHKMIITPINGSLSHP (SEQ ID NO: 5410)
	AAATGGATCATTATCACACCCA
92	TCTTCATACAACCATAAAATGATAATTACACCCAT	SSYNHKMIITPINSSLSHP (SEQ ID NO: 5411)
	AAATTCATCATTATCACACCCA
93	AGTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPIN (SEQ ID NO: 5352) ** LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
94	AGTCGATACAACCATAAAATGATAATTACACCCAT	SRYNHKMIITPIN (SEQ ID NO: 5397) ** LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
95	AGTGGATACAACCATAAAATGATAATTACACCCAT	SGYNHKMIITPIN (SEQ ID NO: 5398) ** LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
96	AGTTCATACAACCATAAAATGATAATTACACCCAT	SSYNHKMIITPIN (SEQ ID NO: 5399) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
97	AGTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPING(SEQ ID NO: 5364) * LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
98	AGTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPINS(SEQ ID NO: 5365) * LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
99	AGTCGATACAACCATAAAATGATAATTACACCCAT	SRYNHKMIITPING (SEQ ID NO: 5400) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
100	AGTCGATACAACCATAAAATGATAATTACACCCAT	SRYNHKMIITPINS (SEQ ID NO: 5401) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
101	AGTGGATACAACCATAAAATGATAATTACACCCAT	SGYNHKMIITPING (SEQ ID NO: 5402) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
102	AGTGGATACAACCATAAAATGATAATTACACCCAT	SGYNHKMIITPINS (SEQ ID NO: 5403) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
103	AGTTCATACAACCATAAAATGATAATTACACCCAT	SSYNHKMIITPING (SEQ ID NO: 5404) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
104	AGTTCATACAACCATAAAATGATAATTACACCCAT	SSYNHKMIITPINS (SEQ ID NO: 5405) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
105	AGTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPIN (SEQ ID NO: 5352)*SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
106	AGTCGATACAACCATAAAATGATAATTACACCCAT	SRYNHKMIITPIN (SEQ ID NO: 5397)*SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
107	AGTGGATACAACCATAAAATGATAATTACACCCAT	SGYNHKMIITPIN (SEQ ID NO: 5398) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
108	AGTTCATACAACCATAAAATGATAATTACACCCAT	SSYNHKMIITPIN (SBQ ID NO: 5399) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
109	AGTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPINGSLSHP (SEQ ID NO: 5373)
	AAATGGATCATTATCACACCCA
110	AGTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPINSSLSHP (SEQ ID NO: 5374)
	AAATTCATCATTATCACACCCA
111	AGTCGATACAACCATAAAATGATAATTACACCCAT	SRYNHKMIITPINGSLSHP (SEQ ID NO: 5406)
	AAATGGATCATTATCACACCCA
112	AGTCGATACAACCATAAAATGATAATTACACCCAT	SRYNHKMITPINSSLSHP (SEQ ID NO: 5407)
	AAATTCATCATTATCACACCCA
113	AGTGGATACAACCATAAAATGATAATTACACCCAT	SGYNHKMIITPINGSLSHP (SEQ ID NO: 5408)
	AAATGGATCATTATCACACCCA
114	AGTGGATACAACCATAAAATGATAATTACACCCAT	SGYNHKMIITPINSSLSHP (SEQ ID NO: 5409)
	AAATTCATCATTATCACACCCA
115	AGTTCATACAACCATAAAATGATAATTACACCCAT	SSYNHKMIITPINGSLSHP (SEQ ID NO: 5410)
	AAATGGATCATTATCACACCCA
116	AGTTCATACAACCATAAAATGATAATTACACCCAT	SSYNHKMIITPINSSLSHP (SEQ ID NO: 5411)
	AAATTCATCATTATCACACCCA
117	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMIITPIN (SEQ ID NO: 5412) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
118	TGTCGATACAACCCTAAAATGATAATTACACCCAT	CRYNPKMIITPIN (SEQ ID NO: 5413) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
119	TGTGGATACAACCCTAAAATGATAATTACACCCAT	CGYNPKMITPIN (SEQ ID NO: 5414) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
120	TGTTCATACAACCCTAAAATGATAATTACACCCAT	CSYNPKMIITPIN (SEQ ID NO: 5415) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
121	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMIITPING (SEQ ID NO: 5416) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
122	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMIITPINS (SEQ ID NO: 5417) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
123	TGTCGATACAACCCTAAAATGATAATTACACCCAT	CRYNPKMIITPING (SEQ ID NO: 5418) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
124	TGTCGATACAACCCTAAAATGATAATTACACCCAT	CRYNPKMIITPINS (SEQ ID NO: 5419) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
125	TGTGGATACAACCCTAAAATGATAATTACACCCAT	CGYNPKMIITPING (SEQ ID NO: 5420) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
126	TGTGGATACAACCCTAAAATGATAATTACACCCAT	CGYNPKMIITPINS (SEQ ID NO: 5421) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
127	TGTTCATACAACCCTAAAATGATAATTACACCCAT	CSYNPKMIITPING (SEQ ID NO: 5422) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
128	TGTTCATACAACCCTAAAATGATAATTACACCCAT	CSYNPKMIITPINS (SEQ ID NO: 5423) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
129	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMIITPIN (SEQ ID NO: 5412) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
130	TGTCGATACAACCCTAAAATGATAATTACACCCAT	CRYNPKMIITPIN (SEQ ID NO: 5413) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
131	TGTGGATACAACCCTAAAATGATAATTACACCCAT	CGYNPKMIITPIN (SEQ ID NO: 5414) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
132	TGTTCATACAACCCTAAAATGATAATTACACCCAT	CSYNPKMITPIN (SEQ ID NO: 5415) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
133	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMITPINGSLSHP (SEQ ID NO: 5424)
	AAATGGATCATTATCACACCCA
134	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMIITPINSSLSHP (SEQ ID NO: 5425)
	AAATTCATCATTATCACACCCA
135	TGTCGATACAACCCTAAAATGATAATTACACCCAT	CRYNPKMIITPINGSLSHP (SEQ ID NO: 5426)
	AAATGGATCATTATCACACCCA
136	TGTCGATACAACCCTAAAATGATAATTACACCCAT	CRYNPKMIITPINSSLSHP (SEQ ID NO: 5427)
	AAATTCATCATTATCACACCCA
137	TGTGGATACAACCCTAAAATGATAATTACACCCAT	CGYNPKMITPINGSLSHP (SEQ ID NO: 5428)
	AAATGGATCATTATCACACCCA
138	TGTGGATACAACCCTAAAATGATAATTACACCCAT	CGYNPKMIITPINSSLSHP (SEQ ID NO: 5429)
	AAATTCATCATTATCACACCCA
139	TGTTCATACAACCCTAAAATGATAATTACACCCAT	CSYNPKMIITPINGSLSHP (SEQ ID NO: 5430)
	AAATGGATCATTATCACACCCA
140	TGTTCATACAACCCTAAAATGATAATTACACCCAT	CSYNPKMIITPINSSLSHP (SEQ ID NO: 5431)
	AAATTCATCATTATCACACCCA
141	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPIN (SEQ ID NO: 5352)**LSPP (SEQ
	AAATTGATAATTATCACCCCCA	ID NO: 5432)
142	TGTCGATACAACCATAAAATGATAATTACACCCAT	CRYNHKMIITPIN(SEQ ID) NO: 5361) * *LSPP (SEQ
	AAATTGATAATTATCACCCCCA	ID NO: 5432)
143	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPIN(SEQ ID NO: 5362) * *LSPP (SEQ
	AAATTGATAATTATCACCCCCA	ID NO: 5432)
144	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMIITPIN(SEQ ID NO: 5363) * *LSPP (SEQ
	AAATTGATAATTATCACCCCCA	ID NO: 5432)
145	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPING(SEQ ID NO: 5364) * LSPP (SEQ
	AAATGGATAATTATCACCCCCA	DD NO: 5432)
146	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPINS(SEQ ID NO: 5365) * LSPP (SEQ
	AAATTCATAATTATCACCCCCA	ID NO: 5432)
147	TGTCGATACAACCATAAAATGATAATTACACCCAT	CRYNHKMIITPING(SEQ ID NO: 5366) * LSPP (SEQ
	AAATGGATAATTATCACCCCCA	ID NO: 5432)
148	TGTCGATACAACCATAAAATGATAATTACACCCAT	CRYNHKMIITPINS(SEQ ID NO: 5367) * LSPP (SEQ
	AAATTCATAATTATCACCCCCA	ID NO: 5432)
149	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPING(SEQ ID NO: 5368) * LSPP (SEQ
	AAATGGATAATTATCACCCCCA	ID NO: 5432)
150	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPINS(SEQ ID NO: 5369) * LSPP (SEQ
	AAATTCATAATTATCACCCCCA	ID NO: 5432)
151	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMIITPING(SBQ ID NO: 5370) * LSPP (SEQ
	AAATGGATAATTATCACCCCCA	ID NO: 5432)
152	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMIITPINS(SEQ ID NO: 5371) * LSPP (SEQ
	AAATTCATAATTATCACCCCCA	ID NO: 5432)
153	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPIN (SEQ ID NO: 5352)*SLSPP (SEQ
	AAATTGATCATTATCACCCCCA	ID NO: 5433)
154	TGTCGATACAACCATAAAATGATAATTACACCCAT	CRYNHKMIITPIN(SEQ ID NO: 5361) * SLSPP (SEQ
	AAATTGATCATTATCACCCCCA	ID NO: 5433)
155	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPIN(SEQ ID NO: 5362) * SLSPP (SEQ
	AAATTGATCATTATCACCCCCA	ID NO: 5433)
156	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMIITPIN(SEQ ID NO: 5363) * SLSPP (SEQ
	AAATTGATCATTATCACCCCCA	ID NO: 5433)
157	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPINGSLSPP (SEQ ID NO: 5434)
	AAATGGATCATTATCACCCCCA
158	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPINSSLSPP (SEQ ID NO: 5435)
	AAATTCATCATTATCACCCCCA
159	TGTCGATACAACCATAAAATGATAATTACACCCAT	CRYNHKMIITPINGSLSPP (SEQ ID NO: 5436)
	AAATGGATCATTATCACCCCCA
160	TGTCGATACAACCATAAAATGATAATTACACCCAT	CRYNHKMIITPINSSLSPP (SEQ ID NO: 5437)
	AAATTCATCATTATCACCCCCA
161	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPINGSLSPP (SEQ ID NO: 5354)
	AAATGGATCATTATCACCCCCA
162	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPINSSLSPP (SEQ ID NO: 5438)
	AAATTCATCATTATCACCCCCA
163	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMIITPINGSLSPP (SEQ ID NO: 5439)
	AAATGGATCATTATCACCCCCA
164	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMIITPINSSLSPP (SEQ ID NO: 5440)
	AAATTCATCATTATCACCCCCA
165	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMIITPIN (SEQ ID NO: 5412) **LSPP (SEQ
	AAATTGATAATTATCACCCCCA	ID NO: 5432)
166	TGTCGATACAACCCTAAAATGATAATTACACCCAT	CRYNPKMIITPIN (SEQ ID NO: 5413) **LSPP (SEQ
	AAATTGATAATTATCACCCCCA	ID NO: 5432)
167	TGTGGATACAACCCTAAAATGATAATTACACCCAT	CGYNPKMIITPIN (SEQ ID NO: 5414) **LSPP (SEQ
	AAATTGATAATTATCACCCCCA	ID NO: 5432)
168	TGTTCATACAACCCTAAAATGATAATTACACCCAT	CSYNPKMIITPIN (SEQ ID NO: 5415) **LSPP (SEQ
	AAATTGATAATTATCACCCCCA	ID NO: 5432)
169	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMIITPING (SEQ ID NO: 5416) *LSPP (SEQ
	AAATGGATAATTATCACCCCCA	ID NO: 5432)
170	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMIITPINS (SEQ ID NO: 5417) *LSPP (SEQ
	AAATTCATAATTATCACCCCCA	ID NO: 5432)
171	TGTCGATACAACCCTAAAATGATAATTACACCCAT	CRYNPKMIITPING (SEQ ID NO: 5418) *LSPP (SEQ
	AAATGGATAATTATCACCCCCA	ID NO: 5432)
172	TGTCGATACAACCCTAAAATGATAATTACACCCAT	CRYNPKMIITPINS (SEQ ID NO: 5419) *LSPP (SEQ
	AAATTCATAATTATCACCCCCA	ID NO: 5432)
173	TGTGGATACAACCCTAAAATGATAATTACACCCAT	CGYNPKMIITPING (SEQ ID NO: 5420) *LSPP (SEQ
	AAATGGATAATTATCACCCCCA	ID NO: 5432)
174	TGTGGATACAACCCTAAAATGATAATTACACCCAT	CGYNPKMIITPINS (SEQ ID NO: 5421) *LSPP (SEQ
	AAATTCATAATTATCACCCCCA	ID NO: 5432)
175	TGTTCATACAACCCTAAAATGATAATTACACCCAT	CSYNPKMITPING (SEQ ID NO: 5422) *LSPP (SEQ
	AAATGGATAATTATCACCCCCA	ID NO: 5432)
176	TGTTCATACAACCCTAAAATGATAATTACACCCAT	CSYNPKMIITPINS (SEQ ID NO: 5423) *LSPP (SEQ
	AAATTCATAATTATCACCCCCA	ID NO: 5432)
177	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMIITPIN (SEQ ID NO: 5412) *SLSPP (SEQ
	AAATTGATCATTATCACCCCCA	ID NO: 5433)
178	TGTCGATACAACCCTAAAATGATAATTACACCCAT	CRYNPKMIITPIN (SEQ ID NO: 5413) *SLSPP (SEQ
	AAATTGATCATTATCACCCCCA	ID NO: 5433)
179	TGTGGATACAACCCTAAAATGATAATTACACCCAT	CGYNPKMIITPIN (SEQ ID NO: 5414) *SLSPP (SEQ
	AAATTGATCATTATCACCCCCA	ID NO: 5433)
180	TGTTCATACAACCCTAAAATGATAATTACACCCAT	CSYNPKMIITPIN (SEQ ID NO: 5415) *SLSPP (SEQ
	AAATTGATCATTATCACCCCCA	ID NO: 5433)
181	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMIITPINGSLSPP (SEQ ID NO: 5441)
	AAATGGATCATTATCACCCCCA
182	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMIITPINSSLSPP (SEQ ID NO: 5442)
	AAATTCATCATTATCACCCCCA
183	TGTCGATACAACCCTAAAATGATAATTACACCCAT	CRYNPKMIITPINGSLSPP (SEQ ID NO: 5443)
	AAATGGATCATTATCACCCCCA
184	TGTCGATACAACCCTAAAATGATAATTACACCCAT	CRYNPKMITPINSSLSPP (SEQ ID NO: 5444)
	AAATTCATCATTATCACCCCCA
185	TGTGGATACAACCCTAAAATGATAATTACACCCAT	CGYNPKMIITPINGSLSPP (SEQ ID NO: 5445)
	AAATGGATCATTATCACCCCCA
186	TGTGGATACAACCCTAAAATGATAATTACACCCAT	CGYNPKMIITPINSSLSPP (SEQ ID NO: 5446)
	AAATTCATCATTATCACCCCCA
187	TGTTCATACAACCCTAAAATGATAATTACACCCAT	CSYNPKMIITPINGSLSPP (SEQ ID NO: 5447)
	AAATGGATCATTATCACCCCCA
188	TGTTCATACAACCCTAAAATGATAATTACACCCAT	CSYNPKMIITPINSSLSPP (SEQ ID NO: 5448)
	AAATTCATCATTATCACCCCCA
189	TGTTGATACAACCATAAAACGATAATTACACCCAT	C*YNHKTIITPIN (SEQ ID NO: 5449) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
190	TGTCGATACAACCATAAAACGATAATTACACCCAT	CRYNHKTIITPIN (SEQ ID NO: 5450) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
191	TGTGGATACAACCATAAAACGATAATTACACCCAT	CGYNHKTIITPIN (SEQ ID NO: 5451) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
192	TGTTCATACAACCATAAAACGATAATTACACCCAT	CSYNHKTIITPIN (SEQ ID NO: 5452) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
193	TGTTGATACAACCATAAAACGATAATTACACCCAT	C*YNHKTIITPING (SEQ ID NO: 5453) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
194	TGTTGATACAACCATAAAACGATAATTACACCCAT	C*YNHKTIITPINSLSHP (SEQ ID NO: 5353)
	AAATTCATAATTATCACACCCA
195	TGTCGATACAACCATAAAACGATAATTACACCCAT	CRYNHKTIITPING (SEQ ID NO: 5454) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
196	TGTCGATACAACCATAAAACGATAATTACACCCAT	CRYNHKTIITPINS (SEQ ID NO: 5455) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
197	TGTGGATACAACCATAAAACGATAATTACACCCAT	CGYNHKTIITPING (SEQ ID NO: 5456) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
198	TGTGGATACAACCATAAAACGATAATTACACCCAT	CGYNHKTIITPINS (SEQ ID NO: 5457) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
199	TGTTCATACAACCATAAAACGATAATTACACCCAT	CSYNHKTIITPING (SEQ ID NO: 5458) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
200	TGTTCATACAACCATAAAACGATAATTACACCCAT	CSYNHKTIITPINS (SEQ ID NO: 5459) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
201	TGTTGATACAACCATAAAACGATAATTACACCCAT	C*YNHKTIITPIN (SEQ ID NO: 5449) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
202	TGTCGATACAACCATAAAACGATAATTACACCCAT	CRYNHKTIITPIN (SEQ ID NO: 5450) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
203	TGTGGATACAACCATAAAACGATAATTACACCCAT	CGYNHKTIITPIN (SEQ ID NO: 5451) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
204	TGTTCATACAACCATAAAACGATAATTACACCCAT	CSYNHKTIITPIN (SEQ ID NO: 5452) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
205	TGTTGATACAACCATAAAACGATAATTACACCCAT	C*YNHKTIITPINGSLSHP (SEQ ID NO: 5460)
	AAATGGATCATTATCACACCCA
206	TGTTGATACAACCATAAAACGATAATTACACCCAT	C*YNHKTIITPINSSLSHP (SEQ ID NO: 5461)
	AAATTCATCATTATCACACCCA
207	TGTCGATACAACCATAAAACGATAATTACACCCAT	CRYNHKTIITPINGSLSHP (SEQ ID NO: 5462)
	AAATGGATCATTATCACACCCA
208	TGTCGATACAACCATAAAACGATAATTACACCCAT	CRYNHKTIITPINSSLSHP (SEQ ID NO: 5463)
	AAATTCATCATTATCACACCCA
209	TGTGGATACAACCATAAAACGATAATTACACCCAT	CGYNHKTIITPINGSLSHP (SEQ ID NO: 5355)
	AAATGGATCATTATCACACCCA
210	TGTGGATACAACCATAAAACGATAATTACACCCAT	CGYNHKTIITPINSSLSHP (SEQ ID NO: 5464)
	AAATTCATCATTATCACACCCA
211	TGTTCATACAACCATAAAACGATAATTACACCCAT	CSYNHKTITPINGSLSHP (SEQ ID NO: 5465)
	AAATGGATCATTATCACACCCA
212	TGTTCATACAACCATAAAACGATAATTACACCCAT	CSYNHKTITPINSSLSHP (SEQ ID NO: 5466)
	AAATTCATCATTATCACACCCA
213	TGTTGATCCAACCATAAAATGATAATTACACCCAT	C*SNHKMIITPIN (SEQ ID NO: 5467) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
214	TGTCGATCCAACCATAAAATGATAATTACACCCAT	CRSNHKMIITPIN (SEQ ID NO: 5468) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
215	TGTGGATCCAACCATAAAATGATAATTACACCCAT	CGSNHKMIITPIN (SEQ ID NO: 5469) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
216	TGTTCATCCAACCATAAAATGATAATTACACCCAT	CSSNHKMIITPIN (SEQ ID NO: 5470) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
217	TGTTGATCCAACCATAAAATGATAATTACACCCAT	C*SNHKMIITPING (SEQ ID NO: 5471) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
218	TGTTGATCCAACCATAAAATGATAATTACACCCAT	C*SNHKMIITPINS (SEQ ID NO: 5472) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
219	TGTCGATCCAACCATAAAATGATAATTACACCCAT	CRSNHKMIITPING (SEQ ID NO: 5473) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
220	TGTCGATCCAACCATAAAATGATAATTACACCCAT	CRSNHKMIITPINS (SEQ ID NO: 5474) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
221	TGTGGATCCAACCATAAAATGATAATTACACCCAT	CGSNHKMIITPING (SEQ ID NO: 5475) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
222	TGTGGATCCAACCATAAAATGATAATTACACCCAT	CGSNHKMIITPINS (SEQ ID NO: 5476) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
223	TGTTCATCCAACCATAAAATGATAATTACACCCAT	CSSNHKMIITPING (SEQ ID NO: 5477) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
224	TGTTCATCCAACCATAAAATGATAATTACACCCAT	CSSNHKMITPINS (SEQ ID NO: 5478) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
225	TGTTGATCCAACCATAAAATGATAATTACACCCAT	C*SNHKMIITPIN (SEQ ID NO: 5467) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
226	TGTCGATCCAACCATAAAATGATAATTACACCCAT	CRSNHKMITPIN (SEQ ID NO: 5468) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
227	TGTGGATCCAACCATAAAATGATAATTACACCCAT	CGSNHKMIITPIN (SEQ ID NO: 5469) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
228	TGTTCATCCAACCATAAAATGATAATTACACCCAT	CSSNHKMIITPIN (SEQ ID NO: 5470) *SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
229	TGTTGATCCAACCATAAAATGATAATTACACCCAT	C*SNHKMIITPINGSLSHP (SEQ ID NO: 5372)
	AAATGGATCATTATCACACCCA
230	TGTTGATCCAACCATAAAATGATAATTACACCCAT	C*SNHKMIITPINSSLSHP (SEQ ID NO: 5479)
	AAATTCATCATTATCACACCCA
231	TGTCGATCCAACCATAAAATGATAATTACACCCAT	CRSNHKMIITPINGSLSHP (SEQ ID NO: 5480)
	AAATGGATCATTATCACACCCA
232	TGTCGATCCAACCATAAAATGATAATTACACCCAT	CRSNHKMIITPINSSLSHP (SEQ ID NO: 5481)
	AAATTCATCATTATCACACCCA
233	TGTGGATCCAACCATAAAATGATAATTACACCCAT	CGSNHKMIITPINGSLSHP (SEQ ID NO: 5356)
	AAATGGATCATTATCACACCCA
234	TGTGGATCCAACCATAAAATGATAATTACACCCAT	CGSNHKMIITPINSSLSHP (SEQ ID NO: 5482)
	AAATTCATCATTATCACACCCA
235	TGTTCATCCAACCATAAAATGATAATTACACCCAT	CSSNHKMIITPINGSLSHP (SEQ ID NO: 5483)
	AAATGGATCATTATCACACCCA
236	TGTTCATCCAACCATAAAATGATAATTACACCCAT	CSSNHKMIITPINSSLSHP (SEQ ID NO: 5484)
	AAATTCATCATTATCACACCCA
237	TGTTGATACAACCATAAAATGATAATTCACCCATA	C*YNHKMIIHP (SEQ ID NO: 5485) *IDNYHTP
	AATTGATAATTATCACACCCCA	(SEQ ID NO: 5486)
238	TGTTGATACAACCATAAAATGATAATTCACCCATC	C*YNHKMIIHPSIDNYHTP (SEQ ID NO: 5487)
	AATTGATAATTATCACACCCCA
239	TGTTCATACAACCATAAAATGATAATTCACCCATA	CSYNHKMIIHP (SEQ ID NO: 5488) *IDNYHTP
	AATTGATAATTATCACACCCCA	(SEQ ID NO: 5486)
240	TGTTCATACAACCATAAAATGATAATTCACCCATC	CSYNHKMIIHPSIDNYHTP (SEQ ID NO: 5489)
	AATTGATAATTATCACACCCCA
241	TGTGGATACAACCATAAAATGATAATTCACCCATA	CGYNHKMIIHP (SEQ ID NO: 5490) *IDNYHTP
	AATTGATAATTATCACACCCCA	(SEQ ID NO: 5486)
242	TGTGGATACAACCATAAAATGATAATTCACCCATC	CGYNHKMIIHPSIDNYHTP (SEQ ID NO: 5491)
	AATTGATAATTATCACACCCCA
243	TGTCGATACAACCATAAAATGATAATTCACCCATA	CRYNHKMIIHP (SEQ ID NO: 5492) *IDNYHTP
	AATTGATAATTATCACACCCCA	(SEQ ID NO: 5486)
244	TGTCGATACAACCATAAAATGATAATTCACCCATC	CRYNHKMIIHPSIDNYHTP (SEQ ID NO: 5493)
	AATTGATAATTATCACACCCCA
245	TGTTGATACAACCATAAAATGATAATTACCACCCA	C*YNHKMIITTHKLIIITP (SEQ ID NO: 5494)
	TAAATTGATAATTATCACACCC
246	TGTTGATACAACCATAAAATGATAATTACCACCCC	C*YNHKMIITTPKLIIITP (SEQ ID NO: 5495)
	TAAATTGATAATTATCACACCC
247	TGTTGATACAACCATAAAATGATAATTACCACCCA	C*YNHKMIITTHTLIIITP (SEQ ID NO: 5496)
	TACATTGATAATTATCACACCC
248	TGTTGATACAACCATAAAATGATAATTACCACCCC	C*YNHKMIITTPTLIIITP (SEQ ID NO: 5497)
	TACATTGATAATTATCACACCC
249	TGTTCATACAACCATAAAATGATAATTACCACCCA	CSYNHKMIITTHKLIITP (SEQ ID NO: 5498)
	TAAATTGATAATTATCACACCC
250	TGTTCATACAACCATAAAATGATAATTACCACCCC	CSYNHKMITTPKLIIITP (SEQ ID NO: 5499)
	TAAATTGATAATTATCACACCC
251	TGTTCATACAACCATAAAATGATAATTACCACCCA	CSYNHKMIITTHTLIIITP (SEQ ID NO: 5500)
	TACATTGATAATTATCACACCC
252	TGTTCATACAACCATAAAATGATAATTACCACCCC	CSYNHKMIITTPTLIITP (SEQ ID NO: 5501)
	TACATTGATAATTATCACACCC
253	TGTGGATACAACCATAAAATGATAATTACCACCCA	CGYNHKMIITTHKLIIITP (SEQ ID NO: 5502)
	TAAATTGATAATTATCACACCC
254	TGTGGATACAACCATAAAATGATAATTACCACCCC	CGYNHKMIITTPKLIIITP (SEQ ID NO: 5503)
	TAAATTGATAATTATCACACCC
255	TGTGGATACAACCATAAAATGATAATTACCACCCA	CGYNHKMIITTHTLIITP (SEQ ID NO: 5504)
	TACATTGATAATTATCACACCC
256	TGTGGATACAACCATAAAATGATAATTACCACCCC	CGYNHKMIITTPTLIIITP (SEQ ID NO: 5505)
	TACATTGATAATTATCACACCC
257	TGTCGATACAACCATAAAATGATAATTACCACCCA	CRYNHKMIITTHKLIIITP (SEQ ID NO: 5506)
	TAAATTGATAATTATCACACCC
258	TGTCGATACAACCATAAAATGATAATTACCACCCC	CRYNHKMIITTPKLIIITP (SEQ ID NO: 5507)
	TAAATTGATAATTATCACACCC
259	TGTCGATACAACCATAAAATGATAATTACCACCCA	CRYNHKMITTHTLIITP (SEQ ID NO: 5508)
	TACATTGATAATTATCACACCC
260	TGTCGATACAACCATAAAATGATAATTACCACCCC	CRYNHKMIITTPTLIITP (SEQ ID NO: 5509)
	TACATTGATAATTATCACACCC
18	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPIN (SEQ ID NO: 5352)**LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
69	TCTTGATACAACCATAAAATGATAATTACACCCAT	S*YNHKMIITPIN (SEQ ID NO: 5352)**LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
23	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPIN(SEQ ID NO: 5362) * *LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
264	TGTTTATACAACCATAAAATGATAATTACACCCAT	CLYNHKMIITPIN (SEQ ID NO: 5510) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
24	TGTTCATACAACCATAAAATGATAATTACACCCAT	CSYNHKMIITPIN(SEQ ID NO: 5363) * *LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
266	TGTTGAAACAACCATAAAATGATAATTACACCCAT	C*NNHKMIITPIN (SEQ ID NO: 5511) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
213	TGTTGATCCAACCATAAAATGATAATTACACCCAT	C*SNHKMIITPIN (SEQ ID NO: 5467) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
268	TGTTGATACATCCATAAAATGATAATTACACCCAT	C*YIHKMITPIN (SEQ ID NO: 5512) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
269	TGTTGATACACCCATAAAATGATAATTACACCCAT	C*YTHKMIITPIN (SEQ ID NO: 5513) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
270	TGTTGATACAGCCATAAAATGATAATTACACCCAT	C*YSHKMIITPIN (SEQ ID NO: 5514) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
271	TGTTGATACAACAATAAAATGATAATTACACCCAT	C*YNNKMIITPIN (SEQ ID NO: 5515) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
272	TGTTGATACAACCTTAAAATGATAATTACACCCAT	C*YNLKMIITPIN (SEQ ID NO: 5516) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
117	TGTTGATACAACCCTAAAATGATAATTACACCCAT	C*YNPKMITPIN (SEQ ID NO: 5412) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
274	TGTTGATACAACCAAAAAATGATAATTACACCCAT	C*YNQKMIITPIN (SEQ ID NO: 5517) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
275	TGTTGATACAACCAGAAAATGATAATTACACCCAT	C*YNQKMIITPIN (SEQ ID NO: 5517) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
276	TGTTGATACAACCATATAATGATAATTACACCCAT	C*YNHIMIITPIN (SEQ ID NO: 5518) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
277	TGTTGATACAACCATACAATGATAATTACACCCAT	C*YNHTMIITPIN (SEQ ID NO: 5519) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
278	TGTTGATACAACCATAAATTGATAATTACACCCAT	C*YNHKLIITPIN (SEQ ID NO: 5520) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
279	TGTTGATACAACCATAAACTGATAATTACACCCAT	C*YNHKLIITPIN (SEQ ID NO: 5520) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
280	TGTTGATACAACCATAAAGTGATAATTACACCCAT	C*YNHKVIITPIN (SEQ ID NO: 5521) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
189	TGTTGATACAACCATAAAACGATAATTACACCCAT	C*YNHKTIITPIN (SEQ ID NO: 5449) **LSHP (SEQ
	AAATTGATAATTATCACACCCA	ID NO: 5353)
282	TGTTGATACAACCATAAAATTATAATTACACCCAT	C*YNHKIIITPIN (SEQ ID NO: 5522) **LSHP (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5353)
283	TGTTGATACAACCATAAAATCATAATTACACCCAT	C*YNHKIIITPIN (SEQ ID NO: 5522) **LSHP (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5353)
284	TGTTGATACAACCATAAAATAATAATTACACCCAT	C*YNHKIIITPIN (SEQ ID NO: 5522) **LSHP (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5353)
285	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPII (SEQ ID NO: 5523) **LSHP (SEQ ID NO:
	AATTTGATAATTATCACACCCA	5353)
286	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPIT (SEQ ID NO: 5524) **LSHP (SEQ
	AACTTGATAATTATCACACCCA	ID NO: 5353)
287	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPIS (SEQ ID NO: 5526) **LSHP (SEQ
	AAGTTGATAATTATCACACCCA	ID NO: 5353)
25	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPING(SEQ ID NO: 5364) * LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
289	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPINL (SEQ ID NO: 5527) *LSHP (SEQ
	AAATTTATAATTATCACACCCA	ID NO: 5353)
26	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPINS(SEQ ID NO: 5365) * LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
291	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPIN (SEQ ID NO: 5352)*QLSHP (SEQ
	AAATTGACAATTATCACACCCA	ID NO: 5528)
292	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPIN (SEQ ID NO: 5352)*LLSHP (SEQ
	AAATTGATTATTATCACACCCA	ID NO: 5529)
33	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPIN (SEQ ID NO: 5352)*SLSHP (SEQ
	AAATTGATCATTATCACACCCA	ID NO: 5372)
294	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPIN (SEQ ID NO: 5352)**LSNP (SEQ
	AAATTGATAATTATCAAACCCA	ID NO: 5543)
298	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPIN (SEQ ID NO: 5352)**LSLP (SEQ
	AAATTGATAATTATCACTOCCA	ID NO: 5544)
141	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPIN (SEQ ID NO: 5352)**LSPP (SEQ
	AAATTGATAATTATCACCCCCA	ID NO: 5432)
29	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPING (SEQ ID NO: 5368) * LSHP
	AAATGGATAATTATCACACCCA	(SEQ ID NO: 5353)
298	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPINL (SEQ ID NO: 5530) *LSHP (SEQ
	AAATTTATAATTATCACACCCA	ID NO: 5353)
30	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPINS (SEQ ID NO: 5369) * LSHP
	AAATTCATAATTATCACACCCA	(SEQ ID NO: 5353)
300	TGTTTATACAACCATAAAATGATAATTACACCCAT	CLYNHKMITPING (SEQ ID NO: 5531) *LSHP (SEQ
	AAATGGATAATTATCACACCCA	ID NO: 5353)
301	TGTTTATACAACCATAAAATGATAATTACACCCAT	CLYNHKMIITPINL (SEQ ID NO: 5532) *LSHP (SEQ
	AAATTTATAATTATCACACCCA	ID NO: 5353)
302	TGTTTATACAACCATAAAATGATAATTACACCCAT	CLYNHKMIITPINS (SEQ ID NO: 5533) *LSHP (SEQ
	AAATTCATAATTATCACACCCA	ID NO: 5353)
303	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPINGLLSHP (SEQ ID NO: 5534)
	AAATGGATTATTATCACACCCA
304	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPINLLLSHP (SEQ ID NO: 5535)
	AAATTTATTATTATCACACCCA
305	TGTTGATACAACCATAAAATGATAATTACACCCAT	C*YNHKMIITPINSLLSHP (SEQ ID NO: 5536)
	AAATTCATTATTATCACACCCA
306	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPINGLLSHP (SEQ ID NO: 5537)
	AAATGGATTATTATCACACCCA
307	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPINLLLSHP (SEQ ID NO: 5538)
	AAATTTATTATTATCACACCCA
308	TGTGGATACAACCATAAAATGATAATTACACCCAT	CGYNHKMIITPINSLLSHP (SEQ ID NO: 5539)
	AAATTCATTATTATCACACCCA
309	TGTTTATACAACCATAAAATGATAATTACACCCAT	CLYNHKMIITPINGLLSHP (SEQ ID NO: 5540)
	AAATGGATTATTATCACACCCA
310	TGTTTATACAACCATAAAATGATAATTACACCCAT	CLYNHKMIITPINLLLSHP (SEQ ID NO: 5541)
	AAATTTATTATTATCACACCCA
302	TGTTTATACAACCATAAAATGATAATTACACCCAT	CLYNHKMIITPINSLLSHP (SEQ ID NO: 5542)
	AAATTCATTATTATCACACCCA

Frame 2

18	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCACACCCA	**LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
316	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCACACCCA	*LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
283	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCACACCCA	*LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
318	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLHP (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5549) *IDNYHT[Q/H] (SEQ ID NO: 5546)
319	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHP (SEQ ID NO: 5550)
	AAATTGATAATTATCACACCCA	*IDNYHT[Q/H] (SEQ ID NO: 5546)
320	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHP (SEQ ID NO: 5551)
	AAATTGATAATTATCACACCCA	*IDNYHT[Q/H] (SEQ ID NO: 5546)
321	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCACACCCA	**LHPSIDNYHT[Q/H] (SEQ ID NO: 5552)
322	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATCACACCCA	*LHPSIDNYHT[Q/H] (SEQ ID NO: 5552)
323	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCACACCCA	*LHPSIDNYHT[Q/H] (SEQ ID NO: 5552)
324	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCACACCCA	*SLHPSIDNYHT[Q/H] (SEQ ID NO: 5553)
325	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHPSIDNYHT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCACACCCA	5554)
326	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHPSIDNYHT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCACACCCA	5555)
327	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCACACCCA	**LPP*IDNYHT[Q/H] (SEQ ID NO: 5546)
328	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCACACCCA	*LPP*IDNYHT[Q/H] (SEQ ID NO: 5546)
329	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCACACCCA	*LPP*IDNYHT[Q/H] (SEQ ID NO: 5546)
330	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLPP (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5556) *IDNYHT[Q/H] (SEQ ID NO: 5546)
331	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPP (SEQ ID NO: 5557)
	AAATTGATAATTATCACACCCA	*IDNYHT[Q/H] (SEQ ID NO: 5546)
332	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPP (SEQ ID NO: 5558)
	AAATTGATAATTATCACACCCA	*IDNYHT[Q/H] (SEQ ID NO: 5546)
333	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCACACCCA	**LPPSIDNYHT[Q/H] (SEQ ID NO: 5559)
334	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATCACACCCA	*LPPSIDNYHT[Q/H] (SEQ ID NO: 5559)
335	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCACACCCA	*LPPSIDNYHT[Q/H] (SEQ ID NO: 5559)
336	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCACACCCA	*SLPPSIDNYHT[Q/H] (SEQ ID NO: 5560)
337	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPPSIDNYHT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCACACCCA	5561)
338	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPPSIDNYHT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCACACCCA	5562)
339	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCCCACCCA	**LHP*IDNYPT[Q/H] (SEQ ID NO: 5563)
340	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCCCACCCA	*LHP*IDNYPT[Q/H] (SEQ ID NO: 5563)
341	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCCCACCCA	*LHP*IDNYPT[Q/H] (SEQ ID NO: 5563)
342	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLHP (SEQ ID NO:
	AAATTGATAATTATCCCACCCA	5549) *IDNYPT[Q/H] (SEQ ID NO: 5563)
343	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHP (SEQ ID NO: 5550)
	AAATTGATAATTATCCCACCCA	*IDNYPT[Q/H] (SEQ ID NO: 5563)
344	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHP (SEQ ID NO: 5551)
	AAATTGATAATTATCCCACCCA	*IDNYPT[Q/H] (SEQ ID NO: 5563)
345	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCA	**LHPSIDNYPT[Q/H] (SEQ ID NO: 5564)
346	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATCCCACCCA	*LHPSIDNYPT[Q/H] (SEQ ID NO: 5564)
347	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCCCACCCA	*LHPSIDNYPT[Q/H] (SEQ ID NO: 5564)
348	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCA	*SLHPSIDNYPT[Q/H] (SEQ ID NO: 5565)
349	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHPSIDNYPT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCCCACCCA	5566)
350	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHPSIDNYPT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCCCACCCA	5567)
351	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) **LHP*IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
352	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547) *LHP*IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
353	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548) *LHP*IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
354	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLHP (SEQ ID NO:
	AAATTGATAATTATCACACCCC	5549) *IDNYHTP (SEQ ID NO: 5486)
355	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHP (SEQ ID NO: 5550) *IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
356	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHP (SEQ ID NO: 5551) *IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
357	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) **LHPSIDNYHTP
	CAATTGATAATTATCACACCCC	(SEQ ID NO: 5568)
358	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547) *LHPSIDNYHTP
	CAATTGATAATTATCACACCCC	(SEQ ID NO: 5568)
359	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548) *LHPSIDNYHTP
	CAATTGATAATTATCACACCCC	(SEQ ID NO: 5568)
360	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLHPSIDNYHTP
	CAATTGATAATTATCACACCCC	(SEQ ID NO: 5569)
361	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHPSIDNYHTP (SEQ ID NO: 5570)
	CAATTGATAATTATCACACCCC
362	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHPSIDNYHTP (SEQ ID NO: 5571)
	CAATTGATAATTATCACACCCC
363	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCCCACCCA	**LPP*IDNYPT[Q/H] (SEQ ID NO: 5563)
364	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCCCACCCA	*LPP*IDNYPT[Q/H] (SEQ ID NO: 5563)
365	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCCCACCCA	*LPP*IDNYPT[Q/H] (SEQ ID NO: 5563)
366	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLPP (SEQ ID NO:
	AAATTGATAATTATCCCACCCA	5556) *IDNYPT[Q/H] (SEQ ID NO: 5563)
367	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPP (SEQ ID NO: 5557)
	AAATTGATAATTATCCCACCCA	*IDNYPT[Q/H] (SEQ ID NO: 5563)
368	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPP (SEQ ID NO: 5558)
	AAATTGATAATTATCCCACCCA	*IDNYPT[Q/H] (SEQ ID NO: 5563)
369	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCA	**LPPSIDNYPT[Q/H] (SEQ ID NO: 5572)
370	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATCCCACCCA	*LPPSIDNYPT[Q/H] (SEQ ID NO: 5572)
371	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCCCACCCA	*LPPSIDNYPT[Q/H] (SEQ ID NO: 5572)
372	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SBQ ID NO: 5545)
	CAATTGATAATTATCCCACCCA	*SLPPSIDNYPT[Q/H] (SEQ ID NO: 5792)
373	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPPSIDNYPT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCCCACCCA	5793)
374	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPPSIDNYPT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCCCACCCA	5794)
375	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545) **LPP*IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
376	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547) *LPP*IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
377	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548) *LPP*IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
378	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLPP (SEQ ID NO:
	AAATTGATAATTATCACACCCC	5556) *IDNYHTP (SEQ ID NO: 5486)
379	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPP (SEQ ID NO: 5557) *IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
380	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPP (SEQ ID NO: 5558) *IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
381	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545) **LPPSIDNYHTP
	CAATTGATAATTATCACACCCC	(SEQ ID NO: 5795)
382	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATCACACCCC	*LPPSIDNYHTP(SEQ ID NO: 5795)
383	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCACACCCC	*LPPSIDNYHTP(SBQ ID NO: 5795)
384	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCACACCCC	*SLPPSIDNYHTP(SEQ ID NO: 5796)
385	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPPSIDNYHTP(SEQ ID NO: 5797)
	CAATTGATAATTATCACACCCC
386	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPPSIDNYHTP(SEQ ID NO: 5798)
	CAATTGATAATTATCACACCCC
387	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCCCACCCC	**LHP*IDNYPTP(SEQ ID NO: 5799)
388	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCCCACCCC	*LHP*IDNYPTP(SEQ ID NO: 5799)
389	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCCCACCCC	*LHP*IDNYPTP(SEQ ID NO: 5799)
390	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLHP (SEQ ID NO:
	AAATTGATAATTATCCCACCCC	5549) *IDNYPTP(SEQ ID NO: 5799)
391	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHP (SEQ ID NO: 5550)
	AAATTGATAATTATCCCACCCC	*IDNYPTP(SEQ ID NO: 5799)
392	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHP (SEQ ID NO: 5551)
	AAATTGATAATTATCCCACCCC	*IDNYPTP(SEQ ID NO: 5799)
393	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) **LHPSIDNYPTP
	CAATTGATAATTATCCCACCCC	(SEQ ID NO: 5800)
394	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATCCCACCCC	*LHPSIDNYPTP(SEQ ID NO: 5800)
395	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCCCACCCC	*LHPSIDNYPTP(SEQ ID NO: 5800)
396	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCC	*SLHPSIDNYPTP(SEQ ID NO: 5801)
397	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHPSIDNYPTP (SEQ ID NO: 5802)
	CAATTGATAATTATCCCACCCC
398	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHPSIDNYPTP (SEQ ID NO: 5803)
	CAATTGATAATTATCCCACCCC
399	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCCCACCCC	**LPP*IDNYPTP(SEQ ID NO: 5799)
400	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCCCACCCC	*LPP*IDNYPTP(SEQ ID NO: 5799)
401	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCCCACCCC	*LPP*IDNYPTP(SEQ ID NO: 5799)
402	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLPP (SEQ ID NO:
	AAATTGATAATTATCCCACCCC	5556) *IDNYPTP(SEQ ID NO: 5799)
403	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPP (SEQ ID NO: 5557)
	AAATTGATAATTATCCCACCCC	*IDNYPTP(SEQ ID NO: 5799)
404	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPP (SEQ ID NO: 5558)
	AAATTGATAATTATCCCACCCC	*IDNYPTP(SEQ ID NO: 5799)
405	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545) **LPPSIDNYPTP
	CAATTGATAATTATCCCACCCC	(SEQ ID NO: 5804)
406	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATOCCACCCC	*LPPSIDNYPTP(SEQ ID NO: 5804)
407	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCCCACCCC	*LPPSIDNYPTP(SEQ ID NO: 5804)
408	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCC	*SLPPSIDNYPTP(SEQ ID NO: 5805)
409	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPPSIDNYPTP(SEQ ID NO: 5806)
	CAATTGATAATTATCCCACCCC
410	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPPSIDNYPTP (SEQ ID NO: 5807)
	CAATTGATAATTATCCCACCCC
411	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTCTCACACCCA	**LHP*IDNSHT[Q/H](SEQ ID NO: 5837)
316	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCACACCCA	*LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
283	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCACACCCA	*LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
318	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLHP (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5549) *IDNYHT[Q/H] (SEQ ID NO: 5546)
319	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHP (SEQ ID NO: 5550)
	AAATTGATAATTATCACACCCA	*IDNYHT[Q/H] (SEQ ID NO: 5546)
320	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHP (SEQ ID NO: 5551)
	AAATTGATAATTATCACACCCA	*IDNYHT[Q/H] (SEQ ID NO: 5546)
321	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCACACCCA	**LHPSIDNYHT[Q/H] (SEQ ID NO: 5552)
322	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATCACACCCA	*LHPSIDNYHT[Q/H] (SEQ ID NO: 5552)
323	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCACACCCA	*LHPSIDNYHT[Q/H] (SEQ ID NO: 5552)
324	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCACACCCA	*SLHPSIDNYHT[Q/H] (SEQ ID NO: 5553)
325	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHPSIDNYHT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCACACCCA	5554)
326	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHPSIDNYHT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCACACCCA	5555)
327	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCACACCCA	**LPP*IDNYHT[Q/H] (SEQ ID NO: 5546)
328	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCACACCCA	*LPP*IDNYHT[Q/H] (SEQ ID NO: 5546)
329	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCACACCCA	*LPP*IDNYHT[Q/H] (SEQ ID NO: 5546)
330	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLPP (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5556) *IDNYHT[Q/H] (SEQ ID NO: 5546)
331	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPP (SEQ ID NO: 5557)
	AAATTGATAATTATCACACCCA	*IDNYHT[Q/H] (SEQ ID NO: 5546)
332	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPP (SEQ ID NO: 5558)
	AAATTGATAATTATCACACCCA	*IDNYHT[Q/H] (SEQ ID NO: 5546)
333	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCACACCCA	**LPPSIDNYHT[Q/H] (SEQ ID NO: 5559)
334	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATCACACCCA	*LPPSIDNYHT[Q/H] (SEQ ID NO: 5559)
335	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCACACCCA	*LPPSIDNYHT[Q/H] (SEQ ID NO: 5559)
336	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCACACCCA	*SLPPSIDNYHT[Q/H] (SEQ ID NO: 5560)
337	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPPSIDNYHT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCACACCCA	5561)
338	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPPSIDNYHT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCACACCCA	5562
339	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCCCACCCA	**LHP*IDNYPT[Q/H] (SEQ ID NO: 5563)
340	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCCCACCCA	*LHP*IDNYPT[Q/H] (SEQ ID NO: 5563)
341	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCCCACCCA	*LHP*IDNYPT[Q/H] (SEQ ID NO: 5563)
342	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLHP (SEQ ID NO:
	AAATTGATAATTATCCCACCCA	5549) *IDNYPT[Q/H] (SEQ ID NO: 5563)
343	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHP (SEQ ID NO: 5550)
	AAATTGATAATTATCCCACCCA	*IDNYPT[Q/H] (SEQ ID NO: 5563)
344	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHP (SEQ ID NO: 5551)
	AAATTGATAATTATCCCACCCA	*IDNYPT[Q/H] (SEQ ID NO: 5563)
345	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCA	**LHPSIDNYPT[Q/H] (SEQ ID NO: 5564)
346	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATCCCACCCA	*LHPSIDNYPT[Q/H] (SEQ ID NO: 5564)
347	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCCCACCCA	*LHPSIDNYPT[Q/H] (SEQ ID NO: 5564)
348	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCA	*SLHPSIDNYPT[Q/H] (SEQ ID NO: 5565)
349	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHPSIDNYPT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCCCACCCA	5566)
350	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHPSIDNYPT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCCCACCCA	5567)
351	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) **LHP*IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
352	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547) *LHP*IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
353	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548) *LHP*IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
354	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLHP (SEQ ID NO:
	AAATTGATAATTATCACACCCC	5549) *IDNYHTP (SEQ ID NO: 5486)
355	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHP (SEQ ID NO: 5550) *IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
356	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHP (SEQ ID NO: 5551) *IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
357	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) **LHPSIDNYHTP
	CAATTGATAATTATCACACCCC	(SEQ ID NO: 5568)
358	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547) *LHPSIDNYHTP
	CAATTGATAATTATCACACCCC	(SEQ ID NO: 5568)
359	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548) *LHPSIDNYHTP
	CAATTGATAATTATCACACCCC	(SEQ ID NO: 5568)
360	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLHPSIDNYHTP
	CAATTGATAATTATCACACCCC	(SEQ ID NO: 5569)
361	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHPSIDNYHTP (SEQ ID NO: 5570)
	CAATTGATAATTATCACACCCC
362	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHPSIDNYHTP (SEQ ID NO: 5571)
	CAATTGATAATTATCACACCCC
363	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCCCACCCA	**LPP*IDNYPT[Q/H] (SEQ ID NO: 5563)
364	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCCCACCCA	*LPP*IDNYPT[Q/H] (SEQ ID NO: 5563)
365	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCCCACCCA	*LPP*IDNYPT[Q/H] (SEQ ID NO: 5563)
366	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLPP (SEQ ID NO:
	AAATTGATAATTATCCCACCCA	5556) *IDNYPT[Q/H] (SEQ ID NO: 5563)
367	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPP (SEQ ID NO: 5557)
	AAATTGATAATTATCCCACCCA	*IDNYPT[Q/H] (SEQ ID NO: 5563)
368	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPP (SEQ ID NO: 5558)
	AAATTGATAATTATCCCACCCA	*IDNYPT[Q/H] (SEQ ID NO: 5563)
369	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCA	**LPPSIDNYPT[Q/H] (SEQ ID NO: 5572)
370	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATCCCACCCA	*LPPSIDNYPT[Q/H] (SEQ ID NO: 5572)
371	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCCCACCCA	*LPPSIDNYPT[Q/H] (SEQ ID NO: 5572)
372	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCA	*SLPPSIDNYPT[Q/H] (SEQ ID NO: 5792)
373	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPPSIDNYPT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCCCACCCA	5793)
374	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPPSIDNYPT[Q/H] (SEQ ID NO:
	CAATTGATAATTATCCCACCCA	5794)
375	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545) **LPP*IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
376	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547) *LPP*IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
377	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548) *LPP*IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
378	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLPP (SEQ ID NO:
	AAATTGATAATTATCACACCCC	5556) *IDNYHTP (SEQ ID NO: 5486)
379	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPP (SEQ ID NO: 5557) *IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
380	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPP (SEQ ID NO: 5558) *IDNYHTP
	AAATTGATAATTATCACACCCC	(SEQ ID NO: 5486)
381	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCACACCCC	**LPPSIDNYHTP(SEQ ID NO: 5795)
382	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATCACACCCC	*LPPSIDNYHTP(SEQ ID NO: 5795)
383	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCACACCCC	*LPPSIDNYHTP(SEQ ID NO: 5795)
384	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCACACCCC	*SLPPSIDNYHTP(SEQ ID NO: 5796)
385	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPPSIDNYHTP(SEQ ID NO: 5797)
	CAATTGATAATTATCACACCCC
386	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPPSIDNYHTP(SEQ ID NO: 5798)
	CAATTGATAATTATCACACCCC
387	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCCCACCCC	**LHP*IDNYPTP(SEQ ID NO: 5799)
388	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCCCACCCC	*LHP*IDNYPTP(SEQ ID NO: 5799)
389	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCCCACCCC	*LHP*IDNYPTP(SEQ ID NO: 5799)
390	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLHP (SEQ ID NO:
	AAATTGATAATTATCCCACCCC	5549) *IDNYPTP(SEQ ID NO: 5799)
391	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHP (SEQ ID NO: 5550)
	AAATTGATAATTATCCCACCCC	*IDNYPTP(SEQ ID NO: 5799)
392	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHP (SEQ ID NO: 5551)
	AAATTGATAATTATCCCACCCC	*IDNYPTP(SEQ ID NO: 5799)
393	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCC	**LHPSIDNYPTP(SEQ ID NO: 5800)
394	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATOCCACCCC	*LHPSIDNYPTP(SEQ ID NO: 5800)
395	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCCCACCCC	*LHPSIDNYPTP(SEQ ID NO: 5800)
396	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCC	*SLHPSIDNYPTP(SEQ ID NO: 5801)
397	TGTTGATACAACCATAAAAGGATCATTACACCCAT	[X]VDTTIKGSLHPSIDNYPTP (SEQ ID NO: 5802)
	CAATTGATAATTATCCCACCCC
398	TGTTGATACAACCATAAAATCATCATTACACCCAT	[X]VDTTIKSSLHPSIDNYPTP (SEQ ID NO: 5803)
	CAATTGATAATTATCCCACCCC
399	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCCCACCCC	**LPP*IDNYPTP(SEQ ID NO: 5799)
400	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCCCACCCC	*LPP*IDNYPTP(SEQ ID NO: 5799)
401	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCCCACCCC	*LPP*IDNYPTP(SEQ ID NO: 5799)
402	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLPP (SEQ ID NO:
	AAATTGATAATTATCCCACCCC	5556) *IDNYPTP(SEQ ID NO: 5799)
403	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPP (SEQ ID NO: 5557)
	AAATTGATAATTATCCCACCCC	*IDNYPTP(SEQ ID NO: 5799)
404	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPP (SEQ ID NO: 5558)
	AAATTGATAATTATCCCACCCC	*IDNYPTP(SEQ ID NO: 5799)
405	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCC	** LPPSIDNYPTP(SEQ ID NO: 5804)
406	TGTTGATACAACCATAAAAGGATAATTACCCCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	CAATTGATAATTATCCCACCCC	*LPPSIDNYPTP(SEQ ID NO: 5804)
407	TGTTGATACAACCATAAAATCATAATTACCCCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	CAATTGATAATTATCCCACCCC	*LPPSIDNYPTP(SEQ ID NO: 5804)
408	TGTTGATACAACCATAAAATGATCATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCCCACCCC	*SLPPSIDNYPTP(SEQ ID NO: 5805)
409	TGTTGATACAACCATAAAAGGATCATTACCCCCAT	[X]VDTTIKGSLPPSIDNYPTP (SEQ ID NO: 5806)
	CAATTGATAATTATCCCACCCC
410	TGTTGATACAACCATAAAATCATCATTACCCCCAT	[X]VDTTIKSSLPPSIDNYPTP(SEQ ID NO: 5807)
	CAATTGATAATTATCCCACCCC
507	TGTTGATACAACCATAAAATGATAATTCACCCATA	[X]VDTTIK (SEQ ID NO: 5545) **FTHKLIIITPT
	AATTGATAATTATCACACCCAC	(SEQ ID NO: 5808)
508	TGTTGATACAACCATAAAAGGATAATTCACCCATA	[X]VDTTIKG (SEQ ID NO: 5547) *FTHKLIIITPT
	AATTGATAATTATCACACCCAC	(SEQ ID NO: 5808)
509	TGTTGATACAACCATAAAATCATAATTCACCCATA	[X]VDTTIKS (SEQ ID NO: 5548) *FTHKLIITPT
	AATTGATAATTATCACACCCAC	(SEQ ID NO: 5808)
510	TGTTGATACAACCATAAAATGATCATTCACCCATA	[X]VDTTIK (SEQ ID NO: 5545) *SFTHKLIIITPT
	AATTGATAATTATCACACCCAC	(SEQ ID NO: 5809)
511	TGTTGATACAACCATAAAAGGATCATTCACCCATA	[X]VDTTIKGSFTHKLIIITPT (SEQ ID NO: 5810)
	AATTGATAATTATCACACCCAC
512	TGTTGATACAACCATAAAATCATCATTCACCCATA	[X]VDTTIKSSFTHKLIIITPT (SEQ ID NO: 5811)
	AATTGATAATTATCACACCCAC
513	TGTTGATACAACCATAAAATGATAATTCACCCCTA	[X]VDTTIK (SEQ ID NO: 5545) **FTPKLIITPT
	AATTGATAATTATCACACCCAC	(SEQ ID NO: 5812)
514	TGTTGATACAACCATAAAAGGATAATTCACCCCTA	[X]VDTTIKG (SEQ ID NO: 5547) *FTPKLIITPT
	AATTGATAATTATCACACCCAC	(SEQ ID NO: 5812)
515	TGTTGATACAACCATAAAATCATAATTCACCCCTA	[X]VDTTIKS (SEQ ID NO: 5548) *FTPKLIIITPT
	AATTGATAATTATCACACCCAC	(SEQ ID NO: 5812)
516	TGTTGATACAACCATAAAATGATCATTCACCCCTA	[X]VDTTIK (SEQ ID NO: 5545) *SFTPKLIIITPT
	AATTGATAATTATCACACCCAC	(SEQ ID NO: 5813)
517	TGTTGATACAACCATAAAAGGATCATTCACCCCTA	[X]VDTTIKGSFTPKLIHITPT (SEQ ID NO: 5814)
	AATTGATAATTATCACACCCAC
518	TGTTGATACAACCATAAAATCATCATTCACCCCTA	[X]VDTTIKSSFTPKLIIITPT (SEQ ID NO: 5815)
	AATTGATAATTATCACACCCAC
18	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCACACCCA	**LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
520	TGTTAATACAACCATAAAATGATAATTACACCCAT	[X]VNTTIK(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5816)**LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
521	TGTTGTTACAACCATAAAATGATAATTACACCCAT	[X]VVTTIK(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5817)**LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
522	TGTTGCTACAACCATAAAATGATAATTACACCCAT	[X]VATTIK(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5818)**LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
523	TGTTGGTACAACCATAAAATGATAATTACACCCAT	[X]VGTTIK(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5819)**LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
277	TGTTGATACAACCATACAATGATAATTACACCCAT	[X]VDTTIQ(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5820)**LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
525	TGTTGATACAACCATAATATGATAATTACACCCAT	[X]VDTTII(SEQ ID NO: 5821)**LHP*IDNYHT[Q/H]
	AAATTGATAATTATCACACCCA	(SEQ ID NO: 5546)
526	TGTTGATACAACCATAACATGATAATTACACCCAT	[X]VDTTIT(SEQ ID NO: 5822)**LHP*IDNYHT[Q/H]
	AAATTGATAATTATCACACCCA	(SEQ ID NO: 5546)
278	TGTTGATACAACCATAAATTGATAATTACACCCAT	[X]VDTTIN(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5823)**LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
279	TGTTGATACAACCATAAACTGATAATTACACCCAT	[X]VDTTIN**LHP*IDNYHT[Q/H] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5546)
316	TGTTGATACAACCATAAAAGGATAATTACACCCAT	[X]VDTTIKG (SEQ ID NO: 5547)
	AAATTGATAATTATCACACCCA	*LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
282	TGTTGATACAACCATAAAATTATAATTACACCCAT	[X]VDTTIKL(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5824)*LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
283	TGTTGATACAACCATAAAATCATAATTACACCCAT	[X]VDTTIKS (SEQ ID NO: 5548)
	AAATTGATAATTATCACACCCA	*LHP*IDNYHT[Q/H] (SEQ ID NO: 5546)
532	TGTTGATACAACCATAAAATGACAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *QLHP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5825)*IDNYHT[Q/H] (SEQ ID NO: 5546)
533	TGTTGATACAACCATAAAATGATTATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *LLHP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5826)*IDNYHT[Q/H] (SEQ ID NO: 5546)
318	TGTTGATACAACCATAAAATGATCATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545) *SLHP (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5549) *IDNYHT[Q/H] (SEQ ID NO: 5546)
535	TGTTGATACAACCATAAAATGATAATTAAACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCACACCCA	**LNP*IDNYHT[Q/H] (SEQ ID NO: 5546)
536	TGTTGATACAACCATAAAATGATAATTACTCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCACACCCA	**LLP*IDNYHT[Q/H] (SEQ ID NO: 5546)
327	TGTTGATACAACCATAAAATGATAATTACCCCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCACACCCA	**LPP*IDNYHT[Q/H] (SEQ ID NO: 5546)
538	TGTTGATACAACCATAAAATGATAATTACAACCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCACACCCA	**LQP*IDNYHT[Q/H] (SEQ ID NO: 5546)
539	TGTTGATACAACCATAAAATGATAATTACAGCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCACACCCA	**LQP*IDNYHT[Q/H] (SEQ ID NO: 5546)
540	TGTTGATACAACCATAAAATGATAATTACACCCAC	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCACACCCA	**LHPQIDNYHT[Q/H](SEQ ID NO: 5827)
541	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	TAATTGATAATTATCACACCCA	**LHPLIDNYHT[Q/H](SEQ ID NO: 5828)
321	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	CAATTGATAATTATCACACCCA	**LHPSIDNYHT[Q/H] (SEQ ID NO: 5552)
543	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTAATAATTATCACACCCA	**LHP*INNYHT[Q/H](SEQ ID NO: 5829)
544	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGTTAATTATCACACCCA	**LHP*IVNYHT[Q/H](SEQ ID NO: 5830)
545	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGCTAATTATCACACCCA	**LHP*IANYHT[Q/H](SEQ ID NO: 5831)
546	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGGTAATTATCACACCCA	**LHP*IGNYHT[Q/H](SEQ ID NO: 5832)
547	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATATTTATCACACCCA	**LHP*IDIYHT[Q/H](SEQ ID NO: 5833)
548	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATACTTATCACACCCA	**LHP*IDTYHT[Q/H](SEQ ID NO: 5834)
549	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAGTTATCACACCCA	**LHP*IDSYHT[Q/H](SEQ ID NO: 5835)
550	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATAATCACACCCA	**LHP*IDNNHT[Q/H](SEQ ID NO: 5836)
411	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTCTCACACCCA	**LHP*IDNSHT[Q/H](SEQ ID NO: 5837)
552	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATAACACCCA	**LHP*IDNYNT[Q/H](SEQ ID NO: 5838)
553	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCTCACCCA	**LHP*IDNYLT[Q/H](SEQ ID NO: 5839)
339	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCCCACCCA	**LHP*IDNYPT[Q/H] (SEQ ID NO: 5563)
294	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCAAACCCA	**LHP*IDNYQT[Q/H](SEQ ID NO: 5840)
556	TGTTGATACAACCATAAAATGATAATTACACCCAT	[X]VDTTIK (SEQ ID NO: 5545)
	AAATTGATAATTATCAGACCCA	**LHP*IDNYQT[Q/H](SEQ ID NO: 5840)
557	TGTTGATACAACCATAAAATGATTATTACACCCAT	[X]VDTTIK (SBQ ID NO: 5545)
	TAATTGATAATTATCACACCCA	*LLHPLIDNYHT[Q/H](SEQ ID NO: 5841)
558	TGTTGATACAACCATAAAAGGATTATTACACCCAT	[X]VDTTIKGLLHPLIDNYHT[Q/H] (SEQ ID NO:
	TAATTGATAATTATCACACCCA	5842)
559	TGTTGATACAACCATAAAATTATTATTACACCCAT	[X]VDTTIKLLLHPLIDNYHT[Q/H] (SEQ ID NO:
	TAATTGATAATTATCACACCCA	5843)
560	TGTTGATACAACCATAAAATCATTATTACACCCAT	[X]VDTTIKSLLHPLIDNYHT[Q/H] (SEQ ID NO:
	TAATTGATAATTATCACACCCA (551)	5844)

Frame 3

18	TGTTGATACAACCATAAAATGATAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDNYTHKLIIITP[X](SEQ ID NO: 5748)
565	TGTTGATACAACCATCAAATGATAATTACACCCAT	[M/L/V]LIQPSNDNYTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5747)
566	TGTTGATACAACCATAAAATGATAATTACACCCCT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDNYTPKLIIITP[X] (SEQ ID NO: 5739)
567	TGTTGATACAACCATCAAATGATAATTACACCCCT	[M/L/V]LIQPSNDNYTPKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5749)
568	TGTTGATACAACCATAAAATGATAATTCCACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDNSTHKLIIITP[X] (SEQ ID NO: 5736)
569	TGTTGATACAACCATCAAATGATAATTCCACCCAT	[M/L/V]LIQPSNDNSTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5750)
570	TGTTGATACAACCATAAAATGATAATTCCACCCCT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDNSTPKLIIITP[X] (SEQ ID NO: 5751)
571	TGTTGATACAACCATCAAATGATAATTCCACCCCT	[M/L/V]LIQPSNDNSTPKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5752)
572	TGTTGATACAACCATAAAATGGTAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NGNYTHKLIIITP[X](SEQ ID NO: 5731)
573	TGTTGATACAACCATCAAATGGTAATTACACCCAT	[M/L/V]LIQPSNGNYTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5358)
574	TGTTGATACAACCATAAAATGGTAATTACACCCCT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NGNYTPKLIIITP[X] (SEQ ID NO: 5753)
575	TGTTGATACAACCATCAAATGGTAATTACACCCCT	[M/L/V]LIQPSNGNYTPKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5754)
576	TGTTGATACAACCATAAAATGGTAATTCCACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NGNSTHKLIIITP[X] (SEQ ID NO: 5755)
577	TGTTGATACAACCATCAAATGGTAATTCCACCCAT	[M/L/V]LIQPSNGNSTHKLIUITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5756)
578	TGTTGATACAACCATAAAATGGTAATTCCACCCCT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NGNSTPKLIIITP[X] (SEQ ID NO: 5757)
579	TGTTGATACAACCATCAAATGGTAATTCCACCCCT	[M/L/V]LIQPSNGNSTPKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5758)
580	TGTTGATACAACCATAAAATGATAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5724)*NDNYTHTLIIITP[X](SEQ ID NO: 5743)
581	TGTTGATACAACCATCAAATGATAATTACACCCAT	[M/L/V]LIQPSNDNYTHTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5759)
582	TGTTGATACAACCATAAAATGATAATTACACCCCT	[M/L/V]LIQP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5724)*NDNYTPTLIIITP[X] (SEQ ID NO: 5760)
583	TGTTGATACAACCATCAAATGATAATTACACCCCT	[M/L/V]LIQPSNDNYTPTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5761)
584	TGTTGATACAACCATAAAATGATAATTCCACCCAT	[M/L/V]LIQP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5724)*NDNSTHTLIIITP[X] (SEQ ID NO: 5762)
585	TGTTGATACAACCATCAAATGATAATTCCACCCAT	[M/L/V]LIQPSNDNSTHTLIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5763)
586	TGTTGATACAACCATAAAATGATAATTCCACCCCT	[M/L/V]LIQP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5724)*NDNSTPTLIIITP[X] (SEQ ID NO: 5764)
587	TGTTGATACAACCATCAAATGATAATTCCACCCCT	[M/L/V]LIQPSNDNSTPTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5765)
588	TGTTGATACAACCATAAAATGGTAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5724)*NGNYTHTLIIITP[X] (SEQ ID NO: 5766)
589	TGTTGATACAACCATCAAATGGTAATTACACCCAT	[M/L/V]LIQPSNGNYTHTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5767)
590	TGTTGATACAACCATAAAATGGTAATTACACCCCT	[M/L/V]LIQP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5724)*NGNYTPTLIIITP[X] (SEQ ID NO: 5768)
591	TGTTGATACAACCATCAAATGGTAATTACACCCCT	[M/L/V]LIQPSNGNYTPTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5769)
592	TGTTGATACAACCATAAAATGGTAATTCCACCCAT	[M/L/V]LIQP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5724)*NGNSTHTLIIITP[X] (SEQ ID NO: 5770)
593	TGTTGATACAACCATCAAATGGTAATTCCACCCAT	[M/L/V]LIQPSNGNSTHTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5771)
594	TGTTGATACAACCATAAAATGGTAATTCCACCCCT	[M/L/V]LIQP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5724)*NGNSTPTLIIITP[X] (SEQ ID NO: 5772)
595	TGTTGATACAACCATCAAATGGTAATTCCACCCCT	[M/L/V]LIQPSNGNSTPTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5773)
596	TGTTGATACCACCATAAAATGATAATTACACCCAT	[M/L/V]LIPP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5774)*NDNYTHKLIIITP[X](SEQ ID NO: 5748)
597	TGTTGATACCACCATCAAATGATAATTACACCCAT	[M/L/V]LIPPSNDNYTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5775)
598	TGTTGATACCACCATAAAATGATAATTACACCCCT	[M/L/V]LIPP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5774)*NDNYTPKLIIITP[X](SEQ ID NO: 5739)
599	TGTTGATACCACCATCAAATGATAATTACACCCCT	[M/L/V]LIPPSNDNYTPKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5776)
600	TGTTGATACCACCATAAAATGATAATTCCACCCAT	[M/L/V]LIPP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5774)*NDNSTHKLIIITP[X](SEQ ID NO: 5736)
601	TGTTGATACCACCATCAAATGATAATTCCACCCAT	[M/L/V]LIPPSNDNSTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5777)
602	TGTTGATACCACCATAAAATGATAATTCCACCCCT	[M/L/V]LIPP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5774)*NDNSTPKLIIITP[X] (SEQ ID NO: 5751)
603	TGTTGATACCACCATCAAATGATAATTCCACCCCT	[M/L/V]LIPPSNDNSTPKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5778)
604	TGTTGATACCACCATAAAATGGTAATTACACCCAT	[M/L/V]LIPP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5774)*NGNYTHKLIIITP[X](SEQ ID NO: 5731)
605	TGTTGATACCACCATCAAATGGTAATTACACCCAT	[M/L/V]LIPPSNGNYTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5779)
606	TGTTGATACCACCATAAAATGGTAATTACACCCCT	[M/L/V]LIPP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5774)*NGNYTPKLIIITP[X] (SEQ ID NO: 5753)
607	TGTTGATACCACCATCAAATGGTAATTACACCCCT	[M/L/V]LIPPSNGNYTPKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5780)
608	TGTTGATACCACCATAAAATGGTAATTCCACCCAT	[M/L/V]LIPP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5774)*NGNSTHKLIIITP[X] (SEQ ID NO: 5755)
609	TGTTGATACCACCATCAAATGGTAATTCCACCCAT	[M/L/V]LIPPSNGNSTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5781)
610	TGTTGATACCACCATAAAATGGTAATTCCACCCCT	[M/L/V]LIPP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5774)*NGNSTPKLIIITP[X]
611	TGTTGATACCACCATCAAATGGTAATTCCACCCCT	[M/L/V]LIPPSNGNSTPKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5782)
612	TGTTGATACCACCATAAAATGATAATTACACCCAT	[M/L/V]LIPP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5774)*NDNYTHTLIIITP[X](SEQ ID NO: 5743)
613	TGTTGATACCACCATCAAATGATAATTACACCCAT	[M/L/V]LIPPSNDNYTHTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5783)
614	TGTTGATACCACCATAAAATGATAATTACACCCCT	[M/L/V]LIPP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5774)*NDNYTPTLIIITP[X] (SEQ ID NO: 5760)
615	TGTTGATACCACCATCAAATGATAATTACACCCCT	[M/L/V]LIPPSNDNYTPTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5784)
616	TGTTGATACCACCATAAAATGATAATTCCACCCAT	[M/L/V]LIPP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5774)*NDNSTHTLIIITP[X] (SEQ ID NO: 5762)
617	TGTTGATACCACCATCAAATGATAATTCCACCCAT	[M/L/V]LIPPSNDNSTHTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5785)
618	TGTTGATACCACCATAAAATGATAATTCCACCCCT	[M/L/V]LIPP(SEQ ID NO: 5774)*NDNSTPTLIIITP[X]
	ACATTGATAATTATCACACCCA	(SEQ ID NO: 5764)
619	TGTTGATACCACCATCAAATGATAATTCCACCCCT	[M/L/V]LIPPSNDNSTPTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5786)
620	TGTTGATACCACCATAAAATGGTAATTACACCCAT	[M/L/V]LIPP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5774)*NGNYTHTLIIITP[X] (SEQ ID NO: 5766)
621	TGTTGATACCACCATCAAATGGTAATTACACCCAT	[M/L/V]LIPPSNGNYTHTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5787)
622	TGTTGATACCACCATAAAATGGTAATTACACCCCT	[M/L/V]LIPP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5774)*NGNYTPTLIIITP[X] (SEQ ID NO: 5768)
623	TGTTGATACCACCATCAAATGGTAATTACACCCCT	[M/L/V]LIPPSNGNYTPTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5788)
624	TGTTGATACCACCATAAAATGGTAATTCCACCCAT	[M/L/V]LIPP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5774)*NGNSTHTLIIITP[X] (SEQ ID NO: 5770)
625	TGTTGATACCACCATCAAATGGTAATTCCACCCAT	[M/L/V]LIPPSNGNSTHTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5789)
626	TGTTGATACCACCATAAAATGGTAATTCCACCCCT	[M/L/V]LIPP(SEQ ID NO: 5774)*NGNSTPTLIIITP[X]
	ACATTGATAATTATCACACCCA	(SEQ ID NO: 5772)
627	TGTTGATACCACCATCAAATGGTAATTCCACCCCT	[M/L/V]LIPPSNGNSTPTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5790)
18	TGTTGATACAACCATAAAATGATAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDNYTHKLIIITP[X](SEQ ID NO: 5748)
629	TGTTGATACTACCATAAAATGATAATTACACCCAT	[M/L/V]LILP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5791)*NDNYTHKLIIITP[X](SEQ ID NO: 5748)
596	TGTTGATACCACCATAAAATGATAATTACACCCAT	[M/L/V]LIPP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5774)*NDNYTHKLIIITP[X](SEQ ID NO: 5748)
631	TGTTGATACAACCACAAAATGATAATTACACCCAT	[M/L/V]LIQPQNDNYTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5745)
632	TGTTGATACAACCATTAAATGATAATTACACCCAT	[M/L/V]LIQPLNDNYTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5746)
565	TGTTGATACAACCATCAAATGATAATTACACCCAT	[M/L/V]LIQPSNDNYTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5747)
278	TGTTGATACAACCATAAATTGATAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*IDNYTHKLIIITP[X](SEQ ID NO: 5725)
279	TGTTGATACAACCATAAACTGATAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*TDNYTHKLIIITP[X](SEQ ID NO: 5726)
280	TGTTGATACAACCATAAAGTGATAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*SDNYTHKLIIITP[X](SEQ ID NO: 5727)
284	TGTTGATACAACCATAAAATAATAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NNNYTHKLIIITP[X](SEQ ID NO: 5728)
638	TGTTGATACAACCATAAAATGTTAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NVNYTHKLIIITP[X](SEQ ID NO: 5729)
639	TGTTGATACAACCATAAAATGCTAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NANYTHKLIIITP[X](SEQ ID NO: 5730)
572	TGTTGATACAACCATAAAATGGTAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NGNYTHKLIIITP[X](SEQ ID NO: 5731)
641	TGTTGATACAACCATAAAATGATATTTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDIYTHKLIIITP[X](SEQ ID NO: 5732)
642	TGTTGATACAACCATAAAATGATACTTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDTYTHKLIIITP[X](SEQ ID NO: 5733)
643	TGTTGATACAACCATAAAATGATAGTTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDSYTHKLIIITP[X](SEQ ID NO: 5734)
644	TGTTGATACAACCATAAAATGATAATAACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDNNTHKLIIITP[X](SEQ ID NO: 5735)
568	TGTTGATACAACCATAAAATGATAATTCCACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDNSTHKLIIITP[X](SEQ ID NO: 5736)
646	TGTTGATACAACCATAAAATGATAATTACACCAAT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDNYTNKLIIITP[X](SEQ ID NO: 5737)
647	TGTTGATACAACCATAAAATGATAATTACACCCTT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDNYTLKLIIITP[X](SEQ ID NO: 5738)
566	TGTTGATACAACCATAAAATGATAATTACACCCCT	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDNYTPKLIIITP[X](SEQ ID NO: 5739)
649	TGTTGATACAACCATAAAATGATAATTACACCCAA	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDNYTQKLIIITP[X](SEQ ID NO: 5740)
650	TGTTGATACAACCATAAAATGATAATTACACCCAG	[M/L/V]LIQP(SEQ ID NO:
	AAATTGATAATTATCACACCCA	5724)*NDNYTQKLIIITP[X](SEQ ID NO: 5740)
321	TGTTGATACAACCATAAAATGATAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	CAATTGATAATTATCACACCCA	5724)*NDNYTHQLIIITP[X](SEQ ID NO: 5741)
652	TGTTGATACAACCATAAAATGATAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	ATATTGATAATTATCACACCCA	5724)*NDNYTHILIIITP[X](SEQ ID NO: 5742)
580	TGTTGATACAACCATAAAATGATAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	ACATTGATAATTATCACACCCA	5724)*NDNYTHTLIIITP[X](SEQ ID NO: 5743)
285	TGTTGATACAACCATAAAATGATAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AATTTGATAATTATCACACCCA	5724)*NDNYTHNLIIITP[X](SEQ ID NO: 5744)
286	TGTTGATACAACCATAAAATGATAATTACACCCAT	[M/L/V]LIQP(SEQ ID NO:
	AACTTGATAATTATCACACCCA	5724)*NDNYTHNLIIITP[X](SEQ ID NO: 5744)
656	TGTTGATACAACCATTAAATGGTAATTACACCCAT	[M/L/V]LIQPLNGNYTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5703)
657	TGTTGATACAACCATTAAATGATAATTCCACCCAT	[M/L/V]LIQPLNDNSTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5704)
658	TGTTGATACAACCATTAAATGATAATTACACCCAA	[M/L/V]LIQPLNDNYTQKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5705)
659	TGTTGATACAACCATTAAATGATAATTACACCCAT	[M/L/V]LIQPLNDNYTHILIIITP[X] (SEQ ID NO:
	ATATTGATAATTATCACACCCA	5706)
660	TGTTGATACAACCATTAAATGATAATTACACCCAT	[M/L/V]LIQPLNDNYTHNLIIITP[X] (SEQ ID NO:
	AATTTGATAATTATCACACCCA	5707)
661	TGTTGATACAACCATTAAATAATAATTCCACCCAT	[M/L/V]LIQPLNNNSTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5708)
662	TGTTGATACAACCATTAAATGTTAATTCCACCCAT	[M/L/V]LIQPLNVNSTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5709)
663	TGTTGATACAACCATTAAATGCTAATTCCACCCAT	[M/L/V]LIQPLNANSTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5710)
664	TGTTGATACAACCATTAAATGGTAATTCCACCCAT	[M/L/V]LIQPLNGNSTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5711)
665	TGTTGATACAACCATTAAATGATAATTCCACCAAT	[M/L/V]LIQPLNDNSTNKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5712)
666	TGTTGATACAACCATTAAATGATAATTCCACCCTT	[M/L/V]LIQPLNDNSTLKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5713)
667	TGTTGATACAACCATTAAATGATAATTCCACCCCT	[M/L/V]LIQPLNDNSTPKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5714)
668	TGTTGATACAACCATTAAATGATAATTCCACCCAA	[M/L/V]LIQPLNDNSTQKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5715)
669	TGTTGATACAACCATTAAATGATAATTCCACCCAG	[M/L/V]LIQPLNDNSTQKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5715)
670	TGTTGATACAACCATTAAATGATAATTCCACCCAT	[M/L/V]LIQPLNDNSTHQLIIITP[X] (SEQ ID NO:
	CAATTGATAATTATCACACCCA	5716)
671	TGTTGATACAACCATTAAATGATAATTCCACCCAT	[M/L/V]LIQPLNDNSTHILIIITP[X] (SEQ ID NO:
	ATATTGATAATTATCACACCCA	5717)
672	TGTTGATACAACCATTAAATGATAATTCCACCCAT	[M/L/V]LIQPLNDNSTHTLIIITP[X] (SEQ ID NO:
	ACATTGATAATTATCACACCCA	5718)
673	TGTTGATACAACCATTAAATGATAATTCCACCCAT	[M/L/V]LIQPLNDNSTHNLIIITP[X] (SEQ ID NO:
	AATTTGATAATTATCACACCCA	5719)
674	TGTTGATACAACCATTAAATGATAATTCCACCCAT	[M/L/V]LIQPLNDNSTHNLIIITP[X] (SEQ ID NO:
	AACTTGATAATTATCACACCCA	5719)
664	TGTTGATACAACCATTAAATGGTAATTCCACCCAT	[M/L/V]LIQPLNGNSTHKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5711)
668	TGTTGATACAACCATTAAATGATAATTCCACCCAA	[M/L/V]LIQPLNDNSTQKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5715)
671	TGTTGATACAACCATTAAATGATAATTCCACCCAT	[M/L/V]LIQPLNDNSTHILIIITP[X] (SEQ ID NO:
	ATATTGATAATTATCACACCCA	5717)
678	TGTTGATACAACCATTAAATGGTAATTCCACCCAT	[M/L/V]LIQPLNGNSTHILIIITP[X] (SEQ ID NO:
	ATATTGATAATTATCACACCCA	5720)
679	TGTTGATACAACCATTAAATGATAATTCCACCCAA	[M/L/V]LIQPLNDNSTQILIIITP[X] (SEQ ID NO:
	ATATTGATAATTATCACACCCA	5721)
680	TGTTGATACAACCATTAAATGGTAATTCCACCCAA	[M/L/V]LIQPLNGNSTQKLIIITP[X] (SEQ ID NO:
	AAATTGATAATTATCACACCCA	5722
681	TGTTGATACAACCATTAAATGGTAATTCCACCCAA	[M/L/V]LIQPLNGNSTQILIIITP[X] (SEQ ID NO:
	ATATTGATAATTATCACACCCA	5360)

Frame 4

682	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHFMVVST(SEQ ID NO: 5678)
	TCATTTTATGGTTGTATCAACA
683	GGGGTGTGATAATTATCAATTTATGGGTGTAATTA	GV**LSIYGCNYHFMVVST(SEQ ID NO: 5678)
	TCATTTTATGGTTGTATCAACA
684	TTGGTGTGATAATTATCAATTTATGGGTGTAATTAT	LV**LSIYGCNYHFMVVST(SEQ ID NO: 5678)
	CATTTTATGGTTGTATCAACA
685	TCGGTGTGATAATTATCAATTTATGGGTGTAATTA	SV**LSIYGCNYHFMVVST(SEQ ID NO: 5678)
	TCATTTTATGGTTGTATCAACA
686	TGGGTGGGATAATTATCAATTTATGGGTGTAATTA	WVG*LSIYGCNYHEMVVST(SEQ ID NO: 5678)
	TCATTTTATGGTTGTATCAACA
687	TGGGTGTTATAATTATCAATTTATGGGTGTAATTAT	WVL*LSIYGCNYHFMVVST(SEQ ID NO: 5678)
	CATTTTATGGTTGTATCAACA
688	TGGGTGTCATAATTATCAATTTATGGGTGTAATTA	WVS*LSIYGCNYHFMVVST(SEQ ID NO: 5678)
	TCATTTTATGGTTGTATCAACA
689	TGGGTGTGACAATTATCAATTTATGGGTGTAATTA	WV*QLSIYGCNYHFMVVST(SEQ ID NO: 5679)
	TCATTTTATGGTTGTATCAACA
690	TGGGTGTGATTATTATCAATTTATGGGTGTAATTAT	WV*LLSIYGCNYHFMVVST(SEQ ID NO: 5680)
	CATTTTATGGTTGTATCAACA
691	TGGGTGTGATCATTATCAATTTATGGGTGTAATTA	WV*SLSIYGCNYHFMVVST(SEQ ID NO: 5681)
	TCATTTTATGGTTGTATCAACA
692	TGGGTGTGATAATTATCAATTAATGGGTGTAATTA	WV**LSINGCNYHFMVVST(SEQ ID NO: 5682)
	TCATTTTATGGTTGTATCAACA
693	TGGGTGTGATAATTATCAATTTCTGGGTGTAATTA	WV**LSISGCNYHFMVVST (SEQ ID NO: 5683)
	TCATTTTATGGTTGTATCAACA
694	TGGGTGTGATAATTATCAATTTATGGGAGTAATTA	WV**LSIYGSNYHFMVVST(SEQ ID NO: 5684)
	TCATTTTATGGTTGTATCAACA
695	TGGGTGTGATAATTATCAATTTATGGGGGTAATTA	WV**LSIYGGNYHFMVVST(SEQ ID NO: 5685)
	TCATTTTATGGTTGTATCAACA
696	TGGGTGTGATAATTATCAATTTATGGGTCTAATTA	WV**LSIYGSNYHFMVVST(SEQ ID NO: 5684)
	TCATTTTATGGTTGTATCAACA
697	TGGGTGTGATAATTATCAATTTATGGGTGTATTTAT	WV**LSIYGCIYHFMVVST(SEQ ID NO: 5686)
	CATTTTATGGTTGTATCAACA
698	TGGGTGTGATAATTATCAATTTATGGGTGTACTTA	WV**LSIYGCTYHFMVVST(SEQ ID NO: 5687)
	TCATTTTATGGTTGTATCAACA
699	TGGGTGTGATAATTATCAATTTATGGGTGTAGTTA	WV**LSIYGCSYHFMVVST(SEQ ID NO: 5688)
	TCATTTTATGGTTGTATCAACA
700	TGGGTGTGATAATTATCAATTTATGGGTGTAATAA	WV**LSIYGCNNHPMVVST(SEQ ID NO: 5689)
	TCATTTTATGGTTGTATCAACA
701	TGGGTGTGATAATTATCAATTTATGGGTGTAATTC	WV**LSIYGCNSHFMVVST(SEQ ID NO: 5690)
	TCATTTTATGGTTGTATCAACA
702	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYNFMVVST(SEQ ID NO: 5691)
	TAATTTTATGGTTGTATCAACA
703	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYLFMVVST(SEQ ID NO: 5692)
	TCTTTTTATGGTTGTATCAACA
704	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYPFMVVST(SEQ ID NO: 5693)
	TCCTTTTATGGTTGTATCAACA
705	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYQFMVVST(SEQ ID NO: 5694)
	TCAATTTATGGTTGTATCAACA
706	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYQFMVVST(SEQ ID NO: 5694)
	TCAGTTTATGGTTGTATCAACA
707	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHLMVVST(SEQ ID NO: 5695)
	TCATCTTATGGTTGTATCAACA
708	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHIMVVST(SEQ ID NO: 5696)
	TCATATTATGGTTGTATCAACA
709	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHVMVVST(SEQ ID NO: 5697)
	TCATGTTATGGTTGTATCAACA
710	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHSMVVST(SEQ ID NO: 5698)
	TCATTCTATGGTTGTATCAACA
711	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHLMVVST(SEQ ID NO: 5695)
	TCATTTAATGGTTGTATCAACA
712	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHLMVVST(SEQ ID NO: 5695)
	TCATTTGATGGTTGTATCAACA
713	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHFLVVST(SEQ ID NO: 5699)
	TCATTTTTTGGTTGTATCAACA
714	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHFLVVST(SEQ ID NO: 5699)
	TCATTTTCTGGTTGTATCAACA
715	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHFVVVST(SEQ ID NO: 5700)
	TCATTTTGTGGTTGTATCAACA
716	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHFTVVST(SEQ ID NO: 5701)
	TCATTTTACGGTTGTATCAACA
717	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHFIVVST(SEQ ID NO: 5702)
	TCATTTTATTGTTGTATCAACA
718	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHFIVVST(SEQ ID NO: 5702)
	TCATTTTATCGTTGTATCAACA
719	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	WV**LSIYGCNYHFIVVST(SEQ ID NO: 5702)
	TCATTTTATAGTTGTATCAACA
685	TCGGTGTGATAATTATCAATTTATGGGTGTAATTA	SV**LSIYGCNYHFMVVST(SEQ ID NO: 5678)
	TCATTTTATGGTTGTATCAACA
721	TCGGTGTCATAATTATCAATTTATGGGTGTAATTAT	SVS*LSIYGCNYHFMVVST(SEQ ID NO: 5678)
	CATTTTATGGTTGTATCAACA
722	TCGGTGTCACAATTATCAATTTATGGGTGTAATTA	SVSQLSIYGCNYHFMVVST(SEQ ID NO: 5644)
	TCATTTTATGGTTGTATCAACA
723	TCGGTGTCATTATTATCAATTTATGGGTGTAATTAT	SVSLLSIYGCNYHFMVVST (SEQ ID NO: 5645)
	CATTTTATGGTTGTATCAACA
724	TCGGTGTCATCATTATCAATTTATGGGTGTAATTAT	SVSSLSIYGCNYHFMVVST(SEQ ID NO: 5646)
	CATTTTATGGTTGTATCAACA
725	TCGGTGTCACAATTATCAATTTATGGGTGTAATTA	SVSQLSIYGCNYHFLVVST(SEQ ID NO: 5647)
	TCATTTTTTGGTTGTATCAACA
726	TCGGTGTCATTATTATCAATTTATGGGTGTAATTAT	SVSLLSIYGCNYHFLVVST(SEQ ID NO: 5648)
	CATTTTTTGGTTGTATCAACA
727	TCGGTGTCATCATTATCAATTTATGGGTGTAATTAT	SVSSLSIYGCNYHFLVVST(SEQ ID NO: 5649)
	CATTTTTTGGTTGTATCAACA
728	TCGGTGTCACAATTATCAATTTATGGGTGTAATTA	SVSQLSIYGCNYHLMVVST(SEQ ID NO: 5650)
	TCATTTAATGGTTGTATCAACA
729	TCGGTGTCATTATTATCAATTTATGGGTGTAATTAT	SVSLLSIYGCNYHLMVVST(SEQ ID NO: 5651)
	CATTTAATGGTTGTATCAACA
730	TCGGTGTCATCATTATCAATTTATGGGTGTAATTAT	SVSSLSIYGCNYHLMVVST(SEQ ID NO: 5652)
	CATTTAATGGTTGTATCAACA
731	TCGGTGTCACAATTATCAATTTATGGGTGTAATTA	SVSQLSIYGCNYLFMVVST(SEQ ID NO: 5653)
	TCTTTTTATGGTTGTATCAACA
732	TCGGTGTCATTATTATCAATTTATGGGTGTAATTAT	SVSLLSIYGCNYLFMVVST(SEQ ID NO: 5654)
	CTTTTTATGGTTGTATCAACA
733	TCGGTGTCATCATTATCAATTTATGGGTGTAATTAT	SVSSLSIYGCNYLFMVVST(SEQ ID NO: 5655)
	CTTTTTATGGTTGTATCAACA
734	TCGGTGTCACAATTATCAATTTATGGGTGTAATAA	SVSQLSIYGCNNHFMVVST(SEQ ID NO: 5656)
	TCATTTTATGGTTGTATCAACA
735	TCGGTGTCATTATTATCAATTTATGGGTGTAATAAT	SVSLLSIYGCNNHFMVVST(SEQ ID NO: 5657)
	CATTTTATGGTTGTATCAACA
736	TCGGTGTCATCATTATCAATTTATGGGTGTAATAA	SVSSLSIYGCNNHFMVVST(SEQ ID NO: 5658)
	TCATTTTATGGTTGTATCAACA
737	TCGGTGTCACAATTATCAATTTATGGGTGTATTTAT	SVSQLSIYGCIYHFMVVST(SEQ ID NO: 5659)
	CATTTTATGGTTGTATCAACA
738	TCGGTGTCATTATTATCAATTTATGGGTGTATTTAT	SVSLLSIYGCIYHFMVVST(SEQ ID NO: 5660)
	CATTTTATGGTTGTATCAACA
739	TCGGTGTCATCATTATCAATTTATGGGTGTATTTAT	SVSSLSIYGCIYHFMVVST(SEQ ID NO: 5661)
	CATTTTATGGTTGTATCAACA
740	TCGGTGTCACAATTATCAATTTATGGGGGTAATTA	SVSQLSIYGGNYHFMVVST(SEQ ID NO: 5662)
	TCATTTTATGGTTGTATCAACA
741	TCGGTGTCATTATTATCAATTTATGGGGGTAATTAT	SVSLLSIYGGNYHFMVVST(SEQ ID NO: 5663)
	CATTTTATGGTTGTATCAACA
742	TCGGTGTCATCATTATCAATTTATGGGGGTAATTA	SVSSLSIYGGNYHFMVVST(SEQ ID NO: 5664)
	TCATTTTATGGTTGTATCAACA
743	TCGGTGTCACAATTATCAATTAATGGGTGTAATTA	SVSQLSINGCNYHFMVVST(SEQ ID NO: 5665)
	TCATTTTATGGTTGTATCAACA
744	TCGGTGTCATTATTATCAATTAATGGGTGTAATTAT	SVSLLSINGCNYHFMVVST(SEQ ID NO: 5666)
	CATTTTATGGTTGTATCAACA
745	TCGGTGTCATCATTATCAATTAATGGGTGTAATTA	SVSSLSINGCNYHFMVVST (SEQ ID NO: 5667)
	TCATTTTATGGTTGTATCAACA
728	TCGGTGTCACAATTATCAATTTATGGGTGTAATTA	SVSQLSIYGCNYHLMVVST(SEQ ID NO: 5650)
	TCATTTAATGGTTGTATCAACA
728	TCGGTGTCATTATTATCAATTTATGGGTGTAATTAT	SVSLLSIYGCNYHLMVVST(SEQ ID NO: 5651)
	CATTTAATGGTTGTATCAACA
730	TCGGTGTCATCATTATCAATTTATGGGTGTAATTAT	SVSSLSIYGCNYHLMVVST(SEQ ID NO: 5652)
	CATTTAATGGTTGTATCAACA
749	TCGGTGTCACAATTATCAATTTATGGGTGTAATTA	SVSQLSIYGCNYHILLVVST(SEQ ID NO: 5668)
	TCATTTATTGGTTGTATCAACA
750	TCGGTGTCATTATTATCAATTTATGGGTGTAATTAT	SVSLLSIYGCNYHLLVVST(SEQ ID NO: 5669)
	CATTTATTGGTTGTATCAACA
751	TCGGTGTCATCATTATCAATTTATGGGTGTAATTAT	SVSSLSIYGCNYHLLVVST(SEQ ID NO: 5670)
	CATTTATTGGTTGTATCAACA
752	TCGGTGTCACAATTATCAATTTATGGGTGTAATTA	SVSQLSIYGCNYLLLVVST(SEQ ID NO: 5671)
	TCTTTTATTGGTTGTATCAACA
753	TCGGTGTCATTATTATCAATTTATGGGTGTAATAAT	SVSLLSIYGCNNHLLVVST(SEQ ID NO: 5672)
	CATTTATTGGTTGTATCAACA
754	TCGGTGTCATCATTATCAATTTATGGGTGTATTTAT	SVSSLSIYGCIYHLLVVST(SEQ ID NO: 5673)
	CATTTATTGGTTGTATCAACA
755	TCGGTGTCACAATTATCAATTTATGGGGGTAATTA	SVSQLSIYGGNYHLLVVST(SEQ ID NO: 5674)
	TCATTTATTGGTTGTATCAACA
756	TCGGTGTCATTATTATCAATTAATGGGTGTAATTAT	SVSLLSINGCNYHLLVVST(SEQ ID NO: 5675)
	CATTTATTGGTTGTATCAACA
757	TCGGTGTCATCATTATCAATTAATGGGGGTAATAA	SVSSLSINGGNNLLLVVST(SEQ ID NO: 5676)
	TCTTTTATTGGTTGTATCAACA
758	TCGGTGTCACAATTATCAATTAATGGGGGTATTAA	SVSQLSINGGINLLLVVST(SEQ ID NO: 5677)
	TCTTTTATTGGTTGTATCAACA

Frame 5

682	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[X]GCDNYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5613)
760	TGGGAGTGATAATTATCAATTTATGGGTGTAATTA	[X]GSDNYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5614)
761	TGGGGGTGATAATTATCAATTTATGGGTGTAATTA	[X]GGDNYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5615)
762	TGGGTCTGATAATTATCAATTTATGGGTGTAATTA	[X]GSDNYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5614)
763	TGGGTGTAATAATTATCAATTTATGGGTGTAATTA	[X]GCNNYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5616)
764	TGGGTGTGTTAATTATCAATTTATGGGTGTAATTAT	[X]GCVNYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	CATTTTATGGTTGTATCAACA	5617)
765	TGGGTGTGCTAATTATCAATTTATGGGTGTAATTA	[X]GCANYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5618)
766	TGGGTGTGGTAATTATCAATTTATGGGTGTAATTA	[X]GCGNYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5619)
767	TGGGTGTGATATTTATCAATTTATGGGTGTAATTAT	[X]GCDIYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	CATTTTATGGTTGTATCAACA	5620)
768	TGGGTGTGATACTTATCAATTTATGGGTGTAATTA	[X]GCDTYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5621)
769	TGGGTGTGATAGTTATCAATTTATGGGTGTAATTA	[X]GCDSYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5622)
770	TGGGTGTGATAATAATCAATTTATGGGTGTAATTA	[X]GCDNNQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5623)
771	TGGGTGTGATAATTCTCAATTTATGGGTGTAATTA	[X]GCDNSQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5624)
772	TGGGTGTGATAATTATCTATTTATGGGTGTAATTAT	[X]GCDNYLFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	CATTTTATGGTTGTATCAACA	5625}
773	TGGGTGTGATAATTATCCATTTATGGGTGTAATTA	[X]GCDNYPFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5626)
774	TGGGTGTGATAATTATCAACTTATGGGTGTAATTA	[X]GCDNYQLMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5627)
775	TGGGTGTGATAATTATCAAATTATGGGTGTAATTA	[X]GCDNYQIMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5628)
776	TGGGTGTGATAATTATCAAGTTATGGGTGTAATTA	[X]GCDNYQVMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5629)
777	TGGGTGTGATAATTATCAATCTATGGGTGTAATTA	[X]GCDNYQSMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5630)
692	TGGGTGTGATAATTATCAATTAATGGGTGTAATTA	[X]GCDNYQLMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5627)
779	TGGGTGTGATAATTATCAATTGATGGGTGTAATTA	[X]GCDNYQLMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5627)
780	TGGGTGTGATAATTATCAATTTTTGGGTGTAATTAT	[X]GCDNYQFLGVIIILWLYQ[Q/H] (SEQ ID NO:
	CATTTTATGGTTGTATCAACA	5631)
693	TGGGTGTGATAATTATCAATTTCTGGGTGTAATTA	[X]GCDNYQFLGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5631)
782	TGGGTGTGATAATTATCAATTTGTGGGTGTAATTA	[X]GCDNYQFVGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5632)
783	TGGGTGTGATAATTATCAATTTACGGGTGTAATTA	[X]GCDNYQFTGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5633)
784	TGGGTGTGATAATTATCAATTTATTGGTGTAATTAT	[X]GCDNYQFIGVIIILWLYQ[Q/H] (SEQ ID NO:
	CATTTTATGGTTGTATCAACA	5634)
785	TGGGTGTGATAATTATCAATTTATCGGTGTAATTA	[X]GCDNYQFIGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5634)
786	TGGGTGTGATAATTATCAATTTATAGGTGTAATTA	[X]GCDNYQFIGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5634)
787	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[X]GCDNYQFMGVIIILGLYQ[Q/H] (SEQ ID NO:
	TCATTTTAGGGTTGTATCAACA	5635)
717	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[X]GCDNYQFMGVIIILLLYQ[Q/H] (SEQ ID NO:
	TCATTTTATTGTTGTATCAACA	5636)
789	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[X]GCDNYQFMGVIIILSLYQ[Q/H] (SEQ ID NO:
	TCATTTTATCGTTGTATCAACA	5637)
790	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[X]GCDNYQFMGVIIILWLNQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGAATCAACA	5638)
791	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[X]GCDNYQFMGVIIILWLSQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTCTCAACA	5639)
792	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[X]GCDNYQFMGVIIILWLYL[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCTACA	5640)
793	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[X]GCDNYQFMGVIIILWLYP[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCCACA	5641)
760	TGGGAGTGATAATTATCAATTTATGGGTGTAATTA	[X]GSDNYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5614)
795	TGGGAGTGGTAATTATCAATTTATGGGTGTAATTA	[X]GSGNYQFMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5642)
796	TGGGAGTGGTAATTATCAAATTATGGGTGTAATTA	[X]GSGNYQIMGVIIILWLYQ[Q/H] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5643)

Frame 6

682	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5591)*LSFYGCIN[X](SEQ ID NO: 5592)
798	TGGGTGTGATAATTATCATTTTATGGGTGTAATTAT	[M/L/V]GVIIIILWV(SEQ ID NO:
	CATTTTATGGTTGTATCAACA	5593)*LSFYGCIN[X](SEQ ID NO: 5592)
799	TGGGTGTGATAATTATCACTTTATGGGTGTAATTA	[M/L/V]GVIIITLWV(SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5594)*LSFYGCIN[X](SEQ ID NO: 5592)
800	TGGGTGTGATAATTATCAGTTTATGGGTGTAATTA	[M/L/V]GVIIISLWV(SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5595)*LSFYGCIN[X](SEQ ID NO: 5592)
801	TGGGTGTGATAATTATCAATTTAGGGGTGTAATTA	[M/L/V]GVIIINLGV(SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5596)*LSFYGCIN[X](SEQ ID NO: 5592)
784	TGGGTGTGATAATTATCAATTTATTGGTGTAATTAT	[M/L/V]GVIIINLLV(SEQ ID NO:
	CATTTTATGGTTGTATCAACA	5597)*LSFYGCIN[X](SEQ ID NO: 5592)
785	TGGGTGTGATAATTATCAATTTATCGGTGTAATTA	[M/L/V]GVIIINLSV(SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5598)*LSFYGCIN[X](SEQ ID NO: 5592)
804	TGGGTGTGATAATTATCAATTTATGGGTGCAATTA	[M/L/V]GVIIINLWVQLSFYGCIN[X] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5599)
805	TGGGTGTGATAATTATCAATTTATGGGTGTTATTAT	[M/L/V]GVIIINLWVLLSFYGCIN[X] (SEQ ID NO:
	CATTTTATGGTTGTATCAACA	5600)
806	TGGGTGTGATAATTATCAATTTATGGGTGTCATTA	[M/L/V]GVIIINLWVSLSFYGCIN[X] (SEQ ID NO:
	TCATTTTATGGTTGTATCAACA	5601)
807	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV(SEQ ID NO:
	TCACTTTATGGTTGTATCAACA	5591)*LSLYGCIN[X](SEQ ID NO: 5602)
705	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV (SEQ ID NO:
	TCAATTTATGGTTGTATCAACA	5591)*LSIYGCIN[X](SEQ ID NO: 5603)
706	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV (SEQ ID NO:
	TCAGTTTATGGTTGTATCAACA	5591)*LSVYGCIN[X](SEQ ID NO: 5604)
707	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV (SEQ ID NO:
	TCATCTTATGGTTGTATCAACA	5591)*LSSYGCIN[X](SEQ ID NO: 5605)
811	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV(SEQ ID NO:
	TCATTATATGGTTGTATCAACA	5591)*LSLYGCIN[X](SEQ ID NO: 5602)
812	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV(SEQ ID NO:
	TCATTGTATGGTTGTATCAACA	5591)*LSLYGCIN[X](SEQ ID NO: 5602)
711	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV(SBQ ID NO:
	TCATTTAATGGTTGTATCAACA	5591)*LSFNGCIN[X](SEQ ID NO: 5606)
714	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV(SEQ ID NO:
	TCATTTTCTGGTTGTATCAACA	5591)*LSFSGCIN[X](SEQ ID NO: 5607)
815	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV(SEQ ID NO:
	TCATTTTATGGTAGTATCAACA	5591)*LSFYGSIN[X] (SEQ ID NO: 5612)
816	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV(SEQ ID NO:
	TCATTTTATGGTGGTATCAACA	5591)*LSFYGGIN[X](SEQ ID NO: 5608)
817	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV(SEQ ID NO:
	TCATTTTATGGTTCTATCAACA	5591)*LSFYGSIN[X] (SEQ ID NO: 5612)
818	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV (SEQ ID NO:
	TCATTTTATGGTTGTATCATCA	5591)*LSFYGCII[X ](SEQ ID NO: 5609)
819	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV (SEQ ID NO:
	TCATTTTATGGTTGTATCACCA	5591)*LSFYGCIT[X](SEQ ID NO: 5610)
820	TGGGTGTGATAATTATCAATTTATGGGTGTAATTA	[M/L/V]GVIIINLWV(SEQ ID NO:
	TCATTTTATGGTTGTATCAGCA	5591)*LSFYGCIS[X](SEQ ID NO: 5610)
798	TGGGTGTGATAATTATCATTTTATGGGTGTAATTAT	[M/L/V]GVIIIILWV(SEQ ID NO:
	CATTTTATGGTTGTATCAACA	5593)*LSFYGCIN[X](SEQ ID NO: 5592)
822	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSFYGCIN[X] (SEQ ID NO:
	CATTTTATGGTTGTATCAACA	5575)
823	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLYGCIN[X] (SEQ ID NO:
	CATTATATGGTTGTATCAACA	5576)
824	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLNGCIN[X] (SEQ ID NO:
	CATTAAATGGTTGTATCAACA	5577)
825	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLYGSIN[X] (SEQ ID NO:
	CATTATATGGTAGTATCAACA	5578)
826	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLYGSIN[X] (SEQ ID NO:
	CATTATATGGTTCTATCAACA	5578)
827	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLYGCII[X] (SEQ ID NO:
	CATTATATGGTTGTATCATCA	5579)
828	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLYGCIT[X] (SEQ ID NO:
	CATTATATGGTTGTATCACCA	5580)
829	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLYGCIS[X] (SEQ ID NO:
	CATTATATGGTTGTATCAGCA	5581)
830	TGGGTGTGATAATTATCATTTTAGGGGTGTTATTAT	[M/L/V]GVIIIILGVLLSLYGCIN[X] (SEQ ID NO:
	CATTATATGGTTGTATCAACA	5582)
831	TGGGTGTGATAATTATCATTTTATTGGTGTTATTAT	[M/L/V]GVIIIILLVLLSLYGCIN[X] (SEQ ID NO:
	CATTATATGGTTGTATCAACA	5583)
832	TGGGTGTGATAATTATCATTTTATCGGTGTTATTAT	[M/L/V]GVIIIILSVLLSLYGCIN[X] (SEQ ID NO:
	CATTATATGGTTGTATCAACA	5584)
833	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLNGSIN[X] (SEQ ID NO:
	CATTAAATGGTAGTATCAACA	5585)
834	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLNGSIN[X] (SEQ ID NO:
	CATTAAATGGTTCTATCAACA	5585)
835	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLNGSII[X] (SEQ ID NO:
	CATTAAATGGTAGTATCATCA	5586)
836	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLNGSII[X] (SEQ ID NO:
	CATTAAATGGTTCTATCATCA	5586)
837	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLNGSIS[X] (SEQ ID NO:
	CATTAAATGGTAGTATCAGCA	5587)
838	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLNGSIS[X] (SEQ ID NO:
	CATTAAATGGTTCTATCAGCA	5587)
839	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLYGSIS[X] (SEQ ID NO:
	CATTATATGGTAGTATCAGCA	5588)
840	TGGGTGTGATAATTATCATTTTATGGGTGTTATTAT	[M/L/V]GVIIIILWVLLSLYGSIS[X] (SEQ ID NO:
	CATTATATGGTTCTATCAGCA	5588)
841	TGGGTGTGATAATTATCATTTTAGGGGTGTTATTAT	[M/L/V]GVIIIILGVLLSLYGSIS[X] (SEQ ID NO:
	CATTATATGGTAGTATCAGCA	5589)
842	TGGGTGTGATAATTATCATTTTATTGGTGTTATTAT	[M/L/V]GVIIIILLVLLSLYGSIS[X] (SEQ ID NO:
	CATTATATGGTTCTATCAGCA	5590)
843	TGGGTGTGATAATTATCATTTTAGGGGTGTTATTAT	[M/L/V]GVIIIILGVLLSLNGSIS[X] (SEQ ID NO:
	CATTAAATGGTAGTATCAGCA	5574)
844	TGGGTGTGATAATTATCATTTTATTGGTGTTATTAT	[M/L/V]GVIIIILLVLLSLNGSIS[X] (SEQ ID NO:
	CATTAAATGGTTCTATCAGCA	5573)

TABLE 2
Selected engineered (right) transposon end variant sequences

			57-bp
			transposon
ID	Alias	Description	right end	Amino acid sequence
WT	WT_minimal_	57-bp	TGTTGATACAACC	C*YNHKMIITPIN**LSHP
	pDonor,	WT	ATAAAATGATAAT	(in frame 1)
	Linker v1	TnR	TACACCCATAAAT	(SEQ ID NOs:
			TGATAATTATCAC	5352-5353)
			ACCCA
			(SEQ ID NO: 1)
ORF1a	Linker v2	TnR	TGTgGATACAACC	CGYNHKMITPINGSLSPP
		variant	ATAAAATGATAAT	(SEQ ID NOs: 5354)
		ORF1a	TACACCCATAAAT
			gGATcATTATCAC
			cCCCA
			(SEQ ID NO: 2)
ORF1b	Linker v3	TnR	TGTgGATACAACC	CGYNHKTIITPINGSLSHP
		variant	ATAAAAcGATAAT	(SEQ ID NOs: 5355)
		ORF1b	TACACCCATAAAT
			gGATcATTATCAC
			ACCCA (SEQ ID
			NO: 3)
ORF1c	Linker v4	TnR	TGTgGATcCAACC	CGSNHKMITPINGSLSHP
		variant	ATAAAATGATAAT	(SEQ ID NOs: 5356)
		ORF1c	TACACCCATAAAT
			gGATcATTATCAC
			ACCCA (SEQ ID
			NO: 4)
ORF2a	Linker v5	TR	TGTTGATACAACC	[X]VDTTIKGLLHPLIDNYHT
		variant	ATAAAAgGATtAT	[Q/H](SEQ ID NO: 5357)
		ORF2a	TACACCCATIAAT
			TGATAATTATCAC
			ACCCA (SEQ ID
			NO: 5)
ORF3a	Linker v6	TnR	TGTTGATACAACC	[M/L/V]LIQPSNGNYTHKLIIITP
		variant	ATcAAATGgTAAT	[X](SEQ ID NO: 5358)
		ORF3a	TACACCCATAAAT
			TGATAATTATCAC
			ACCCA (SEQ ID
			NO: 6)
ORF3b	Linker v7	TnR	TGTTGATACAACC	[M/L/V]LIQPLNDNSTHNLIITP
		variant	ATAAATGATAATT	[X](SEQ ID NO: 5359)
		ORF3b	CCACCCATAAtTT
			GATAATTATCACA
			CCCA (SEQ ID
			NO: 7)
ORF3c	Linker v8	TnR	TGTTGATACAACC	[M/L/V]LIQPLNGNSTQILIITP
		variant	ATAAATGgTAATT	[X](SEQ ID NO: 5360)
		ORF3c	CCACCCAaAtATT
			GATAATTATCACA
			CCCA
			(SEQ ID NO: 8)

TABLE 3
IHF protein constructs

		SEQ ID
Protein name	Protein sequence	NO
hCO dcIHFA-NLS	MALTKAEMSEYLFDKLGLSKRDAKELVELFFEEIRRALEN	5136
	GEQVKLSGFGNFDLRDKNQRPGRNPKTGEDIPITARRVVT
	FRPGQKLKSRVENASPKDEGSGKRTADGSEFESPKKKRKV
	*
hCO NLS-dcIHFA	MGKRTADGSEFESPKKKRKVGSGMALTKAEMSEYLFDKLG	5137
	LSKRDAKELVELFFEEIRRALENGEQVKLSGFGNFDLRDK
	NQRPGRNPKTGEDIPITARRVVTFRPGQKLKSRVENASPK
	DE*
hCO dcIHFB-NLS	MGTKSELIERLATQQSHIPAKTVEDAVKEMLEHMASTLAQ	5138
	GERIEIRGFGSFSLHYRAPRTGRNPKTGDKVELEGKYVPH
	FKPGKELRDRANIYGGSGKRTADGSEFESPKKKRKV*
hCO NLS-dcIHFB	MGKRTADGSEFESPKKKRKVGSGMGTKSELIERLATQQSH	5139
	IPAKTVEDAVKEMLEHMASTLAQGERIEIRGFGSFSLHYR
	APRTGRNPKTGDKVELEGKYVPHFKPGKELRDRANIYG*
hCO NLS-scIHF2	MGTKSELIERLATQQSHIPAKTVEDAVKEMLEHMASTLAQ	5140
	GGSGGLTKAEMSEYLFDKLGLSKRDAKELVELFFEEIRRA
	LENGEQVKLSGFGNFDLRDKNQRPGRNPKTGEDIPITARR
	VVTFRPGQKLKSRVENAGGGERIEIRGFGSFSLHYRAPRT
	GRNPKTGDKVELEGKYVPHFKPGKELRDRANIYG*
hCO scIHF2	MGTKSELIERLATQQSHIPAKTVEDAVKEMLEHMASTLAQ	5141
	GGSGGLTKAEMSEYLFDKLGLSKRDAKELVELFFEEIRRA
	LENGEQVKLSGFGNFDLRDKNQRPGRNPKTGEDIPITARR
	VVTFRPGQKLKSRVENAGGGERIEIRGFGSFSLHYRAPRT
	GRNPKTGDKVELEGKYVPHFKPGKELRDRANIYG*
TnsA-NLS-	MYIRNLRKPSPNKNVFKFASTKVSSVVMCESSLEFDACFH	5142
GSGSGG-IHF-	HEYNDLIESFGSQPEGFKYEFMGKSLPYTPDALISYTDKT
XTEN-GS-TasB	QKYHEYKPYSKIASPLFRABFAAKRAASLKLGIDLVLVTD
	RQIRVNPILNNLKLLHRYSGVYGISGIQKELLSFIHKSGV
	IKLNDISSQVGIPIGETRSFLFGLMHKGLVKADLGCDDLT
	NNPTLWATPGSGSGKRTADGSEFESPKKKRKVGSGSGGMG
	TKSELIERLATQQSHIPAKTVEDAVKEMLEHMASTLAQGG
	SGGLTKAEMSEYLFDKLGLSKRDAKELVELFFEEIRRALE
	NGEQVKLSGFGNFDLRDKNQRPGRNPKTGEDIPITARRVV
	TFRPGQKLKSRVENAGGGERIEIRGFGSFSLHYRAPRTGR
	NPKTGDKVELEGKYVPHFKPGKELRDRANIYGSGSETPGT
	SESATPESGGSGSSGGSGSSGGMTDFFNEFDESLVPLKPQ
	TPTQYVKLDDANLIQRDLDTFSDTFKNQALQRYKLISTID
	KKLSRGWTQRNLDPILDELFKGGDVVRPNWRTVARWRKKY
	IESNGDIASLADKNHKMGNRTNRIKGDDKFEDKALERFLD
	AKRPTIATAYQYYKDLIVIENESIVEGKIPIISYNAFNKR
	IKAIPPYAVAVARHGKFKADQWFAYCAAHVPPTRILERVE
	IDHTPLDLILLDDELLIPIGRPYLTLLIDVFSGCVLGFHL
	SYKSPSYVSAAKAITHAIKPKSLDALNIELQNDWPCFGKF
	ENLVVDNGAEFWSKNLEHACQSAGINIQYNPVRKPWLKPF
	IERFFGVMNEYFLPELPGKTFSNILEKEEYKPEKDAIMRF
	STFVEEFHRWIADVYHQDSNSRETRIPIKRWQQGFDAYPP
	LTMNEEEETRESMLMRISDSRTLTRNGFKYQELMYDSTAL
	ADYRKHYPQTKETVKKLIKVDPDDISKIYVYLEELESYLE
	VPCTDPTGYTDGLSIYEHKTIKKINREVIRESKDSLGLAK
	ARMAIHERVKQEQEVFIESKTKAKITAVKKQAQIADVSNT
	GTSTIKVSEESAAPVQKHISNDNSDDWDDDLEAFE*
TnsA-NLS-	MYIRNLRKPSPNKNVFKFASTKVSSVVMCESSLEFDACFH	5143
GSGSGG-XTEN-	HEYNDLIESFGSQPEGFKYEFMGKSLPYTPDALISYTDKT
IHF-XTEN-GS-	QKYHEYKPYSKIASPLFRAEFAAKRAASLKLGIDLVLVTD
TnsB	RQIRVNPILNNLKLLHRYSGVYGISGIQKELLSFIHKSGV
	IKLNDISSQVGIPIGETRSFLFGLMHKGLVKADLGCDDLT
	NNPTLWATPGSGSGKRTADGSEFESPKKKRKVGSSGSETP
	GTSESATPESSGGSSGGSSTMGTKSELIERLATQQSHIPA
	KTVEDAVKEMLEHMASTLAQGGSGGLTKAEMSEYLEDKLG
	LSKRDAKELVELFFEEIRRALENGEQVKLSGFGNFDLRDK
	NQRPGRNPKTGEDIPITARRVVTFRPGQKLKSRVENAGGG
	ERIEIRGFGSFSLHYRAPRTGRNPKTGDKVELEGKYVPHF
	KPGKELRDRANIYGSGSETPGTSESATPESGGSGSSGGSG
	SSGGMTDFFNEFDESLVPLKPQTPTQYVKLDDANLIQRDL
	DTFSDTFKNQALQRYKLISTIDKKLSRGWTQRNLDPILDE
	LFKGGDVVRPNWRTVARWRKKYIESNGDIASLADKNHKMG
	NRTNRIKGDDKFFDKALERFLDAKRPTIATAYQYYKDLIV
	IENESIVEGKIPIISYNAFNKRIKAIPPYAVAVARHGKFK
	ADQWFAYCAAHVPPTRILERVEIDHTPLDLILLDDELLIP
	IGRPYLTLLIDVFSGCVLGFHLSYKSPSYVSAAKAITHAI
	KPKSLDALNIELQNDWPCFGKFENLVVDNGAEFWSKNLEH
	ACQSAGINIQYNPVRKPWLKPFIERFFGVMNEYFLPELPG
	KTESNILEKEEYKPEKDAIMRESTFVEEFHRWIADVYHQD
	SNSRETRIPIKRWQQGFDAYPPLTMNEEEETRFSMLMRIS
	DSRTLTRNGFKYQELMYDSTALADYRKHYPQTKETVKKLI
	KVDPDDISKIYVYLEELESYLEVPCTDPTGYTDGLSIYEH
	KTIKKINREVIRESKDSLGLAKARMAIHERVKQEQEVFIE
	SKTKAKITAVKKQAQIADVSNTGTSTIKVSEESAAPVQKH
	ISNDNSDDWDDDLEAFE*
TnsA-NLS-(GGS)6-	MYIRNLRKPSPNKNVFKFASTKVSSVVMCESSLEFDACFH	5144
IHF-(XTEN)3-TnsB	HEYNDLIESFGSQPEGFKYEFMGKSLPYTPDALISYTDKT
	QKYHEYKPYSKIASPLFRAEFAAKRAASLKLGIDLVLVTD
	RQIRVNPILNNLKLLHRYSGVYGISGIQKELLSFIHKSGV
	IKLNDISSQVGIPIGETRSFLFGLMHKGLVKADLGCDDLT
	NNPTLWATPGSGSGKRTADGSEFESPKKKRKVGSGGSGGS
	GGSGGSGGSGGSMGTKSELIERLATQQSHIPAKTVEDAVK
	EMLEHMASTLAQGGSGGLTKAEMSEYLFDKLGLSKRDAKE
	LVELFFEBIRRALENGEQVKLSGFGNFDLRDKNQRPGRNP
	KTGEDIPITARRVVTFRPGQKLKSRVENAGGGERIBIRGF
	GSFSLHYRAPRTGRNPKTGDKVELEGKYVPHFKPGKELRD
	RANIYGSGGSSGGSSGSETPGTSESATPESSGSETPGTSE
	SATPESSGSETPGTSESATPESSGGSSGGSSTMTDFFNEF
	DESLVPLKPQTPTQYVKLDDANLIQRDLDTFSDTFKNQAL
	QRYKLISTIDKKLSRGWTQRNLDPILDELFKGGDVVRPNW
	RTVARWRKKYIESNGDIASLADKNHKMGNRTNRIKGDDKF
	FDKALERFLDAKRPTIATAYQYYKDLIVIENESIVEGKIP
	IISYNAFNKRIKAIPPYAVAVARHGKFKADQWFAYCAAHV
	PPTRILERVEIDHTPLDLILLDDELLIPIGRPYLTLLIDV
	FSGCVLGFHLSYKSPSYVSAAKAITHAIKPKSLDALNIEL
	QNDWPCFGKFENLVVDNGAEFWSKNLEHACQSAGINIQYN
	PVRKPWLKPFIERFFGVMNEYFLPELPGKTFSNILEKEEY
	KPEKDAIMRESTFVEEFHRWIADVYHQDSNSRETRIPIKR
	WQQGFDAYPPLTMNEEEETRESMLMRISDSRTLTRNGFKY
	QELMYDSTALADYRKHYPQTKETVKKLIKVDPDDISKIYV
	YLEELESYLEVPCTDPTGYTDGLSIYEHKTIKKINREVIR
	ESKDSLGLAKARMAIHERVKQEQEVFIESKTKAKITAVKK
	QAQIADVSNTGTSTIKVSEESAAPVQKHISNDNSDDWDDD
	LEAFE*
TnsA-NLS-	MYIRNLRKPSPNKNVFKFASTKVSSVVMCESSLEFDACFH	5145
(XTEN)3-IHF-	HEYNDLIESFGSQPEGFKYEFMGKSLPYTPDALISYTDKT
(GGS)6-TnsB	QKYHEYKPYSKIASPLFRAEFAAKRAASLKLGIDLVLVTD
	RQIRVNPILNNLKLLHRYSGVYGISGIQKELLSFIHKSGV
	IKLNDISSQVGIPIGETRSFLFGLMHKGLVKADLGCDDLT
	NNPTLWATPGSGSGKRTADGSEFESPKKKRKVGSSGGSSG
	GSSGSETPGTSESATPESSGSETPGTSESATPESSGSETP
	GTSESATPESSGGSSGGSSTMGTKSELIERLATQQSHIPA
	KTVEDAVKEMLEHMASTLAQGGSGGLTKAEMSEYLFDKLG
	LSKRDAKELVELFFEEIRRALENGEQVKLSGFGNFDLRDK
	NQRPGRNPKTGEDIPITARRVVTFRPGQKLKSRVENAGGG
	ERIEIRGFGSFSLHYRAPRTGRNPKTGDKVELEGKYVPHF
	KPGKELRDRANIYGGGSGGSGGSGGSGGSGGSMTDFFNEF
	DESLVPLKPQTPTQYVKLDDANLIQRDLDTFSDTFKNQAL
	QRYKLISTIDKKLSRGWTQRNLDPILDELFKGGDVVRPNW
	RTVARWRKKYIESNGDIASLADKNHKMGNRTNRIKGDDKF
	FDKALERFLDAKRPTIATAYQYYKDLIVIENESIVEGKIP
	IISYNAFNKRIKAIPPYAVAVARHGKFKADQWFAYCAAHV
	PPTRILERVEIDHTPLDLILLDDELLIPIGRPYLTLLIDV
	FSGCVLGFHLSYKSPSYVSAAKAITHAIKPKSLDALNIEL
	QNDWPCFGKFENLVVDNGAEFWSKNLEHACQSAGINIQYN
	PVRKPWLKPFIERFFGVMNEYFLPELPGKTFSNILEKEEY
	KPEKDAIMRFSTFVEEFHRWIADVYHQDSNSRETRIPIKR
	WQQGFDAYPPLTMNEEEETRESMLMRISDSRTLTRNGFKY
	QELMYDSTALADYRKHYPQTKETVKKLIKVDPDDISKIYV
	YLEELESYLEVPCTDPTGYTDGLSIYEHKTIKKINREVIR
	ESKDSLGLAKARMAIHERVKQEQEVFIESKTKAKITAVKK
	QAQIADVSNTGTSTIKVSEESAAPVQKHISNDNSDDWDDD
	LEAFE*
IHF-dCas9	MPKKKRKVGGSGGSMGTKSELIERLATQQSHIPAKTVEDA	5146
	VKEMLEHMASTLAQGGSGGLTKAEMSEYLFDKLGLSKRDA
	KELVELFFEEIRRALENGEQVKLSGFGNFDLRDKNQRPGR
	NPKTGEDIPITARRVVTFRPGQKLKSRVENAGGGERIEIR
	GFGSFSLHYRAPRTGRNPKTGDKVELEGKYVPHFKPGKEL
	RDRANIYGGGGSGGGSGTGGSGGSGGSGGSGGSGRPMDKK
	YSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIK
	KNLIGALLEDSGETAEATRLKRTARRRYTRRKNRICYLQE
	IFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVD
	EVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMIKF
	RGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINAS
	GVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIAL
	SLGLTPNEKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGD
	QYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKR
	YDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYID
	GGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRT
	FDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKIL
	TFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDK
	GASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNEL
	TKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQL
	KEDYFKKIECFDSVEISGVEDRENASLGTYHDLLKIIKDK
	DFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFD
	DKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLK
	SDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHI
	ANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMA
	RENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENT
	QLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQ
	SFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWR
	QLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVET
	RQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVS
	DFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKL
	ESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMN
	FFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVR
	KVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKK
	DWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELL
	GITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLF
	ELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEK
	LKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILAD
	ANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAF
	KYEDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQ
	LGGDGGSGGSGGSGGSGGSASGGGSGGGSKRPAATKKAGQ
	AKKKKGGSGSGATNFSLLKQAGDVEENPGPAAA*
Integration host	MALTKAEMSEYLEDKLGLSKRDAKELVELFFEEIRRALEN	5147
factor subunit alpha	GEQVKLSGFGNFDLRDKNQRPGRNPKTGEDIPITARRVVT
(E. coli)	FRPGQKLKSRVENASPKDE
Integration host	MTKSELIERLATQQSHIPAKTVEDAVKEMLEHMASTLAQG	5148
factor subunit beta	ERIEIRGFGSFSLHYRAPRTGRNPKTGDKVELEGKYVPHF
(E. coli)	KPGKELRDRANIYG
Integration host	MALTKAELAEALFEQLGMSKRDAKDTVEVFFEEIRKALES	5149
factor subunit alpha	GEQVKLSGFGNFDLRDKNERPGRNPKTGEDIPITARRVVT
(Vibrio cholerae	FRPGQKLKARVENIKVEK
HE-45)
Integration host	MTKSELIERLCAEQTHLSAKEIEDAVKNILEHMASTLEAG	5150
factor subunit beta	ERIEIRGFGSFSLHYREPRVGRNPKTGDKVELEGKYVPHF
(Vibrio cholerae	KPGKELRERVNL
HE-45)
Integration host	MALTKADIAEHLFEKLGINKKDAKDLVEAFFEEIRSALEK	5151
factor subunit alpha	GEQVKLSGFGNFDLRDKKERPGRNPKTGEDIPISARRVVT
(Psuedoalteromonas	FRPGQKLKTRVEVGTSKAK
sp. S983)
Integration host	MTKSELIETLAEQHAHVPVKDVENAVKEILEQMAGSLSTS	5152
factor subunit beta	DRIEIRGFGSFSLHYRAPRTGRNPKTGDTVELDGKHVPHF
(Psuedoalteromonas	KPGKELRDRVNESIA
sp. S983)

TABLE 4
Selected Variant Transposition

normalized

									log2 fold-
									change

log2 fold-change

log2

abundance (Ab) =

log2(AbOutput/

(foldchange/

Read count

(count/total_counts)

AbInput)

average WT foldchange)

Read count

ID	input	LR	RL	input	LR	RL	LR	RL	LR	RL	input
ORF1a	1420	585	715	0.0426	0.0597	0.0323	0.4861	−0.3989	1.22	−1.47	1420
ORF1b	2578	672	883	0.0773	0.0685	0.0399	−0.1742	−0.9548	0.56	−2.03	2578
ORF1c	2368	729	791	0.0710	0.0744	0.0357	0.0658	−0.9910	0.80	−2.06	2368
ORF2a	2365	973	708	0.0710	0.0992	0.0320	0.4842	−1.1491	1.22	−2.22	2365
ORF3a	778	621	695	0.0233	0.0633	0.0314	1.4403	0.4282	2.18	−0.64	778
ORF3b	1124	1170	877	0.0337	0.1193	0.0396	1.8233	0.2330	2.56	−0.84	1124
ORF3c	2525	903	629	0.0758	0.0921	0.0284	0.2820	−1.4142	1.02	−2.49	2525

normalized

									log2 fold-
									change

log2 fold-change

log2

abundance (Ab) =

log2(AbOutput/

(foldchange/

Read count

(count/total_counts)

AbInput)

average_WT_foldchange)

	ID	LR	RL	input	LR	RL	LR	RL	LR	RL
	ORF1a	677	955	0.0426	0.0378	0.0765	0.8443	−0.1720	1.49	−1.08
	ORF1b	822	1209	0.0773	0.0479	0.0929	0.2639	−0.6922	0.91	−1.60
	ORF1c	742	1183	0.0710	0.0468	0.0838	0.2388	−0.6009	0.89	−1.51
	ORF2a	999	953	0.071	0.0377	0.1129	0.6696939	−0.9110151	1.32	−1.82
	ORF3a	651	1066	0.0233	0.0422	0.0736	1.6558648	0.8546424	2.30	−0.05
	ORF3b	1058	1021	0.0337	0.0404	0.1195	1.825675	0.2616178	2.47	−0.65
	ORF3c	645	972	0.0758	0.0385	0.0729	−0.0559349	−0.9769782	0.59	−1.89

TABLE 5
Tn6677 hyperactive transposon right end variants.

Enrichment score =

Ab = Abundance =

Log2 (FC = Fold Change =

Variant

Read count

(count/total_counts)

(Ab_Output/Ab_Input))

SEQ ID NO:	Input	RL	LR	input	RL	LR	RL
2691	144	534	62	0.00833458	0.04369821	0.01347144	2.39039236
2692	165	522	74	0.00955004	0.04271623	0.01607881	2.16120521
2693	502	1453	170	0.02905528	0.11890169	0.03693781	2.03289686
2694	497	1323	170	0.02876589	0.10826354	0.03693781	1.91211673
2695	343	880	147	0.01985251	0.07201203	0.03194034	1.85891638
2696	591	1530	183	0.03420652	0.12520274	0.03976247	1.87192305
2697	416	1192	165	0.02407768	0.09754357	0.03585141	2.01835023
2698	661	1483	194	0.03825805	0.12135664	0.04215256	1.66541785
2699	873	2177	301	0.05052841	0.17814795	0.06540166	1.81790928
2700	528	1279	190	0.03056014	0.10466294	0.04128344	1.77602786
2701	711	1706	186	0.041152	0.13960514	0.04041431	1.76231761
2702	680	1639	217	0.03935775	0.13412241	0.04715003	1.76883063

		Enrichment score =
		Log2 (FC = Fold Change =	Normalized enrichment	Normalized FC =
	Variant	(Ab_Output/Ab_Input))	Log2 (Normalized FC)	Normalized enrichment {circumflex over ( )} 2

	SEQ ID NO:	LR	RL	LR	RL	LR
	2691	0.69272194	1.39407206	1.12302665	2.628194525	2.178034264
	2692	0.75158178	1.16488491	1.18188649	2.242153283	2.268732461
	2693	0.34629801	1.03657656	0.77660272	2.051354117	1.713092104
	2694	0.36073952	0.91579643	0.79104424	1.886610275	1.730326441
	2695	0.68605821	0.86259607	1.11636292	1.818307337	2.16799724
	2696	0.21713614	0.87560274	0.64744086	1.834774472	1.566387177
	2697	0.57433312	1.02202993	1.00463784	2.030774332	2.006439757
	2698	0.13985701	0.66909755	0.57016172	1.590078014	1.484689989
	2699	0.37223246	0.82158898	0.80253717	1.767351477	1.744165777
	2700	0.43391212	0.77970756	0.86421683	1.716782839	1.820351217
	2701	−0.0260963	0.76599731	0.4042084	1.700545149	1.323362588
	2702	0.26061092	0.77251033	0.69091564	1.708239584	1.614307751

TABLE 6
Tn6677 hyperactive transposon left end variants.

Enrichment score =

Ab = Abundance =

Log2 (FC = Fold Change =

Variant

Read count

(count/total_counts)

(Ab_Output/Ab_Input))

SEQ ID NO:	Input	RL	LR	input	RL	LR	RL
4666	366	1970	638	0.029638	0.12776461	0.12956682	2.10796813
4667	778	3348	727	0.063001	0.21713499	0.14764119	1.78514552
4668	613	2242	687	0.04963961	0.14540521	0.13951788	1.55051536
4669	565	1992	494	0.04575266	0.12919143	0.1003229	1.49758293
4670	596	2077	444	0.04826298	0.13470411	0.09016876	1.48080504
4671	774	2499	666	0.06267709	0.16207298	0.13525314	1.37063349
4672	875	2802	448	0.07085588	0.18172408	0.09098109	1.35879009
4673	655	2086	623	0.05304069	0.13528781	0.12652058	1.3508604

		Enrichment score =
		Log2 (FC = Fold Change =	Normalized enrichment	Normalized FC =
	Variant	(Ab_Output/Ab_Input))	Log2 (Normalized FC)	Normalized enrichment {circumflex over ( )} 2

	SEQ ID NO:	LR	RL	LR	RL	LR
	4666	2.1281762	1.36927774	1.54104242	2.583411998	2.910046931
	4667	1.22864863	1.04645514	0.64151485	2.065448574	1.559966286
	4668	1.49088645	0.81182497	0.90375267	1.755430611	1.870926224
	4669	1.1327236	0.75889254	0.54558982	1.692191145	1.45961696
	4670	0.90171077	0.74211465	0.31457699	1.672625717	1.243646952
	4671	1.10965203	0.6319431	0.52251825	1.549650742	1.436460428
	4672	0.36067914	0.6200997	−0.2264546	1.536981393	0.854732805
	4673	1.25420068	0.61217001	0.6670669	1.528556638	1.587841491

TABLE 7
Transposon Left end Variants SEQ ID NOs: 3120-4665

	Normalized	Normalized
	enrichment = Log2	enrichment = Log2
SEQ	(Normalized	(Normalized
ID	FC) − RL	FC) − RL
NO	(1st Replicate)	(2nd Replicate)

3120	−0.0920	−0.1196
3121	−0.1589	−0.1221
3122	−0.3028	−0.1583
3123	−0.1687	−0.0930
3124	0.3025	0.7183
3125	−0.0271	0.0739
3126	−0.0323	−0.1814
3127	−0.0960	0.0584
3128	0.2132	−0.0754
3129	−0.0700	−0.1073
3130	−0.1346	−0.1114
3131	−0.1020	−0.0508
3132	−0.4968	−0.3233
3133	0.0804	0.0462
3134	0.0547	0.1251
3135	−0.0254	−0.1459
3136	−0.4439	−0.0746
3137	0.3111	0.1639
3138	0.4355	0.3983
3139	−0.3595	−0.2221
3140	−0.1083	−0.0183
3141	−0.5151	−0.3808
3142	−0.3106	−0.2442
3143	−0.1557	0.0135
3144	0.1481	0.3777
3145	−0.4356	−0.1720
3146	−0.7206	−0.5393
3147	−0.3510	−0.1659
3148	−0.1876	−0.0795
3149	−0.3738	−0.0162
3150	−0.2141	−0.0705
3151	−0.0857	0.0537
3152	−0.6942	−0.3374
3153	−0.4993	−0.3103
3154	−0.0674	0.4852
3155	−0.7764	−0.5471
3156	−0.4871	0.1020
3157	−0.5977	0.0836
3158	−0.9712	−0.3965
3159	−0.4368	0.0634
3160	−1.1051	−0.4840
3161	−0.7405	−0.3679
3162	−0.6708	−0.1799
3163	−1.1210	−0.4550
3164	−1.0947	−0.4992
3165	−2.2545	−1.3719
3166	−1.2450	−0.4252
3167	−1.5277	−0.8136
3168	−0.7241	−0.4416
3169	−0.5053	−0.1762
3170	−0.2774	0.1031
3171	−0.2312	−0.2834
3172	0.3464	0.2509
3173	−0.0615	−0.1089
3174	−0.0863	−0.0523
3175	−0.2961	0.0501
3176	−1.2165	−0.4332
3177	−1.4467	−0.7979
3178	−0.7622	−0.4362
3179	−1.5470	−0.8870
3180	−1.6309	−0.9422
3181	0.3110	1.0091
3182	−1.2189	−0.1928
3183	−1.6377	−0.9052
3184	−1.2608	−0.4924
3185	−0.4089	−0.1479
3186	−1.6843	−0.7709
3187	−0.4196	0.2258
3188	−0.2757	−0.0805
3189	−0.6227	−0.3051
3190	−0.4993	0.0297
3191	−0.4146	−0.2337
3192	−0.6172	−0.2926
3193	−0.4065	0.2214
3194	−0.9305	−0.4781
3195	0.7222	0.7256
3196	−0.1765	0.1603
3197	−1.1174	−0.5726
3198	−0.3624	−0.2735
3199	−0.4419	−0.0944
3200	−0.9599	−0.3779
3201	−1.3623	−0.5538
3202	−0.7134	−0.2438
3203	−0.2653	−0.1483
3204	−0.4222	0.1532
3205	−0.0904	0.0000
3206	−0.6912	−0.4357
3207	−0.4444	−0.1814
3208	0.1603	−0.0410
3209	0.2512	−0.0580
3210	0.4014	−0.1544
3211	−0.5184	−0.2894
3212	−0.3019	−0.3769
3213	0.3582	−0.1970
3214	0.0402	0.0218
3215	−0.1361	−0.1799
3216	−0.2938	−0.3356
3217	−0.0483	0.0935
3218	−0.3091	−0.1700
3219	−0.2061	−0.0907
3220	−0.3132	−0.2378
3221	−0.0732	0.0267
3222	−0.1509	−0.1241
3223	0.6388	0.6740
3224	−0.1398	−0.0764
3225	−0.3265	−0.1962
3226	0.0372	−0.0264
3227	0.0936	0.1591
3228	−0.1101	0.0757
3229	−0.0869	−0.0397
3230	−0.8036	−0.3790
3231	−0.1971	−0.1186
3232	−0.2289	−0.1483
3233	−0.1512	0.1710
3234	−0.1102	0.2761
3235	−0.6459	0.4398
3236	−0.8987	−0.2954
3237	0.3283	0.7435
3238	−0.8013	0.0096
3239	−0.6420	−0.2563
3240	−0.6780	−0.2798
3241	−1.0339	−0.5114
3242	−0.7362	−0.1432
3243	−2.5286	−1.5930
3244	−0.8623	−0.3292
3245	−1.0364	−0.3680
3246	−0.7861	−0.4232
3247	0.1000	0.0769
3248	−0.1173	−0.0413
3249	−0.1518	−0.0069
3250	−0.2585	−0.1758
3251	−0.2599	−0.2256
3252	0.3003	0.3741
3253	0.0931	0.0056
3254	−1.2538	−0.5527
3255	−1.3846	−0.7316
3256	−0.3987	−0.1798
3257	−1.1606	−0.5933
3258	−0.2277	0.6652
3259	−0.4728	−0.1899
3260	−1.9077	−0.7874
3261	−1.7705	−0.8829
3262	−0.8518	−0.2210
3263	−0.1836	0.2494
3264	−1.5606	−0.7171
3265	−0.8294	−0.1546
3266	−0.1933	0.0878
3267	−0.5022	0.1007
3268	−0.6472	−0.2745
3269	−0.5700	−0.2469
3270	−0.5368	0.0313
3271	−0.3058	0.0662
3272	−0.9554	−0.3724
3273	0.0478	0.1511
3274	−0.5997	−0.4512
3275	−0.7102	−0.1341
3276	−0.4344	−0.2913
3277	−0.6564	−0.2087
3278	−0.9131	−0.3402
3279	−1.0881	−0.5730
3280	−0.3899	−0.0133
3281	−0.3274	−0.2099
3282	−0.1650	−0.0922
3283	0.2040	−0.0634
3284	0.0921	0.0261
3285	−0.1805	−0.1135
3286	0.1486	0.0127
3287	0.0990	0.3949
3288	0.2114	0.2833
3289	−0.3099	−0.1482
3290	−0.4794	−0.2858
3291	−0.1380	0.0129
3292	0.2457	0.2287
3293	0.0376	0.1233
3294	0.2507	0.1959
3295	0.9627	1.3754
3296	0.1975	0.4383
3297	−0.0636	−0.0953
3298	−0.0051	0.1238
3299	−0.1011	−0.1423
3300	−0.2047	−0.1775
3301	0.1215	0.0730
3302	−0.0021	−0.0055
3303	−0.1110	−0.0867
3304	0.1024	0.0244
3305	−0.0874	−0.0071
3306	0.1709	−0.0268
3307	−0.1435	−0.0171
3308	−0.1460	−0.0564
3309	−0.3433	−0.1020
3310	0.0335	0.2450
3311	−1.7266	−0.9350
3312	−0.7628	−0.3291
3313	−0.1637	−0.1701
3314	−0.1959	−0.0276
3315	−0.1566	−0.2424
3316	0.0087	0.1330
3317	−0.2125	−0.0344
3318	0.1286	0.2256
3319	0.1407	0.3080
3320	0.0017	0.0141
3321	−0.1934	−0.1629
3322	0.0123	0.1363
3323	−0.0615	−0.0465
3324	−0.3329	−0.2224
3325	0.2673	0.2911
3326	0.2965	0.1062
3327	−0.1085	0.1041
3328	0.2418	0.3614
3329	−0.1223	0.1349
3330	−0.5580	−0.2829
3331	−0.2965	−0.0249
3332	−0.1642	−0.1712
3333	−0.1894	−0.0493
3334	0.0089	0.3469
3335	−0.0443	0.1667
3336	−0.1064	0.3599
3337	0.0058	0.3173
3338	0.1012	0.3787
3339	−0.3249	−0.1124
3340	0.0041	0.1095
3341	−0.2369	−0.0245
3342	−0.1359	0.0205
3343	0.0239	−0.1785
3344	−0.2065	0.0451
3345	−0.3686	−0.2144
3346	−0.0556	0.0326
3347	−0.0034	−0.0777
3348	−0.3918	−0.2598
3349	0.1169	0.0718
3350	0.2011	0.1090
3351	0.1952	0.0993
3352	−0.0069	0.0273
3353	−0.3104	−0.2498
3354	−0.3173	−0.1654
3355	0.4345	0.5069
3356	−0.2530	0.0221
3357	0.3429	0.3979
3358	0.1199	0.0532
3359	−0.1156	−0.1410
3360	0.1217	0.4870
3361	0.2641	0.2933
3362	−0.2793	−0.2661
3363	−0.0905	−0.0442
3364	0.0124	0.1125
3365	−0.0289	0.0489
3366	0.0567	0.0723
3367	−0.0845	−0.1613
3368	−0.0775	−0.1692
3369	−0.0821	0.0659
3370	−0.1032	−0.0300
3371	0.1267	0.1648
3372	−0.2152	−0.2285
3373	−0.0131	0.0466
3374	−0.4187	−0.0983
3375	−0.3211	−0.1103
3376	0.1035	0.0352
3377	0.2394	0.0875
3378	−0.2170	0.0367
3379	0.6321	0.7869
3380	−0.0529	0.0122
3381	0.2605	0.1699
3382	−0.0120	0.2825
3383	0.3446	0.2396
3384	0.2301	0.1138
3385	0.1555	0.2009
3386	−0.2475	−0.0450
3387	−0.1752	−0.0094
3388	−0.2281	−0.0269
3389	−0.3734	−0.0695
3390	−0.1926	0.0413
3391	0.2229	0.2883
3392	−0.8778	−0.3497
3393	−0.0055	0.1300
3394	0.1687	0.3511
3395	−0.5498	0.0737
3396	−0.5859	−0.0805
3397	−0.5661	−0.1748
3398	−0.7318	−0.3400
3399	−0.3771	−0.1687
3400	−0.9319	−0.1577
3401	−0.8696	−0.3717
3402	−0.5608	−0.2061
3403	−0.7624	−0.0910
3404	−0.6219	−0.0357
3405	−1.8231	−0.9065
3406	−0.5600	−0.1328
3407	−0.7157	−0.1934
3408	−0.2219	−0.0521
3409	0.3523	0.2468
3410	0.5827	0.8577
3411	−0.1792	−0.1491
3412	−0.0789	0.2508
3413	−0.0919	0.0581
3414	−0.6321	−0.3010
3415	−0.0199	0.2168
3416	−1.3578	−0.1074
3417	−1.4147	−0.7307
3418	−0.2736	−0.0535
3419	−0.7568	−0.0674
3420	−1.2528	−0.4814
3421	−0.4604	−0.2260
3422	−1.2567	−0.4108
3423	−1.4159	−0.7229
3424	−0.5361	0.0017
3425	−0.4040	−0.2998
3426	−1.8369	−1.1365
3427	−0.1699	−0.1922
3428	0.1036	0.2169
3429	0.2003	0.3173
3430	−0.1211	0.2013
3431	−0.1378	0.0908
3432	−0.5235	−0.1654
3433	−0.0093	0.0811
3434	−0.3919	−0.0171
3435	−0.3491	−0.1702
3436	−0.2486	−0.0474
3437	−0.3026	0.0605
3438	0.0117	0.1561
3439	−0.7688	−0.3225
3440	−0.4209	−0.1694
3441	−0.3198	0.1408
3442	0.1465	0.2436
3443	0.0376	0.0952
3444	−0.0460	0.1093
3445	−0.1387	−0.0593
3446	−1.3196	−0.5134
3447	−0.0984	−0.0301
3448	−0.0306	0.0171
3449	−0.1654	0.2429
3450	−0.6395	−0.1631
3451	−0.1463	−0.0198
3452	−0.6391	−0.2697
3453	−0.4937	−0.2199
3454	−0.0693	0.0612
3455	0.3442	0.2163
3456	0.2390	0.2447
3457	−0.3429	−0.0750
3458	−7.3745	−5.9937
3459	−1.7851	−0.9890
3460	−0.2636	−0.0484
3461	−3.0977	−2.0777
3462	−0.2877	0.0686
3463	−6.7372	−6.6300
3464	−7.0578	−6.9688
3465	−2.9142	−2.3904
3466	−0.2604	−0.1799
3467	−0.0770	0.1278
3468	−0.3130	−0.3243
3469	−0.1209	−0.0712
3470	−0.2249	−0.1187
3471	−0.1566	−0.1059
3472	−0.1984	−0.0975
3473	0.1227	0.0603
3474	0.2934	0.2998
3475	−0.1029	−0.1788
3476	0.2117	0.2663
3477	−0.0304	−0.0821
3478	0.0310	0.0949
3479	0.0662	0.1999
3480	−0.0961	0.0490
3481	−0.1820	−0.0806
3482	0.0491	−0.0610
3483	0.1072	0.0660
3484	−0.3046	−0.2405
3485	0.2195	0.2661
3486	−0.6998	−0.2431
3487	−0.2508	−0.1478
3488	−0.5263	−0.3600
3489	−0.7341	−0.5099
3490	−1.6229	−0.7069
3491	−1.3102	−0.5617
3492	−1.5812	−0.7399
3493	−1.4361	−0.5874
3494	−2.0186	−0.8282
3495	−1.7076	−0.6839
3496	−1.8013	−0.8024
3497	−0.5524	−0.3481
3498	−1.2646	−0.6822
3499	−1.9382	−1.1565
3500	−2.6612	−1.6674
3501	−2.4133	−1.3353
3502	−2.1137	−1.3538
3503	−2.2442	−1.1592
3504	−1.7341	−0.9315
3505	−0.6662	−0.1042
3506	−0.7563	−0.1913
3507	−0.8098	−0.2350
3508	−0.5032	−0.1595
3509	−0.2582	0.0262
3510	−0.3906	0.0897
3511	−0.2851	−0.0764
3512	−0.0261	0.0610
3513	−0.1052	0.0931
3514	−0.3196	−0.1720
3515	−0.3190	−0.2229
3516	−0.6221	−0.1924
3517	−1.2209	−0.6594
3518	−1.8688	−0.9356
3519	−1.1462	−0.7795
3520	−2.0041	−1.0151
3521	−1.7712	−0.7010
3522	−0.2104	0.9835
3523	0.4923	0.7954
3524	−1.1093	−0.4603
3525	−1.9721	−1.2051
3526	−2.8726	−1.5430
3527	−2.9835	−1.7603
3528	−2.8047	−1.5229
3529	−1.5927	−0.4979
3530	−1.6275	−0.8578
3531	−0.7395	−0.3344
3532	−0.4259	−0.1069
3533	−0.2840	0.0671
3534	−0.0872	−0.0409
3535	0.0044	0.1133
3536	−0.3071	−0.0952
3537	−0.1912	−0.0794
3538	0.1357	0.2275
3539	0.4049	0.4807
3540	0.3191	0.3877
3541	−0.0670	−0.0732
3542	−0.0357	−0.1296
3543	−1.9226	−0.9763
3544	−2.0594	−1.1209
3545	−0.1766	0.3661
3546	−0.1285	−0.0182
3547	−0.0085	0.1802
3548	−0.2488	−0.1044
3549	0.0240	0.2932
3550	−0.3492	−0.0432
3551	−0.9267	−0.2694
3552	−1.0129	−0.3493
3553	−0.9017	−0.4108
3554	−0.4854	−0.2118
3555	−0.3588	−0.0785
3556	−0.1686	0.0217
3557	−0.1206	−0.0503
3558	−0.2258	−0.0206
3559	−0.0992	0.2240
3560	−0.0296	−0.0301
3561	−0.6978	−0.3727
3562	−0.1886	−0.1335
3563	−0.2675	−0.2049
3564	0.1400	0.1143
3565	−0.3684	−0.2679
3566	−0.0912	−0.1272
3567	0.1647	0.1701
3568	0.2549	0.4486
3569	−0.4684	0.0186
3570	−1.2810	−0.6467
3571	−1.5004	−0.7471
3572	−1.6255	−0.8515
3573	−1.6050	−0.9353
3574	−2.1740	−1.1812
3575	−0.9718	−0.5020
3576	−0.8027	−0.3189
3577	−0.1506	−0.0606
3578	−1.7236	−1.1256
3579	−2.1236	−1.5141
3580	−2.7275	−1.6364
3581	−3.2774	−2.1109
3582	−2.2367	−1.1165
3583	−1.6533	−0.6486
3584	−1.0185	−0.4380
3585	−0.1122	0.2742
3586	−0.2750	0.2113
3587	−0.6347	−0.1979
3588	−0.3931	−0.1860
3589	−0.6175	−0.2544
3590	−1.8680	−1.2824
3591	−0.0024	0.1526
3592	−7.4639	−6.2221
3593	−7.9885	−6.4635
3594	−8.3930	−9.6810
3595	−7.3423	−10.9782
3596	−0.3903	−0.3416
3597	0.0917	0.1494
3598	−0.0758	−0.0618
3599	−0.2396	−0.2441
3600	−0.2948	−0.0989
3601	−0.2653	−0.1860
3602	−0.1487	−0.1682
3603	0.2530	0.2161
3604	0.1562	0.1653
3605	0.0556	−0.0740
3606	−0.3582	−0.3250
3607	−0.6016	−0.2498
3608	−0.4632	−0.1732
3609	−0.7017	−0.2571
3610	−0.6669	−0.3597
3611	−0.4609	−0.0806
3612	−1.1828	−0.5130
3613	−1.3720	−0.5901
3614	−2.2294	−1.3354
3615	−2.6956	−1.6841
3616	−0.9745	−0.3097
3617	−0.4727	−0.4828
3618	−0.2409	−0.0700
3619	−0.7012	−0.3244
3620	−0.7103	−0.0184
3621	−1.5205	−0.8541
3622	−1.9097	−1.1174
3623	−1.4267	−0.7179
3624	−0.9269	−0.5197
3625	−0.5775	−0.1805
3626	−1.6068	−0.8562
3627	−1.8065	−0.8846
3628	−0.6095	−0.2797
3629	0.0616	0.1545
3630	−0.4946	−0.1218
3631	0.2111	0.5455
3632	0.1446	0.2120
3633	−0.0361	0.2558
3634	0.2105	0.3505
3635	−0.5164	−0.2773
3636	−0.3142	−0.1470
3637	−0.3062	−0.0815
3638	−1.2010	−0.5013
3639	−1.3650	−0.6889
3640	−2.7044	−1.5048
3641	−2.4767	−1.2990
3642	−0.3075	0.1915
3643	0.0668	0.2320
3644	0.1260	0.1088
3645	−0.2224	−0.0350
3646	−0.4072	−0.0328
3647	−1.2555	−0.6835
3648	−1.9614	−0.9218
3649	−1.7198	−0.9177
3650	−1.1859	−0.6095
3651	−0.6788	−0.1107
3652	−1.3040	−0.7265
3653	−0.8762	−0.2100
3654	−0.0706	−0.0031
3655	0.1123	0.1012
3656	0.4096	0.5286
3657	0.1043	0.1039
3658	0.2247	0.3261
3659	−0.4147	−0.3101
3660	−0.3476	−0.0225
3661	−0.1968	−0.0928
3662	−0.1174	0.1090
3663	−1.1018	−0.4812
3664	−0.3143	−0.0155
3665	0.0859	0.0522
3666	−0.5218	−0.1111
3667	−0.2070	0.0362
3668	0.1721	0.1037
3669	−0.1819	−0.0326
3670	−1.0517	−0.4065
3671	−0.9464	−0.0715
3672	0.2220	0.4830
3673	0.3636	0.3177
3674	0.4927	0.4113
3675	0.1753	0.2096
3676	0.2912	0.1367
3677	−0.0267	−0.0441
3678	−0.0622	0.0076
3679	0.8972	0.8312
3680	−0.0575	0.0481
3681	0.2716	0.2170
3682	0.3474	0.6009
3683	0.1165	0.2648
3684	0.0354	0.1638
3685	0.1521	0.1534
3686	0.1855	0.2316
3687	0.0816	0.1675
3688	−0.2594	−0.0299
3689	−0.1511	−0.1117
3690	−0.0788	0.2959
3691	0.0219	0.4376
3692	−0.6198	0.0010
3693	−0.9111	0.0283
3694	−2.7198	−1.5187
3695	−2.3341	−1.1304
3696	−0.8652	−0.3453
3697	−0.1374	0.0439
3698	−0.6141	−0.2269
3699	−0.3952	0.0503
3700	−0.7037	−0.2627
3701	−1.5155	−0.7281
3702	−1.4859	−0.7755
3703	−0.5488	−0.0770
3704	−0.1624	−0.0285
3705	−0.4721	0.0344
3706	−0.9048	−0.3789
3707	−0.4851	0.0210
3708	−0.1538	−0.0593
3709	−0.4584	−0.1921
3710	0.9657	0.7010
3711	−0.5900	−0.3670
3712	−0.3751	−0.2187
3713	−6.6103	−6.4389
3714	−6.6670	−5.8711
3715	−6.5462	−6.3747
3716	0.1479	−0.0674
3717	0.0185	0.1212
3718	0.1261	0.2565
3719	0.2649	0.1810
3720	0.1467	0.0603
3721	−0.2376	−0.1994
3722	−0.4029	−0.3422
3723	0.0912	0.2361
3724	−0.0448	0.0067
3725	−7.1208	−6.5508
3726	−7.8909	−7.3410
3727	−7.9173	−6.3129
3728	−6.3232	−6.8299
3729	−6.5660	−6.6576
3730	−6.5578	−6.5881
3731	−1.9897	−1.1980
3732	−1.3420	−0.1297
3733	−0.8629	−0.2536
3734	−0.6479	−0.0343
3735	−1.3591	−0.6919
3736	−1.6052	−0.9177
3737	−1.2376	−0.4101
3738	−2.1335	−1.0905
3739	−2.2272	−0.9022
3740	−1.7603	−0.9709
3741	−1.5292	−0.8834
3742	−0.9992	−0.5166
3743	−1.1001	−0.4502
3744	−1.6066	−0.8165
3745	−3.1501	−2.0481
3746	−3.0733	−1.6838
3747	−2.7858	−1.7811
3748	−2.0530	−1.1040
3749	−1.0257	−0.4796
3750	−1.4423	−0.7901
3751	−0.8159	−0.1649
3752	−0.5485	−0.1426
3753	−0.2077	0.0230
3754	−0.1692	0.0353
3755	0.2299	0.3595
3756	0.1226	0.2551
3757	0.3669	0.3405
3758	0.0226	0.1316
3759	0.1025	0.1716
3760	0.0937	0.2427
3761	0.4615	0.4891
3762	−0.0471	0.1277
3763	0.0771	0.3126
3764	0.1602	0.3812
3765	0.1168	0.1601
3766	−0.1229	−0.0133
3767	0.0377	0.1236
3768	−0.1936	0.2087
3769	−1.1037	−0.3663
3770	−2.7142	−1.8371
3771	−2.2169	−0.9507
3772	−0.8267	−0.2781
3773	−0.5995	−0.0810
3774	−0.1158	0.1724
3775	−0.7023	−0.1228
3776	−1.2452	−0.4765
3777	−1.2617	−0.7049
3778	−2.0607	−0.9821
3779	−0.4303	0.9917
3780	−0.4639	−0.0857
3781	−0.0586	0.0715
3782	−0.1455	0.0497
3783	−0.2681	0.1055
3784	0.3717	0.3063
3785	0.2207	0.2138
3786	−0.1653	0.1069
3787	−0.5095	0.0159
3788	−0.6963	−0.1975
3789	−2.0648	−1.0341
3790	−2.5705	−1.2881
3791	−2.3167	−1.2264
3792	−2.8388	−1.5957
3793	−2.8725	−1.4941
3794	−2.3413	−1.1979
3795	−1.3551	−0.4832
3796	−0.9870	−0.5305
3797	−0.7153	−0.1909
3798	−0.8816	−0.3397
3799	−2.8112	−1.5518
3800	−1.8032	−0.9632
3801	−2.5367	−1.1941
3802	−2.4224	−1.3335
3803	−1.2752	−0.2312
3804	−1.3238	−0.6241
3805	−0.8582	−0.3499
3806	−0.2521	0.1802
3807	−0.2855	−0.0192
3808	−0.2604	−0.0882
3809	−0.2029	0.0489
3810	−0.6620	−0.2028
3811	−0.1029	0.0875
3812	−0.8157	−0.2993
3813	−1.8832	−0.9071
3814	−2.1965	−1.0238
3815	−2.2303	−1.4157
3816	−1.4450	−0.0178
3817	−2.5140	−1.3709
3818	−2.6814	−1.4115
3819	−1.9138	−0.7965
3820	−2.5097	−1.4805
3821	−1.3987	−0.7231
3822	−1.0824	−0.4571
3823	−0.3037	0.1448
3824	−0.6652	0.0205
3825	−2.1865	−1.2341
3826	−2.5509	−1.5239
3827	−2.1358	−1.0643
3828	−1.8494	−0.8651
3829	−1.1086	−0.4576
3830	−1.3151	−0.5997
3831	−1.5385	−0.8916
3832	−0.8832	−0.2915
3833	−0.9407	−0.3956
3834	−0.0136	0.1605
3835	−0.0252	0.1395
3836	−0.1409	0.1251
3837	−0.1000	−0.1398
3838	0.0507	−0.0084
3839	0.2537	0.2821
3840	−0.4245	−0.2666
3841	−0.4470	−0.5817
3842	−7.7951	−7.7392
3843	−6.6152	−6.5507
3844	−7.3824	−6.3879
3845	−6.6939	−8.0370
3846	−8.2173	−7.4610
3847	−7.1848	−7.6763
3848	−0.8947	−0.3952
3849	−1.7841	−1.0846
3850	−1.0333	−0.3654
3851	−0.4336	−0.0154
3852	−0.4770	−0.3016
3853	−1.8007	−0.9576
3854	−2.3532	−1.4240
3855	−2.7858	−1.7034
3856	−3.2892	−2.0858
3857	−3.6335	−2.7189
3858	−4.4349	−2.5291
3859	−3.8024	−2.5555
3860	−1.5494	−0.5047
3861	−3.4732	−2.3159
3862	−1.4722	−0.7757
3863	−2.9028	−1.7105
3864	−3.2498	−1.8531
3865	−2.7448	−1.0525
3866	−3.0800	−1.7711
3867	−2.5465	−1.4106
3868	−1.1538	−0.2917
3869	−1.4123	−0.7039
3870	−0.8210	−0.3623
3871	−0.4194	−0.3083
3872	−0.1116	−0.0424
3873	0.0020	0.3486
3874	0.1383	0.2687
3875	−0.3176	−0.1227
3876	−0.1069	0.0395
3877	−0.3039	−0.0814
3878	0.1043	0.2540
3879	0.0634	0.2149
3880	−0.2647	−0.1246
3881	−0.1912	−0.0254
3882	−0.6951	−0.3121
3883	−0.3633	−0.0565
3884	−0.7923	−0.1811
3885	−1.8221	−1.0672
3886	−1.8377	−1.1566
3887	−1.9299	−1.1633
3888	−1.1371	−0.2829
3889	−0.2420	0.1446
3890	−0.1731	−0.8035
3891	−0.0754	0.2170
3892	−0.8371	−0.3460
3893	−2.2494	−1.1168
3894	−2.5760	−1.7004
3895	−2.2619	−1.3856
3896	−1.1496	−0.4850
3897	1.0843	1.0330
3898	0.0194	0.0300
3899	0.4735	0.3391
3900	0.0364	0.2375
3901	−0.2936	−0.3552
3902	−0.1969	−0.1804
3903	−0.4510	−0.1950
3904	−0.6307	−0.3177
3905	−0.9492	−0.4200
3906	−0.8309	−0.2319
3907	−2.1130	−1.2277
3908	−2.3936	−1.3696
3909	−2.7245	−1.5341
3910	−3.2207	−1.8024
3911	−2.7229	−1.8116
3912	−2.7452	−1.7118
3913	−2.6558	−1.2485
3914	−2.2330	−1.3629
3915	−2.8029	−1.7141
3916	−1.9187	−1.2206
3917	−2.9916	−1.8797
3918	−3.3533	−2.0066
3919	−3.3050	−1.9791
3920	−2.3746	−1.4180
3921	−2.3163	−1.0773
3922	−0.7157	−0.6205
3923	−0.0575	0.2491
3924	−0.1865	−0.1292
3925	0.0081	0.1496
3926	0.0834	0.4999
3927	−0.6296	−0.1794
3928	−0.7982	−0.2766
3929	−0.5029	−0.0635
3930	−0.9681	−0.1932
3931	−1.6209	−0.5626
3932	−1.4860	−0.6959
3933	−2.4215	−1.3238
3934	−2.7021	−1.5688
3935	−2.8460	−1.6477
3936	−3.3087	−1.8582
3937	−2.9202	−1.6205
3938	−2.4528	−1.1929
3939	−3.0506	−1.8012
3940	−2.4127	−1.5068
3941	−2.6009	−1.3663
3942	−1.6939	−0.4220
3943	−2.5743	−1.6360
3944	−2.4953	−1.5113
3945	−2.5817	−1.4304
3946	−2.1973	−1.0842
3947	−2.1175	−1.1388
3948	−1.6923	−1.1109
3949	−1.8457	−0.9609
3950	−1.0391	−0.5563
3951	−0.4103	−0.3085
3952	−0.1065	−0.1810
3953	−0.2992	−0.3197
3954	0.0080	−0.0273
3955	0.1571	0.0018
3956	0.1187	−0.0014
3957	−4.2770	−2.5534
3958	−3.2419	−2.3449
3959	−0.6152	−0.3664
3960	−0.7793	−0.3715
3961	−0.9565	−0.4858
3962	−0.8604	−0.5104
3963	−0.8511	−0.4197
3964	−1.7232	−0.9323
3965	−2.1794	−1.1737
3966	−3.7282	−2.4069
3967	−3.6827	−2.2868
3968	−3.9633	−2.5074
3969	−3.6147	−2.3600
3970	−5.7595	−4.3250
3971	−5.1180	−3.4529
3972	−3.0156	−1.7906
3973	−4.5720	−2.8892
3974	−5.7903	−3.8463
3975	−5.8893	−4.4369
3976	−4.2119	−2.5864
3977	−3.5761	−1.8017
3978	−4.2974	−2.8132
3979	−3.3266	−2.1330
3980	−3.1987	−2.0847
3981	−4.7911	−3.0516
3982	−2.8451	−1.8240
3983	−3.4318	−2.2881
3984	−1.5112	−1.0627
3985	−4.7825	−3.3026
3986	−2.4516	−1.3520
3987	−3.5690	−2.8254
3988	−6.9564	−6.4631
3989	−3.5961	−2.5577
3990	−4.8013	−3.7384
3991	−4.9157	−3.7048
3992	−2.5321	−1.8533
3993	−4.9343	−3.3363
3994	−6.3558	−3.7381
3995	−5.0854	−3.3609
3996	−3.4805	−2.0429
3997	−3.3227	−2.2239
3998	−4.2238	−2.8769
3999	−3.2264	−1.5717
4000	−5.5634	−4.3255
4001	−5.0848	−4.2353
4002	−6.8895	−6.4243
4003	−8.6461	−7.6267
4004	−4.0559	−2.9363
4005	−6.5983	−5.1467
4006	−15.0000	−6.1749
4007	−5.1914	−3.8524
4008	−3.8071	−2.5748
4009	−4.6349	−2.8150
4010	−3.6521	−2.1964
4011	−4.6661	−2.7536
4012	−5.0217	−3.1467
4013	−3.7002	−2.1919
4014	−4.0916	−2.5890
4015	−2.8705	−1.4735
4016	−3.8946	−2.2092
4017	−5.2073	−3.4416
4018	−3.9015	−2.7375
4019	−5.2557	−4.5279
4020	−3.2722	−1.8281
4021	−2.9829	−1.7571
4022	−7.9421	−5.0862
4023	−3.4527	−2.2656
4024	−5.3789	−4.4139
4025	−5.6407	−4.0497
4026	−4.8675	−3.3783
4027	−4.0998	−3.2053
4028	−4.5055	−2.8720
4029	−3.2422	−2.5015
4030	−5.9397	−4.6163
4031	−4.3377	−2.3926
4032	−7.8855	−5.3218
4033	−6.6498	−5.3354
4034	−5.6591	−3.7222
4035	−4.2866	−2.3426
4036	−4.1994	−2.6555
4037	−0.5867	−0.1385
4038	−0.4394	0.0374
4039	−0.7508	−0.3047
4040	0.0941	0.2647
4041	−0.6200	−0.2123
4042	−0.0213	0.3888
4043	−0.9611	−0.4077
4044	0.0388	0.3442
4045	−1.1953	−0.7035
4046	−0.2093	0.0686
4047	−0.3223	−0.2660
4048	−0.4455	−0.1354
4049	−0.1302	−0.0055
4050	−0.2372	−0.1959
4051	−0.1709	−0.2292
4052	0.8826	0.5588
4053	−0.0737	0.3054
4054	−0.6169	0.6621
4055	−0.1614	0.2482
4056	−0.5976	−0.2513
4057	−0.7230	−0.2977
4058	−0.5139	−0.0925
4059	−0.6313	−0.4020
4060	−0.6281	−0.2748
4061	−0.6786	−0.4674
4062	−0.5161	−0.2033
4063	−0.6426	−0.4339
4064	−0.0836	−0.0126
4065	−0.1998	−0.0269
4066	−0.1543	−0.2367
4067	−0.4159	−0.2229
4068	−0.3122	0.0737
4069	−0.6880	−0.3456
4070	−0.7606	−0.3950
4071	−0.5957	−0.3650
4072	−0.2804	−0.1135
4073	−1.2219	−0.5064
4074	−0.9748	−0.4882
4075	−0.6093	−0.3414
4076	−1.6243	−0.7931
4077	−2.4821	−1.3362
4078	−7.5388	−4.9923
4079	−7.5635	−5.7196
4080	−3.5944	−2.5715
4081	−4.7852	−2.6058
4082	−0.2801	−0.1887
4083	−0.6145	−0.0889
4084	−3.5454	−1.9086
4085	−3.6858	−1.9000
4086	−1.8691	−0.7719
4087	−2.9235	−1.6448
4088	−2.0571	−1.2492
4089	−2.4869	−1.3495
4090	−1.2984	−0.6806
4091	−0.8234	−0.5493
4092	−0.0748	−0.0459
4093	−1.0120	−0.6734
4094	−1.4180	−0.7176
4095	−3.1132	−1.9571
4096	−4.6135	−2.7551
4097	−7.3866	−5.5293
4098	−9.3999	−6.3354
4099	−4.4924	−3.1233
4100	−0.7228	−0.3319
4101	−4.8721	−2.8886
4102	−9.1119	−6.8701
4103	−9.1708	−7.4144
4104	−10.3534	−9.4451
4105	−8.1852	−10.0138
4106	−3.3964	−1.5781
4107	−1.6429	−0.9812
4108	−1.1936	−0.5794
4109	−1.8197	−0.7503
4110	−1.3845	−0.5896
4111	−2.8410	−1.5967
4112	−1.4996	−0.7388
4113	−1.5744	−1.0508
4114	0.1891	0.3493
4115	−0.2963	−0.1535
4116	−0.5279	−0.2648
4117	−2.4876	−1.2704
4118	−8.0899	−5.7091
4119	−3.9825	−2.0838
4120	−1.4939	−0.6887
4121	−0.5932	−0.2624
4122	−0.5714	−0.2354
4123	−0.9800	−0.1823
4124	−0.1340	−0.0585
4125	−0.2942	−0.0188
4126	−0.6273	−0.3336
4127	−1.0036	0.0136
4128	−1.6053	−0.7043
4129	−2.7858	−1.5551
4130	−5.2728	−3.0045
4131	−5.5197	−3.8659
4132	−0.5016	−0.1254
4133	−0.8077	−0.4151
4134	−0.4514	0.0587
4135	−2.4424	−1.6148
4136	−3.9106	−2.0814
4137	−3.2782	−1.7224
4138	−7.6419	−7.1810
4139	−8.9810	−7.2247
4140	−8.1018	−7.4449
4141	−0.3868	−0.0189
4142	−1.7988	−0.8596
4143	−6.9247	−6.8845
4144	−0.8343	−0.5536
4145	−7.0229	−5.8863
4146	−1.3126	−0.9575
4147	−5.7091	−6.9609
4148	−8.0609	−5.6524
4149	−2.6741	−1.7829
4150	−4.7610	−4.0261
4151	−0.2993	−0.3204
4152	−1.7133	−1.0255
4153	−2.4119	−1.3197
4154	−2.5067	−1.8653
4155	−3.4838	−2.1707
4156	−3.7982	−2.3365
4157	−3.8067	−2.4165
4158	−3.2825	−2.0355
4159	−2.3802	−1.2325
4160	−0.6672	−0.1661
4161	−2.7418	−1.7506
4162	−5.4951	−4.1905
4163	−6.9981	−4.7910
4164	−7.4257	−5.4888
4165	−7.1841	−6.5102
4166	−8.9882	−5.5437
4167	−6.3946	−5.6668
4168	−7.2991	−6.1277
4169	−6.5179	−4.6685
4170	−3.5445	−2.4481
4171	−4.4952	−4.4211
4172	−4.6834	−4.0124
4173	−5.6052	−3.6136
4174	−5.6899	−3.8132
4175	−6.3603	−5.2273
4176	−6.0123	−4.3598
4177	−5.7591	−3.3904
4178	−5.0021	−3.6083
4179	−3.9751	−2.1187
4180	−3.6606	−2.1447
4181	−4.3178	−2.8447
4182	−5.8759	−3.3404
4183	−3.6016	−2.3733
4184	−2.7036	−1.5494
4185	−2.3867	−1.3141
4186	−0.4156	−0.0812
4187	−2.8466	−1.7705
4188	−5.0731	−3.4696
4189	−5.6188	−4.0734
4190	−5.9523	−4.5810
4191	−8.2778	−5.8168
4192	−6.2424	−4.1052
4193	−4.5717	−2.6943
4194	−1.1539	−0.4645
4195	−1.3774	−0.7380
4196	−4.4779	−2.8896
4197	−6.8045	−6.0767
4198	−8.5362	−6.9053
4199	−10.0015	−7.3707
4200	−8.1663	−7.2579
4201	−8.6062	−8.1129
4202	−8.5856	−7.8292
4203	−7.3784	−6.1481
4204	−7.2603	−5.0533
4205	−7.1605	−5.7411
4206	−6.5793	−5.4410
4207	−6.7388	−5.5674
4208	−6.5820	−5.0287
4209	−8.3013	−5.5719
4210	−10.5450	−7.1256
4211	−8.5315	−7.4532
4212	−9.2981	−10.1267
4213	−11.0468	−7.7054
4214	−9.2545	−6.3282
4215	−6.2852	−4.7993
4216	−6.0291	−3.6251
4217	−4.3772	−2.3729
4218	−3.4461	−2.0312
4219	−3.3663	−1.8611
4220	−2.1677	−1.2129
4221	−4.1013	−2.7563
4222	−3.9280	−2.5983
4223	−4.0370	−2.7000
4224	−4.2518	−3.0081
4225	−4.7767	−2.6367
4226	−2.5234	−1.4724
4227	−3.1750	−2.1840
4228	−3.0882	−1.9811
4229	−3.4769	−2.1071
4230	−4.2505	−2.7741
4231	−2.7144	−1.7127
4232	−1.3113	−0.4433
4233	−5.9920	−4.4421
4234	−8.3474	−6.2584
4235	−8.6983	−6.7196
4236	−7.3016	−6.3417
4237	−1.7008	−0.7549
4238	−3.2926	−1.9782
4239	−4.9849	−3.1806
4240	−4.6550	−3.4998
4241	−5.0363	−3.6425
4242	0.0887	0.0823
4243	−0.0654	−0.1674
4244	−0.4098	−0.2030
4245	−0.4623	−0.0904
4246	−0.8455	−0.3030
4247	−0.9395	−0.5686
4248	−5.7367	−4.4057
4249	−1.4331	−0.5754
4250	−1.2159	−0.4522
4251	−8.6796	−5.1390
4252	−6.1987	−5.0590
4253	−6.8613	−6.8419
4254	−4.2232	−3.2601
4255	−2.0656	−1.0923
4256	−1.8605	−0.9405
4257	−5.3148	−4.5783
4258	−3.0681	−1.8346
4259	−4.9889	−3.0140
4260	−7.1633	−4.4339
4261	−4.9989	−3.5511
4262	−6.9439	−5.8396
4263	−6.6411	−5.3745
4264	−6.4560	−4.2666
4265	−2.7336	−1.8293
4266	−0.0882	0.0523
4267	−0.3627	−0.2952
4268	−0.2184	−0.1239
4269	0.1647	0.0885
4270	0.5787	0.7525
4271	0.1581	0.1731
4272	−0.2887	−0.3198
4273	0.1893	−0.0354
4274	0.1482	0.0429
4275	−0.0734	−0.1184
4276	0.0515	−0.0510
4277	0.3467	0.2425
4278	−0.0413	−0.0977
4279	−0.1681	−0.0926
4280	−0.4317	−0.2283
4281	−1.2357	−0.3548
4282	−1.3706	−0.6826
4283	−1.7344	−0.9155
4284	−2.3167	−1.1726
4285	−2.8847	−1.5462
4286	−2.5894	−1.5156
4287	−2.5242	−1.2164
4288	−2.5027	−1.3552
4289	−2.9463	−1.5414
4290	−2.5669	−1.4039
4291	−2.8592	−1.5864
4292	−2.8346	−1.6958
4293	−3.1266	−1.8493
4294	−2.9827	−1.5558
4295	−3.5692	−1.6892
4296	−2.9646	−1.6460
4297	−3.1527	−1.6093
4298	−3.1710	−1.9017
4299	−3.1493	−2.1030
4300	−3.0906	−1.8630
4301	−3.3345	−1.9880
4302	−3.2093	−1.9537
4303	−3.0574	−1.8476
4304	−3.1651	−1.7519
4305	−3.0836	−1.7950
4306	−3.2920	−1.6702
4307	−3.9095	−2.2168
4308	−5.1460	−2.8286
4309	−5.1286	−3.2552
4310	−5.3711	−3.8778
4311	−6.9313	−5.0754
4312	−7.0657	−5.2280
4313	−6.3463	−4.0456
4314	6.7799	−5.3943
4315	−7.3159	−5.1026
4316	−8.6164	−6.0824
4317	−8.2670	−6.0314
4318	−9.2838	−6.5274
4319	−9.3181	−5.8836
4320	−6.6746	−5.4658
4321	−9.1124	−4.8749
4322	−8.0568	−6.1077
4323	−8.9872	−6.1153
4324	−6.9138	−5.7728
4325	−7.1361	−4.5153
4326	−7.2192	−5.2784
4327	−7.0939	−6.0220
4328	−7.1006	−4.7979
4329	−7.6235	−4.9840
4330	−6.8873	−4.7544
4331	−6.6799	−5.0611
4332	−6.5452	−4.7704
4333	−5.2359	−3.4795
4334	−7.0448	−5.6510
4335	−7.9245	−5.6461
4336	−7.4728	−5.6493
4337	−8.2866	−6.1152
4338	−7.3930	−5.4281
4339	−7.8563	−5.2698
4340	−6.8064	−5.2364
4341	−7.7156	−5.1905
4342	−7.3397	−5.6593
4343	−7.4485	−5.7971
4344	−7.3961	−5.5120
4345	−7.8495	−6.0260
4346	−7.8940	−6.1377
4347	−8.3984	−6.1395
4348	−7.1395	−6.3120
4349	−7.7741	−5.9550
4350	−7.5347	−6.5978
4351	−7.8147	−6.3732
4352	−7.9215	−6.1651
4353	−8.1969	−5.9000
4354	−7.8234	−5.9857
4355	−7.6703	−5.8208
4356	−7.7217	−6.1810
4357	−7.1485	−6.6445
4358	−7.4051	−5.8913
4359	−8.0773	−6.2108
4360	−7.6286	−6.7314
4361	−8.5862	−6.2994
4362	−9.4599	−7.0661
4363	−8.5372	−7.7284
4364	−10.0959	−8.4651
4365	−10.8159	−9.4745
4366	−11.5988	−11.4273
4367	−10.9058	−9.4124
4368	−12.5255	−12.3540
4369	−10.2981	−12.1267
4370	−11.6616	−15.0000
4371	−12.3976	−11.2262
4372	−9.4886	−11.9021
4373	−10.7323	−11.5609
4374	−11.0354	−11.8640
4375	−15.0000	−8.7991
4376	−9.6562	−10.0697
4377	−15.0000	−9.7136
4378	−0.0928	0.1697
4379	−0.0251	0.2248
4380	0.0893	0.2538
4381	−0.1069	0.1382
4382	−0.2477	0.0638
4383	−0.4002	0.0274
4384	−0.5858	−0.1915
4385	0.0916	0.4503
4386	0.2029	0.4486
4387	−0.2848	−0.0601
4388	−0.2576	0.1287
4389	−0.1256	0.1868
4390	−0.5482	−0.1718
4391	−0.5317	0.0013
4392	0.2628	0.3622
4393	0.4406	0.9444
4394	−0.3541	−0.1041
4395	−0.6106	−0.4553
4396	−0.9846	−0.1801
4397	−0.1535	0.2033
4398	−0.1171	0.2453
4399	−0.0859	0.2548
4400	−0.8444	−0.0676
4401	−0.4879	0.0232
4402	−0.5299	−0.2444
4403	−0.5009	−0.1025
4404	0.0003	0.1529
4405	0.2422	0.2800
4406	−0.5640	−0.0561
4407	−0.4763	−0.2973
4408	−0.2658	−0.2175
4409	−0.0299	0.1849
4410	0.2592	0.3388
4411	−0.0641	0.1207
4412	0.1802	0.3054
4413	0.2669	−0.0556
4414	−0.3153	0.1862
4415	−0.6194	−0.0127
4416	−0.3937	0.2567
4417	0.1141	0.6298
4418	−0.6399	−0.1898
4419	0.5921	−0.2310
4420	−0.2786	0.2818
4421	−0.2468	0.2338
4422	0.1563	0.3611
4423	−0.4409	−0.2822
4424	−0.4965	0.2816
4425	−0.4324	0.2135
4426	−1.0210	−0.5078
4427	−0.4199	−0.0059
4428	−0.6114	−0.2296
4429	−0.1407	0.1940
4430	−0.3626	0.0942
4431	−0.9248	−0.3784
4432	−1.2743	−0.5287
4433	−0.3835	0.2901
4434	−0.4619	0.3310
4435	−0.8648	−0.2030
4436	−1.3171	−0.6714
4437	−0.8105	−0.1554
4438	−0.9386	−0.1473
4439	−0.3446	−0.0717
4440	−0.7553	−0.5013
4441	−0.4459	−0.1539
4442	−1.2869	−0.4868
4443	−0.3469	−0.0234
4444	−0.1531	0.0689
4445	0.0781	0.2614
4446	−0.3784	−0.0855
4447	−0.0805	0.1194
4448	−0.4057	−0.0809
4449	−0.2716	0.1137
4450	−0.8925	−0.5200
4451	−0.4112	0.0335
4452	−0.6856	−0.2091
4453	−0.8151	−0.3294
4454	−0.5609	−0.2483
4455	−0.5952	0.0039
4456	−1.2291	−0.4587
4457	−0.4150	0.2526
4458	−0.4832	0.0149
4459	−0.6890	−0.0668
4460	−1.1077	−0.5728
4461	−1.3577	−0.5443
4462	−1.1894	−0.3917
4463	−0.8944	−0.3646
4464	−0.8404	−0.6107
4465	−0.9863	−0.4765
4466	−1.0465	−0.6295
4467	−1.2109	−0.5278
4468	−1.7276	−1.0368
4469	−0.8500	−0.2302
4470	−0.8042	−0.1729
4471	0.9338	−0.2728
4472	−1.5495	−0.6623
4473	−1.9489	−1.0847
4474	−1.2539	−0.6980
4475	−0.5823	−0.1411
4476	−0.7785	−0.6120
4477	−0.4596	−0.2037
4478	−1.1086	−0.3935
4479	−0.9981	−0.5321
4480	−0.4792	0.2191
4481	−0.4174	−0.0481
4482	−0.4710	−0.2168
4483	0.2574	0.7933
4484	−0.4876	−0.2359
4485	−0.8438	−0.5064
4486	−0.0597	0.2937
4487	−0.0668	0.4310
4488	−0.0075	0.2802
4489	−0.1956	0.2812
4490	−0.0306	0.2927
4491	−0.5503	0.0206
4492	−0.2502	0.1515
4493	−0.2575	0.2769
4494	0.0050	0.2684
4495	−0.2255	0.2695
4496	−0.0617	0.3281
4497	−0.3405	0.0236
4498	−0.7789	−0.3568
4499	−0.2473	0.3700
4500	−0.3735	−0.3020
4501	−0.2268	−0.0706
4502	−0.5106	−0.2395
4503	−0.3317	0.1984
4504	−1.2502	−0.5835
4505	−0.8524	−0.1787
4506	−0.3267	−0.0736
4507	−0.5326	0.0119
4508	−1.2168	−0.4554
4509	−0.5952	−0.0832
4510	−0.5800	−0.2684
4511	−0.7149	−0.3167
4512	−0.3789	−0.0173
4513	−0.1780	−0.0380
4514	−1.2420	−0.6912
4515	−0.2325	0.0433
4516	−0.0582	0.2535
4517	0.7464	1.0213
4518	0.2554	0.3988
4519	0.0968	0.2240
4520	−0.3460	−0.1079
4521	−0.1834	0.1124
4522	0.4059	0.0557
4523	−0.5902	−0.1390
4524	−0.4918	−0.0294
4525	−0.7562	−0.2440
4526	−0.7892	−0.1810
4527	−0.9519	−0.2061
4528	−0.7984	−0.3081
4529	−0.8061	−0.2020
4530	−0.5900	−0.0788
4531	0.8137	−0.1631
4532	−0.4139	0.0775
4533	−1.1626	−0.4566
4534	−1.1039	−0.4323
4535	−0.8349	−0.4786
4536	−0.4696	−0.1873
4537	−0.7593	−0.4944
4538	−1.0887	−0.5375
4539	−1.2355	−0.4869
4540	−1.1856	−0.4518
4541	−1.1643	−0.3410
4542	−0.9590	−0.3608
4543	−0.8976	−0.3216
4544	−1.0774	−0.2992
4545	−1.8020	−1.0098
4546	−0.9263	−0.4451
4547	−0.9774	−0.6273
4548	−0.9892	−0.5318
4549	−0.1300	0.0608
4550	−1.2471	−0.4383
4551	−0.7886	−0.4694
4552	−0.5649	−0.2256
4553	−0.5073	−0.1512
4554	−0.3131	−0.0067
4555	0.1132	0.8137
4556	−0.7470	−0.5433
4557	−0.9315	−0.4381
4558	−0.1049	0.1342
4559	0.2612	0.3757
4560	−0.1107	0.1276
4561	−0.1799	0.1240
4562	0.1302	0.3577
4563	−0.3948	−0.0947
4564	−0.3401	0.0482
4565	−0.1454	0.2078
4566	−0.2097	−0.0351
4567	−0.1966	0.0107
4568	−0.1539	0.4095
4569	0.4565	0.9229
4570	−0.5050	−0.1828
4571	−0.3595	−0.1506
4572	−0.2938	0.0304
4573	−0.2609	−0.0050
4574	−0.5506	−0.2852
4575	−0.3034	0.0140
4576	−0.9504	−0.4560
4577	−0.7329	−0.3105
4578	−0.4157	0.0093
4579	−0.4979	0.0034
4580	−0.8566	−0.4617
4581	−0.9013	−0.3083
4582	−0.7945	−0.5184
4583	0.2312	0.2493
4584	−0.3961	−0.2553
4585	−0.5433	0.0358
4586	−0.3481	−0.0839
4587	−0.4486	−0.1328
4588	−0.1857	0.0088
4589	0.2189	0.1929
4590	0.4798	0.5300
4591	−0.1226	−0.0760
4592	−0.4566	−0.1437
4593	−8.3927	−9.3367
4594	−4.5421	−2.6510
4595	−3.1208	−1.8725
4596	−8.7566	−11.5852
4597	−15.0000	−8.2338
4598	−8.1118	−5.8335
4599	−11.8058	−11.6344
4600	−7.7253	−5.3663
4601	−3.4032	−1.8883
4602	−3.0625	−1.9392
4603	−7.3621	−9.1907
4604	−8.2431	−8.6566
4605	−7.6721	−4.5938
4606	−8.3143	−8.7279
4607	−3.4931	−1.6561
4608	−2.7917	−1.2435
4609	−4.0705	−2.1201
4610	−2.8478	−1.6354
4611	−3.3968	−1.7887
4612	−2.9980	−1.6567
4613	−3.6085	−2.1055
4614	−3.3854	−2.3520
4615	−4.6649	−2.6861
4616	−3.8048	−2.2184
4617	−3.5524	−1.9691
4618	−3.7235	−2.1103
4619	−4.1942	−2.0228
4620	−4.5216	−2.6159
4621	−4.9591	−3.6842
4622	−4.5748	−2.3500
4623	−4.1324	−2.8369
4624	−3.9852	−2.5375
4625	−3.3849	−1.7604
4626	−3.2030	−1.5389
4627	−4.3883	−2.5741
4628	−4.2066	−2.1698
4629	−3.4566	−1.8250
4630	−3.0797	−1.7268
4631	−4.2604	−2.1355
4632	−4.5075	−2.6036
4633	−4.9475	−3.1968
4634	−4.5765	−2.5791
4635	−4.4585	−2.5478
4636	−4.0757	−2.4245
4637	−3.4836	−1.8664
4638	−3.3376	−2.1104
4639	−3.8391	−2.3916
4640	−3.2730	−1.7013
4641	−3.5346	−1.5280
4642	−4.2236	−3.0402
4643	−6.3577	−4.0488
4644	−6.8833	−10.1714
4645	−7.6141	−4.4427
4646	−8.2277	−15.0000
4647	−7.3042	−8.1328
4648	−11.1685	−10.9971
4649	−2.0207	−0.7528
4650	−9.0291	−8.5358
4651	−3.6645	−2.5888
4652	−2.9125	−2.2111
4653	−5.4147	−3.6583
4654	−5.9467	−4.5798
4655	−5.4437	−3.8747
4656	−3.1928	−2.1734
4657	−4.8176	−3.4793
4658	−9.0656	−6.8942
4659	−4.1729	−2.8270
4660	−4.6152	−2.9950
4661	−7.0611	−5.7966
4662	−6.6003	−4.8189
4663	−7.8195	−4.8180
4664	−6.6203	−5.9964
4665	−7.0256	−5.3181

TABLE 8
Transposon Right end Variants SEQ ID NOs: 845-2690

	Normalized	Normalized
	enrichment =	enrichment =
	Log2 (Normalized	Log2 (Normalized
SEQ ID	FC) - RL (1st	FC) - RL (2nd
NO	Replicate)	Replicate)

845	−0.0972	−0.0917
846	0.1133	0.0709
847	0.1499	0.2162
848	−0.1129	−0.0245
849	−0.2200	−0.0967
850	−0.0175	0.0266
851	−0.0715	−0.0576
852	−0.5016	−0.2900
853	0.0165	0.0605
854	−0.0212	0.0131
855	−0.1773	−0.0457
856	−0.0125	−0.0060
857	0.0242	0.0000
858	0.1188	0.1580
859	0.1927	0.0611
860	0.0026	0.0011
861	−0.2103	−0.0695
862	−0.0484	0.0157
863	−0.2294	−0.0776
864	−0.1197	−0.0652
865	0.1329	0.0411
866	0.0305	0.0139
867	0.0908	0.1321
868	−0.0285	−0.0594
869	−0.0538	−0.1167
870	−0.0690	−0.0491
871	−0.0171	−0.0639
872	−0.0248	0.0467
873	−0.2783	−0.0966
874	−0.3390	−0.3395
875	−0.1778	−0.1568
876	−0.3871	−0.3062
877	−0.0506	0.0656
878	−0.2168	−0.1973
879	−0.4239	−0.2132
880	−0.4862	−0.2364
881	−0.3112	0.0123
882	−0.2186	−0.2249
883	−0.1887	−0.1332
884	−0.1433	−0.1747
885	0.0795	0.0436
886	−0.0144	0.0158
887	−0.1188	−0.0667
888	0.1965	0.1410
889	−0.0110	−0.0979
890	0.1291	0.0906
891	0.1271	0.1828
892	−0.6427	−0.4707
893	−0.7523	−0.5963
894	−0.0641	−0.0799
895	−0.5287	−0.6630
896	0.0538	0.1945
897	−0.0415	−0.0249
898	−0.5239	−0.3676
899	−0.7044	−0.5808
900	−0.5191	−0.3504
901	−0.1370	0.0589
902	−0.7140	−0.7370
903	−0.1906	−0.2914
904	−0.1037	−0.0799
905	0.1294	0.1549
906	−0.4808	−0.4430
907	−0.2015	−0.1620
908	0.0207	0.0031
909	−0.0069	0.1029
910	−0.0639	−0.0663
911	−0.1108	−0.1709
912	−0.3188	−0.2430
913	−0.2313	−0.2410
914	−0.5408	−0.3811
915	−0.1487	−0.0595
916	−0.2023	−0.2057
917	0.0030	−0.1030
918	−0.4366	−0.3627
919	−0.3066	−0.1887
920	−0.1731	0.1401
921	−0.8055	−0.7116
922	−0.4143	−0.1711
923	−0.2934	0.0030
924	−0.4469	−0.2285
925	0.0162	0.1070
926	−0.0903	−0.1001
927	−0.3575	−0.3030
928	−0.5593	−0.2101
929	−0.5401	−0.2754
930	−0.2162	−0.0815
931	−0.6106	−0.4018
932	−0.4470	−0.2328
933	−0.5047	−0.4051
934	−0.5751	−0.4384
935	−0.1005	0.1509
936	−0.6109	−0.2998
937	−0.1516	0.0573
938	−0.3121	−0.3291
939	−0.5857	−0.3550
940	−0.5489	−0.4308
941	−0.6264	−0.4099
942	0.0565	0.3352
943	−0.1753	−0.0650
944	−0.4000	−0.4042
945	−0.7127	−0.4350
946	0.0251	−0.2093
947	−0.4439	−0.3738
948	−0.4076	−0.3305
949	−0.4771	−0.3682
950	−0.9827	−0.8885
951	−0.2673	−0.3466
952	−0.4213	−0.5371
953	−0.1103	0.0186
954	0.0836	0.0535
955	0.0757	−0.0860
956	−0.1355	−0.0196
957	−0.1310	−0.1235
958	0.0618	−0.1443
959	−0.1458	−0.1082
960	0.0306	0.0718
961	−0.8817	−0.7317
962	−0.9083	−0.9826
963	−0.0536	−0.0798
964	0.2161	−0.4247
965	−0.7814	−0.8480
966	0.0470	−0.1558
967	−0.8321	−0.9597
968	−0.6211	−0.5975
969	−0.1929	−0.2793
970	−0.0364	−0.1358
971	−1.2181	−1.2482
972	−0.1452	−0.0881
973	0.3667	0.3038
974	0.1401	−0.0801
975	−0.4893	−0.5730
976	−0.2694	−0.1883
977	−0.2019	−0.0446
978	0.4096	0.4099
979	−0.2269	−0.1175
980	−0.4636	−0.4742
981	−0.2837	−0.2560
982	−0.6064	−0.5119
983	−0.0641	−0.0852
984	−0.0505	−0.0569
985	−1.4198	−1.2264
986	−0.8098	−0.6498
987	−0.2677	−0.2607
988	0.0986	0.1762
989	−0.0479	0.0529
990	0.8539	1.0127
991	−1.3086	−1.2200
992	−0.5181	−0.3570
993	−0.5095	−0.3630
994	−0.6538	−0.4741
995	−0.0613	−0.0722
996	−0.5768	−0.3511
997	−0.8888	−0.7021
998	−0.7110	−0.5351
999	−0.3799	−0.3643
1000	−0.2306	−0.1073
1001	−0.8315	−0.7541
1002	−0.3623	−0.0686
1003	−0.4499	−0.5013
1004	−0.3464	−0.2103
1005	−1.0335	−0.7974
1006	−0.5741	−0.4152
1007	−0.8813	−0.6250
1008	−0.6577	−0.4492
1009	−0.5500	−0.3941
1010	−1.9146	−1.5090
1011	−0.5733	−0.4754
1012	−0.2210	−0.2784
1013	−0.1405	−0.1524
1014	−0.1962	−0.0545
1015	0.2993	0.2331
1016	0.1498	0.3270
1017	1.3602	1.4722
1018	0.0515	−0.1304
1019	0.3793	0.3130
1020	−0.2447	−0.1861
1021	−0.7838	−0.7585
1022	−0.9265	−0.8223
1023	0.1286	−0.0335
1024	−0.4673	−0.6612
1025	−0.2544	−0.3110
1026	−0.2247	−0.3731
1027	−1.3635	−1.3215
1028	−0.5855	−0.3110
1029	−0.5955	−0.5531
1030	−0.0980	−0.2128
1031	−1.2607	−1.0972
1032	−0.0756	−0.2187
1033	0.2025	0.0598
1034	−0.1733	−0.2244
1035	−0.0949	−0.1540
1036	0.0484	−0.0482
1037	−0.0613	−0.0422
1038	−0.6332	−0.5313
1039	−0.0677	−0.1704
1040	−0.0583	−0.0652
1041	−0.2022	−0.2329
1042	−0.3770	−0.3858
1043	0.1607	0.4341
1044	−0.1388	−0.1000
1045	−0.0984	0.0814
1046	−0.5026	−0.4517
1047	0.1214	0.1101
1048	0.2508	0.1662
1049	−0.1773	−0.2940
1050	−0.1284	−0.0849
1051	−0.1162	−0.1769
1052	−0.2483	−0.2220
1053	0.2150	0.1375
1054	−0.0343	−0.0760
1055	0.3564	0.3269
1056	0.1272	0.1034
1057	−0.7125	−0.7111
1058	−0.4534	−0.3559
1059	−0.1197	0.0009
1060	0.1311	0.0775
1061	0.2255	0.2426
1062	−0.9085	−0.7188
1063	−6.4750	−5.3052
1064	−1.0147	−0.6019
1065	−0.1005	−0.0524
1066	−2.4832	−1.9162
1067	−0.6184	−0.4395
1068	−6.1709	−5.4441
1069	−6.6114	−6.7160
1070	−1.9540	−1.6726
1071	0.0191	0.1691
1072	−0.2429	−0.2170
1073	−0.2817	−0.1854
1074	−0.1426	−0.1629
1075	−0.1736	−0.1749
1076	−0.0508	−0.0561
1077	−0.1196	−0.1088
1078	−0.0218	0.0241
1079	−0.0763	−0.1423
1080	−0.0041	0.0526
1081	−0.0071	−0.0316
1082	0.0937	0.0666
1083	−0.0049	−0.0924
1084	−0.1870	−0.0910
1085	−0.1287	−0.1056
1086	−0.0072	0.1001
1087	0.3397	0.3328
1088	0.1505	0.1116
1089	0.0103	−0.0031
1090	0.0763	0.1241
1091	−0.2111	−0.1293
1092	0.0470	0.0065
1093	−0.2505	−0.1845
1094	−0.2878	−0.2396
1095	−0.5054	−0.4204
1096	−0.6403	−0.4591
1097	−0.0201	0.0192
1098	−0.2590	−0.2499
1099	−0.0900	−0.0843
1100	1.2979	1.4027
1101	−0.7546	−0.5592
1102	−0.5416	−0.4750
1103	−0.7140	−0.4936
1104	−0.5335	−0.4716
1105	−1.2368	−0.9783
1106	−0.1365	−0.0905
1107	0.5732	0.7451
1108	−0.8582	−0.6030
1109	−0.4895	−0.2336
1110	−0.8601	−0.5282
1111	−0.3335	−0.0574
1112	−0.5970	−0.5052
1113	−0.5596	−0.4172
1114	−0.7238	−0.6062
1115	−0.6959	−0.7126
1116	−1.1843	−0.7625
1117	−0.5295	−0.5207
1118	−0.3534	−0.3543
1119	−1.0659	−0.8250
1120	−0.5712	−0.5344
1121	−0.4024	−0.4923
1122	0.5495	0.4422
1123	−0.7704	−0.6445
1124	−1.2678	−1.1422
1125	−2.2415	−2.1220
1126	−3.2710	−3.0021
1127	−1.8651	−1.6938
1128	−1.1325	−0.8602
1129	−0.0103	−0.0302
1130	0.1811	−0.0566
1131	−0.8755	−0.7693
1132	0.1435	0.0482
1133	−0.6978	−0.5524
1134	−0.9802	−0.9319
1135	−0.8680	−0.7714
1136	−1.1320	−0.9297
1137	−0.3590	−0.4287
1138	−1.1004	−0.7888
1139	−1.9804	−1.7244
1140	−1.0642	−0.8442
1141	−0.6490	−0.6346
1142	−0.3133	−0.3279
1143	−1.3951	−1.2839
1144	−1.4158	−1.2992
1145	−2.8650	−2.5688
1146	−3.8628	−3.7285
1147	−1.9540	−1.7465
1148	−0.4532	−0.2019
1149	−0.5588	−0.5654
1150	−0.8854	−0.7707
1151	−0.3970	−0.4226
1152	−0.1217	−0.1515
1153	−0.2943	−0.2989
1154	−0.4198	−0.4741
1155	−1.1598	−0.9642
1156	−0.1363	0.1526
1157	−6.3693	−6.4833
1158	−6.7049	−6.3689
1159	−6.1630	−6.5027
1160	−6.2235	−6.6506
1161	−0.2925	−0.2750
1162	−0.0191	0.0153
1163	−0.2720	−0.1613
1164	−0.1078	−0.1073
1165	−0.1771	−0.1057
1166	0.0599	0.0633
1167	−0.4888	−0.2902
1168	−0.0771	−0.0866
1169	−0.0023	−0.0596
1170	−0.0355	−0.0004
1171	−0.3142	−0.1313
1172	−0.2688	−0.2331
1173	−0.1434	−0.1321
1174	−0.2966	−0.0615
1175	−0.1991	−0.0429
1176	−0.5519	−0.4188
1177	−0.8182	−0.4566
1178	−0.0872	−0.0421
1179	−0.0327	−0.1015
1180	−0.0860	−0.1599
1181	0.0660	−0.0014
1182	−0.1228	−0.1465
1183	−0.6048	−0.3343
1184	−0.6977	−0.5532
1185	−0.1949	−0.2821
1186	−0.0167	−0.1439
1187	−0.1985	−0.2580
1188	−0.4633	−0.4195
1189	−0.4746	−0.3123
1190	−0.8289	−0.6101
1191	−0.4667	−0.1463
1192	−0.2454	0.1051
1193	−0.4368	−0.1116
1194	−0.4125	−0.2973
1195	−0.4247	−0.2010
1196	−0.8292	−0.4289
1197	−1.2878	−0.9080
1198	−0.6738	−0.5303
1199	−1.5567	−1.3018
1200	−0.8928	−0.6332
1201	−0.1547	−0.1702
1202	−0.3243	−0.2689
1203	−0.1981	−0.1769
1204	−0.3098	−0.3504
1205	−0.2624	−0.2906
1206	−0.7014	−0.7713
1207	−0.6682	−0.5498
1208	−0.1719	−0.3577
1209	−0.0287	0.0170
1210	−0.2438	0.0253
1211	−0.9559	−0.8861
1212	−0.8260	−0.5582
1213	−0.1419	−0.2345
1214	−0.4096	−0.2837
1215	−0.1997	−0.0628
1216	−0.5405	−0.4261
1217	−0.8223	−0.7210
1218	−0.7911	−0.6729
1219	−1.9800	−1.9652
1220	−1.6845	−1.2165
1221	−0.6741	−0.6091
1222	−0.3867	−0.2421
1223	−0.2994	−0.2956
1224	−0.2320	−0.1583
1225	−0.3325	−0.4582
1226	−0.6108	−0.6203
1227	−0.9205	−0.9350
1228	−0.1911	−0.2540
1229	−0.3531	−0.2884
1230	−0.6742	−0.6006
1231	−0.4128	−0.3220
1232	−0.1489	−0.1944
1233	0.4748	0.2843
1234	−0.2267	−0.1731
1235	−0.9208	−0.7290
1236	−0.3935	−0.2296
1237	−0.1188	−0.1454
1238	−5.4023	−4.2914
1239	−6.2608	−6.6389
1240	−6.6528	−6.5892
1241	0.1282	0.3011
1242	0.1017	0.2009
1243	−0.0179	0.0286
1244	−0.0006	0.0162
1245	−0.1826	−0.0935
1246	0.0299	0.1719
1247	−0.2954	−0.2584
1248	−0.0437	−0.0372
1249	−0.1558	−0.0856
1250	−6.2442	−7.0622
1251	−6.2726	−6.9032
1252	−5.1789	−6.2329
1253	−5.8702	−5.9493
1254	−6.2998	−6.1229
1255	−5.6230	−4.5139
1256	−1.6586	−1.2090
1257	−1.6549	−1.4101
1258	−0.7977	−0.7664
1259	−0.8858	−0.7854
1260	−1.4355	−1.1652
1261	−1.1663	−0.9791
1262	−1.1320	−0.8006
1263	−1.6870	−1.5627
1264	−2.3376	−2.1798
1265	−2.0035	−1.8135
1266	−0.9422	−0.8684
1267	−0.2612	−0.3539
1268	−0.6164	−0.6386
1269	−0.6856	−0.4844
1270	−2.4235	−2.2130
1271	−2.3696	−2.1270
1272	−1.2745	−1.1873
1273	−1.7032	−1.4048
1274	−0.9630	−0.9131
1275	−0.8272	−0.5738
1276	−0.3831	−0.3797
1277	−0.6403	−0.5088
1278	−0.5832	−0.3960
1279	−1.4093	−1.1704
1280	−1.8790	−1.5266
1281	−2.0245	−1.7991
1282	−0.4959	−0.4118
1283	−1.5819	−1.4164
1284	−1.7800	−1.9283
1285	−1.8205	−1.6594
1286	−0.7893	−0.6376
1287	−0.6421	−0.4161
1288	2.2631	3.3117
1289	−0.6097	−0.6117
1290	−2.1778	−2.0476
1291	−0.7624	−0.5950
1292	−1.7240	−1.4001
1293	−2.0112	−1.9930
1294	−0.9688	−0.8796
1295	−1.6290	−1.6665
1296	−0.8800	−0.7230
1297	−0.3333	−0.1335
1298	−0.4204	−0.3192
1299	−0.4270	−0.2141
1300	−0.4963	−0.3980
1301	−0.5979	−0.3694
1302	−0.8924	−0.5570
1303	−0.7206	−0.3899
1304	−0.4632	−0.2903
1305	−0.4186	−0.3804
1306	−0.5212	−0.3291
1307	−0.3875	−0.3266
1308	−0.7989	−0.4965
1309	−0.3785	−0.2717
1310	−0.3116	−0.1766
1311	−0.0443	−0.1059
1312	−0.5944	−0.4761
1313	−1.0815	−0.8558
1314	−0.4181	−0.3187
1315	−0.5631	−0.1885
1316	−0.7481	−0.4902
1317	−0.3174	−0.1767
1318	−0.6081	−0.5006
1319	−0.2492	−0.0642
1320	−0.1930	−0.2224
1321	0.2232	0.2194
1322	−0.0202	−0.0266
1323	−0.1394	−0.0830
1324	−0.3632	−0.2088
1325	−0.3346	−0.2052
1326	−0.1587	−0.1470
1327	−6.4665	−7.1605
1328	−7.1385	−7.3766
1329	−6.7434	−6.9995
1330	−5.4555	−5.7622
1331	−5.9898	−5.9362
1332	−6.4308	−7.9428
1333	−0.8973	−0.9353
1334	−1.9011	−1.5292
1335	−0.9008	−0.7775
1336	−0.5444	−0.5008
1337	−0.8960	−0.7826
1338	−0.8754	−0.7413
1339	−2.7074	−2.4673
1340	−3.2654	−2.9906
1341	−3.8603	−4.0416
1342	−4.3731	−4.3634
1343	−4.4177	−4.1405
1344	−4.2119	−4.1793
1345	−2.0898	−2.1689
1346	−3.9532	−3.5811
1347	−1.5566	−1.2616
1348	−2.7740	−2.6573
1349	−2.8774	−2.5098
1350	−3.1250	−2.7771
1351	−1.4608	−1.3436
1352	−0.5113	−0.2069
1353	−1.3287	−1.1224
1354	−0.7777	−0.7775
1355	−0.5907	−0.5901
1356	−1.4064	−1.0720
1357	−0.2079	−0.2277
1358	−0.4067	−0.3810
1359	−0.8437	−0.7015
1360	−2.1790	−2.3925
1361	−3.3607	−3.6427
1362	−3.0680	−3.0051
1363	−3.6556	−3.3395
1364	−2.0201	−1.9637
1365	−1.8558	−1.6892
1366	−2.2051	−2.2177
1367	−1.0293	−0.9951
1368	−1.8634	−1.6804
1369	−1.8889	−1.7740
1370	−2.0082	−1.8146
1371	−1.5300	−1.2530
1372	−1.0915	−0.9600
1373	−1.0420	−0.8164
1374	−0.6743	−0.5696
1375	−0.4950	−0.3779
1376	−0.3242	−0.2599
1377	−0.6377	−0.4441
1378	−0.6059	−0.3460
1379	−1.2272	−0.9050
1380	−0.5863	−0.4034
1381	−1.0569	−0.7652
1382	−0.2362	0.0128
1383	−0.6351	−0.4266
1384	−1.0605	−0.8107
1385	−0.7557	−0.5987
1386	−1.0498	−0.6704
1387	−0.5410	−0.3941
1388	−0.7122	−0.5841
1389	−0.5807	−0.5413
1390	−0.6753	−0.4423
1391	−0.6652	−0.6053
1392	−0.7209	−0.6220
1393	−0.7501	−0.6532
1394	−0.7056	−0.5295
1395	−0.1582	−0.1418
1396	−0.2646	−0.2887
1397	−0.2260	−0.2113
1398	−0.2210	−0.0953
1399	0.0013	−0.0024
1400	0.3407	0.3379
1401	−0.0032	0.0436
1402	−15.0000	−8.8948
1403	−7.4280	−7.4546
1404	−8.2717	−9.8832
1405	−0.7771	−0.1201
1406	−4.9847	−4.9695
1407	−15.0000	−15.0000
1408	−7.4951	−8.8436
1409	−8.1122	−10.7237
1410	−6.2941	−5.9987
1411	−0.3884	−0.2739
1412	0.2663	0.2334
1413	−2.7730	−2.5333
1414	−3.4387	−3.5539
1415	−0.5907	−0.2066
1416	−1.7891	−1.4545
1417	0.1146	−0.0182
1418	−0.4913	−0.0943
1419	−9.0703	−7.1900
1420	−6.4981	−7.1877
1421	−6.8547	−7.4662
1422	−5.7807	−7.4771
1423	−6.7507	−7.1923
1424	−7.1338	−6.8385
1425	−5.8752	−5.7443
1426	−6.4936	−7.2401
1427	−7.0052	−7.2123
1428	−5.9967	−5.8751
1429	−6.6941	−6.5507
1430	−6.5594	−6.6304
1431	−6.3757	−6.5828
1432	−6.8453	−6.2870
1433	−6.3822	−6.7498
1434	−5.7589	−5.5001
1435	−6.1881	−5.9293
1436	−3.0811	−3.1780
1437	−3.0895	−2.8425
1438	−3.3071	−3.2159
1439	−1.2011	−0.9876
1440	−1.1118	−0.9891
1441	−3.6448	−3.5323
1442	−0.9287	−0.8481
1443	−3.4847	−3.4804
1444	−1.2100	−0.6500
1445	−2.0982	−1.7234
1446	0.0221	0.2485
1447	−0.3289	0.0972
1448	−0.8643	−0.3434
1449	−0.0196	0.3471
1450	0.0714	0.5092
1451	0.1894	0.6446
1452	−0.5919	−0.1541
1453	−0.3533	0.0156
1454	−0.4238	−0.0323
1455	−0.0870	0.2232
1456	−0.1576	0.1996
1457	−0.4935	0.0316
1458	−0.1038	0.2150
1459	0.6302	0.9431
1460	0.0495	0.2278
1461	0.0120	0.2304
1462	0.0921	0.2967
1463	0.5990	0.8271
1464	−0.3096	−0.2101
1465	0.0296	0.2530
1466	−0.4406	−0.3171
1467	−0.3182	−0.1457
1468	−0.1583	−0.0457
1469	−0.3955	−0.1701
1470	−0.3171	0.1276
1471	−0.4759	−0.3844
1472	−0.1222	−0.0686
1473	−0.1232	0.0349
1474	−4.3036	−5.0869
1475	−2.8035	−3.1780
1476	−3.1850	−3.0775
1477	−1.1415	−0.7737
1478	−0.8517	−0.4744
1479	−2.2767	−1.9738
1480	−1.0685	−0.5542
1481	−1.4460	−1.0334
1482	−0.6205	−0.3478
1483	−0.6330	−0.2327
1484	−0.4403	−0.0702
1485	−1.5754	−1.0219
1486	−0.4861	−0.2156
1487	−0.5874	−0.1697
1488	−0.0805	0.1963
1489	−0.3504	−0.0641
1490	0.0258	0.2504
1491	−0.3106	−0.0365
1492	1.1926	1.4901
1493	−0.1134	0.1560
1494	−0.1202	−0.0123
1495	0.3423	0.7625
1496	−0.2646	0.0320
1497	−0.2071	−0.0776
1498	−0.9520	−0.3652
1499	−0.2542	0.0033
1500	0.5712	0.8422
1501	−0.5000	−0.0896
1502	0.1312	0.3586
1503	−0.4072	0.1070
1504	−0.1311	0.1476
1505	−0.1298	0.1228
1506	−0.5973	−0.3471
1507	0.2570	0.4720
1508	−0.8475	−0.5664
1509	−1.5604	−1.2550
1510	−0.7856	−0.6668
1511	−4.7581	−4.6055
1512	−5.0827	−5.0772
1513	−1.9160	−1.5486
1514	−3.1906	−2.7051
1515	−0.3309	−0.3317
1516	0.4344	0.3008
1517	−1.1501	−1.0586
1518	−1.4402	−1.0133
1519	−1.6438	−1.4626
1520	−1.1336	−0.9546
1521	−1.2119	−1.2170
1522	−1.0062	−0.9686
1523	−0.3704	−0.3289
1524	−0.2841	−0.1923
1525	−0.6341	−0.4925
1526	−0.9848	−0.7491
1527	−1.6261	−1.2224
1528	−1.7354	−1.3407
1529	−3.0235	−2.4425
1530	−4.2933	−4.1750
1531	−4.9938	−5.3320
1532	−3.3184	−3.0897
1533	−0.5272	−0.4993
1534	−4.3766	−4.0946
1535	−6.0703	−5.9071
1536	−6.5033	−6.9043
1537	−7.0385	−6.3732
1538	−8.9694	−7.1029
1539	−1.7789	−1.5003
1540	−0.8205	−0.7889
1541	−0.9020	−0.8005
1542	−0.3904	−0.3920
1543	−0.0454	−0.2096
1544	−1.4908	−1.1834
1545	−0.7450	−0.5924
1546	−0.5293	−0.5001
1547	0.1606	0.0061
1548	−0.2372	−0.2860
1549	−0.2588	0.0197
1550	−1.4255	−1.1720
1551	−5.3244	−4.5145
1552	−2.5337	−2.1278
1553	−1.3184	−0.9478
1554	−1.0100	−0.8103
1555	−0.3928	−0.1208
1556	−0.5473	−0.3392
1557	−0.4941	−0.2841
1558	−0.4247	−0.2461
1559	−0.4666	−0.4763
1560	−1.1110	−0.9875
1561	−1.1179	−0.9110
1562	−1.2551	−0.9968
1563	−2.4427	−2.2461
1564	−4.3354	−4.1376
1565	−0.5779	−0.5747
1566	−0.7596	−0.5430
1567	−0.8413	−0.6010
1568	−1.7788	−1.4492
1569	−2.4874	−2.0469
1570	−2.0435	−1.7373
1571	−6.7224	−7.3339
1572	−6.9795	−6.5421
1573	−7.2145	−7.3785
1574	−6.4574	−7.7377
1575	−7.1751	−7.0090
1576	−8.7860	−7.7251
1577	0.0868	−0.1387
1578	−6.5239	−6.5505
1579	−2.2915	−1.9710
1580	−6.4079	−6.2645
1581	−7.1110	−6.5781
1582	−6.5821	−6.7893
1583	−7.3396	−6.7381
1584	−0.0346	−0.1164
1585	−0.6484	−0.4964
1586	−1.9590	−1.8755
1587	−3.7592	−3.1882
1588	−3.3737	−2.9487
1589	−2.8843	−2.6501
1590	−2.8111	−2.5610
1591	−2.9799	−3.2554
1592	−3.4575	−3.1749
1593	−3.9894	−3.9629
1594	−4.1455	−3.4496
1595	−2.9401	−2.7609
1596	−2.9819	−3.4362
1597	−3.5228	−3.6763
1598	−3.3291	−3.0517
1599	−3.1343	−2.7116
1600	−2.9580	−3.2228
1601	−3.4447	−3.3088
1602	−3.3658	−3.2190
1603	−3.5878	−3.1213
1604	−4.0870	−4.2429
1605	−3.3420	−3.8731
1606	−3.0817	−3.4302
1607	−3.8198	−3.1313
1608	−3.1066	−3.5550
1609	−4.7343	−5.9535
1610	−3.8131	−3.4246
1611	−3.2231	−3.1204
1612	−3.3658	−2.7571
1613	−4.3988	−3.9848
1614	−4.0281	−2.9807
1615	−3.1978	−2.9728
1616	−4.7016	−3.1877
1617	−6.5423	−4.8684
1618	−5.3396	−3.8637
1619	−0.2825	−0.2919
1620	−0.9262	−0.5155
1621	−2.1224	−1.5337
1622	−2.7993	−2.4108
1623	−2.6394	−2.3948
1624	−2.9905	−2.5527
1625	−2.1101	−1.8062
1626	−2.3825	−1.9822
1627	−3.6960	−3.4204
1628	−2.9079	−2.3495
1629	−3.2164	−2.6039
1630	−2.6875	−2.3834
1631	−0.9275	−0.3806
1632	−3.4579	−2.7728
1633	−3.0041	−2.2636
1634	−3.1906	−2.9727
1635	−2.4844	−2.2589
1636	−2.2874	−1.8962
1637	−2.3119	−1.7450
1638	−2.1170	−1.5522
1639	−2.5377	−2.3128
1640	−3.1255	−3.2345
1641	−2.4643	−2.1194
1642	−2.7854	−1.7245
1643	−2.5229	−1.7860
1644	−3.7617	−5.1806
1645	−3.4139	−3.3932
1646	−3.3181	−2.9041
1647	−3.2329	−2.2837
1648	−3.4540	−2.1674
1649	−3.4816	−2.9463
1650	−2.9328	−2.3744
1651	−3.5134	−3.1379
1652	−3.8653	−3.1370
1653	−4.1475	−4.7046
1654	−1.0180	−0.6236
1655	−0.5055	−0.3908
1656	−0.5311	−0.3351
1657	−0.3865	−0.3128
1658	−0.2852	−0.2194
1659	−0.6381	−0.3901
1660	−5.4944	−5.1584
1661	−5.1005	−4.0275
1662	−5.8392	−4.8657
1663	−4.6855	−5.5194
1664	−5.2630	−3.9676
1665	−6.2630	−15.0000
1666	−1.2496	−1.2866
1667	−4.2602	−4.4029
1668	−4.1285	−3.8444
1669	−4.6242	−4.4528
1670	−4.3145	−3.8386
1671	−0.8851	−0.6482
1672	−1.1907	−0.9356
1673	−1.5427	−1.1059
1674	−1.2775	−0.8334
1675	−1.6623	−1.3183
1676	0.1396	0.1121
1677	−0.0768	−0.0984
1678	−0.0585	−0.0394
1679	−0.0064	0.0376
1680	−0.2236	−0.1941
1681	−3.5215	−3.7279
1682	−2.6714	−2.7883
1683	−4.3396	−4.4402
1684	−4.3866	−4.1667
1685	−4.9527	−4.9523
1686	−4.7655	−4.2597
1687	−3.8468	−3.6130
1688	−4.5620	−4.6425
1689	−4.6168	−4.4387
1690	−3.6832	−3.5723
1691	−3.2583	−3.2024
1692	−3.4480	−2.7883
1693	−2.7541	−2.7806
1694	−2.7379	−2.4426
1695	−0.8040	−0.5576
1696	−2.1977	−1.8931
1697	−2.2510	−1.8655
1698	−2.7760	−2.1742
1699	−3.5901	−3.4720
1700	−3.5304	−3.1541
1701	−2.9476	−2.2792
1702	−1.8694	−1.5500
1703	−0.4505	0.0106
1704	−3.2837	−2.9155
1705	−1.9120	−1.1677
1706	−2.9507	−2.9248
1707	−2.4326	−1.8728
1708	−2.7768	−1.9866
1709	−0.9301	−1.1666
1710	−1.4375	−1.3610
1711	−1.2607	−1.0543
1712	−1.3637	−1.3520
1713	−1.6181	−1.4154
1714	−6.0565	−5.6680
1715	−3.4589	−3.4855
1716	0.3802	0.2708
1717	−0.1080	0.0978
1718	0.1550	0.2024
1719	−0.1074	−0.1139
1720	−0.2674	−0.2956
1721	−0.4742	−0.3674
1722	−0.4035	−0.4526
1723	−0.3845	−0.4161
1724	−0.8176	−0.6196
1725	−0.6776	−0.6652
1726	−0.8598	−0.7793
1727	−0.8377	−0.6657
1728	−0.6022	−0.5586
1729	−0.7275	−0.5694
1730	−0.4579	−0.2293
1731	−0.5697	−0.4937
1732	−0.6096	−0.4834
1733	−0.7603	−0.6312
1734	−0.5497	−0.3249
1735	−0.6043	−0.4064
1736	−0.5104	−0.3909
1737	−0.8486	−0.7422
1738	−1.8384	−1.1466
1739	−0.6876	−1.3885
1740	0.5184	0.7528
1741	−0.5656	−0.4049
1742	−0.9772	−0.7864
1743	−0.8193	−0.6319
1744	−1.0203	−0.8631
1745	−1.1808	−0.8542
1746	−1.5349	−1.2158
1747	−2.1553	−1.9371
1748	−1.9378	−1.5153
1749	−2.4626	−1.9388
1750	−2.5176	−2.1816
1751	−2.6813	−2.5262
1752	−2.7281	−2.5510
1753	−2.0822	−1.8569
1754	−2.2898	−2.3760
1755	−2.2529	−2.3692
1756	−2.5857	−2.2538
1757	−2.2001	−1.8941
1758	−2.1374	−1.7523
1759	−2.5012	−2.0892
1760	−2.0021	−1.8029
1761	−2.1852	−2.1243
1762	−2.4707	−2.0964
1763	−2.2986	−2.1000
1764	−2.5959	−2.7652
1765	−3.5686	−3.2621
1766	−3.6923	−3.8027
1767	−3.9323	−4.9588
1768	−5.0990	−5.5850
1769	−6.2662	−7.1229
1770	−8.4684	−7.0799
1771	−6.5319	−6.4330
1772	−7.5296	−7.4407
1773	−6.6200	−8.4946
1774	−7.9993	−9.0258
1775	−6.3060	−6.5390
1776	−6.7990	−8.2406
1777	−8.2639	−7.5129
1778	−6.8024	−6.1851
1779	−6.3710	−6.1081
1780	−0.1884	−0.1974
1781	0.0630	0.0212
1782	−0.1593	0.0161
1783	−0.1986	0.1778
1784	−0.3875	0.0668
1785	−0.2767	−0.0735
1786	−0.0521	0.0535
1787	−0.0411	0.0422
1788	0.0279	0.0954
1789	−0.2818	−0.1797
1790	−0.1612	−0.0269
1791	−0.7223	−0.3408
1792	−0.5762	−0.2876
1793	−0.4251	−0.3620
1794	−0.5902	−0.3558
1795	−0.8636	−0.6166
1796	−0.4896	−0.3574
1797	−0.4587	−0.1573
1798	−0.2438	−0.0925
1799	−0.4909	−0.2061
1800	−0.1442	0.2151
1801	−0.2613	0.0109
1802	0.1319	0.4170
1803	−0.3857	−0.1277
1804	−0.7922	−0.5104
1805	−0.5321	−0.3149
1806	−0.5105	−0.2379
1807	−0.6972	−0.4511
1808	−0.6894	−0.3097
1809	−0.3541	−0.1616
1810	−0.1030	0.1145
1811	−0.2913	0.0354
1812	−0.1528	−0.0261
1813	−0.4516	−0.2099
1814	−0.0415	0.0676
1815	−0.8562	−0.4200
1816	−0.5293	−0.3130
1817	−0.5385	−0.4124
1818	−0.8875	−0.7021
1819	−0.8401	−0.3512
1820	−0.9603	−0.5111
1821	−0.5072	−0.2250
1822	−0.7101	−0.4904
1823	−0.1407	−0.0903
1824	−0.4841	−0.2374
1825	−0.7444	−0.4468
1826	−0.4685	−0.4209
1827	−1.1487	−0.6876
1828	−0.9775	−0.4930
1829	−0.6419	−0.4336
1830	−0.9713	−0.6332
1831	−1.2048	−0.8363
1832	−0.9414	−0.6845
1833	−0.8650	−0.4227
1834	−0.7330	−0.5104
1835	−0.8299	−0.5851
1836	−0.6756	−0.4104
1837	−0.7582	−0.4932
1838	−0.7064	−0.5193
1839	−0.9313	−0.5635
1840	−0.9115	−0.5955
1841	−0.7666	−0.5850
1842	0.3330	0.6989
1843	−1.1336	−0.7636
1844	−0.9073	−0.4203
1845	−0.7322	−0.4273
1846	−0.6067	−0.3803
1847	−0.6621	−0.2915
1848	−0.5684	−0.2679
1849	−0.2442	0.1767
1850	−0.6885	−0.2766
1851	−0.2024	−0.0443
1852	−0.7836	−0.5007
1853	−0.9128	−0.8126
1854	−0.6203	−0.3000
1855	−1.0918	−0.8300
1856	−0.6731	−0.5059
1857	−0.4437	−0.3213
1858	−0.7793	−0.4156
1859	−0.8957	−0.7888
1860	−0.7864	−0.5661
1861	−1.2462	−1.0430
1862	−0.8125	−0.6872
1863	−0.9854	−0.7621
1864	−1.3139	−1.1053
1865	−1.0066	−0.8724
1866	−1.1595	−0.9364
1867	−1.2108	−0.8956
1868	−0.9622	−0.6591
1869	−0.5790	−0.2467
1870	−0.8475	−0.5533
1871	−0.8507	−0.6949
1872	−0.7625	−0.6283
1873	−1.0223	−0.7750
1874	−0.7589	−0.4061
1875	−1.3819	−1.0563
1876	−1.2122	−0.9972
1877	−1.1499	−1.0649
1878	−0.1130	0.2623
1879	−1.5241	−1.0467
1880	−1.3777	−1.0445
1881	−0.6467	−0.3516
1882	−0.7509	−0.5474
1883	−0.8189	−0.6615
1884	−0.7177	−0.5154
1885	−0.8996	−0.6612
1886	−0.7738	−0.5940
1887	−0.0443	0.0295
1888	−0.1631	−0.1600
1889	0.3001	0.4333
1890	−0.2806	−0.1864
1891	−0.1069	−0.0491
1892	−0.0120	0.0387
1893	−0.0968	0.0120
1894	2.2330	2.6485
1895	0.0577	0.1408
1896	−0.2540	−0.1755
1897	−0.7489	−0.5314
1898	−0.3929	−0.2966
1899	−0.7261	−0.5368
1900	−0.7723	−0.5430
1901	−0.5906	−0.3447
1902	−0.3956	−0.1664
1903	−1.0014	−0.8067
1904	−0.4138	−0.3394
1905	0.2333	0.2220
1906	0.0273	0.0660
1907	0.3920	0.3043
1908	0.2698	0.1577
1909	−0.0868	−0.1166
1910	0.1876	0.2034
1911	−0.6276	−0.4523
1912	−0.5701	−0.3586
1913	−0.3595	−0.3673
1914	−0.2319	−0.0034
1915	−0.3561	−0.2030
1916	−0.4266	−0.2215
1917	−0.0909	−0.0486
1918	−0.1586	−0.0592
1919	0.0130	−0.0771
1920	0.0714	0.1665
1921	−0.1455	−0.1258
1922	0.0258	0.1298
1923	−0.1644	−0.1790
1924	−0.0984	−0.0910
1925	−0.1995	−0.2254
1926	−0.5606	−0.4220
1927	−0.5821	−0.5888
1928	−0.1674	−0.0622
1929	−0.2583	−0.2485
1930	−0.3176	−0.3128
1931	−0.3263	−0.3692
1932	−0.3893	−0.2425
1933	−0.2021	−0.0572
1934	−0.3504	−0.3393
1935	−0.6217	−0.4515
1936	−0.7025	−0.5324
1937	−0.5436	−0.5048
1938	−0.5724	−0.5725
1939	−0.7523	−0.6730
1940	−0.6490	−0.5514
1941	−0.3388	−0.2195
1942	−0.6093	−0.3722
1943	−0.3920	−0.2775
1944	−0.0366	−0.0747
1945	−0.1956	−0.1438
1946	−0.2370	−0.2130
1947	−0.5926	−0.5318
1948	−0.4041	−0.3099
1949	−0.7922	−0.5728
1950	−0.7085	−0.4343
1951	−0.9558	−0.7619
1952	−0.5265	−0.3775
1953	−0.8583	−0.5741
1954	−0.5944	−0.5618
1955	−0.4876	−0.3517
1956	0.1224	0.4003
1957	−0.6369	−0.3938
1958	−0.4816	−0.3366
1959	0.1016	0.2466
1960	0.2920	0.3992
1961	−0.0340	0.0227
1962	0.0892	0.1377
1963	−0.3507	−0.1711
1964	−0.0673	0.1250
1965	0.2510	0.2611
1966	0.0619	0.1618
1967	−0.2646	−0.1503
1968	−0.4728	−0.1537
1969	−0.4412	−0.3232
1970	−0.1844	−0.1264
1971	−0.3877	−0.1207
1972	−0.3151	−0.1486
1973	−0.3772	−0.2890
1974	−0.2296	−0.0463
1975	−0.6615	−0.4068
1976	−0.3579	−0.1165
1977	−0.1260	0.0405
1978	−0.3375	−0.0468
1979	−0.0578	−0.0330
1980	0.2785	0.4414
1981	0.0003	0.1884
1982	−0.0715	0.1504
1983	−0.4546	−0.2193
1984	0.0270	0.1030
1985	−0.5039	−0.2524
1986	−0.1878	0.1550
1987	−0.6160	−0.2139
1988	−0.5063	−0.2076
1989	−0.0546	0.1704
1990	0.0593	0.0710
1991	−0.0966	0.0191
1992	−0.0087	0.1861
1993	−0.0221	0.2525
1994	−0.0541	0.0957
1995	−7.1129	−8.0140
1996	−3.4969	−3.0592
1997	−7.2803	−8.3069
1998	−7.5205	−7.0877
1999	−2.1667	−1.7954
2000	−7.4835	−9.0950
2001	−7.9785	−6.5104
2002	−3.7134	−3.8140
2003	−6.2523	−6.1914
2004	−2.2890	−2.4537
2005	−5.1505	−6.2702
2006	−6.8435	−6.4107
2007	−0.4196	−0.1150
2008	−1.0520	−0.7302
2009	−0.6689	−0.3614
2010	−1.1280	−0.7370
2011	−0.7297	−0.4421
2012	−0.2258	−0.2086
2013	−0.3872	−0.4002
2014	−1.4100	−1.0541
2015	−0.3620	0.1070
2016	−1.3658	−0.9739
2017	−0.9439	−0.5450
2018	−1.4644	−0.9636
2019	−1.5257	−1.3231
2020	−1.8990	−1.4184
2021	−1.5937	−1.0264
2022	−1.9251	−1.4781
2023	−1.2324	−1.0090
2024	−1.0463	−0.8770
2025	−1.2407	−0.7602
2026	−1.2775	−1.1026
2027	−0.3669	−0.2368
2028	−1.3166	−0.9760
2029	−0.7655	−0.6093
2030	−1.3221	−0.9845
2031	−1.1173	−0.9110
2032	−1.3259	−1.0798
2033	−1.0403	−0.6767
2034	−1.6979	−1.2635
2035	−1.1355	−0.7183
2036	−0.9044	−0.5234
2037	−0.9799	−0.6716
2038	−0.9124	−0.6817
2039	−0.8085	−0.5564
2040	−1.6072	−1.0276
2041	−0.6837	−0.3112
2042	0.1938	0.2889
2043	−3.4340	−2.9613
2044	−3.6451	−3.4329
2045	−3.0815	−2.1385
2046	−6.2508	−6.2774
2047	−2.9912	−2.5729
2048	−6.1049	−6.4116
2049	0.2738	0.3285
2050	−3.4583	−2.4849
2051	−0.7885	−0.5992
2052	−0.6760	−0.2805
2053	−0.8185	−0.5969
2054	−0.7079	−0.4781
2055	−0.9373	−0.5756
2056	−0.5923	−0.4757
2057	−1.3648	−0.9257
2058	−1.3537	−0.9649
2059	−1.9742	−1.6101
2060	−1.1791	−0.9268
2061	−2.0230	−1.8174
2062	−0.8160	−0.3559
2063	−2.2503	−1.5521
2064	−1.7615	−1.3870
2065	−2.7534	−2.2951
2066	−1.5942	−1.3235
2067	−1.4763	−1.1494
2068	−1.6811	−1.2483
2069	−1.7062	−1.2011
2070	−1.8639	−1.3988
2071	−2.7005	−2.0227
2072	−1.7197	−1.4910
2073	−2.4276	−2.0984
2074	−1.6913	−1.3619
2075	−2.3759	−1.6772
2076	−1.9170	−1.6590
2077	−2.4998	−2.1910
2078	−6.1930	−6.3979
2079	−8.2315	−7.3511
2080	−6.6046	−7.1547
2081	−7.5199	−7.3241
2082	−8.4808	−7.5074
2083	−6.3439	−6.4346
2084	−7.7945	−6.5315
2085	−7.9254	−7.9519
2086	−7.6212	−7.4362
2087	−5.5354	−6.8421
2088	−7.9551	−7.5342
2089	−6.6892	−6.6487
2090	−7.2609	−7.0811
2091	−7.0093	−7.0359
2092	−6.6746	−7.2668
2093	−7.0587	−7.2165
2094	−7.2409	−7.8525
2095	−7.6750	−7.1869
2096	−7.3981	−7.0096
2097	−6.9914	−7.0793
2098	−7.1053	−7.3856
2099	−6.8415	−7.3826
2100	−7.2186	−7.5822
2101	−7.3201	−6.9316
2102	−1.5074	−1.2811
2103	−1.8092	−1.3219
2104	−2.2420	−1.6432
2105	−4.0394	−3.3114
2106	−2.1639	−1.8367
2107	−2.9623	−2.6276
2108	−2.1558	−1.8272
2109	−2.0790	−1.8225
2110	−2.5318	−2.1639
2111	−3.5708	−3.2029
2112	−4.2836	−4.0471
2113	−5.6754	−4.8089
2114	−2.2872	−1.5584
2115	−2.0962	−1.3329
2116	−3.0533	−2.4936
2117	−4.8962	−3.9814
2118	−2.4944	−2.1846
2119	−3.1702	−2.5134
2120	−2.4887	−2.1038
2121	−3.3787	−2.7220
2122	−3.3570	−2.8306
2123	−3.9780	−3.2089
2124	−4.9082	−4.3916
2125	−4.9938	−4.6135
2126	−6.3501	−7.6176
2127	−8.3811	−6.6707
2128	−6.1743	−5.7942
2129	−8.0430	−7.9176
2130	−6.2265	−6.6819
2131	−6.5847	−7.1556
2132	−6.9461	−6.5804
2133	−6.7787	−7.9428
2134	−7.8370	−6.3192
2135	−7.9526	−7.2422
2136	−6.6305	−6.8415
2137	−7.1300	−6.4561
2138	−7.4703	−7.2904
2139	−7.7484	−6.7750
2140	−7.5993	−7.3914
2141	−7.7304	−6.7570
2142	−6.1621	−5.8805
2143	−7.7433	−7.9073
2144	−7.7440	−8.6775
2145	−7.0123	−7.6239
2146	−7.2439	−6.5824
2147	−7.5752	−6.8497
2148	−7.3769	−7.3421
2149	−7.7776	−7.5978
2150	−2.0575	−1.6267
2151	−2.3368	−1.8651
2152	−1.9120	−1.5449
2153	−2.3980	−2.0917
2154	−3.2663	−2.8623
2155	−4.8796	−4.3079
2156	−3.3002	−3.0325
2157	−4.6416	−4.4574
2158	−3.9163	−3.3601
2159	−5.4142	−4.7176
2160	−4.1644	−3.6385
2161	−5.9788	−4.6361
2162	−3.2222	−2.7782
2163	−3.2154	−2.7747
2164	−3.5469	−2.8251
2165	−3.5743	−3.2476
2166	−4.0971	−3.6427
2167	−4.4595	−4.7168
2168	−4.1276	−3.9375
2169	−4.9133	−4.8633
2170	−4.2037	−3.6701
2171	−5.0278	−4.8134
2172	−5.1401	−4.8641
2173	−6.2487	−5.4403
2174	−0.7818	−0.2572
2175	−1.1647	−0.7065
2176	−0.6972	−0.5144
2177	−1.2337	−0.5908
2178	−1.4268	−1.1690
2179	−2.1819	−1.7161
2180	−1.5017	−1.2484
2181	−2.1866	−1.4674
2182	−1.3127	−0.9854
2183	−1.9032	−1.3824
2184	−1.2514	−0.7584
2185	−1.9248	−1.3184
2186	−1.5015	−1.1899
2187	−1.4431	−1.1738
2188	−1.3871	−1.1524
2189	−1.8664	−1.3155
2190	−1.5750	−1.3127
2191	−1.9796	−1.6227
2192	−1.8311	−1.3821
2193	−2.1552	−1.8222
2194	−1.4715	−1.0805
2195	−2.1865	−1.5765
2196	−2.0339	−1.6387
2197	−2.2254	−1.7144
2198	−1.7795	−1.4328
2199	−2.6067	−2.0439
2200	−2.4026	−1.9950
2201	−3.0365	−2.4475
2202	−3.4011	−3.0782
2203	−4.4363	−3.8729
2204	−3.5271	−3.3537
2205	−4.7059	−4.6285
2206	−4.0901	−3.5182
2207	−4.7711	−4.9980
2208	−4.1653	−3.6234
2209	−4.9909	−5.6024
2210	−3.1495	−2.4609
2211	−2.8322	−2.1713
2212	−3.0604	−2.6731
2213	−3.0516	−2.2141
2214	−4.6305	−3.8080
2215	−4.8833	−4.5610
2216	−4.3300	−3.7308
2217	−4.6819	−4.4296
2218	−4.6073	−4.1158
2219	−4.5222	−4.5383
2220	−4.4873	−4.6877
2221	−5.4480	−5.1367
2222	−1.2439	−0.8960
2223	−1.5563	−1.2030
2224	−1.2838	−0.9762
2225	−0.8131	−0.4098
2226	−1.3225	−1.0301
2227	−2.5101	−1.9090
2228	−1.2945	−1.0838
2229	−2.6822	−2.2227
2230	−1.5998	−1.3212
2231	−2.2939	−1.9974
2232	−2.3573	−1.9314
2233	−3.3666	−2.6318
2234	−1.7897	−1.5619
2235	−2.0935	−1.6687
2236	−1.6048	−1.2642
2237	−2.3975	−1.9737
2238	−1.9837	−1.5714
2239	−2.4290	−1.9829
2240	−2.0479	−1.7776
2241	−2.3309	−2.0609
2242	−2.0274	−1.6006
2243	−2.4904	−1.9721
2244	−2.3668	−1.9443
2245	−2.5718	−2.4181
2246	−0.8184	−0.5806
2247	−1.1633	−0.7744
2248	−0.9278	−0.6495
2249	−1.6247	−1.2168
2250	−1.6170	−1.4078
2251	−2.2170	−1.9320
2252	−1.5645	−1.2449
2253	−2.8079	−2.0905
2254	−1.5100	−1.2488
2255	−2.3309	−1.7567
2256	−2.3471	−1.8227
2257	−3.1226	−2.5655
2258	−1.9112	−1.4898
2259	−1.7833	−1.4333
2260	−1.7458	−1.4594
2261	−2.6705	−2.2130
2262	−1.9613	−1.5111
2263	−2.7667	−2.0650
2264	−2.2105	−1.9408
2265	−2.7392	−2.1935
2266	−2.0635	−1.5094
2267	−2.4373	−2.1211
2268	−2.5504	−2.1783
2269	−3.2395	−2.6058
2270	−2.0031	−1.7616
2271	−3.2258	−3.3167
2272	−2.3862	−2.1318
2273	−4.6783	−4.2810
2274	−2.0372	−1.7937
2275	−3.1606	−2.6225
2276	−2.4579	−2.0565
2277	−3.6676	−2.9314
2278	−1.1501	−0.8472
2279	−3.2526	−3.0015
2280	−2.4979	−2.3557
2281	−3.2407	−2.9977
2282	−1.5486	−1.2211
2283	−4.2665	−4.1530
2284	−3.5851	−3.0282
2285	−4.9308	−4.9574
2286	−1.2799	−0.9454
2287	−2.7853	−2.7768
2288	−2.6621	−2.3995
2289	−3.2150	−2.9177
2290	−1.1698	−1.0625
2291	−3.0877	−3.1558
2292	−2.6007	−2.1461
2293	−3.2241	−2.8990
2294	−1.6521	−1.2327
2295	−3.1722	−2.5055
2296	−2.1402	−1.5261
2297	−2.1627	−1.9035
2298	−3.3346	−2.9767
2299	−1.6818	−1.3810
2300	−2.5294	−2.1143
2301	−4.1665	−3.8541
2302	−3.3350	−2.6324
2303	−3.6988	−3.1743
2304	−5.0074	−4.4755
2305	−0.8429	−0.6314
2306	−1.7300	−1.3646
2307	−3.3179	−2.8547
2308	−2.1262	−1.7765
2309	−2.4509	−2.1063
2310	−4.2183	−3.8607
2311	−2.5259	−1.9417
2312	−3.0899	−2.6366
2313	−5.2052	−5.0339
2314	−3.5200	−3.1739
2315	−4.5495	−4.4087
2316	−5.5160	−5.3094
2317	−1.2348	−0.9428
2318	−0.9673	−0.6696
2319	−2.2909	−2.0971
2320	−1.6534	−1.3962
2321	−2.0250	−1.3635
2322	−3.4271	−2.7214
2323	−2.1433	−1.7101
2324	−2.0710	−1.7141
2325	−4.2877	−3.5465
2326	−2.9483	−2.3515
2327	−3.1067	−2.8808
2328	−4.8101	−4.5336
2329	−1.2253	−0.8411
2330	−1.4536	−1.1744
2331	−3.0190	−2.6746
2332	−2.2468	−1.8325
2333	−2.5098	−2.0612
2334	−3.6436	−3.1441
2335	−1.8349	−1.5164
2336	−2.2984	−2.0919
2337	−4.2329	−4.3872
2338	−2.8997	−2.6184
2339	−3.4806	−3.0253
2340	−4.6965	−5.0584
2341	−1.2750	−1.0242
2342	−0.9919	−0.5382
2343	−1.1110	−0.1115
2344	−2.4636	−1.7482
2345	−2.3947	−1.9788
2346	−3.8343	−3.7963
2347	−2.5409	−2.2272
2348	−1.1621	−0.4115
2349	−5.4185	−5.6056
2350	−3.9129	−3.4974
2351	−3.8474	−3.3321
2352	−5.5369	−5.4030
2353	−0.9872	−0.8463
2354	−1.7729	−1.1504
2355	−3.4378	−3.1656
2356	−1.3882	−1.0757
2357	−2.7989	−2.3021
2358	−3.7588	−3.6605
2359	−2.5332	−2.0110
2360	−3.3817	−3.0034
2361	−5.4682	−5.2183
2362	−3.8863	−3.5909
2363	−5.1907	−3.9884
2364	−5.8138	−5.7148
2365	−1.5634	−1.0344
2366	−0.8701	−0.6795
2367	−2.8881	−2.5794
2368	−2.0596	−1.6264
2369	−2.3899	−1.8587
2370	−3.1556	−2.4635
2371	−2.7582	−2.3304
2372	−1.9147	−1.6748
2373	−4.2736	−4.3109
2374	−2.8749	−2.4160
2375	−3.4913	−3.0880
2376	−4.1777	−4.5404
2377	−1.4958	−1.1395
2378	−1.3546	−1.0467
2379	−3.5045	−3.0544
2380	−2.1692	−1.6532
2381	−2.4256	−2.0734
2382	−3.7444	−3.6355
2383	−3.1415	−2.4233
2384	−3.0577	−2.6921
2385	−5.3615	−5.4827
2386	−4.1305	−3.8102
2387	−4.6299	−4.2336
2388	−4.9895	−5.1898
2389	−1.5476	−1.0863
2390	−2.1864	−1.8697
2391	−2.6470	−2.1051
2392	−4.3671	−4.7018
2393	−3.4281	−3.0664
2394	−3.2244036	−3.03416
2395	−5.7428663	−5.60897
2396	−3.7571948	−3.68972
2397	−4.6622996	−4.3086
2398	−6.3901301	−6.12124
2399	−4.2512773	−4.36734
2400	−4.6003386	−4.85087
2401	−5.7540541	−5.55823
2402	−1.1998086	−0.90182
2403	−2.6938442	−2.17817
2404	−3.6247429	−3.19543
2405	−1.3007316	−0.93601
2406	−1.665633	−1.39317
2407	−3.3129689	−2.89234
2408	−3.5978822	−3.70323
2409	−1.6714951	−1.18417
2410	−0.6443582	−0.05381
2411	−3.3064288	−2.8295
2412	−5.0439452	−4.53115
2413	−1.6257667	−1.27789
2414	−2.2081452	−1.91854
2415	−3.7917037	−3.40508
2416	−5.2299972	−5.45966
2417	−2.0306575	−1.60323
2418	−3.1938703	−2.59631
2419	−3.1020778	−2.63171
2420	−4.0866251	−4.16129
2421	−2.6919731	−2.15643
2422	−3.0223734	−3.08196
2423	−3.5472507	−2.81784
2424	−4.3000111	−4.05433
2425	−2.7697687	−2.39115
2426	−3.9607477	−4.11782
2427	−3.6215616	−3.71456
2428	−5.4364436	−5.56685
2429	−3.3792833	−2.91573
2430	−4.9416692	−4.724
2431	−4.2123107	−3.62946
2432	−5.6371064	−5.77471
2433	−0.9552548	−0.54186
2434	−2.0904641	−1.72769
2435	−2.6361393	−2.17521
2436	−4.7644931	−4.68502
2437	−1.2263682	−0.98215
2438	−2.1259115	−1.97525
2439	−3.1396055	−2.70105
2440	−5.4744989	−5.00099
2441	−1.4783296	−1.28835
2442	−2.945823	−2.64344
2443	−3.6499764	−3.18021
2444	−6.746999	−6.39917
2445	−1.5437518	−1.21134
2446	−3.3531229	−3.02631
2447	−3.5907464	−3.21483
2448	−6.9172713	−5.73439
2449	−2.3640097	−1.82885
2450	−3.9405414	−3.79419
2451	−3.9522309	−3.55349
2452	−5.3619735	−5.79863
2453	−3.1092079	−2.51519
2454	−4.8881069	−4.87883
2455	−3.9529068	−3.61109
2456	−5.6247684	−6.35178
2457	−3.0368398	−2.6967
2458	−5.4937076	−5.71061
2459	−4.445899	−4.01174
2460	−3.7118987	−2.58093
2461	−3.5066298	−2.80782
2462	−6.4886684	−6.73763
2463	−4.791343	−4.1585
2464	−6.8496709	−7.12778
2465	−1.8442973	−1.23897
2466	−1.0662757	−0.92975
2467	−0.9172488	−0.64154
2468	−1.343801	−1.13897
2469	−1.0569375	−1.0193
2470	−0.9641409	−0.84884
2471	−1.6991112	−1.35393
2472	−1.1482473	−0.99507
2473	−2.2826271	−1.71223
2474	−0.7834575	−0.60894
2475	−1.9516205	−1.47074
2476	−0.8849024	−0.61833
2477	−1.0042589	−0.75109
2478	−0.768967	−0.57988
2479	−1.975371	−1.51916
2480	−1.4702561	−1.07803
2481	−1.0746524	−0.90539
2482	−0.8654849	−0.73141
2483	−0.8323908	−0.61654
2484	−1.5370961	−0.9676
2485	−1.4174268	−1.06563
2486	−1.5507766	−1.05531
2487	−0.740465	−0.62047
2488	−0.7281564	−0.68761
2489	−1.3858569	−0.7984
2490	−2.0566707	−1.66902
2491	−1.9862039	−1.79892
2492	−2.6676277	−2.23875
2493	−1.7611844	−1.42816
2494	−2.7157335	−1.88194
2495	−3.0882586	−2.39104
2496	−1.9364893	−1.5058
2497	−2.5334174	−1.75483
2498	−2.9649654	−2.21136
2499	−2.8221448	−1.96575
2500	−3.0827193	−2.23837
2501	−3.3226189	−3.09228
2502	−0.7451109	−0.49476
2503	−0.4172012	−0.15043
2504	−0.8026727	−0.70425
2505	−0.631294	−0.50701
2506	−0.8920533	−0.72663
2507	−1.2207223	−1.09637
2508	−1.468937	−1.10591
2509	−1.3182826	−0.86912
2510	−1.3150213	−0.93068
2511	−1.211751	−0.79402
2512	−0.6299349	−0.55684
2513	−1.3181023	−1.00404
2514	−1.9384823	−1.49145
2515	−0.7789869	−0.56773
2516	−1.5499598	−1.17679
2517	−1.348204	−0.98181
2518	−0.955361	−0.4166
2519	−0.7541713	−0.60457
2520	−1.5217027	−1.05495
2521	−1.6101307	−1.10727
2522	−1.8296628	−1.40671
2523	−1.4010485	−1.12222
2524	−1.8819491	−1.38106
2525	−1.1862519	−0.63257
2526	−1.2483563	−0.65803
2527	−1.6421789	−1.15805
2528	−2.22162	−1.81946
2529	−2.4782051	−2.22973
2530	−3.9579347	−3.49781
2531	−1.2096058	−0.99288
2532	−1.6775047	−1.25703
2533	−1.044021	−0.91189
2534	−2.2355167	−1.62897
2535	−1.6877766	−1.28834
2536	0.02724083	0.784222
2537	−1.4903288	−0.9019
2538	−1.5998599	−1.41219
2539	−1.7039935	−1.30276
2540	−1.1637701	−0.91641
2541	−1.4936506	−1.19049
2542	−1.1432239	−0.87427
2543	−2.2571491	−2.10763
2544	−0.8651703	−0.74435
2545	−1.4673999	−1.20295
2546	−1.1834394	−0.94604
2547	−1.1495841	−0.81489
2548	−0.8218145	−0.79598
2549	−0.7429876	−0.77766
2550	−1.8530822	−1.56741
2551	−1.7196975	−1.3944
2552	−1.1969268	−0.74649
2553	−1.3933533	−1.12938
2554	−1.6290546	−1.39462
2555	−2.3299007	−1.8233
2556	−2.93717	−2.55668
2557	−0.9019328	−0.72441
2558	−3.419818	−3.08284
2559	−1.9535045	−1.62134
2560	−1.349957	−1.13037
2561	−2.8695668	−2.38107
2562	−0.8395943	−0.64683
2563	−1.2455191	−1.0339
2564	−1.6914905	−1.35227
2565	−1.5440732	−1.47301
2566	−2.288956	−1.98762
2567	−2.4867525	−1.88543
2568	−0.7615909	−0.55264
2569	−0.7306614	−0.53445
2570	−1.5689512	−1.16903
2571	−1.6184381	−1.13484
2572	−1.5978315	−1.01401
2573	−1.8840855	−1.62831
2574	−1.5696043	−1.06584
2575	−1.6548671	−1.21801
2576	−1.0867712	−0.77671
2577	−1.7189417	−1.32657
2578	−1.2091111	−1.04735
2579	−1.056773	−0.7984
2580	−1.6086941	−1.22806
2581	−0.8908394	−0.91648
2582	−1.0966939	−0.97929
2583	−0.6758699	−0.6938
2584	−1.4888911	−0.9447
2585	−0.9416641	−0.59133
2586	1.0872418	1.99433
2587	−1.5358263	−1.14766
2588	−1.2510645	−0.99248
2589	−1.4260377	−1.17687
2590	−1.617369	−1.23074
2591	−1.3032917	−1.10247
2592	−1.138094	−0.83178
2593	−1.4258585	−1.16598
2594	−1.3568068	−0.95222
2595	−1.3538859	−0.65488
2596	−1.4728943	−1.18834
2597	−1.3440397	−1.01486
2598	−0.8687717	−0.36232
2599	−1.5591755	−1.05773
2600	−1.1094687	−0.68192
2601	−1.6662385	−1.05614
2602	−1.1622842	−0.56222
2603	−2.0571823	−1.51761
2604	−2.0460547	−1.36318
2605	−1.9547626	−1.30995
2606	−1.5522903	−1.03328
2607	−1.730117	−1.28007
2608	−1.6485331	−1.15145
2609	−1.5013049	−1.08455
2610	−1.6406066	−1.24156
2611	−1.715239	−1.3998
2612	−2.1452755	−1.85154
2613	−0.2313744	0.381126
2614	−1.7688496	−1.39891
2615	−2.483645	−1.88315
2616	−1.6905582	−1.27752
2617	−4.9549009	−4.28103
2618	−5.0640567	−5.18374
2619	−1.4010726	−0.90183
2620	−1.276142	−1.01086
2621	−1.3836097	−0.86505
2622	−1.1953284	−0.88708
2623	−1.6628601	−1.2592
2624	−1.7796949	−1.56974
2625	−1.2053754	−0.87014
2626	−1.3221893	−1.0371
2627	−1.3017623	−0.98456
2628	−1.7778425	−1.46748
2629	−0.536355	−0.45638
2630	−0.9516366	−0.7336
2631	−1.0044283	−0.79755
2632	−1.188787	−0.98523
2633	−0.8366792	−0.56098
2634	−0.9221736	−0.79839
2635	−0.9532542	−0.61156
2636	−1.2654204	−0.91689
2637	−0.8353265	−0.52821
2638	−0.6644217	−0.62686
2639	−1.115754	−0.78081
2640	−1.1977378	−0.74374
2641	−2.062537	−1.67286
2642	−1.0535857	−0.82071
2643	−1.761709	−1.3486
2644	−6.3310061	−5.80299
2645	−2.0972254	−1.49791
2646	−0.253332	0.060851
2647	−1.3806913	−0.91729
2648	−1.3265892	−0.9581
2649	−1.67489	−1.21814
2650	−1.9512512	−1.48689
2651	−1.8010266	−1.42827
2652	−6.5749452	−6.12758
2653	−2.4658991	−1.68639
2654	−3.2543849	−2.73095
2655	−1.319048	−0.85289
2656	−1.6601983	−1.26504
2657	−1.1338138	−0.87975
2658	−2.416775	−1.81909
2659	−2.3961048	−1.87639
2660	−3.1192493	−2.38701
2661	−2.6166433	−1.99705
2662	−3.9458821	−3.36979
2663	−2.5765975	−1.96871
2664	−3.1717375	−2.70293
2665	−4.5649517	−3.68153
2666	−3.6184972	−3.385
2667	−4.9749445	−4.96835
2668	−4.8768597	−4.17473
2669	−1.3871124	−0.84097
2670	−0.2228668	0.165601
2671	−0.426376	−0.12278
2672	−0.2244834	0.146588
2673	−0.2328573	0.12926
2674	−0.5513359	−0.12122
2675	−0.4143876	−0.01217
2676	0.72846811	1.022007
2677	−0.0193746	0.331152
2678	−0.178882	0.149153
2679	−0.1030894	0.394592
2680	0.19396402	0.611923
2681	−0.2898463	0.074417
2682	−0.3675817	−0.0785
2683	−0.6233649	−0.00046
2684	−0.3323308	−0.0602
2685	−0.3873451	−0.17892
2686	−0.2770517	−0.18569
2687	−0.4180592	−0.08773
2688	−0.1241845	0.293618
2689	−0.1850324	0.150474
2690	−0.0353577	0.097671

TABLE 9
Plasmids

ID	Description	DNA sequence

pSL3352	pUC57_Tn6677_TnL_cargo_TnR (800 bp-miniTn)	5153
pSL1022	pCDF_Vch_PT7_CRISPR(Target4)_QCascade_TnsABC_T7Term	5154
pSL1236	pDonor	5155
pSL1022	pEffector encoding the guide RNA that recognizes target 4	5156
pSL4277	pEffector encoding the guide RNA that recognizes target 5	5157
pSL4278	pEffector encoding the guide RNA that recognizes target 6	5158
pSL4279	pEffector encoding the guide RNA that recognizes target 7	5159
pSL4196	pTarget: Target 4_Downstream 4	5160
pSL4200	pTarget: Target 4_Downstream 5	5161
pSL4201	pTarget: Target 4_Downstream 6	5162
pSL4202	pTarget: Target 4_Downstream 7	5163
pSL4197	pTarget: Target 5_Downstream 5	5164
pSL4203	pTarget: Target 5_Downstream 4	5165
pSL4198	pTarget: Target 6_Downstream 6	5166
pSL4204	pTarget: Target 6_Downstream 4	5167
pSL4199	pTarget: Target 7_Downstream 7	5168
pSL4205	pTarget: Target 7_Downstream 4	5169
pSL3937	pCDF_Vch_PJ23119_CRISPR(tSL0004)_QCascade_TnsABC_300	5170
	bp-miniTn(Tn7R(56 bp)_99 bp_Tn7L)_SmR
pSL3524	pDonor_TnR(WT_H.0001)	5171
pSL3567	pDonor_TnR(ORF1a_H.0141)	5172
pSL3568	pDonor_TnR(ORF1b_H.0189)	5173
pSL3569	pDonor_TnR(ORF1c_H.0213)	5174
pSL3572	pDonor_TnR(ORF2a_H.0452)	5175
pSL3570	pDonor_TnR(ORF3a_H.0506)	5176
pSL3573	pDonor_TnR(ORF3b_H.0597)	5177
pSL3574	pDonor_TnR(ORF3c_H.0645)	5178
pSL3571	oDonor_TnR(ORF3d_H.0653)	5179
pSL0001	pUC19	5180
pSL3496	pCOLA_T7_sfGFP1-10_32AA_sfGFP11	5181
pSL3497	pCOLA_T7_sfGFP1-10_32AA	5182
pSL0008	pCOLADuet-1	5183
pSL3616	pUC19_TnR(132 bp WT)_Pcat_sfGFP11_TnL	5184
pSL3498	pUC57_TnR(WT)_sfGFP11_TnL	5185
pSL4187	pCOLA_T7_sfGFP1-10_TnR(WT)_sfGFP11	5186
pSL4188	pCOLA_T7_sfGFP1-10_TnR(ORF1a)_sfGFP11	5187
pSL4189	pCOLA_T7_sfGFP1-10_TnR(ORF1b)_sfGFP11	5188
pSL4190	pCOLA_T7_sfGFP1-10_TnR(ORF1c)_sfGFP11	5189
pSL4191	pCOLA_T7_sfGFP1-10_TnR(ORF2a)_sfGFP11	5190
pSL4192	pCOLA_T7_sfGFP1-10_TnR(ORF3a)_sfGFP11	5191
pSL4193	pCOLA_T7_sfGFP1-10_TnR(ORF3b)_sfGFP11	5192
pSL4194	pCOLA_T7_sfGFP1-10_TnR(ORF3c)_sfGFP11	5193
pSL4195	pCOLA_T7_sfGFP1-10_TnR(ORF3d)_sfGFP11	5194
pSL3494	pCOLA_T7_sfGFP	5195
pSL1021	pEffector_crRNA-nt	5196
pSL4283	pEffector_crRNA-505 (msrB)	5197
pSL4450	pSIM6_pSC101_Donor_TnR(WT)_GGS	5198
	linker_sfGFP_T7Term_TnL
pSL4451	pSIM6_pSC101_Donor_TnR(ORF2a)_GGS	5199
	linker_sfGFP_T7Term_TnL
pSL4052	pACYC_T7_IHFa_IHFb	5200
pSL2383	pSPIN_Tn7007_atypical	5201
pSL2372	pSPIN_Tn7011_atypical	5202
pSL2376	pSPIN_Tn7014_atypical	5203
pSL2386	pSPIN_Tn7016_atypical	5204
pSL2370	pSPIN_Tn7000_atypical	5205
pSL1213	pCDFL_Vch_PT7_CRISPR(Target4)_QCascade_TnsABC_Tn7R—	5206
	CmR_Tn7L
pSL1131	pCDFL_Vch_PJ23101_CRISPR(Target4)_QCascade_TnsABC—	5207
	Tn7R_CmR_Tn7L
pSL1796	pCDFL_Vch_PJ23119_CRISPR(Target4)_QCascade_TnsABC	5208
pSL5047	pUC57_Tn6677_TnR_cargo_TnR (800 bp-	5209
	miniTn_symmetric_ends_R-R)
pSL5048	pUC57_Tn6677_TnL_cargo_TnL (800 bp-	5210
	miniTn_symmetric_ends_L-L)
pSL4306	pCDF_Tn7_J23119_TnsABCD_TnL_genomic-PBSs_TnR	5211
pSL1233	pSC101_PAM_MSC1_T7_MSC2	5212
pSL2684	pSIM6_pSC101_GamBetaExo	5213
pSL4218		5214
pSL4373		5215
pSL4374		5216
pSL4050	pACYC_bCO_scIHF2	5217
pSL4134	hCO dcIHFA-NLS	5218
pSL4135	hCO NLS-dcIHFA	5219
pSL4136	hCO dcIHFB-NLS	5220
pSL4137	hCO NLS-dcIHFB	5221
pSL4146	hCO NLS-scIHF2	5222
pSL4147	hCO scIHF2	5223
pSL4170	TnsA-NLS-GSGSGG-IHF-XTEN-GS-TnsB	5224
pSL4171	TnsA-NLS-GSGSGG-XTEN-IHF-XTEN-GS-TnsB	5225
pSL4172	TnsA-NLS-(GGS)6-IHF-(XTEN)3-TnsB	5226
pSL4173	TnsA-NLS-(XTEN)3-IHF-(GGS)6-TnsB	5227
pSL4178	IHF-dCas9	5228

The scope of the present invention is not limited by what has been specifically shown and described hereinabove. Those skilled in the art will recognize that there are suitable alternatives to the depicted examples of materials, configurations, constructions, and dimensions. Variations, modifications, and other implementations of what is described herein will occur to those of ordinary skill in the art without departing from the spirit and scope of the invention.

Numerous references, including patents and various publications, are cited and discussed in the description of this invention. The citation and discussion of such references is provided merely to clarify the description of the present invention and is not an admission that any reference is prior art to the invention described herein. All references cited and discussed in this specification are incorporated herein by reference in their entirety.